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Abstract 
Background:  Rheumatoid  arthritis  (RA)  and  psoriatic  arthritis  (PsA)  are  two 
distinct  forms  of  chronic  auto-immunity;  understanding  the  transcriptomic 
profiles of key leukocyte subsets implicated in these arthritides could improve 
the diagnosis and treatment of patients. Current microarray analyses of samples 
derived from RA and PsA patients have examined the genetic profiles of whole 
blood  or  diseased  tissue  which,  although  informative,  can  mask  the  genetic 
contributions of individual cell types. Monocytes and macrophages are a cellular 
subset known to play a major role in PsA and RA through the production of pro-
inflammatory chemokines, cytokines and destructive proteinases.  
Aim: To define the transcriptome in CD14
+ cells separated from the blood and 
synovial fluid of PsA and RA patients, and to then compare and contrast that 
signature in health and disease. Thereafter to define the relevant activities of 
selected novel moieties described in the foregoing analysis.  
Methods & Results: The transcriptomic profiles of healthy, RA and PsA CD14
+ 
blood cells were remarkably similar - few genes could distinguish diseased from 
healthy  CD14
+  cells.  Comparison  of  the  genetic  signature  of  the  RA  and  PsA 
synovial  fluid  CD14
+  cells  revealed  that  just  over  50%  of  the  differentially 
expressed  genes  were  shared  between  the  two  disease  groups.  Furthermore, 
analysing  the  canonical  pathways  in  the  synovial  fluid  cells  compared  to  the 
matched peripheral blood of both patient groups surprisingly revealed Liver X 
receptor  (LXR)  activation  pathway  as  the  most  significantly  upregulated 
pathway: this pathway has been previously shown by our group to play a pro-
inflammatory role in arthritis.  
Examination of specific upregulated mRNAs in the synovial fluid CD14
+ cells from 
both  disease  types  revealed  two  novel  genes  that  had  not  previously  been 
associated with arthritis, the lysosomal enzyme legumain and the cell surface 
molecule plexin A1. Legumain was demonstrated to be present in RA and PsA 
CD14
+  cells  by  RNA  and  protein  analysis  and  was  physiologically  active. 
Incubation of CD14
+ cells with patient synovial fluid under hypoxic conditions 
also potentiated legumain expression. Plexin A1 was confirmed to be expressed 
at the mRNA level within RA synovium. siRNA knockdown of plexin A1 suggested 3 
that it may play a pro-inflammatory role within macrophages since subsequent 
treatment  of  these  macrophages  with  LPS  resulted  in  decreased  TNFα 
production. However, investigations into the identity of the specific ligands for 
plexin A1 in arthritis, known as semaphorins, were inconclusive.  
I  finally  generated  microarray  data  to  evaluate  the  transcriptome  of 
macrophages activated via cel contact with activated T cells. Such cells shared 
only a small percentage of genes with those dysregulated in the RA and PsA 
synovial fluid derived CD14
+ cells suggesting that this model at the time points 
chosen  may  not  be  an  appropriate  in  vitro  representation  of  articular 
macrophages. An imaging system of this in vitro model was also established to 
visualise  the  dynamic  nature  of  the  T  cell  –  macrophage  interactions  and 
demonstrated  that  variables  such  as  duration  or  method  of  T  cell  activation 
could alter the number and duration of interactions between the two cell types.  
Conclusions: These studies demonstrate that the CD14
+ cells isolated from the 
blood are similar transcriptomically between healthy controls and RA and PsA 
patients.  The  synovial  fluid  CD14
+  cells  from  RA  and  PsA  patients  exhibit 
substantial  overlap  in  terms  of  their  genetic  profile.  Two  novel  molecules 
expressed  by  diseased  patients  namely  plexin  A1  and  legumain  have  been 
identified and their preliminary characteristics in the context of synovitis have 
been defined.  4 
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MM      Mis-match 
MMP      Matrix metalloproteinase 
Mo      Monocyte 
MФ      Macrophage 
MTC      Multiple testing correction 16 
NK      Natural killer 
NO      Nitric oxide 
OA      Osteoarthritis 
PAMP     Pathogen associated molecular pattern 
PB      Peripheral blood 
PBMC     Peripheral blood mononuclear cells 
PCA      Principle component analysis 
PDGFA/B    Platelet-derived growth factor alpha/beta polypeptide 
PLX      Plexin 
PM      Perfect match 
PPBP      Pro-platelet basic protein 
PsA      Psoriatic arthritis 
RA      Rheumatoid arthritis 
RANKL    Receptor-activator-of-nuclear-factor-κB ligand 
RANTES    Regulated upon activation, normal T-cell expressed,  
and secreted 
RF      Rheumatoid factor 
RNI      Reactive nitrogen intermediates 
ROS      Reactive oxygen species 
RXR      Retinoid X Receptor 
SEMA      Semaphorin 
SF      Synovial fluid 
SLE      Systemic lupus erythematosus 
SNP      Single nucleotide polymorphism 
SOCS      Suppressor of cytokine signalling 
SpA      Spondylarthritis 
STAT      Signal transducer and activator of transcription 
TACE      TNFα-converting enzyme 
T1D      Type 1 diabetes 
Tck      Cytokine activated T cell 
Th1      T helper 1 cell 
Th2      T helper 2 cell 
TIEG      TGFβ early gene-1 
TIMP      Tissue inhibitor of MMPs 
TNFα      Tumor necrosis factor α 
TLR      Toll-like receptor 
TRAF      TNF receptor associated factor 
Treg      T regulatory cell 
TTCF      Tetanus toxin C fragment 
UPR      Unfolded protein response 
VASH1    Vasohibin 1 
VEGF      Vascular endothelial growth factor 
ZIA      Zymogen induced arthritis 
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1.1  Inflammatory Arthritis: Rheumatoid Arthritis and 
Psoriatic Arthritis 
The  inflammatory  arthritides  compose  a  heterogeneous  group  of  chronic 
inflammatory  rheumatic  diseases.  The  progressive  joint  inflammation  and 
immune cell infiltration typically seen in these diseases leads to progressive and 
irreversible destruction of the cartilage and bone. Arthritis affects 1-3% of the 
general population and is projected to affect 67 million people by 2020 in the 
United  States  alone  [1].  This  disease  is  not  only  associated  with  significant 
healthcare costs but also severe physical limitations and disability within the 
individual  [2].  Rheumatoid  arthritis  affects  0.5-1.1%  of  the  population  [3]. 
Psoriatic arthritis is another common inflammatory arthritis affecting 2-3% of the 
general population and occurring in 7-26% of psoriasis sufferers [4]. 
1.1.1 Definition and Classification 
Rheumatoid  arthritis  (RA)  is  a  chronic  symmetric  polyarticular  arthritis  which 
primarily affects the small joints of the hands and feet [5]. It is characterised by 
inflammation of the joint lining and cellular infiltration into the joint, which 
subsequently causes damage and destruction of bone and cartilage. RA sufferers 
have  a  life  expectancy  decrease  of  3  to  10  years  compared  to  the  general 
population [3]. The current accepted criteria for the classification of RA have 
been  defined  by  the  1987  American  College  of  Rheumatology  (ACR)  criteria 
outlined in Table 1.1 [6]. 19 
Table 1.1 ACR classification criteria for rheumatoid arthritis 
 
A  patient  is  diagnosed  as  having  RA if  they  present  with at  least  4  of  the  7 
criteria with the first four criteria being present for at least 6 weeks: 
1. Morning stiffness 
2. Soft tissue swelling in 3 or more joint areas 
3. Arthritic swelling of the hand joints 
4. Symmetrical presentation of arthritis 
5. Rheumatoid nodules  
6. Serum rheumatoid factor (RF) positive 
7. Radiographic changes including erosions or bony decalcifications. 
 
Psoriatic arthritis (PsA) is a (predominantly) seronegative inflammatory disease 
of  joints,  entheses  and  periarticular  connective  tissue  in  association  with 
psoriasis [7]. Rheumatoid factor and anti-cyclic citrullinated proteins (anti-CCP) 
antibodies are seen in 4.7% and 7.6% of cases respectively [8]. PsA constitutes a 
subset  within  the  spondyloarthropathy  (SpA)  group  due to  it  sharing  common 
clinical features with the other SpA diseases.  Clinical,  radiologic and familial 
evidence has indicated PsA as a distinct disease entity however basic research 
within this disease has been confounded by the absence of widely agreed-upon, 
validated disease criteria. Several classification criteria have been proposed by 
Moll  and  Wright  [9],  Vasey  and  Espinoza  [10]  and  the  European 
Spondyloarthropathy Study Group (ESSG) [11]. A large international study group 
identified  as  the  classification  criteria  for  psoriatic  arthritis  or  CASPAR  study 
group has since been used to construct new classification criteria [8] (see Table 
1.2). 20 
Table 1.2 Classification criteria for psoriatic arthritis (CASPAR) 
 
To meet the CASPAR criteria a patient must have inflammatory articular disease 
(joint, spine or entheseal) with ≥ 3 points from the following categories (1 point 
each): 
1.  Psoriasis (skin, scalp) 
2.  Psoriasis in patient‘s history 
3.  Psoriasis in family history 
4.  Psoriatic nail involvement (now) 
5.  Rheumatoid factor negative (determined by ELISA) 
6.  Dactylitis (inflammation of an entire digit) (now) 
7.  Dactylitis in patient‘s history 
8.  Radiological signs of new bone formation adjacent to the joints  
 
1.1.2 Epidemiology 
Numerous population based studies have been performed on the incidence and 
prevalence of RA and indicate large differences between various communities. 
Studies  performed  in  North  America  and  Northern  Europe  have  found  the 
prevalence of RA to be 0.5-1.1% with an annual incidence of 29-38 per 100,000 
whereas lower prevalence of 0.3-0.7% were demonstrated in Southern Europe 
which had an annual incidence of 16.5 per 100,000 inhabitants [3]. In the UK the 
prevalence  of  RA  is  estimated  to  be  0.8%  [12]  with  an  incidence  of  36  per 
100,000  in  women  and  14  per  100,000  in  men  [13].  There  have  been  few 
prevalence  studies  in  developing  countries  but  those  that  have  taken  place 
suggest  a  significantly  lower  prevalence  of  RA  than  in  North  America  and 
Northern Europe, of 0.1-0.5% [14].  
In  comparison,  fewer  epidemiological  studies  have  been  performed  on  PsA 
possibly due to a previous lack of a widely accepted classification or diagnostic 
criteria. Prevalence is estimated at 0.1-1% [15] which increases in patients with 
psoriasis to 7-26% [4] but has been reported up to 30% in a Swedish study [16]. 
Few population based incidence studies have been undertaken on PsA however, 
the various incidence rates have been reported as 6 in 100,000 individuals in 
Finland [17], 6.59 in 100,000 in the USA [18] and 8 in 100,000 in Sweden [19]. In 
a study performed in Minnesota the age- and sex-adjusted incidence increased 21 
from 3.6 (1970-1979) to 9.8 (1990-2000), reasons for this increased are unknown 
but may be due to better classification and diagnosis of the disease [20]. 
1.1.3 Clinical Features 
RA and PsA often present similar overlapping features of disease, as outlined in 
Table 1.3, such as the presence of rheumatoid factor which occurs in 80% of RA 
patients  but  also  4.7%  of  PsA  patients  [8].  Secondly,  although  PsA  classically 
presents with an asymmetric distribution, symmetry has been detected in up to 
33% of patients with polyarticular disease [21].  The pattern of joint involvement 
is  not  fixed  and  in  a  2  year  follow  up  study  of  early  PsA  patients  initially 
classified  as  polyarticular,  49%  were  subsequently  classified  as  oligoarticular 
[22]. In addition psoriasis, which is a defining feature of PsA, develops after the 
rheumatological  manifestations  in  20%  of  patients  or  does  not  develop  at  all 
[23]. However, there are several differential features between the two diseases 
that  aid  in  differential  diagnosis:  PsA  shares  features  in  common  with  the 
spondyloarthropathies such as HLA-B27 association which are not observed in RA 
[24-26];  also  the  involvement  of the  distal  joints,  spine involvement  and  the 
presence  of  enthesis  are  all  typical  clinical  features  specific  to  PsA  [15]. 
Consequently,  several  factors  must  therefore  be  taken  into  account  when 
distinguishing PsA from RA. 22 
Table 1.3 Comparison of clinical features of RA and PsA 
 
Finding          RA        PsA 
Morning stiffness >1 hour      +++        + 
Standard mortality ratio      1.27 [27]      1.62 [28] 
Rheumatoid Factor       ++ (80%) [6]      +/- (4.7%) [8] 
Articular Features 
Symmetrical Arthritis      +++        +/- [21] 
Dactlylitis          -        +++ 
New bone formation near joints    -        +++ 
Affection of distal finger/toe joints  -        +++ 
 
Extra-articular features   
Rheumatoid arthritis: 
Skin (Rheumatoid nodules, Vasculitis); Cardiac (ischemic heart disease) [29]; 
Respiratory (interstitial lung disease) [30]; Haematological (anaemia) [31] 
 
Psoriatic Arthritis: 
Skin (psoriasis, nail lesions 87% [32]); Ocular (uveitis [33]); Back pain [21]. 
 
 
 
1.1.4  Risk Factors 
The precise cause of RA or PsA is currently unknown, but it is believed to be a 
combination  of  numerous  risk  factors  as  well  as  disregulated  inflammatory 
processes. 
1.1.4.1   Genetic Factors  
There  is  overwhelming  evidence  that  the  risk  of  developing  RA  or  PsA  is 
associated with genetic factors. 
1.1.4.1.1  First-degree relatives and twin studies 
A well established approach to assess and quantify the possible role of genetic 
factors  and  disease  risk  is  to  measure  the  concordance  of  diseases  between 
related individuals. A highly heritable disease will have an increased prevalence 
in  individuals  related  to  the  arthritis  sufferer  compared  to  the  general 
population. A parameter used to measure this is the λR which is the ratio of the 23 
prevalence of a disease among first-degree relatives compared to the general 
population. The λR for RA is 2-17 [34] which is a modest value compared to a 
highly penetrant diseases such as cystic fibrosis which can have a λR value of 500 
[35].  A  recent  study  in  Sweden  demonstrated  an  increased  relative  risk  (the 
probability of the disease occurring) of RA in siblings of affected individuals as 
4.6 and in children as 3.0 [36]. The λR for PsA was determined to be 30.8 in a 
first-degree relative study of 100 PsA patients in Canada [37] and 47 in a similar 
study conducted in the UK [38]. A 2009 Icelandic study also demonstrated that 
first-degree  relatives  had  a  40-fold  increased  risk  of  developing  PsA  whilst 
second-degree relatives had a 12-fold increased risk [39]. Overall these studies 
indicate that PsA a more heritable disease in first- and second-degree relatives 
compared to RA. 
Twin studies are a powerful tool to understand the genetics of a disease. An 
increased incidence of disease amongst monozygotic (identical) twins compared 
to dizygotic twins offers evidence that inherited factors predispose to disease 
[35]. In RA two major twin studies have been undertaken using a Finnish  [40] 
cohort  and  a  British  cohort  [41]  and  the  combined  data  from  these  studies 
suggests that RA is approximately 65% heritable  [42]. Unlike RA there are no 
large twin cohorts available for PsA and the one twin study reported could not 
demonstrate a genetic effect on PsA as it was underpowered [43] however the 
results from the first-degree relative studies have demonstrated that PsA is a 
highly heritable disease. 
1.1.4.1.2  HLA associations 
The largest genetic contribution to RA susceptibility is a combination of a group 
of alleles within the HLA-DRB1 gene found within the major histocompatibility 
complex (MHC) region in chromosome 6p21. These alleles are collectively known 
as  the  shared  epitope  since  they  encompass  a  conserved  sequence  of  amino 
acids in the third hypervariable region of the class II DRβ1 chain (
70Q/R-K/R-R-A-
A
74) [44]. Many studies have demonstrated that HLA-DRB1 alleles are consistently 
linked and associated with RA in every population [45, 46] and have been shown 
to interact with environmental factors such as smoking [47]. Despite being the 
largest  genetic  contribution  to  RA  a  large  UK  based  study  found  no  PsA 
susceptibility association with the HLA-DRB1 alleles [48]. 24 
There have been far fewer genetic mapping studies performed on PsA compared 
to psoriasis which was first found to be associated with HLA class 1 antigens in 
the  1970s  [49],  however  subsequent  studies  have  since  identified  the  same 
psoriasis risk alleles to be associated with PsA. For example, the HLA-Cw*0602 
which comprises the largest genetic contribution to psoriasis is also associated 
with  PsA  patients  who  have  psoriasis  [48].  HLA-B27  is  another  molecule 
containing  PsA  associated  variants  [24-26],  it  is  considered  indicative  of  the 
association of PsA to the spondyloarthropathies and could also be a predictive 
marker  for  clinical  features  such  as  joint  deformity  [50].  PsA  has  also  been 
associated with polymorphisms in the MHC class 1 chain-related gene A (MICA), 
which  was  not  associated  with  psoriasis  alone  [51].  MICA  molecules  are 
considered markers of stress and are expressed by epithelial cells [52], they are 
recognised  by  the  receptor  NKG2D  found  on  CD8  αβ  T  cells,  γδ  T  cells  and 
natural killer (NK) cells and therefore polymorphisms within this molecule may 
subsequently affect the innate immune response. 
1.1.4.1.3  Other genetic associations 
Despite the MHC locus contributing the single strongest genetic risk to RA, it is 
estimated  to  explain  only  30%  of  total  genetic  component  of  susceptibility 
indicating  that  other  genes  may  also  be  involved  in  disease  predisposition. 
Genome wide linkage scans have subsequently identified a number of non-HLA 
genes associated with disease risk.  
PTPN22 
A  variant  within  the  PTPN22  gene  is  the  second  largest  genetic  risk  to  the 
development of RA after the shared epitope. This variant has been associated 
with RA in numerous studies [53, 54] but has been found to be very rare in Asian 
populations  and  is  not  associated  with  RA  in  these  populations  [55].  PTPN22 
codes  for  a  lymphoid-specific  phosphatase  (Lyp),  which  is  an  intracellular 
protein tyrosine phosphatase (PTP) involved in T cell receptor (TCR) signalling. 
Following  engagement  of  the  TCR  complex,  protein  tyrosine  kinases  become 
activated  and  then  phosphorylate  immunoreceptor  tyrosine-based  activation 
motifs  (ITAMs)  in  the  cytoplasmic  tail  of  the  TCR-CD3  chains.  Phosphatases 
dampen this response thereby providing a means of turning the signalling on and 
off.  The  genetic  variant  within  the  PTPN22  gene  associated  with  RA  is  a 
nucleotide change causing an amino acid substitution. This results in a gain of 25 
function for Lyp by increasing its enzymatic activity and causes an overall defect 
in T cell response to antigen stimulation. It has been proposed that this variant 
could predispose to RA by suppressing T cell receptor signalling during thymic 
development resulting in the survival of autoreactive T cells [56]. 
Despite  the  PTPN22  variant  predisposing  to  RA  and  many  other  autoimmune 
diseases such as systemic lupus erythematosus (SLE) [54] and systemic sclerosis 
(SSc) [57] there has been no consistent evidence for an association with PsA [58, 
59].  However,  different  variants  within  the  same  gene  locus  have  been 
associated with psoriasis [60, 61]. 
STAT4 
Signal  transducer  and  activator  of  transcription  4  (STAT4)  is  an  important 
transcription factor in the regulation of the immune response. STAT4 is involved 
in the signalling pathways of IL-12, IL-23 and type 1 interferons in T cells and 
monocytes  leading  to  a  T  helper  type  1  (Th1)  and  Th17  differentiation  and 
monocyte  activation  [62].  A  fine-mapping  study  first  identified  an  RA 
susceptibility  locus  within  the  STAT4  gene  in  a  US  population  [63]  and  this 
association has since been confirmed in other populations of European and Asian 
descent  [64,  65].  Analysis  of  STAT4  deficient  mice  have  underlined  the 
importance of this transcription factor in RA since these mice lack Th1 responses 
and  do  not  develop experimental  arthritis  [66].  However,  further  studies  are 
required to determine the role of the susceptibility variants in RA. There has 
been no reported PsA susceptibility locus in STAT4 however, as has been found 
with PTPN22, a gene polymorphism in STAT4 is associated with psoriasis [67]. 
IL12B and IL23R 
IL12B and IL23R are both proteins which are known to be important in T cell 
development.  Genetic  variants  within  these  genes  have  been  identified  as 
psoriasis genetic susceptibility loci and subsequent studies have also identified 
association with PsA but not RA [68]. 
1.1.4.2   Gender 
Despite PsA showing no gender bias, RA is far more common in women than men 
with the female to male ratio being 3:1 [3]. Gender differences may also play a 
role in the disease activity as women with RA have been found to have worse 26 
disease activity compared to men with RA [69]. The higher incidence of RA in 
women  had  led  many  studies  to  analyse  whether or  not  there  is  a  hormonal 
influence  on  disease  risk.  Studies  on  hormone  levels  are  often  difficult  as 
treatment for the disease or often the disease itself can affect hormone levels 
and reports on pre-disease hormone levels are not often available. One study 
found that serum testosterone levels were lower in males with RA compared to 
healthy controls which is supportive of the hypothesis that male sex hormones 
could protect against RA [70]. RA frequently goes into remission in women during 
pregnancy [71] but will flare up again during breastfeeding [72] which is thought 
to be due to the major hormonal fluctuations taking place. Further studies into 
the use of the oral contraceptive pill (OCP) in women has found that current or 
ever-use of OCP has a protective effect against RA development although it has 
not been determined whether OCP postpones rather than prevents the onset of 
RA [73]. 
1.1.4.3   Environmental and lifestyle factors  
Both  environmental  and  lifestyle  factors  are  influences  that  have  long  been 
considered as potential triggers for the pathogenesis of RA and PsA. 
1.1.4.3.1  Infectious agents 
A potential involvement of infectious agents in the occurrence of RA and PsA has 
been speculated as it is thought that such agents could trigger the development 
of disease in a genetically susceptible host. The identification of bacterial DNA 
in  the  RA  synovium  has  fuelled  this  hypothesis  as  investigations  have 
demonstrated the presence of Mycobacterium [74] and mycoplasma [75] DNA. 
However, the bacterial species identified frequently have an equal occurrence in 
control populations therefore the pathogenic role for these bacteria remain to 
be identified. 
Bacterial infections have also been suggested to have a pathogenic role in PsA as 
there  have  been  reports  of  increased  immunoreactivity  in  the  sera  of  PsA 
patients  to  some  streptococcal  antigens  which  is  not  seen  in  RA  patients  or 
psoriasis patients without arthritis [76]. However, it is difficult to prove a solely 
pathogenic role for such antigens since secondary infections of psoriatic plaques 
are  common.  Anti-enterobacterial  antibodies  have  also  been  detected  in  the 27 
sera of PsA patients at a significantly higher level compared to psoriatic patients 
or healthy controls [77] although the significance of this is yet to be established. 
Interest  into  the  role  of  viral  infection  in  the  initiation  and  propagation  of 
inflammation  in  inflammatory  arthritis  has  been  stimulated  through  several 
observations  such  as  acute  viral  infections  are  occasionally  followed  by  the 
development of an acute polyarthritis similar to early RA. Proposed viral triggers 
associated  with  RA  include  parovirus  B19,  retroviruses,  and  herpes  viruses 
including Epstein-Barr virus (EBV) [78]. EBV was initially proposed as a potential 
factor involved in arthritis by the presence of anti-EBV antibodies in the sera of 
affected  patients  [78].  Subsequent  research  has  since  aimed  to  address  the 
possible role of EBV in RA, Takeda et al found evidence of EBV infection in 47% 
of  RA  synovial  samples  but  none  of  the  30  OA  controls  [79].  However,  two 
following studies by Blaschke et al [80] and Niedobitek et al [81] did not find 
such a high proportion of EBV within the RA synovium (8% and 18% respectively). 
Consequently, since its expression is highly variable in RA synovium it is unlikely 
that EBV plays a primary role in this disease. Hepatitis C infection has been put 
forward as a trigger for PsA since levels of the virus are found at significantly 
higher levels in the sera of PsA patients compared to that of healthy controls 
[82] but once again the role of this virus within disease pathogenesis is unknown.  
Consequently, there has been no conclusive evidence to date which has clearly 
defined the role of any infectious agent in RA or PsA. The persistent expression 
in joint tissue of any one particular pathogen has not been demonstrated but 
interestingly a study analysing the synovial tissue of a variety of inflammatory 
arthritis patients demonstrated that several samples were positive for two or 
more  viral  species  at  the  same  time  [83].  Therefore,  multiple  different 
infections may be needed in order to drive arthritis pathogenesis. 
1.1.4.3.2  Smoking 
Cigarette  smoking  has  been  demonstrated  to  significantly  increase  the  risk, 
severity and outcome of RA in men and women [84, 85]. Smoking is associated 
with a thirteen fold increase in the incidence of the disease and can induce long 
term susceptibility as individuals who have ceased smoking for greater than ten 
years remain twice as likely to develop RA as the general population [86]. 28 
Cigarette  smoking  supports  the  process  of  citrullination  which  is  the  post-
translational  modification  of  the  amino  acid  arginine  within  a  protein  to  the 
amino acid citrulline. This process is catalysed by the enzyme peptidylarginine 
deaminase  4  (PADI4).  Citrullinated  proteins  such  as  fibronectin,  fibrin,  α-
enolase, fibronectin and type-II collagen have been detected in the RA synovium 
and have been demonstrated to be targets of the autoantibody response  [87, 
88]. These anti-citrullinated protein antibodies (ACPAs) have been identified in 
over 90% of RA patients and correlate with disease activity [89]. Citrullinated 
proteins have been suggested to play a pathogenic role by modifying self peptide 
which may then drive an immune response [90]. There is a strong association  
between smoking and the generation of ACPAs in patients with HLA-DRB1 alleles 
demonstrating how genetic and environmental factors may interact to drive RA 
pathology [47]. 
1.1.5 Histopathology 
The  normal  synovium  covers  the  inner  surface  of  the  joints  and  is  relatively 
acellular consisting of 0.5-5 mm thickness. It comprises of a thin intimal layer of 
predominantly  fibroblasts  and  macrophages  and  a  thicker  sublining  layer 
connective tissue layer. Within the joint, a protective smooth layer of cartilage 
acts as a shock absorber and provides a low friction surface to allow the bones to 
gently move over each other. This is lubricated by synovial fluid which within a 
non-diseased joint is relatively acellular with mean counts of 35 cells/μl [91]. 
The synovial fluid also provides nutrients to the chrondrocyte cells within the 
joint cartilage as the cartilage lacks blood vessels.  
During  the  progression  of  chronic  arthritis,  the  synovium  evolves  from  a 
protective structure to an invasive tissue that is characterised by inflammatory 
cell infiltration into the synovial membrane (synovitis) which drives the typical 
symptoms of joint pain and stiffness. In RA, the intimal lining layer thickens to 
over 8 cells deep and in PsA this thickening is 2-3 cells deep [92]. In addition, 
the  synovial  fluid expands abnormally  acquiring  between  10-1000  cell/µl  [93] 
consisting of polymorphonuclear cells as well as monocytes, T cells, DCs, B cells 
and NK cells. 29 
Radiographic examinations reveal a loss of joint space and the destruction of 
underlying  cartilage  and  bone  which  is  caused,  in  part,  by  the  release  of 
proteolytic enzymes from macrophages and fibroblasts. MMP-1, MMP-3 and TIMP-
1 mRNA have been detected at similar levels in the synovium of both RA and PsA 
[94]. Moreover, the activation of bone-resorbing osteoclasts by M-CSF and RANK-
L,  both  of  which  are  up-regulated  by  IL-1  and  TNFα,  is  a  critical  event  for 
progression  of  bone  damage  in  RA  and  PsA  and  levels  of  both  osteoclast 
activating factors are found in both the synovium and peripheral blood of RA and 
PsA patients [95, 96]. In PsA, bony erosions are less common and often appear at 
a  slower  rate  than  in  RA  and  consistent  with  these  findings  the  levels  of 
aggrecans, which are components of the cartilage structure and an indicator of 
damage, are lower in PsA synovial fluid compared to RA synovial fluid [97]. 
This articular destruction is accompanied by pannus formation (intrusion of the 
bone and cartilage by the proliferating synovial membrane) and the infiltration 
of  inflammatory  cells.  The  influx  of  these  cells  can  promote  synovial 
inflammation and damage through the production of chemokines, cytokines and 
proteases which can in turn promote a state of hypoxia and hence pronounced 
angiogenesis.  Angiogenesis  is  a  prominent  feature  of  synovitis  and  is 
fundamental to disease pathology by transmitting oxygen and nutrients to the 
synovium  in  addition to  being  a  means  through  which inflammatory  cells  are 
recruited  to  different  areas  of  the  diseased  tissue.  In  both  RA  and  PsA  pro-
angiogenic factors, such as angiopoetin-1 and -2 and VEGF, are detectable at 
early stages of disease [98, 99] however levels have been found to be higher in 
PsA than RA which may be explained by the significantly increased number of 
blood vessels found in PsA compared to RA [92]. See Figure 1.1 for a comparision 
of an arthritic and normal synovium. 30 
  
Figure 1.1 Comparison of a normal and arthritic synovium 
This illustration demonstrates the presence of inflammatory cell infiltrates characterised by 
macrophages, B cells, T cells and DCs; synovial membrane hyperplasia and cartilage and bone 
destruction. 
 
1.1.6 Immunopathology 
RA  and  PsA  are  both  characterised  by  an  inflammatory  cell  influx  into  the 
diseased joints which drives tissue destruction and inflammation. Consequently, 
in order to elucidate the mechanisms which drive synovitis it is important to 
identify  which  cells  are  present  within  the  synovium  and  how  they  may  be 
contributing to the perpetual inflammatory response.  
See Figure 1.2 for a summary of the interactions between the inflammatory cells 
found within the arthritic joint. 31 
1.1.6.1   The monocyte/macrophage lineage 
Monocytes and macrophages are found at high levels within the synovium of both 
RA and PsA. Circulating monocytes of the peripheral blood also demonstrate an 
increased  level  of  activation  compared  to  healthy  controls.  The  variety  of 
cytokines, chemokines, growth factors and enzymes that are secreted by this 
cell type ensure that they play a central role in the pathogenesis of arthritis. 
Due to this cell type being the focus of this thesis; a full and detailed discussion 
of  monocytes  and  macrophages  will  take  place  in  section  1.2  of  this 
introduction.  
1.1.6.2   Dendritic cells 
Dendritic  cells  (DCs)  arise  from  myeloid  progenitor  cells  and  are  a  highly 
phagocytic cell type. DCs are professional antigen presenting cells (APCs) that 
are critical to the cross talk between the innate and adaptive immune response. 
DCs are found in tissues in a inactive form and upon immune activation by TLR 
ligation  or  antigen  uptake  they  downregulate  their  phagocytic  activity  and 
upregluate  their  ability  to  process  and  present  antigen  and  are  subsequently 
directed to lymph nodes via a CCR7 dependent pathway in order to induce to T 
cell  activation  [100].  There  have  been  two  major  subsets  of  DCs  identified, 
myeloid DCs (mDC) and plasmacytoid DCs (pDC). mDCs have a primary function 
of antigen capture and presentation and are capable of producing a wide variety 
of cytokines such as IL-23, IL-18, IL-12p70, IL-15 and TNFα and therefore are 
able to polarise T helper cells depending on the cytokines they secrete. pDCs 
tend to be present in the circulation at a lower frequency than mDCs and upon 
viral infection are a major source of type I interferon synthesis. In RA and PsA 
the  levels  of  circulating  pDCs  are  significantly  reduced  compared  to  healthy 
controls and the levels of mDCs are significantly reduced in RA patients however 
both  mDCs  and  pDCs  are  found  to  be  present  in  the  SF  of  both  RA  and  PsA 
patients [101]. Depletion of pDCs in a murine model of arthritis has been shown 
to enhance the severity of articular pathology suggesting that they may mediate 
an  anti-inflammatory  function  [102]  whereas  mDC  numbers  have  been 
demonstrated  in  RA  patients  to  inversely  correlate  with  disease  activity 
suggesting that they may contribute to RA activity [103]. 32 
1.1.6.3   T cells  
T cells can be divided into two subgroups, CD4
+ and CD8
+. CD4
+ effector T cells 
can  be  divided  into  distinct  subgroups  depending  on  their  cytokine  secretion 
profile. Th1 cells are classified according to the secretion of the cytokines IL-2 
and IFNγ whilst Th2 cells are known to secrete the cytokines IL-4, IL-5 and IL-13. 
In  addition  another  subset  of  T  cells  designated  Th17  has  recently  been 
described due to their secretion of IL-17A in addition to IL-17F and IL-22. There 
is strong evidence which implicates a role for T cells within the pathogenesis of 
RA and PsA, first CD4
+ T cells contribute a large proportion of infiltrating cells 
into the synovium and synovial fluid of RA and PsA. The number of T cells within 
the synovial fluid are similar in both groups of patients [92]. Secondly, the strong 
association of HLA genes to aggressive pathology in RA and PsA may reveal the 
presentation  of  arthritogenic  peptide  to  autoreactive  T  cell  clones  especially 
since T cells can be detected co-localised to MHC II expressing APCs in RA and 
PsA synovium. In addition, T cells have been demonstrated to play a primary role 
in several murine models of arthritis including CIA [104]. 
RA and PsA were thought to be Th1 mediated diseases due to the predominance 
of Th1 cytokines such as IFNγ and IL-12 within the synovium and the detection of 
Th1 CD4
+ IFNγ
+ cells at an elevated ratio compared to Th2 cells [105]. However, 
more  recently,  studies  in  animal  models  have  favoured  a  mechanism  which 
implicates Th17 cells. IL-6 is known to induce the differentiation of Th17 cells 
and studies have demonstrated that IL6
-/- mice are resistant to the development 
of CIA [106]. In addition, the inhibition or overexpression of IL-17 within the 
murine joints suppresses or increases joint inflammation respectively [104, 105]. 
At  present  it  is  not  known  how  well  these  murine  models  represent  human 
disease as although IL-17 is detected within RA synovial fluid [106] Th17 cells are 
present in low numbers within the RA synovium and may only be induced to 
produce IL-17 following cell contact with activated macrophages  [107]. Other 
studies have also demonstrated that the frequency of Th17 within the synovium 
is  low  compared  to  the  frequency  in  patient  blood  and  Th1  cells  are  the 
predominant T cell subtype within the diseased joint [108]. Additionally, IL-17 is 
now known to be secreted by non-CD4
+ T cells such as γδ T cells, NK cells, CD8 
cells, macrophages, neutrophils and most recently mast cells [109-112] therefore 
it  is  unlikely  that  the  observed  phenotype  upon  IL-17  deletion  is  solely 33 
attributable  to  Th17  cells  but  may  be  a  combination  of  different  cellular 
sources.  IL-17  can  induce  the  secretion  of  numerous  effector  molecules, 
including TNFα, IL-23, IL-6, MCP-1 and RANKL from macrophages, fibroblasts and 
chrondrocytes indicating that blockade of IL-17 may be a beneficial therapeutic 
target for RA and PsA [113]. 
CD4
+,CD25
+ regulatory T cells (Tregs) have become a focus of arthritis research 
due to their participation in controlling effector CD4
+ cell function and their 
ability to regulate the autoimmune response through the production of IL-10 and 
TGFβ [114] and via direct cell contact. Treg cells have been identified within the 
peripheral blood and synovial tissue of RA patients but they have been found to 
have a decreased ability to suppress TNFα and IFNγ from effector CD4
+ cells or 
monocytes [115]. Interestingly, this ability to suppress cytokine secretion from 
effector  CD4
+  cells  was  demonstrated  to  be  mediated  through  TNFα,  since 
treatment with the anti-TNFα antibody infliximab was able to restore the Treg 
suppressive capacity.  
In contrast to CD4
+ T cells, CD8
+ T cells or cytotoxic T cells mediate effector 
function by MHC I directed antigen specific killing of target cells and through 
cytokine production, in particular IFNγ and TNFα. Populations of CD8
+ T cells 
have  been  identified  in  both  RA  and  PsA  synovium  [116,  117].  Of  interest, 
studies  have  reported  a  greater  CD8
+  T  cell  enrichment  in  PsA  synovial  fluid 
compared to RA synovial fluid which may be reflecting a more important role for 
CD8
+ T cells in the former compared to the latter [118] however the role of CD8
+ 
T cells in either disease are at present unclear. 
1.1.6.4   B cells 
B  cells  mediate  adaptive  immunity  through  the  secretion  of  antigen-specific 
antibodies which promote pathogen elimination,  but are also able to present 
antigen.  Upon activation  by  antigen presentation, B cells  will  migrate  to  the 
lymph  nodes  or  spleen  where  they  will  differentiate  into  antibody  secreting 
plasma  cells.  The  production  of  auto-antibodies  can  subsequently  induce 
inflammatory  cell  activation  through  the  binding  of  the  antibodies  to  the  Fc 
receptors expressed on leukocytes. 34 
There  is  a  wealth  of  evidence  which  points  to  a  key  role  of  B  cells  within 
arthritis  pathology  including  the  presence  of  germinal  centres  within  the 
synovium  of  both  RA  and  PsA  [119,  120].  These  germinal  centres  are  in  an 
environment  surrounded  by  pro-inflammatory  cytokines  and  self  antigens  and 
therefore  provide  an  ideal  location  for  antigen  presentation,  plasma  cell 
differentiation and auto-antibody production. In addition, the use of the anti-
CD20 monoclonal antibody therapy rituximab has shown clinical benefits in both 
RA and PsA [121, 122]. Of particular importance, it is recognised that B cells may 
be critical in the initiation of RA since autoantibodies against self citrullinated 
proteins,  type II collagen and rheumatoid factor are present in the serum of 
patients  up  to  10  years  before  the  clinical  manifestation  of  disease  [123].  A 
similar finding has yet to be shown in PsA. 
1.1.6.5   Other inflammatory cell types 
Neutrophils and Mast cells 
Neutrophils  are  found  at  a  high  concentration  within  the  synovial  fluid  and 
synovium of RA and PsA with an increased number being detected in the latter 
disease [124]. At present their primary role within disease pathogenesis is not 
known.  However,  neutrophils  are  activated  by  complement  components  and 
cytokines to release a variety of proinflammatory cytokines such as TNFα, BAFF, 
IL-6 and IL-18 and therefore may generally contribute to the pro-inflammatory 
milieu found within the synovium. Mast cells are also detected in the synovial 
fluid  of  both  RA  and  PsA  [125,  126].  Animal  models  of  arthritis  have  been 
contradictory in determining  the  role that  mast cells  play  within the  disease 
[127, 128]. However, as mentioned above, a recent study has demonstrated that 
mast  cells  within  the  synovium  of  RA  patients  express  the  proinflammatory 
cytokine IL-17A [109] and therefore may be playing a pathogenic role within the 
disease  by  secreting  cytokines  into  the  synovium  which  will  activate  other 
inflammatory cells resulting in a positive feedback loop of inflammation. 
Fibroblasts 
Synovial fibroblasts together with synovial macrophages are the two leading cell 
types within the hyperplastic synovial tissue that invades and degrades adjacent 35 
cartilage and bone. Fibroblasts are well established effectors of inflammation 
within arthritis as they are known to produce a wide variety of inflammatory 
mediators such as IL-1, IL-6, TNFα, MCP-1, IL-8 and M-CSF which in turn can 
potentiate  the  influx,  survival  and  activation  of  several  leukocyte  subtypes 
[129]. Synovial fibroblasts are also an important source of MMPs and cathepsins 
which are enzymes that drive the destruction of articular cartilage and bone. In 
addition,  these  cells  produce  high  levels  of  RANKL  in  both  RA  and  PsA  and 
therefore  can  drive  articular  destruction  indirectly  through  the  induction  of 
osteoclasts and hence osteoclastogenesis [130, 131]. 
Osteoclasts and Chrondrocytes 
The articular structure in healthy individuals is maintained in stable equilibrium 
through  maintaining  a  balance  of  both  bone  resorption  and  deposition  and 
collagen  deposition.  Within  the  diseased  synovium  this  balance  is  skewed  in 
favour  of  bone  resorption  and  collagen  removal  which  leads  to  articular 
degradation,  furthermore  in  PsA  patients  aberrant  bone  formation  may  also 
occur.  Osteoclasts  are  multinucleated  cells  which  mediate  bone  resorption 
through the secretion of acid and MMPs, and are differentiated from monocyte 
precursors in the presence of RANKL and M-CSF [132]. Other cytokines within the 
inflammatory milieu can drive osteoclast formation such as TNFα, IL-1β and IL-17 
which induce RANKL expression.  
Chrondrocytes  are  cells  which,  under  normal  conditions,  maintain  a  stable 
equilibrium between the synthesis and degradation of matrix components such 
as  collagen.  However,  in  arthritis  the  chrondrocyte  cell  participates  in  the 
destruction of its own matrix by releasing a variety of MMPs in response to the 
proinflammatory cytokines present within the synovium such as IL-1 and TNFα. 
The  chrondroytes  themselves  can  also  release  pro-inflammatory  mediators  in 
response  to  cytokine  activation  which  can  further  perpetuate  the  chronic 
cartilage destruction in a paracrine and autocrine fashion [133]. Consequently, it 
is  evident  that  the  synovial  environment  within  RA  and  PsA  can  promote 
articular destruction through several mechanisms.  36 
 
Figure 1.2 Inflammatrory cell types within the synovium 
An overview of the cellular communication between immune cells within the RA and PsA inflamed 
joint. Adapted from [132]. 
 
1.1.7 Mechanisms of inflammation 
The numerous inflammatory cells infiltrating the synovial compartment release 
soluble  factors  including  cytokines,  chemokines  and  MMPs  that  are  directly 
responsible for the disease pathology by activating and promoting recruitment of 
further inflammatory cells. A full explanation of the cytokines and chemokines 
expressed by monocytes and macrophages in RA and PsA are discussed fully in 
section 1.2.4 and 1.2.5. 
1.1.7.1   Cytokines 
Cytokines  are  small  (5  to  50  kDa)  proteins  or  glycoproteins  that  serve  as 
chemical  messengers between cells  and  thus  are  of  significant importance in 
almost  all  aspects  of  innate  and  adaptive  immunity.  Cytokine  levels  are 
significantly  upregulated  in  RA  and  PsA  where  they  regulate  the  chronic 37 
inflammatory response. Within the synovium cytokines can work in an autocrine 
fashion and due to the close proximity of cells they can also work in a paracrine 
(neighbouring cell activation) and juxtacrine (cell-to-cell contact) manner. 
In both RA and PsA numerous pro-inflammatory cytokines including TNFα IL-6, IL-
1α/β, IL-17, IL-18, BAFF and IL-23 are elevated in the serum, synovial fluid and 
synovium  [132]  (see  Table  1.4).  The  critical  role  of  cytokines  within  the 
pathogenesis  of  both  RA  and  PsA  is  exemplified  by  the  success  of  specific 
cytokine targeted therapies such as anti-TNFα and anti-IL-6R [134, 135]. Of note, 
anti-inflammatory  cytokines  such  as  IL-10,  IL-1Ra  and  soluble  TNF-receptor 
(sTNFR) are also detectable in the inflamed synovial compartment. However, the 
levels of these are thought to be too low to be biologically active thus providing 
a disequilibrium of pro- and anti-inflammatory cytokines. 38 
Table 1.4 Major cytokines with a role in inflammatory arthritis 
 
Cytokine  Principle Source      Primary Biological Activity 
 
TNFα    Monocytes, macrophages    activates macrophages and  
    Fibroblasts, T cells, DC,    endothelial cells; induces  
    Neutrophils        neutrophil apoptosis; increases 
              ICAM-1, VCAM-1 and E selectin 
              expression 
 
IL-1α/β  Monocytes, macrophages    induces cytokine secretion from 
    DC, B cell, fibroblasts    monocytes and fibroblasts;  
              increase endothelial adhesion  
              molecule expression; osteoclast 
              activation 
 
IL-1Ra   Monocytes        antagonize effects of IL-1α and 
              IL-1β 
 
IL-18    Monocytes, DC, neutrophils  T cell differentiation; NK cell  
activation; activation of 
monocytes and macrophages 
 
IL-6    Fibroblasts, monocytes,    B cell proliferation and antibody 
    macrophages, T cells,    production; T cell proliferation;  
B cells          acute phase response;  
          thrombopoiesis 
 
IL-10    Monocytes, T cells,     decrease DC activation and  
    B cells, DC, epithelial    cytokine release; decrease  
    cells          synovial fibroblast cytokine and 
              MMP release 
 
Type I IFN  Widespread        antiviral response; macrophage 
              activation; lymphocyte activation 
              and survival 
 
IL-17    T cells, macrophages,    induces proinflammatory cytokine 
    DC and γδ T cells      release from macrophages;  
              fibroblasts and endothelial cells 
 
IL-15    T cells, monocytes,     increased T cell and NK cell  
    macrophages, DC      recruitment, B cell 
differentiation, synovial 
fibroblast and macrophage  
activation 
 
IL-23    monocytes, DC,      Th17 cell proliferation 
    macrophages 
 
RANKL   stromal cells, osteoblasts,   stimulates osteoclast mediated 
    T cells          bone resorption 39 
 
Table 1.4 continued 
 
APRIL   monocytes, macrophages,   promotes T and B cell survival 
    lymphocytes       and proliferation 
 
BAFF    T cells, monocytes,     Promotes B cell survival and 
    macrophages, DC      maturation 
 
GM-CSF  Monocytes, fibroblasts,    Stimulates the differentiation 
    T cells, osteoclasts     and survival of macrophages 
              and neutrophils 
 
M-CSF   Lymphocytes, fibroblasts,   regulator of monocyte 
    monocytes and osteoclasts    differentiation and proliferation 
              and of macrophage survival 
 
 
1.1.7.2   Chemokines 
The influx of inflammatory cells into the synovium is mediated by chemokines 
which  are  small  molecular  weight  (8-12  kDa)  chemoattractant  proteins  that 
primarily  promote  leukocyte  recruitment  and  activation.  Over  50  distinct 
chemokines have been identified and can be classified into four sub-families: 1) 
CXC which can promote angiogenesis, 2) CC which act primarily on monocytes 
and  T  cells,  3)  C  and  4)  CX3C  which  consists  of  the  chemokine  fractalkine 
(CX3CL1) [136]. A number of pro-inflammatory chemokines have been detected 
at elevated levels in both RA and PsA (see Table 1.5). 40 
Table 1.5 Chemokines with a role in inflammatory arthritis 
 
Chemokine ligand  Receptor (s)  Primary source    Physiological  
                  Feature 
 
CC Family 
CCL2 (MCP-1)    CCR2    Fibroblasts, macrophages,  Inflammation, 
Osteoclasts  osteoclast 
differentiation 
 
CCL3 (MIP-1α)   CCR1, CCR5  Macrophages, fibroblasts  Inflammation 
 
CCL4 (MIP-1β)   CCR5    Monocytes, DCs    Inflammation 
 
CCL5 (RANTES)  CCR3, CCR5  T cells, macrophages,    Inflammation 
      CCR1    Fibroblasts 
 
CCL19 (ECL)    CCR7    Macrophages,      Homeostatic,   
          neutrophils      Inflammatory 
 
CCL20 (MIP-3-α)  CCR6    macrophages,     Inflammation, 
          Fibroblasts      bone resorption 
 
CCL21 (SLC)    CCR7    endothelial cells    Inflammation, 
                  Lymphoid neogenesis 
 
C Family 
XCL1 (lymphotactin)  XCR1    mast cells, activated   Inflammation, 
          CD8
+, NK cells     stimulates T cell  
Accumulation 
 
CXC Family 
CXCL1 (gro-alpha)  CXC2R,    Fibroblasts      Inflammation,  
CXCR1           synovial angiogenesis 
 
CXCL5 (ENA-78)  CXCR2   Fibroblasts      Inflammation 
 
CXCL8 (IL-8)    CXCR1,    Macrophages,     Inflammation, 
      CXCR2   fibroblasts, epithelial   synovial angiogenesis 
          cells 
 
CXCL9 (Mig)    CXCR3   macrophages,     Inflammation, 
          Neutrophils      angiostatic 
 
CXCL10 (IP-10)  CXCR3   Fibroblasts, monocytes,  Inflammation, 
          DCs, epithelial cells,    agiostatic 
          Endothelial cells 
 
CX3C Family 
CXC3CL1 (fractalkine) CXC3CR1  Monocytes, fibroblasts,  Inflammation 
          Macrophages, DC 
          Endothelial cells 
 
MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; RANTES, 
regulated on activation normal T cell expressed and secreted; ECL, Epstein-Barr virus-induced 
receptor ligand; SLC, secondary lymphoid  tissue chemokine; ENA, epithelial-derived neutrophil-
activating peptide; MIG, monokine induced by gamma interferon; IP-10, interferon gamma-
induced protein 10kDa. 41 
1.1.8 Current therapies in RA and PsA 
Advances in the knowledge of the mechanisms driving RA and PsA pathology have 
enabled the discovery of new therapeutics. In recent years the purpose of new 
therapeutics has altered from that of simply inhibiting disease progression to the 
ability to prevent the initial onset of disease. 
1.1.8.1   DMARDS 
Disease  modifying  anti-rheumatic  drugs  (DMARDs)  particularly  methotrexate 
have been widely used for the treatment of RA and PsA for decades. Despite 
reports of methotrexate treatment reducing the synovial sublining layer within 
PsA patients [137] it has been increasingly recognised that methotrexate only 
partially inhibits the progression of structural damage in RA [138]. In addition, a 
2-year  retrospective  study  of  matched  PsA  patients  either  on  or  off 
methotrexate  therapy  did  not  show  any  difference  in  radiologic  progression 
scores between the two groups [139]. Furthermore, up to 60% of RA patients 
have reported adverse reactions to methotrexate including nausea, diarrhoea, 
headaches,  hepatitis  and  leukopenia  which  have  only  resolved  with 
discontinuation  of  therapy  [140].  As  a  result  methotrexate  does  not  exert 
therapeutic benefits in a large proportion of patients and may only delay the 
progression  of  disease.  Other  DMARDs  in  use  are  sulfasalazine,  cyclosporine, 
leflunomide and hydroxychloroquine which all demonstrate some clinical benefit 
in a percentage of patients but as with methotrexate are often associated with 
toxicitiy and restricted duration of effectiveness. 
1.1.8.2   Anti-TNFα 
TNFα is a potent pro-inflammatory cytokine that is known to play a critical role 
in  chronic  inflammatory  diseases  such  as  RA  and  PsA  [141].  Soluble  TNFα  is 
produced as a precursor form called transmembrane TNFα (tmTNFα) which is a 
cell surface protein found on activated macrophages and lymphocytes [142]. This 
tmTNFα is cleaved and processed by TNFα-converting enzyme (TACE) to release 
a soluble 17 kDa molecule. The combination of three of these 17 kDa molecules 
as  a  homotrimer  forms  soluble  TNFα,  which  mediates  its  pro-inflammatory 
properties  through  type  1  and  2  TNF  receptors  (TNFR1  and  TNFR2)  [143]. 
Numerous studies have indicated that both soluble TNFα and its precursor form 42 
tmTNFα are involved in the inflammatory response through binding to TNFR1 or 
TNFR2.  Soluble  TNFα  can  act  at  sites  distant  from  the  TNFα-producing  cells 
whereas tmTNFα can exert its function on other cells through direct cell contact 
[144]. 
At  present  there  are  three  anti-TNFα  agents,  infliximab,  etanercept  and 
adalimumab,  which  are  approved  worldwide  for  the  treatment  of  various 
inflammatory  conditions  including  RA,  PsA,  psoriasis,  Crohn‘s  disease  and  AS 
[135]. In addition, other anti-TNFα agents, certolizumab pegol and golimumab, 
have just been approved for clinical use. Infliximab, adalimumab and golimumab 
are  monoclonal  antibodies  against  human  TNFα  and  etanercept  is  engineered 
from human TNF receptors. Adalimumab, infliximab and entanercept all bind to 
soluble or tmTNFα with a similar affinity [145].  
Adalimumab has been demonstrated to have a high level of tissue penetration in 
RA patients as radioscintography demonstrated that labelled adalimumab rapidly 
(within minutes) localised to the inflamed joints after intravenous administration 
[146] and tissue concentrations of the antibody in the synovial fluid range from 
31% to 96% of those in the serum [147]. Greater than two thirds of RA patients 
respond favourably to TNFα inhibitors and administration of adalimumab to RA 
patients has been shown to significantly slow the radiological progression after 
one  year  [148].  PsA  patients  treated  with  adalimumab  over  48  weeks  show 
reduced radiographic progression, reduced disability and improved skin and joint 
manifestations  [149]  therefore this anti-TNFα treatment have proved to be a 
highly effective treatment for the management of inflammatory arthritis. The 
antibody‘s mechanisms of action within the diseased patients include binding 
and hence neutralising soluble TNFα. 
Infliximab  is  a  similar  therapy  to  adalimumab  as  it  is  a  monoclonal  antibody 
against human TNFα. A phase III study of infliximab in 200 PsA patients showed 
significant  benefit  since  at  week  14,  58%  of  patients  achieved  an  ACR20 
response. The presence of dactylitis and enthesitis decreased significantly and 
quality  of  life  measures  also  significantly  improved  [150].  Within  RA  patients 
infliximab has proven to be highly efficacious with ACR20 and ACR50 responses 
of up to 80% and 60% respectively [151]. Etanercept is a soluble receptor for 
TNFα and has been demonstrated to be successful in the treatment of PsA and 43 
RA. In a phase III trial of 205 PsA patients an ACR20 response was achieved by 
59% of etanercept treated patients and psoriatic skin involvement significantly 
decreased  after  24  weeks  of  treatment  [152].  Furthermore,  the  successful 
response of patients to treatment from any of these three anti-TNFα therapies 
are significantly increased when administered in combination with methotrexate 
with which it has synergistic benefits [151, 153, 154]. 
Since  TNFα  can  act  independently,  additively  or  synergistically  within  the 
arthritic  joint  its  neutralisation  can  reduce  the  production  of  other  pro-
inflammatory molecules such as IL-6, IL-1β and MCP-1 from immune cells as well 
as reducing the expression of ICAM-1 and VCAM-1 adhesion molecules which can 
prevent  cell  trafficking  into  the  joint  and  is  the  reason  for  the  reduced 
cellularity seen the inflamed tissue after anti-TNFα therapy [135]. 
1.1.8.3   Rituximab and B cell targeted therapies 
Rituximab is a chimeric human/mouse monoclonal antibody directed at the CD20 
antigen  expressed  by  mature  B  cells  and  pre-B  cells  but  not  on  other  cells 
including  plasma  cells.  It  was  first  used  as  a  treatment  for  non-Hodgkin‘s 
lymphoma but has since been approved for treatment of RA. Although several 
studies have suggested that CD20 may function as a calcium channel or a cell 
surface  signalling  receptor,  its  function  and  the  mechanisms  of  action  in  RA 
remains unclear [155]. In the phase III REFLEX trial rituximab was administered 
to 309 RA patients whilst 209 patients received placebo, and it was found that 
rituximab efficacy versus placebo was evident from 8 weeks onwards and the 
retardation of joint damage was significantly different from placebo after 56 
weeks [122]. Rituximab therapy has also been successful in the treatment of PsA 
[121]. 
Several mechanisms for the observed improvements have been suggested such as 
reduced  antibody  production;  reduced  secretion  of  B  cell  derived  pro-
inflammatory cytokines or reduced antigen presentation. Due to the success of 
rituximab  considerable  effort  has  been  expended  into  developing  biologics 
against  BLyS  (B-lymphocyte  stimulator)  also  known  as  BAFF  (B-cell-activating 
factor of the TNF family) and APRIL (a proliferation induced ligand) which are 
TNF  superfamily  members  and  promote  B  cell  survival,  differentiation  and 44 
activation.  Belimumab  is  a  fully  human  monoclonal  antibody  that  specifically 
targets BLyS, the reports of a phase II study of this antibody in RA demonstrated 
a reduction in B cells and rheumatoid factor however the ACR responses were 
low in comparison to those seen with rituximab as only 29% of patients achieved 
an ACR20 response [156]. 
1.1.8.4   Anti IL-6 receptor 
Since  anti-TNFα  therapy  is  ineffective  in  a  proportion  of  patients,  other 
therapies  are  required  to  treat  such  non-responder  patients.  Tocilizumab,  a 
human monoclonal antibody against the IL-6 receptor, has provided encouraging 
results  in  patients  who  have  previously  failed  anti-TNFα  therapy  [134].  In 
addition,  as  has  been  observed  with  anti-TNFα  therapy,  the  optimal  clinical 
responses  are  seen  when  tocilizumab  is  administered  in  combination  with 
methotrexate  [157].  At  present  there  have  been  no  trials  investigating  the 
efficacy of tocilizumab in psoriatic arthritis. 
1.1.8.5   Abatacept 
Abatacept is a recombinant human fusion protein of the extracellular domain of 
the cytotoxic T lymphocyte-associated antigen 4 (CTLA4) linked to the Fc portion 
of human IgG1. Abatacept functions to block T cell activation by binding to the 
CD80/86 receptor on an antigen presenting cell thus blocking the second signal 
activation of the CD28 receptor on the T cell. During clinical trials of RA patients 
abatacept treatment resulted in a high ACR response and it is now approved in 
Europe for treatment of RA [158]. A recent trial has also found that abatacept is 
an efficacious therapy for PsA resulting in significant improvements in patients 
compared to placebo controls [159]. 
1.1.8.6   Other therapies 
Ustekinumab  is  an  IL12/23  inhibitor  and  its  administration  has  demonstrated 
significant  efficacy  in  psoriasis  since  IL-12  and  IL-23  are  over  expressed  in 
psoriasis  plaques.  This  inhibitor  has  also  shown  efficacy  in  preliminary  PsA 
studies by reducing the signs and symptoms of arthritis [160]. 45 
1.2   Monocytes and Macrophages  
1.2.1  Monocyte and macrophage origin 
Leukocytes are a diverse group of cells types which mediate the body‘s immune 
response.  They  have  a  shared  origin  of  hematopoietic  stem  cells  (HSC)  and 
develop  along  divergent  differentiation  pathways  in  response  to  internal  and 
external cues. The mononuclear phagocyte system represents a population of 
leukocytes originating as bone marrow derived myeloid cells [161] and comprises 
of  bone  marrow  monoblasts  and  promonocytes,  peripheral  blood  monocytes, 
tissue macrophages and dendritic cells (DCs). 
Current models propose that blood monocytes originate in vivo from HSC derived 
progenitors  with  myeloid  restricted  differentiation  potential.  Successive 
commitment  steps  include  common  myeloid  progenitors  (CMPs)  and 
macrophage/DC progenitors (MDPs). Each of these differentiation steps involves 
cell fate decisions which subsequently restrict cell development potential [162]. 
MDPs are a subset of proliferating cells in the bone marrow that differentiate 
into both monocytes, which give rise to the macrophage subsets, and common 
DC precursors (CDPs), which give rise to the DC subsets [161]. See Figure 1.3 for 
an overview of monocyte and macrophage differentiation. 46 
 
Figure 1.3 Differentiation of the macrophage/DC progenitor and origin of macrophage and 
DC subsets 
Differentiation of monocytes and macrophages in humans. Hematopetic stem cells (HSC) give rise 
to common myeloid progenitors (CMPs) which can differentiate into macrophage/DC progenitors 
(MDPs) within the bone marrow. The MDPs will then give rise to monocytes which will then 
differentiate into tissue macrophages, alternatively the MDPs will differentiate into common DC 
precursors (CDPs) within the blood. The CDPs will then differentiate into classical DCs (cDC) or 
plasmacytoid DCs (pDC). 
 
1.2.2 Monocytes 
Circulating blood monocytes supply peripheral tissues with macrophage and DC 
precursors  and  within  the  setting  of  infection  contribute  to  immune  defense 
against microbial pathogens. Newly formed monocytes are thought to remain in 
the  bone  marrow  for  less  than  24  hours  before  entering  into  the  peripheral 
blood.  In  humans  and  mice,  monocytes  contribute  4-10%  of  all  circulating 
leukocytes [163] and share some typical morphological features such as irregular 
cell shape, cytoplasmic vesicles and high cytoplasm to nucleus ratio.  47 
1.2.2.1   Monocyte subsets 
In humans, circulating monocytes are not a homeogenous population and can be 
divided  into  two  distinct  subsets  on  the  basis  of  the  expression  of  CD14,  a 
component of the LPS receptor complex, and CD16 the FcγRIII immunoglobulin 
receptor [164]. These subsets are designated CD14
+CD16
-, otherwise known as 
CD14
+ monocytes, and CD14
lowCD16
+, otherwise called CD16
+ cells [165]. These 
two  monocyte  subsets  express  distinct  chemokine,  immunoglobulin,  adhesion 
and scavenger receptors and have varying levels of cytokine production, antigen 
presentation  and  transendothelial  migration  [166].  See  Table  1.6  for  the 
characteristics of these two monocyte subtypes. 
CD14
+  monocytes  are  large  ~18  μm  in  diameter  and  represent  80-90%  of 
circulating  monocytes,  in  contrast  CD16
+  monocytes  are  smaller  ~14  μm  in 
diameter and constitute ~10% of circulating monocytes [166]. CD14
+ cells express 
high levels of the chemokine CCR2 and low levels of CX3CR1; consequently, their 
phenotype resembles that of mouse Ly6c
+ (Gr1
+) monocytes [161, 165] whereas 
CD16
+  cells  resemble  the  phenotype  of  mouse  Ly6c
lo(Gr1
lo)  monocytes.  TLR4 
stimulation of both CD14
+ and CD16
+ monocytes with LPS induced similar levels 
of TNFα mRNA within the two cell types whilst the IL-10 mRNA was low to absent 
in CD16
+ monocytes [167]. In addition, intracellular cytokine staining of CD14
+ 
and  CD16
+  monocytes  demonstrated  a  higher  level  of  TNF  protein  within  the 
CD16
+ in response to TLR4 and TLR2 stimulation [168]. This combination of low 
IL-10 levels and high TNF levels meant that CD16
+ monocytes became known as 
pro-inflammatory monocytes. 
Despite  monocytes  being  far  less  efficient  than  DCs  at  MHC  class  II  antigen 
presentation  to  CD4
+  T  cells  [169],  both  CD14
+  and  CD16
+  monocytes 
demonstrated  the  ability  to  present  tetanus  toxin  antigen  to  T  cells  [170]. 
However,  CD16
+  monocytes  have  demonstrated  a  higher  level  of  HLA-DR 
expression  compared  to  CD14
+  monocytes  [164]  and  have  been  shown  to 
preferentially  develop  into  DCs  with  high  antigen  presentation  capacity  in 
response to TLR stimulation [171] suggesting that this monocyte subset and their 
DC progeny may be superior antigen presenting cells. 48 
A third human monocyte subset has been recently reported that is defined by 
the expression  of  CD14
+  CD16
+  and  CD64
+  (FcγR-I)  [172].  These  cells  combine 
characteristics of macrophages and DCs as they have high expression of CD68 
and  HLA-DR  and  high  T  cell  stimulatory  activity.  In  comparison  to  CD14
+ 
monocytes,  CD14
+CD16
+CD64
+  monocytes  have  a  similarly  high  phagocytic 
activity and produce large amounts of cytokines such as TNFα and IL-6. But they 
also share characteristics with CD16
+ monocytes such as a greater stimulatory 
activity in mixed leukocyte reactions (MLR) compared to CD14
+ cells [173]. At 
present the origins of this subset are not know but they are speculated to be an 
intermediate phenotype between monocytes and DCs [172]. 49 
Table 1.6 Characteristics of human monocyte subsets 
 
        CD14
+ (CD14
+CD16
-)     CD16
+ (CD14
lowCD16
+) 
 
Monocyte markers 
CD14          ++          +/— 
CD16          —          + 
CD11b         +          + 
 
Chemokine receptors 
CCR1          +          — 
CCR2          +          — 
CCR4          +/—          — 
CX3CR1        +/—          ++ 
CXCR4         +/—          + 
 
Adhesion molecule 
CD62L         +          — 
 
 
1.2.2.2   Monocyte diapedesis  
A central component of monocyte trafficking is the continuous transition from 
the blood circulation into the tissue and vice versa, as this process enables the 
monocyte cells to differentiate and develop into functional macrophages. The 
endothelium within the vasculature represents the interface between these two 
compartments  and  acts  as  a  barrier  to  leukocyte  trafficking  whilst  also 
instructing leukocyte adhesion and transmigration. Egress of the monocytes from 
the  bone  marrow  into  the  circulation  or  from  the  circulation  into  the  tissue 
requires  migration  across  the  monolayer  of  endothelial  cells  which  line  the 
vascular circulatory system, known as diapedesis. 
Extravasation of monocytes can be divided into several steps and the process 
begins when monocytes accumulate on the luminal side of the endothelium and 
undergo  transient  rolling  interactions  mediated  by  selectins  [163],  which 
facilitates  sensing  of  chemokines  presented  on  the  endothelial  surface  and 
enables  the  monocytes  to  respond  to  them.  This  triggers  the  interaction  of 
monocyte integrin receptors with their endothelial ligands which results in cell 
arrest, these molecules include junctional adhesion molecule-like (JAML) which 
has been demonstrated to contribute to monocyte adhesion and transmigration 
in vitro [174]. Once the cells have arrested on the endothelium they undergo 
actin polarisation and integrin-dependent lateral migration. This process is to 
allow  the  monocytes  to  search  for  sites  permissive  for  endothelial  barrier 50 
penetration [175] and once a site has been found the monocytes breach and 
transmigrate  across  the  endothelium.  The  movement  across  the  endothelium 
may  either  be  paracellular  where  the  monocytes  move  in  between  two 
endothelial cells or transcellular where the monocytes pass directly through an 
individual endothelial cell through the formation of a transcellular pore [176]. 
As mentioned previously, CD14
+ cells preferentially express the chemokine CCR2 
which allows monocyte intravasation into the circulation from the bone marrow 
through interaction with its ligands CCL2 (otherwise known as MCP-1) and CCL7 
[177].  This  finding  is  further  exemplified  in  CCR2
-/-  mice  which  express  a 
diminished  number  of  Ly6C
+  mouse  monocytes  in  the  circulation  under 
homeostatic  conditions  [178]  demonstrating  that  the  exit  of  CD14
+  or  Ly6C
+ 
monocytes from the bone marrow is mediated in part by CCR2. Inflammation is 
associated  with  an  increase  in  CCL2  within  the  circulation  therefore  in  the 
presence  of  a  local  inflammatory  stimulus,  circulating  CD14
+  monocytes 
extravasate  into  the  affected  non-lymphoid  areas  in  a  CCR2-CCL2  dependent 
manner where they differentiate into macrophage or DC subsets  [179]. These 
and many other studies has resulted in the human CD14
+ cells and the equivalent 
mouse Ly6C
+ cells becoming known as the ―inflammatory‖ subset. 
In contrast, CD16
+ monocytes lack CCR2 expression and undergo transendothelial 
migration through the expression of CX3CR1, which is the fractalkine receptor, 
and  CCR5  which  is  the  receptor  for  CCL3  (otherwise  known  as  MIP1α)  [163]. 
Studies performed by Auffray et al have demonstrated that the Ly6C
- subset of 
murine  monocytes,  which  are  equivalent  to  the  CD16
+  human  monocytes, 
continuously  migrate  over  the  luminal  surface  of  dermal  and  mesenteric 
microvascular endothelium where they are thought to be patrolling for signs of 
infection or tissue damage [180]. This patrolling behaviour was dependent on the 
integrin ICAM-1 and the chemokine receptor CX3XR1 and is responsible for this 
cell subset becoming known as ―resident‖ monocytes. Upon tissue damage such 
as  exposure  to  irritants,  aseptic  wounding  or  peritoneal  infection  these 
patrolling resident monocytes extravasated rapidly within 1 hour and invaded 
the  surrounding  tissue  where  they  were  the  main  producers  of  the  pro-
inflammatory  cytokines  TNFα  and  IL-1  and  were  shown  to  differentiate  into 
macrophages. The Ly6C
+ cells were shown to enter the immune site at a later 
time  and  differentiated  into  inflammatory  DCs.  These  results  elegantly 51 
demonstrated  the  functions  of  the  two  monocyte  subsets  within  an  immune 
response [180]. Since human CD16
+ monocytes share a phenotype similar to the 
resident  Ly6C
-  mouse  monocytes  these  cells  could  have  a  similar  patrolling 
function within human immune system surveillance. 
1.2.2.3   Monocyte function in immune defense  
Monocytes  were  previously  considered  to  be  merely  a  developmental 
intermediate  between  bone  marrow  precursors  and  tissue  macrophages. 
However, it is now clear that monocytes can carry out specific effector functions 
during inflammation. Monocytes have been demonstrated to be crucial for host 
defense  again  a  wide  variety  of  pathogens  such  as  Listeria  monocytogenes, 
Mycobacterium tuberculosis, toxoplasma gondii and various fungi. CCR2
-/- mice 
are susceptible to infections caused by all of the above bacteria/fungi indicating 
that CCR2 mediated recruitment of Ly6C
+ monocytes is crucial for host immune 
defense [166]. This result is verified by experiments performed in MCP-1
-/- mice 
which are also more susceptible to bacterial infections such as L. monocytogens 
infection, MCP-1 is a ligand for CCR2 and is released during infection [181] and 
therefore plays a role in monocyte trafficking. Once at the site of infection it 
has been shown that monocytes produce reactive nitrogen intermediates (RNIs) 
and  reactive  oxygen  intermediates  (ROIs)  and  increase  the  production  of 
phagolysosomal enzymes in order to destroy the bacteria and bring the infection 
to an end [182]. 
1.2.3  Macrophages 
The term ―macrophage‖ was first used over 100 years ago by Elie Metchnikoff to 
describe the large mononuclear phagocytic cells he observed in tissues  [183]. 
Since  this  first  observation  an enormous  amount  of  research  to  establish  the 
function and importance of this cell type has taken place. It is now known that 
macrophages,  along  with  DCs,  form  networks  of  phagocytic  cells  throughout 
most tissues where they play major roles in host development, inflammation, 
scavenging and antipathogen defences.  Most  macrophages in the  tissue  of  an 
adult are derived from circulating monocytes which replenish these populations 
and there is  substantial  debate  about  whether  specific  monocyte  populations 
develop  into  specific  tissue  macrophage  subsets  [184].  In  addition,  some 
macrophages  such  as  those  found  within  the  lung  and  brain,  undergo  self-52 
renewal and proliferation and do not need circulating precursor monocytes to 
maintain their population [185].  
1.2.3.1   Macrophage heterogeneity 
Macrophages are distributed constitutively throughout the body and known to 
have  a  very  high  degree  of  heterogeneity  which  reflects  the  specialized 
functions adopted by these cells in different tissue localisations. Apart from the 
inflammatory monocyte derived macrophages which will be discussed in detail in 
section  1.2.3.3  there  are  several  other  macrophage  types  that  have  been 
identified. Examples of these cell types include: Langerhan cells which are a 
self-renewing subset found within the epidermis [186]; the bone re-modelling 
osteoclasts  which  require  M-CSF  and  RANKL  for  development  [187,  188]; 
microglia  and  choroid-plexus  macrophages  which  reside  within  the  CNS;  and 
Kupffer cells which are the resident macrophages of the liver and are involved in 
the clearance of particulate and soluble substances. 
1.2.3.2   Macrophage function 
The  heterogeneous  nature  of  the  macrophage,  its  diverse  distribution  and 
numerous  cell  subsets  indicate  that  it  has  several  physiological  functions. 
However,  there  are  two  main  function  shared  by  most  macrophage  subsets; 
phagocytosis and antigen presentation. 
1.2.3.2.1  Phagocytosis  
Macrophages represent a major defense against invasion of the host by a wide 
variety  of  microorganisms  including  bacteria,  viruses,  fungi  and  protozoa. 
Macrophages also play a role in the clearance of apoptotic cells and the process 
by which they carry out these two important functions is phagocytosis. Apoptosis 
is a feature that is conserved through all eukaryotic cells and constitutes a series 
of  cellular  events  through  which  the  cells  orchestrate  their  own  demise.  A 
critical feature of apoptosis is the ability of the apoptotic cell to be recognised 
by the innate immune system and phagocytes. One of the most studied apoptotic 
signals is the change in the plasma membrane phospholipid distribution on the 
apoptotic cell, especially the exposure of the phospholipid phosphatidylserine 
(PS). PS is normally found in the inner leaflet of the plasma membrane of viable 
cells. However during apoptosis PS is exposed on the outer membrane of the cell 53 
and is a marking of an apoptotic cell. It has been proposed that PS exposure is a 
sufficient  signal  for  macrophage-mediated  phagocytosis  [189].  Macrophages 
appear to use several receptors in the recognition and phagocytosis of apoptotic 
cells  such  as  PS-R,  CD36  and  CD14  [190]  which  is  thought  to  maintain  the 
efficient clearance of apoptotic bodies as different receptors may engage with 
different phases of apoptosis. CD14-dependent clearance of apoptotic cells by 
macrophages has been demonstrated in both murine and human systems [190, 
191] and it has been shown to interact specifically with ICAM-3, a glycosylated 
leukocyte protein, during the clearance of apoptotic leukocytes [192].  
Macrophages also have specialised surface receptors that detect the presence of 
microorganisms before phagocytosis takes place. These receptors can directly 
interact with the microorganism through the recognition of pathogen associated 
molecules  such  as  surface  carbohydrates,  peptidoglycans  or  lipoproteins.  The 
macrophage  can  also  recognise  the  pathogen  through  opsonins.  Opsonins  are 
host factors such as IgG and components of the complement cascade that attach 
to the pathogen surface. These opsonins are then recognised by receptors on the 
macrophage  such  as  Fcγ  receptors  (FcγR)  and  complement  receptor  3  (CR3) 
[193].  
Once the macrophage has recognised the apoptotic cell or the microorganism it 
will engulf the cell or pathogen by advancing pseudopodia over the regions of 
the  cell/microorganism  that  are  linked  to  the  cell  surface  receptors.  This 
internalisation requires reorganisation of the macrophage cyotoskeleton as well 
as  delivery  of  membrane  to  accompany  the  increased  surface  area  of  the 
phagocytic cup which engulfs and surrounds the apoptotic cell/microorganism. A 
process  called  phagosome  maturation  then  takes  place  inside  the  phagocytic 
macrophage  by  which  the  phagosome  undergoes  sequential  fusion  with  early 
endosomes,  late  endosomes  and  lysosomes  which  are  increasingly  acidified 
membrane  bound  structures  [194].  The  fusion  of  these  structures  to  the 
phagosome eventually leads to degradation of the phagocytosed pathogens or 
cells. Although most pathogens are phagocytosed and destroyed with ease by the 
macrophages, certain pathogens have developed mechanisms through which they 
avoid  phagocytosis  such  as  M.  Tuberculosis  which  inhibits  phagosomal 
maturation and L.pneumophila which can redirect the phagosomal maturation 
pathway in order to allow bacterial replication [193]. 54 
1.2.3.2.2  Antigen processing and presentation 
Macrophages are one of several antigen presenting cells (APCs) which present 
antigen to T cells or to B cells within follicles of the lymph node [195]. Indeed 
one of the important functions of the macrophage is to assist in initiating and 
facilitating  cell-mediated  immune  responses  against  pathogens  through  the 
processes of secreting cytokines and inflammatory mediators as well as antigen 
presentation.  As  professional  phagocytes,  macrophages  express  a  variety  of 
receptors that participate in the phagocytic uptake of antigens including those 
which  recognise  complement  activation  products  or  Ig  Fc  fragments. 
Macrophages express both MHC class I and class II molecules and therefore are 
able  to  present  antigen  derived  from  cytosolic  or  extracellular  proteins  for 
recognition by the appropriate CD8
+ (MHC class II expressing) or CD4
+ (MHC class 
I  expressing)  restricted  antigen  specific  T  cells.  In  addition  macrophages  can 
deliver  the  second  co-stimulation  signal  required  by  the  T  cell  to  enhance 
cellular  adhesion and  signalling  and promote  maximal cross-talk  between  the 
macrophage  and  the  T  cell.  These  signals  include  CD80/86  and  CD40  which 
interact with CD28 and CD154 respectively on the T cells [196]. The process of 
antigen  presentation  amplifies  the  inflammatory  signal  through  subsequent  T 
cell cytokine production and clonal expansion. 
1.2.3.3   Macrophage activation  
Macrophages  are  an  extremely  heterogenous  cell  type  and  as  a  result  have 
demonstrated  remarkable  plasticity  which  allows  them  to  respond  to 
environmental cues and change their phenotype. These stimuli can be exogenous 
or endogenous and can  be produced by innate immune cells, antigen-specific 
cells or the macrophages themselves. This extensive network of potential stimuli 
can give rise to diverse populations of macrophages with distinct physiology and 
much  work  has  been  devoted  to  phenotyping  and  understanding  these 
macrophage populations. 
One of the first populations of activated macrophages to be described were the 
classically  activated  macrophages  which  designates  the  effector  macrophage 
population  that  are  produced  during  the  process  of  cell-mediated  immune 
responses [197]. The first description of a classically activated macrophage was 
the  result  of  research  performed  in  the  1960s  by  Mackaness  et  al  which 55 
demonstrated  that  the  infection  of  mice  with  Mycobacterium  bovis  bacillus 
Calmette-Guerin (BCG)  or  Listeria  monocytogenes  enhanced  the  antimicrobial 
ability of macrophages in a stimulus dependent but antigen independent manner 
[198].  Since  this  first  observation,  several  studies  have  shown  that  classical 
macrophage activation depends on the pro-inflammatory cytokines produced by 
T helper 1 (Th1) cells and NK cells, in particular TNFα and IFNγ, and microbial 
products [199]. The combination of these two signals resulted in a macrophage 
population which had enhanced microbicidal activity and secreted high levels of 
pro-inflammatory cytokines [200].  
IFNγ can be produced by both innate and adaptive immune cells. NK cells are an 
early  source  of  this  cytokine  as  they  produce  IFNγ  in  response  to  stress  and 
infection.  This  cytokine  can  prime  macrophages  to  secrete  pro-inflammatory 
cytokines  and  produce  oxygen  and  nitrogen  radicals  to  increase  their  killing 
ability [201]. However this production of IFNγ by NK cells is transient and cannot 
maintain a population of macrophages. Therefore an adaptive immune response 
is  normally  needed  to  sustain  the  activated  macrophages  and  sustain  host 
defense  against  intracellular  pathogens.  In  this  situation  IFNγ  can  also  be 
provided  by  Th1  cells  which  are  antigen  specific  however  the  microbicidal 
macrophages that the IFNγ induces can kill and phagocytose randomly. 
Other  mechanisms  of  classical  macrophage  activation  include  TLR  ligation  by 
bacterial pathogens which, acting in a MyD88-dependent manner, induces the 
transcription of TNFα which will then assist IFNγ and activate the macrophage 
population in an autocrine manner. In addition to this mechanism of activation, 
TLR  ligands  can  also  activate  TIR-domain-containing  adaptor  protein  inducing 
IFNβ (TRIF)-dependent pathways, which signal through IRN-regulatory factor 3 
(IRF3)  and  result  in  IFNβ  production  [202],  this  IFNβ  can  induce  classical 
macrophage  activation  in  place  of  IFNγ  indicating  that  TLR  agonists  can 
overcome the IFNγ dependent classical macrophage activation. 
The role of classically activated macrophages in the host defense to intracellular 
pathogens has been well established. Studies have shown that mice lacking in 
IFNγ expression are more susceptible to various bacterial or viral infections and 
treating  macrophages  with  IFNγ  and  TNFα  before  infection  with  Leishmania 
parasites  results  in  a  population  of  macrophages  which  can  kill  the  parasite. 56 
However the complex combination of genes and cytokines that are expressed 
and produced as a result of classical activation require both the IFNγ receptor 
ligation and either TNFα receptor ligation or TLR ligation. Since stimulation of 
macrophages with IFNγ alone resulted in macrophages that could not clear the 
Leishmania parasite effectively but exogenous treatment with TNFα or a TLR 
ligand restored the macrophage ability to clear the parasite completely [197]. 
In  conclusion,  classically  activated  macrophages  can  be  produced  by  innate 
stimuli  following  a  pathogenic  infection  and  cell-mediated  immune  response. 
This activation usually requires two stimuli consisting of IFNγ and TNF or TLR 
ligation but this can be overcome by certain TLR agonists that can induce TNF 
and IFNβ production from the macrophages which acts in an autocrine manner. 
The resultant macrophages have increased microbicidal activity and can produce 
high  levels  of  pro-inflammatory  cytokines.  The  pro-inflammatory  cytokines 
produced by classically activated macrophages, such as IL-1, IL-6 and IL-23, are 
known to induce the development and expansion of Th17 cells [197, 203] which 
can contribute to numerous inflammatory autoimmune pathologies.  Therefore 
although  classically  activated  macrophages  are  a  fundamental  constituent  of 
host defense, their regulation must be tightly controlled to avoid extensive host 
damage. 
Since  the  identification  of  classically  activated  macrophages  numerous 
investigations  have  demonstrated  that  macrophages  can  also  be  activated  by 
other  stimuli  which  results  in  the  upregulation  of  cell  surface  markers  and 
phenotypic changes that are distinct from those induced by IFNγ. These studies 
analysing different subset of activated macrophages came after reports of the 
macrophage  mannose  receptor,  which  is  expressed  on  resident  macrophages, 
being specifically downregulated by IFNγ but upregulated by the cytokine IL-4 
[204,  205].  It  was  proposed  that  IL-4  induced  an  ―alternative‖  form  of 
macrophage  activation  compared  to  the  classical  activation  and  subsequently 
other workers introduced the term M1 and M2 for classically and alternatively 
activated  macrophages  respectively  to  emulate  the  T  helper  cell  polarisation 
literature  [206].  Further  work  has  demonstrated  that  IL-13  can  also  induce 
alternative macrophage activation [207] by upregulating the mannose receptor 
which is dependent on IL4Rα1 which is the common IL-4 and IL-13 receptor alpha 
chain [208]. 57 
Alternatively  activated  macrophages  are  similar  to  classically  activated 
macrophages as they can develop in response to innate or adaptive signals. IL-4 
is thought to be one of the first cytokines released during tissue injury  [209] 
where one of the main sources of this cytokine are basophils and mast cells. 
However, as has been demonstrated with classically activated macrophages, the 
transient  secretion of  activating  cytokines by  innate  cells  is  not  sufficient  to 
maintain the sustained macrophage activation therefore the adaptive immune 
response  is  necessary  to  develop  and  maintain  an  alternatively  activated 
macrophage  population.  In  contrast  to  the  classically  activated  macrophages 
which  require  a  Th1  immune  response  to  produce  the  cytokines  needed  for 
activation  the  alternatively  activated  macrophages  require  a  Th2  immune 
response.  Th2  immune  responses  are  primarily  induced  in  response  to 
disturbance at mucosal surfaces such as the intestine or the lung but can also be 
induced at non-mucosal surfaces such as in response to helmith infections [210]. 
The main cytokines which are produced by Th2 cells are IL-4 and IL-13 which 
directly  induce  the  alternative  activation  of  macrophages,  however  other 
cytokines  have  also  been  demonstrated  to  indirectly  induce  alternative 
macrophage activation through Th2 cells. IL-33 is one such cytokine and binds to 
it receptor ST2 on Th2 cells which therefore amplifies Th2 cytokine production 
and hence alternative macrophage activation [211]. 
Alternatively  activated  macrophages  act  upon  inflammatory  and  immune 
processes  and  their  main  role  is  to  counteract  pro-inflammatory  and  cellular 
immune  mechanisms  through  regulatory  and  inhibitory  functions.  Treating 
macrophages  in  vitro  with  IL-4  and  IL-13  induces  macrophages  that  fail  to 
present antigen to T cells, produce minimal levels of pro-inflammatory cytokines 
and are much less efficient at producing oxygen and nitrogen radicals and killing 
intracellular pathogens compared to classically activated macrophages [212]. IL-
4 can also stimulate arginase activity in these macrophages which allows them to 
convert arginine to ornithine, since ornithine is a precursor of collagen these 
cells  can  therefore  contribute  to  the  production  of  extracellular  matrix. 
Consequently,  alternatively  activated  macrophages  are  often  referred  to  as 
wound healing macrophages [197].  
Alternatively  activated  macrophages  also  have  a  role  in  parasitic  infections 
where they contribute to the clearance of helmiths by aiding in the expulsion of 58 
the  worms  in  an  arginase-dependent  manner  [213].  Recent  reports  have 
suggested  that  this  protective  effect  mediated  by  alternatively  activated 
macrophages may be due to these macrophages controlling the underlying Th-1 
responses  during  the  helmith  infections  which  if  left  unregulated  would 
contribute  to  pathogenesis  of  the  infection  [210].  Alternatively  activated 
macrophages  can  also  secrete  the  chemokine  CCL22  which  induces  the 
recruitment of Th2 cells into affected tissue to aid in the removal of parasitic 
infection [214]. This macrophage subgroup has also been identified in the lungs 
of  mice  with  experimental  asthma  and  also  in  those  of  humans  with  asthma 
where they are thought to play a role in the recruitment of inflammatory cells 
into the lung through their secretion of the chemokines CCL24 and CCL17. These 
chemokines  recruit  several  cell  types  into  the  lung  including  basophils, 
eosinophils,  mast  cells  and  Th2  cells  which  may  lead  to  excessive  type  2 
inflammation and airway hyperreactivity and therefore contribute to the clinical 
disease pathogenesis [211, 215].  
Previously,  during  the  investigations  into  the  phenotypes  and  subsets  of 
macrophages the term ―alternative activation‖ was used to describe all forms of 
non-classical  activation  of  macrophages.  This  loose  definition  obscured  the 
phenotypic  differences  observed  in  macrophages  which  were  activated  by 
cytokines or factors other than IFNγ in a non-classical manner. Consequently, 
three  subsets  of  the  M2  alternative  activation  were  proposed:    M2a  are 
macrophages activated by IL-4 and IL-13; M2b are macrophages that are induced 
by agonists of TLRs or IL-1 receptors; and M2c macrophages are induced by IL-10 
and glucocorticoid hormones [216]. However, a recent review by David Mosser 
and Justin Edwards proposed a different grouping of macrophage subsets and 
propositioned a new population of macrophages called regulatory macrophages 
[197].  These  regulatory  macrophages  would  appear  to  be  most  like  the  M2c 
subset as they are induced by glucocorticoids, IL-10, apoptotic cells and immune 
complexes  and  have  anti-inflammatory  activity.  Glucocorticoids  are  naturally 
produced hormones which are released by the adrenal gland in response to stress 
and  can  inhibit  macrophage  mediated  host  defense  by  preventing  the 
transcription of genes coding for pro-inflammatory cytokines such as IL-1β and 
TNFα  [217].  Glucocorticoids  can  exert  both  direct  and  indirect  effects  on 
immune responses as glucocorticoid treated APCs either fail to present antigen 59 
to  T cells  or  induce the development  of  regulatory  T cells  which can  inhibit 
immune responses [218] therefore the macrophages induced by glucocorticoids 
are primarily anti-inflammatory.  
The first report of regulatory macrophages was by Gerber and Mosser in 2001 
who demonstrated that following in vitro stimulation with immune complexes 
and the TLR4 agonist LPS, the subsequent macrophage population produced high 
levels  of  the  anti-inflammatory  cytokine  IL-10  [219].  Following  studies 
demonstrated that the same IL-10 producing regulatory macrophages could be 
obtained  by  activating  macrophages  with  various  stimuli  including  IL-10  and 
apoptotic  cells  [197,  220].  Similar  to  the  induction  of  classically  activated 
macrophages, regulatory macrophages require two signals to induce their anti-
inflammatory activity. The first signal of glutocorticoids, immune complexes or 
apoptotic cells for example will generally have little stimulatory function on the 
macrophage however when combined with a second signal, such as a TLR ligand, 
these two signals will induce the macrophages to produce IL-10 which is the 
most reliable characteristic of regulatory macrophages. In addition, regulatory 
macrophages also downregulate IL-12 production [219] therefore the ratio of IL-
10 to IL-12 can be used to define regulatory macrophage populations. Due to the 
ability of IL-10 to downregulate the production of pro-inflammatory, regulatory 
macrophages are effective inhibitors of inflammation although they do maintain 
their  ability  to  produce  pro-inflammatory  cytokines  [197].  Regulatory 
macrophages are unable to contribute to the extracellular matrix which is seen 
in alternatively activated macrophages however they do express high levels of 
the co-stimulatory molecules CD80 and CD86 and as a result can still present 
antigens to T cells [212]. 
In summary, the regulatory macrophages represent a newly defined subset of 
activated  macrophages  that  have  a  predominantly  anti-inflammatory  function 
through  the  production  of  IL-10.  However  several  studies  have  demonstrated 
that incorrect regulation of these macrophage can have deleterious effects on 
the  host  and  regulatory  macrophages  have  been  found  to  play  a  role  in  the 
neoplastic growth of tumours [197]. Tumour associated macrophages have been 
found to have a regulatory phenotype and produce high levels of IL-10 and can 
also contribute to angiogenesis and tumour growth [221]. However, the function 60 
and exact role that these regulatory macrophages play in tumour progression is 
still to be elucidated. 
To conclude, the plasticity of macrophages has made classification of activated 
populations very difficult and there is controversy regarding the phenotype of 
these  populations  as  research  groups  denote  different  identifications  of  the 
macrophage subsets. As demonstrated above the classification of macrophages is 
more  complex  that  an  M1  or  M2  macrophage  because  unlike  T  cells,  which 
undergo major epigenetic modifications during differentiation, macrophages will 
maintain their plasticity and continue to respond to environmental cues [222]. 
Therefore rather than being strict phenotypic characteristics the three subsets 
of  macrophages  discussed  here  represent  a  spectrum  of  activation  and  these 
macrophages will have the ability to change from one subset to another and may 
even display attributes of two subsets depending on the host environment. See 
Figure  1.4  for  a  cartoon  representation  of  the  three  macrophage  population 
which arise as a result of different mechanisms of activation. 61 
 
Figure 1.4 Innate and acquired immune activation of macrophages 
Classically activated macrophages develop in response to the cytokines IFNγ, which can be 
produced during an adaptive immune response by Th1 cells or during an innate immune response 
by NK cells, and TNFα which can be produced by NK cells, Th1 cells or APCs. Alternatively, 
classical macrophage activation can develop as a result of TLR ligation by microbial products. 
Alternatively activated macrophages arise in response to IL-4 and IL-13 which are produced during 
a Th2 adaptive response or during a granulocyte innate response. IL-33 can activate Th2 cells and 
amplify their cytokine production and therefore alternative macrophage activation. Regulatory 
macrophages develop in response to various stimuli including IL-10, apoptotic cells, immune 
complexes and glucocorticoids. Each of these macrophage populations has a different phenotype 
and role within host defense, classically activated macrophages have microbicidal activity whereas 
alternatively activated macrophages have a role in tissue repair and parasite expulsion and 
regulatory macrophages produce high levels of IL-10 to dampen the immune response. The 
development of the macrophage populations shown here are not permanent changes to the cells 
and due to remarkable plasticity of macrophage cells they retain the ability to change from one 
subset to another depending on the environmental stimuli. Adapted from [197]. 62 
1.2.4 Monocytes and macrophages in inflammatory arthritis 
Autoimmune disorders such as PsA and RA are characterised by the obliteration 
of self-tolerance and the appearance of self-reactive lymphocytes. Monocytes 
and macrophages are one of the cell types implicated in the perpetuation of 
arthritic disease and are found in dense populations within the diseased synovial 
membrane. 
1.2.4.1   Blood monocytes in RA and PsA 
Within healthy individuals the circulating blood monocyte population will consist 
of  approximately  90%  CD14
+CD16
-  cells  and  10%  CD14
lowCD16
+  cells  [166].  In 
comparison to the CD14
+CD16
- monocytes, CD14
+CD16
- (CD16
+) monocytes have 
shown  distinct  patterns  of  additional  surface  molecules  such  as  MHC  class  II, 
ICAM-1  and  LFA-1  [164,  223]  and  are  thought  to  bear  resemblance  to  tissue 
macrophages. CD16
+ monocytes are thought to be of pathological significance 
since they are expanded in inflammatory conditions such as asthma  [224] and 
sepsis [225] and have been discovered to be at a higher ratio in the blood of RA 
patients.  The  percentage  of  CD16
+  monocytes  is  significantly  increased  in  RA 
blood  (11-15%)  compared  to  healthy  blood  (9-9.5%)  [226-229]  and  the  RA 
diseased blood monocytes also had increased levels of surface TLR2 compared to 
the  healthy  controls  [227].  CD16
+  cells  produce  larger  amounts  of  TNFα  in 
response to TLR2-specific ligands compared to CD16
- cells [168] suggesting that 
the RA blood monocytes may be more proinflammatory and have higher levels of 
activation compared to those of the healthy controls. 
The expression of CD16 on blood monocytes in RA patients has also been shown 
to be correlated to the disease activity of the patients which also substantiates 
the  hypothesis  that  CD14
+CD16
+  monocytes  in  RA  contribute  to  the  disease 
pathogenesis  [226,  228,  229].  In  addition,  the  plasma  concentrations  of 
cytokines which are known to induce CD16
+ expression such as M-CSF, TGFβ1 and 
IL-10 are increased in RA patients. In addition, to being at an increased level in 
the  blood  of  RA  patients,  CD16
+  monocytes  are  also  overrepresented  in  the 
synovium of patients where they again correlate with disease activity and the 
degree of joint destruction [229]. Moreover, circulating CD16
+ monocytes as well 
as the lining layer in the synovial tissue of RA patients show increased expression 
of CX3CR1 which is the receptor for fractalkine (CX3CL1). CX3CR1 is capable of 63 
mediating leukocyte migration and firm adhesion, and high levels of fractalkine 
have been detected in the serum and synovial fluid of RA patients indicating that 
this receptor – ligand complex may be mediating the migration and recruitment 
of CD16
+ monocytes from the blood into the synovium [230]. 
In addition to the work performed on CD16
+ overexpression within the blood of 
RA patients other studies investigating the function of monocytes in RA have 
further demonstrated their pathogenic role within the disease. For example, RA 
CD14
+  monocytes  have  been  shown  to  inhibit  synovial  T  cell  glucocorticoid  –
mediated apoptosis though the release of soluble factors rather than via direct 
cell  contact.  Therefore  RA  monocytes  could  provide  a  mechanism  for  the 
increased survival of synovial T cells within the disease and may be a mechanism 
for the differences in response to glucocorticoid treatment for RA [231]. 
In  comparison  to  the  RA  literature  there  has  been  little  research  into  the 
presence of an elevated CD16
+ monocyte population in PsA patients. However, a 
very recent study by Chiu et al noted that there was an increased frequency of 
circulating CD14
+CD16
+ monocytes in PsA patients compared to healthy controls 
(0.91%  versus  0.46%  respectively)  [232].  It  had  been  previously  demonstrated 
that circulating monocytes in PsA were able to mature into osteoclasts, which 
are cells that directly absorb bone, without any exogenous stimuli  [233]. The 
results of the current study demonstrate that the osteoclast cells were mainly 
derived from the CD14
+CD16
+ cells in PsA and increased CD16 expression was 
associated with increased bone erosion in PsA [232]. However, this result is in 
direct contrast to those of Komano et al who isolated monocytes from the blood 
of RA patients and illustrated that the CD16
- monocyte subset but not the CD16
+ 
population were able to differentiate into osteoclasts by stimulation of the cells 
with  RANKL  in  combination  with  M-CSF.  In  contrast,  the  CD16
+  monocytes 
expressed  larger  amounts  of  TNFα  and  IL-6  which  were  enhanced  by  RANKL 
stimulation therefore this would suggest that the RA blood monocytes consist of 
two  functionally  distinct  subsets  which  respond  in  alternative  ways  to  RANKL 
stimulation  [234].  The  difference  demonstrated  between  the  ability  of  CD16
+ 
cells to form osteoclasts in PsA but not in RA is at present inexplicable but may 
be due to differences in the monocyte subsets between the two diseases. 
 64 
1.2.4.1.1  Chemokine receptor expression on diseased monocytes 
The majority of cells which form the infiltrate in RA and PsA synovial tissue are 
derived from the circulation and the synovial inflammation seen in both diseases 
is dependent on the infiltration and retention of these inflammatory cells within 
the  joint.  Chemokines  and  their  receptors  play  a  crucial  role  within  these 
processes as they allow the immune cells to chemotax from the blood to the 
synovium  and  the  upregulated  expression  of  chemokine  receptors  is  a 
characteristic of diseased monocytes. The chemokine network represents a large 
group of chemotatic proteins which are structurally related. To date there are 
around 50 chemokines signalling through  20 different receptors which can be 
constitutively expressed on cells or be up- or down-regulated dependent on cell 
activation.  
Arthritic  blood  monocytes  have  previously  been  demonstrated  to  express 
chemokine receptors at a significantly increased level compared to normal blood 
monocytes.  As  mentioned  previously  fractalkine  (CX3CL1)  is  expressed  at  a 
higher level on RA CD16
+ monocytes which is thought to mediate the migration 
of these cells into the diseased joint [230]. An additional study has also found 
that RA PB monocytes express both CCR1, which will bind a variety of ligands 
including  CCL3  and  CCL5,  and  CCR2,  which  binds  with  CCL2,  while  RA  SF 
macrophages  have  upregulated  levels  of  CCR5  and  CCR3.  This  differential 
chemokine  receptor  expression  would  suggest  that  CCR1  and  CCR2  may  be 
involved in monocyte recruitment from the blood and CCR3 and CCR5 may be 
involved in retention of the monocytes within the synovium [235]. In addition, a 
recent paper had revealed the expression of the chemokine receptor CCR9 on RA 
PB monocytes as well as RA synovia, the expression of CCR9‘s only known ligand 
CCL25 was also detected in RA synovia co-localised with CD14
+ monocytes and 
CD68
+ macrophages. CCL25 induced strong chemotaxis of PB monocytes and also 
the differentiation of monocytes into macrophages and therefore this receptor-
ligand complex may play a dual role in the pathogenesis of monocytes in RA by 
inducing their movement into the synovium and promoting their differentiation 
into a destructive macrophage phenotype [236]. 
The  RA  and  PsA  synovium  also  contains  high  levels  of  monocyte  chemotactic 
chemokines including the ligands for the chemokines receptors mentioned above 
which are expressed on PB monocytes such as CCL5 and CCL3 [237, 238] which 65 
will  enable  the  migration  of  blood  monocytes  into  the  synovium  in  order  to 
differentiate  into  pathogenic  macrophages  and  maintain  their  continual 
pathogenic secretion of pro-inflammatory cytokines and chemokines.  
A  recent  interesting  imaging  study  which  investigated  the  migration  of  RA 
monocytes, isolated CD14
+ monocytes from patients and labelled them with a 
radioactive tracer before re-infusing these monocytes back into the patients. 
The patients were imaged and the results determined that a small number of the 
monocytes  had  migrated  into  the  diseased  joints  after  1  hour  and  had  a 
continuous movement into the joint [239]. These results demonstrate the short 
migration time of monocytes from the blood into the synovial compartment and 
reveal the strong migratory potential of these monocytes possibly led in part by 
the  high  levels  of  chemotactic  proteins  expressed  within  both  the  patient 
synovium and serum and the upregulation of adhesion molecules on the surface 
of the cells [230, 240].  
The  proinflammatory  milieu  within  the  serum  of  arthritis  patients  can  also 
induce blood monocytes to produce chemokines and pro-inflammatory cytokines 
therefore the blood monocytes are not only the precursors for the inflammatory 
macrophages seen in the synovium but can also contribute to the inflammatory 
environment themselves.  For example,  a recent study demonstrated that the 
pro-inflammatory molecule osteopontin which is found at increased levels in the 
serum of RA patients induced the expression of the chemokines CCL2 and CCL4 
in CD14
+ monocytes [241]. Monocytes have also been shown to secrete TNFα in 
response to immune complexes found in the serum of arthritis patients  [242] 
indicating  that  these  cells  play  a  role  in  the  elevated  serum  chemokine  and 
cytokine levels observed in RA and PsA.  
1.2.5 Macrophages in RA and PsA 
Once the peripheral blood monocytes have entered the arthritic synovium they 
will  mature  and  develop  into  macrophages  which  express  broad  pro-
inflammatory, remodelling and destructive potential and contribute significantly 
to  the  inflammation  and  joint  destruction  observed  in  RA  and  PsA.  Similar 
numbers  of  CD68
+  macrophage  populations  are  found  within  the  lining  and 
sublining  of  the  synovium  in  RA  and  PsA  [243]  and  upregulated  levels  of 66 
monocytes and macrophages have been found in the synovial fluid of RA and PsA 
patients  [244].  The  importance  of  macrophages  for  the  pathogenesis  of 
inflammatory arthritis has been demonstrated by several studies such as those 
performed by Tak et al who illustrated that the number of synovial macrophages 
correlate with the scores for knee pain and also the levels of TNFα and IL-6 
expression [245]. In addition, the radiographic progression of joint destruction in 
RA  has  been  found  to  correlate  with  the  degree  of  synovial  macrophage 
infiltration [246] which underscores the important role the macrophage plays in 
synovial inflammation.  Furthermore,  an  ex vivo cellular model of rheumatoid 
arthritis  which  was  set  up  using  cultures  of  synovial  tissue  from  RA  patients 
revealed that the spontaneous reconstruction of inflammatory tissue which was 
visualised after 4 weeks of culture could be inhibited by depleting CD14
+ cells  
from the synovial tissue. They suggested that these results imply a critical role 
of  CD14
+  monocytes  and  macrophages  in  the  development  of  the  destructive 
pannus tissue observed in RA [247]. Studies in animal models have also revealed 
the importance of macrophages in arthritis as op/op mice which are deficient in 
the macrophage differentiation cytokine M-CSF fail to develop collagen induced 
arthritis [248]. 
1.2.5.1   Stimulation of macrophage activation in RA and PsA 
The  differentiation  and  activation  of  infiltrating  monocytes  into  pathogenic 
macrophages underlies the systemic inflammation observed in both RA and PsA 
and  is  a  complex  interaction  of  paracrine  mechanisms  through  cell-cell 
interaction as well as the result of soluble stimuli and autocrine mechanisms. 
1.2.5.1.1  Cell-cell interaction 
A  considerable  part  of  macrophage  effector  responses  is  mediated  by  cell 
contact dependent signalling with different inflammatory or mesenchymal cells. 
Due to the large numbers of fibroblasts and macrophages within synovial tissue 
the interaction of these cell types is essential for the resulting tissue damage 
and inflammation.  The direct cell contact of these two cell types elicits the 
production of IL-6, GM-CSF and IL-8 which can be enhanced by the addition of 
other  pro-inflammatory  cytokines  or  inhibited  by  the  addition  of  regulatory 
cytokines or by neutralising CD14 [249].  67 
The interaction between monocytes and endothelial cells in arthritis is necessary 
for the sustained influx of cells into the synovium through the interaction of 
selectin/intergrin  pairs  on  the  surface  of  the  two  cell  types.  The  synovial 
cytokine environment upregulates the expression of these ligand pairs and leads 
to  the  further  influx  and  activation  of  peripheral  blood  monocytes  [250].  In 
addition, cell contact between macrophages and monokine-activated NK cells 
induces  TNFα  production  from  the  macrophages  demonstrating  a  further 
mechanism for macrophage activation [251]. 
A substantial amount of work has been dedicated to analysing the cell contact 
dependent activation of macrophages by T cells which will be discussed in detail 
in section 1.2.5.3. This cell contact activation occurs in the absence of antigen 
but there have also been reports of macrophages acting as APCs within the joint 
and presenting autoantigens such as collagen to T cells [252]. 
1.2.5.1.2  Soluble stimuli 
There are numerous soluble stimuli present in the arthritic joint which are able 
to activate macrophages of these the most notable stimuli are cytokines. Many 
of the cytokines present have a pro-inflammatory effect on the macrophages and 
several of them, such as TNFα, IL-1 and IL-15, are produced by macrophages 
themselves and therefore will activate the macrophages in an autocrine fashion 
and result in a subset of perpetually activated macrophages. T cells within the 
joint can also produce inflammatory cytokines that will affect the macrophage 
population such as IL-17 which has pro-inflammatory and amplifying effects on 
macrophages in RA [113]. In addition to their inflammatory effects, there are 
also  cytokine  stimuli  within  the  joint  which  have  a  regulatory  effect  on  the 
synovial macrophages such as IL-4 and IL-13 which are produced by T cells and 
are involved in the alternative activation of macrophages as discussed previously 
and  also  IL-10  which  is  produced  by  macrophages  themselves  and  may  be  a 
mechanism  of  autocrine  regulation  in  order  to  try  and  reduce  the  chronic 
inflammation taking place. 
An  interesting  study  undertaken  by  Vandooren  et  al  demonstrated  that  the 
synovial fluid from SpA patients which included a subset of PsA patients was able 
to induce the preferential expression of the M2 (alternative activation) markers 
CD163 and CD200R on peripheral blood monocytes in comparison to synovial fluid 68 
from RA patients [253]. Previous studies had also shown an increased number of 
CD163 expressing macrophages in the synovium of SpA patients [254, 255], these 
studies  demonstrate  that  the  local  inflammatory  synovial  environment  is 
different in SpA compared to RA and could be preferentially inducing a more 
wound  healing  alternative  macrophage  phenotype  which  may  be  contributing 
towards maintaining tissue integrity although at present no differences in the 
subsequent destructive processes in SpA and RA have been identified. 
1.2.5.2   Macrophage effector molecules in RA and PsA 
Once  the  blood  monocytes  have  been  differentiated  and  fully  activated  into 
synovial  macrophages  they  start  to  produce  a  number  of  pro-inflammatory 
effector  molecules  that  contribute  to  the  continual  inflammation  and  joint 
destruction  seen  within  the  arthritic  joint.  Subsets  of  these  molecules  are 
outlined below. 
1.2.5.2.1   Chemokines  
As discussed previously chemokine receptor expression play a significant role in 
the infiltration of blood monocytes into the synovium. Once in the arthritic joint 
the differentiated macrophage will upregulate a different profile of chemokine 
receptors  such  as  CCR3  and  CCR5  which  may  be  involved  in  their  retention 
within  the  synovium  [235]  and  in  addition  will  also  secrete  chemokines  in 
response to the pro-inflammatory environment. Synovial macrophages have been 
shown to produce a range of CXC and CC chemokines and will often produce the 
ligands for the chemokine receptors expressed on the diseased blood monocytes 
in order to increase the number of infiltrating monocytes entering the synovium. 
One such chemokine is CXCL16 which is the sole ligand for CXCR6 and is found in 
the RA synovial tissue lining and interstitial macrophage cells. CXCL16 is involved 
in monocyte recruitment into the RA synovial tissue [256]. 
In addition to secreting monocyte chemotactic chemokines synovial macrophages 
also produce chemokines such as CXCL8 (IL-8), CXCL1 (Groα), CXCL7 (CTAP-III) 
and CCL18 (PARC) which are chemotactic for other inflammatory cells such as 
neutrophils and T cells [257, 258]. CCL22 is also secreted by macrophages in RA 
and  PsA  synovium  and  is  thought  to  be  involved  in  the  migration  of  CCR4 
expressing memory T cells to the joint [259]. These secreted chemokines can 69 
become  part  of  autocrine  loops  of  macrophage  activation  as  their  cognate 
receptors  are  often  found  on  the  surface  of  the  macrophages  themselves. 
Furthermore, some of the macrophage-expressed chemokines such as IL-8 are 
powerful promoters of angiogenesis and thus provide a link between macrophage 
activation and the prominent neo-vascularisation of the RA and PsA synovium 
[136]. 
1.2.5.2.2  Cytokines, proteinases and growth factors 
 
TNFα 
In RA and PsA, TNFα is mostly produced by macrophages at the cartilage pannus 
junction  and  in  the  synovial  membrane  [250],  this  cytokine  can  induce  the 
production of adhesion molecules, collagenase and collagen from synovial cells 
and can also act on macrophages in an autocrine manner to produce numerous 
products including IL-6, IL-8, MCP-1 and MIP-1α [258]. Due to its significant pro-
inflammatory capabilities TNFα is of critical importance in the pathogenesis of 
RA  and  PsA  and  neutralisation  of  the  cytokine  through  the  use  of  anti-TNFα 
antibodies is now used as a therapy for both diseases [135, 148, 149]. 
IL-1 
IL-1 is another pro-inflammatory cytokine found within the synovial joint that is 
predominantly secreted by CD14
+ macrophages [260], and synovial fluid levels of 
this cytokine have been found to correlate with joint inflammation [261]. IL-1 
influences proteoglycan synthesis and degradation and hence articular damage 
underscoring the pathogenic effect macrophages and their products can have on 
the chronic nature of arthritis. In addition, the IL-1 type 1 receptor (IL-1R1), 
which mediates IL-1-induced cell activation, is found on numerous cells within 
the synovium of RA patients [262] indicating the pro-inflammatory capacity of IL-
1  within  the  synovium.  The  type  II  receptor  (IL-1R2)  which  does  not  induce 
cellular activation and is therefore anti-inflammatory is found at low levels in 
the arthritic synovium [263]. However, IL-1 receptor antagonist (IL-1RA) which 
blocks  the  action  of  IL-1  by  binding  to  IL-1R1  is  constitutively  expressed  by 
differentiated  macrophages  and  is  produced  at  increased  levels  by  the 
mononuclear  cells  of  RA  patients  compared  to  healthy  controls  [264].  In 
addition, IL-1RA levels in the sera of PsA patients correlate with the number of 
swollen  joints  [265].  These  findings  may  help  to  explain  why  therapeutic 
application  of  IL-1RA  (anakinra)  appears  to  be  only  modestly  effective  in  RA 70 
[266] and PsA [267] despite being an effective therapeutic for several hereditary 
autoimmune diseases.  
IL-15 
IL-15 is an IL-2 family member cytokine that has chemoattractant properties for 
memory T cells, it is produced by lining layer cells including macrophages and is 
increased in the synovial fluid of RA patients [268]. Peripheral or synovial T cells 
stimulated with this cytokine can induce macrophages to produce IL-1β, TNFα, 
MCP-1 and IL-8 but not the anti-inflammatory IL-10 [269]. Since IL-15 is produced 
by the macrophages themselves, this may re-stimulate the T cells and result in a 
self-perpetuating pro-inflammatory loop [268].  
IL-6 
IL-6 has also been shown to be produced by synovial macrophages in addition to 
synovial fibroblasts, it is elevated in the synovial fluid of RA and inflammatory 
arthritis during the acute phase of disease and has been shown to have phase 
dependent effects  as  it  protects  the cartilage  in acute disease  but  promotes 
excessive bone formation during chronic disease [250]. However, despite these 
opposing effects of IL-6 within the disease setting clinical trials of an anti-IL-6 
receptor antibody suggest it may be used as an effective treatment for RA [134, 
157] although at present no trials have investigated the use of such antibodies in 
PsA. 
IL-18 
IL-18  is  a  member  of  the  IL-1  family  of  cytokines  and  its  expression  is  up-
regulated within the synovial membrane as well as the serum and synovial fluids 
of  RA  and  PsA  patients  [270,  271].  It  is  expressed  by  CD68
+  macrophages 
contained within lymphoid aggregates as well as by fibroblast-like synoviocytes 
and RA synovial fluid CD14
+ macrophages also express the IL-18 receptor (IL-18R) 
[272].  Several  lines  of  investigation  have  demonstrated  the  pro-inflammatory 
role of IL-18 in arthritis: (a) IL-18 deficient mice exhibit reduced incidence and 
severity of disease in the CIA and ZIA mouse models of arthritis [273-275] (b) 
anti-IL-18  antibodies  can  effectively  reduce  development  and  established 
arthritis in both streptococcal cell wall induced arthritis (a strongly macrophage-
dependent model) and CIA [276, 277] (c) treatment with low doses of IL-18 prior 
to induction of CIA was able to increase the severity and incidence of disease 
[278] and (d) IL-18 is selectively overexpressed in the bone marrow of patients 71 
with juvenile idiopathic arthritis and macrophage activation syndrome [279]. IL-
18 has also been demonstrated to correlate with CRP levels in arthritis patients 
and  their  levels  decrease  in  parallel  in  synovial  tissue  and  serum  following 
effective treatment with DMARDs [271]. A recent study performed by Ruth et al 
engrafted human synovial tissue into SCID mice and investigated whether the 
injection  of  IL-18  into  these  grafts  could  induce  the  migration  of  human  PB 
monocytes which were administered to the mice. They found that IL-18 could 
indeed induce monocyte recruitment to the synovial tissue and in addition IL-18 
gene knockout mice showed pronounced reductions in joint inflammation during 
ZIA model of arthritis once again indicating the dominant role of IL-18 within 
arthritis  and  its  ability  to  act  in  an  autocrine  manner  and  induce  monocyte 
migration to sites of inflammation [275]. 
MIF 
Macrophage  migration  inhibitory  factor  (MIF)  is  an  early-response  cytokine 
abundantly released by macrophages. This cytokine can stimulate macrophage 
functions in an autocrine manner such as the release of TNF-α and phagocytosis. 
MIF can also confer resistance to apoptosis in both macrophages and synovial 
fibroblasts within the synovial joint  [250]. In RA, MIF is overexpressed in the 
serum  and  synovial  fluid  of  patients  and  correlates  with  disease  activity  and 
arthritis  severity  is  significantly  reduced  in  MIF
-/-  mice  in  comparison to  wild 
type mice and is associated with reduced T cell activation [280]. 
Proteinases 
Matrix metalloproteinases (MMPs) are enzymes involved in extracellular matrix 
degradation that is a central part of the joint destruction seen in arthritis. There 
are  around  30  known  MMPs  and  of  these  mainly  MMP-1  (collagenase),  MMP-2 
(gelatinase A) and MMP-9 (gelatinase B) are released by RA synovial macrophages 
[258, 281]. MMP-1 and MMP-3 (stromelysin) mRNA has also been detected in the 
synovium  of  PsA  patients  [94].  Synovial  macrophages  also  produce  tissue 
inhibitors of MMPs such as TIMP-1 and TIMP-2 that anatagonise the effects of 
MMPs. 
Growth factors 
Growth  factors  are  involved  in  the  synovial  angiogenesis,  inflammation  and 
fibrosis  occurring  in  the  arthritic  joint.    Synovial  macrophages  are  known  to 
secrete several such factors including platelet-derived growth factor (PDGF) and 72 
vascular endothelial growth factor (VEGF) [258]. PDGF-C and PDGF-D are the two 
isoforms expressed by synovial tissue macrophages and the latter isoform has 
been previously shown to increase the production of the enzyme MMP-1 within 
the synovium [282]. VEGF levels are significantly increased in the sera of PsA and 
RA patients and correlate with disease activity  [98, 283].  The VEGF receptor 
(VEGFR-1/Flt-1)  has  previously  been implicated  in  macrophage activation  and 
angiogenesis  in  RA  [284].  VEGFR-1  deficient  mice  were  shown  to  obtain 
diminished clinical symptoms of induced arthritis compared to wild type mice 
and  this  VEGFR-1  deficiency  was  associated  with  reduced  macrophage 
differentiation  and  function  including  a  decrease  in  the  secretion  of  pro-
inflammatory mediators [284]. 
1.2.5.2.3  Anti-inflammatory cytokines 
In addition to producing a large variety of pro-inflammatory mediators in the 
synovial joint macrophages also produce anti-inflammatory cytokines, namely IL-
1RA as mentioned previously and IL-10. IL-10 is a macrophage and Th2 derived 
cytokine which reduces antigen presentation by macrophages and prevents the 
production of pro-inflammatory cytokines by synovial macrophages [250]. The ex 
vivo production of IL-10 by RA PBMCs is negatively correlated with radiographic 
joint damage suggesting that IL-10 is protective however several studies have 
found a deficiency of IL-10 in the synovial compartments [285] which proposes 
that the synovial macrophages may be reducing their regulatory cytokine output 
in favour of a highly pro-inflammatory profile. 
An outline of the characteristics and pro-inflammatory potential of inflammatory 
arthritis monocytes and macrophages are shown in Figure 1.5. 73 
 
Figure 1.5 Phenotypic overview of RA and PsA monocytes and macrophages 
An overview of the functional differences between healthy monocytes and RA or PsA diseased 
monocytes in the blood (A) and the arthritic joint (B). This figure demonstrates the inflammatory 
phenotype of these cellular subtypes and the mechanisms of their activation in RA and PsA. 
 
1.2.5.3  In vitro model of inflammatory arthritis 
The use of in vitro model systems within the investigation of chronic arthritis is 
valuable for the detailed analysis of patient cells to fully understand how they 
activate  and  interact  with  other  cells.  One  such  in  vitro  model  has  been 
established  to  investigate  the  contact-dependent,  antigen  independent 
interactions occurring in the synovial joint between macrophages and stimulated 
T cells. Since histologically, T cells are often found within close contact with 
macrophages within RA synovial tissue [286]. In addition, T cell cytokines such as 
IL-4, IL-10, TGF-β and IL-13 have predominantly anti-inflammatory effects and 74 
IFN-γ  alone  displays  weak  activation  capacity  in  terms  of  IL-1β  and  TNF-α 
induction which suggests that the soluble factors produced by T cells are not 
pathological mediators. Therefore it was hypothesised that within the synovium, 
one method through which T cells could exert a pathological effect would be 
through  direct  cellular  contact  with  macrophages  to  induce  cytokine  and 
chemokine secretion from the latter cell type. 
The history of contact mediated activation of macrophages by stimulated T cells 
began  in  the  mid-eighties  when  it  was  observed  that  the  expression  of 
membrane- associated IL-1 (IL-1α) in mouse macrophages was mediated by both 
soluble mediators and direct cell contact with T cells  [287]. The same group 
subsequently demonstrated that this T cell contact mediated IL-1 induction in 
monocytes took place with both Th1 and Th2 cells in the absence of lymphokine 
release [288]. Following this result a similar experiment was setup with human 
cells and it was demonstrated that the production of IL-1β by human monocytes 
also  required  direct  cell  contact  with  anti-CD3  stimulated  cells  [289]. 
Accordingly, other investigators have shown that the induction of macrophage 
effector  functions  mediated  through  T  lymphocytes  in  living  cell  co-cultures 
involved signals from cell-cell contact in addition to IFNγ [290]. Furthermore, by 
using isolated plasma membranes from T cells stimulated with PHA/PMA Vey et 
al demonstrated that this contact activation was sufficient for the activation of 
the human  monocytic  cell  line  THP-1 and their  subsequent  secretion  of  IL-6, 
TNFα and IL-1β in the absence of T cell derived cytokines. This cytokine release 
did  not  occur  when  the  cells  were  physically  separated  by  a  permeable 
membrane [291].  
Antigen  independent,  direct  contact  mediated  activation  of  monocytes  and 
macrophages by stimulated T cells was found to be as potent as LPS in inducing 
cytokine production in monocytes and monocytic cell lines [291-293]. However, 
besides  PHA/PMA  various  stimuli  for  the  T  cells  were  found  to  activate 
monocytes by direct cellular contact such as cross-linking CD3 by anti-CD3 mAb 
and the addition of cytokines to the T cells. In addition, depending on the T cell 
type and the stimulus, direct cell-cell contact between stimulated T cells and 
monocytes/macrophages induced different patterns of products secreted from 
the latter cell type (see Table 1.7).  75 
Table 1.7 Depending on T cell stimulus, various products are induced in the 
monocyes/macrophages upon direct cell contact 
 
Stimulus     T cell     Monocyte    Products   
 
PHA/PMA    PB T cells,    PB mo, THP-1  TNFα, IL-1β, IL-6, 
      Synovial, Jurkat,        IL-8, IL-1α, MMP-1, 
      Th1 and Th2,          MMP-9, TIMP-1 
HUT-78          [291, 293-295] 
 
PdBu/ionomycine  PB T cells    PB mo     IL-10, TNFα [296] 
 
Anti-CD3    PB and synovial   PB mo, THP-1  IL-10, IL-1β, TNFα, 
      T cells            MMP-1 [296-299] 
 
Anti-CD3    PB T cells    PMA/IFNγ treated  IL-10, IL-12, TNFα, 
            U937      IL-4 [300] 
 
IL-15 or IL-2    PB T cells,    U937, PB mo,  TNFα, IL-1β, IL-10  
      Synovial T cells,  THP-1, synovial  [301, 302] 
      Th1 and Th2   mo 
 
IL-2, IL-6, TNFα  PB T cells,     PB mo     TNFα, MCP-1, 
      Synovial T cells        MCP-1, MIP-1α, 
MIP-1β, RANTES,  
IL-8, GROα, IP-10,  
IL-1β [269, 298] 
 
 
The  observations  outlined  in  Table  1.7  suggested  that  multiple  ligands  and 
counter-ligands  are  involved  in  the  contact  mediated  activation.  It  was 
hypothesised that membrane associated cytokines or soluble cytokines may play 
a role however the Dayer group consistently demonstrated that neither soluble 
TNFα receptors or IL-1Ra blocked T cell mediated signalling of the monocyte. 
Additionally  neutralisation  of  TNFα,  IL-1,  IL-2,  GM-CSF  and  IFNγ  all  failed  to 
affect  monocyte  activation by  membranes  from  stimulated  T cells  [291,  293, 
297].  In  addition  to  membrane-associated  cytokines  other  surface  molecules 
were investigated for their ability to activate macrophages upon contact with 
stimulated T cells. The CD40/CD40L interaction was shown to be involved in the 
contact activation of both human and mouse macrophages by T cells stimulated 
for 6 hours [303] but T cells isolated from a CD40L knockout mouse were also 
able to trigger macrophage activation although this activation was less than that 
seen from wild type murine T cells [304]. Furthermore, blocking antibodies to 
CD40L  or  soluble  CD40  failed  to  inhibit  contact-induced  activation  of 76 
macrophages  by  48  hour  activated  T  cells.  HUT-78  cells,  which  are  able  to 
induce cytokine production from macrophages, do not express CD40L mRNA in 
the resting or activated state [305]. Finally, Th1 but not Th2 clones stimulated 
with IL-15 were able to induce IL-1β production from monocytes, in the former 
system blockade of the CD40/CD40L interaction resulted in inhibition of IL-1β 
production despite similar levels of CD40L expression in the Th1 and Th2 cells 
indicating  the  selective  requirement  of  CD40  engagement  upon  monocyte 
activation  by  Th1  clones  [301].  Other  groups  have  also  demonstrated  the 
presence of surface molecules such as CD69, LFA-1 and ICAM-1 on simulated T 
cells play a role in macrophage activation through the use of blocking antibodies 
which effectively inhibited macrophage activation [291, 302, 306]. 
Histological studies of the RA synovium have indicated that this tissue is very 
cellular and that several different cell types including macrophages and T cells 
are in close proximity  [286]. This could therefore suggest that direct contact 
between  macrophages  and  T  cells  could  be  important  in  vivo  in  modulating 
synovial macrophage function. It was first reported in 1994 that a cocktail of 
cytokines, namely IL-2, IL-6 and TNFα, could activated T cells in the absence of 
antigen which in turn stimulated B cells [307]. Since the RA synovial joint is a 
highly  pro-inflammatory  environment  containing  a  milieu  of  pro-inflammatory 
cytokines it was hypothesised that these cytokines could activate the T cells 
contained  within  the  joint  which  would  subsequently  activate  the  synovial 
macrophages  by  direct  cell  contact  and  be  a  mechanism  for  the  increased 
production of pro-inflammatory mediators.  
In 1997, McInnes et al demonstrated that IL-15 alone, which is a cytokine found 
within RA synovium [268], could activate T cells isolated from the PB or SF of RA 
patients; these fixed T cells were then able to activate U937 cells or matched RA 
PB or SF monocytes to produce TNFα. This monocyte activation was cell contact 
dependent since the TNFα production was abrogated in the presence of a semi 
permeable membrane. Furthermore, it was demonstrated that the T cell surface 
molecules  CD69,  LFA-1  and  ICAM-1  were  involved  in  this  activation  since 
antibodies against these molecules prevented the secretion of TNFα from the 
monocyte  [302].  In  the  same  year  Brennan  and  Feldmann  used  the  cytokine 
cocktail IL-2, IL-6 and TNFα to stimulate PB T cells and demonstrated that the 
manner in which the T cells were activated influenced the profile of cytokines 77 
secreted by the monocytes. Thus, if blood T cells were activated with cross-
linked anti-CD3 this induced the production of TNFα and IL-10 from monocytes 
[296]. However, if the T cells were stimulated with the cocktail of cytokines for 
8  days,  the  monocytes  produced  TNFα  production  but  not  IL-10  [269].  Such 
observations suggested that these cytokine stimulated T cells, designated Tcks, 
could be similar to the T cells found in the synovial tissue of RA patients since 
they induce an unbalanced pro-inflammatory cytokine response from monocytes.  
Consequently, further work performed by the Brennan and Feldmann group set 
out to investigate fully these Tck cells and their relevance to RA. This group 
demonstrated that the TNFα production in RA synovium was T cell dependent as 
the removal of CD3-positive T cells from RA synovial mononuclear cells resulted 
in the significant reduction of macrophage TNFα, in addition this TNFα output 
was abrogated if physical contact between the two cell types was blocked [298]. 
It was also shown that Tck cells but not T cell receptor dependent stimulated T 
cells  induced  TNFα  production  in  monocytes  in  an  NF-κB  dependent  manner. 
Conversely, phosphatidylinositol 3-kinase (PI3K) inhibitors were found to block T 
cell receptor stimulated T cell activation of monocytes but did not affect Tck 
mediated  monocyte  activation  indicating  the  different  signalling  mechanisms 
employed  by  the  two  differentially  activated  T  cells  [298].  Interestingly,  RA 
synovial T cells were also found to employ the same signalling mechanisms as 
Tcks since the induction of TNFα in resting PB monocytes by synovial T cells was 
NF-κB  dependent  and  were  superinduced  if  PI3K  was  blocked  [298].  These 
results provided evidence that the IL-2, IL-6, TNFα activated Tcks were similar 
to the synovial T cells found in RA and provided a basis for an in vitro model of 
inflammatory arthritis.  
Subsequent  investigations  have  also  substantiated  this  finding  and  provided 
evidence for the Tck cell contact activated macrophages as a model of arthritis. 
For  example,  the  chemokines  produced  by  M-CSF  differentiated  macrophages 
after contact with fixed Tck cells have been analysed and it was revealed that 
they produce several CC and CXC chemokines such as MCP-1, MIP-1α, MIP-1β, 
RANTES,  IL-8,  GROα  and  IP-10.  Interestingly,  blockade  of  NF-κB  signalling 
through IκBα overexpression inhibits Tck and synovial T cell induced macrophage 
secretion  of  CXC  but  not  CC  chemokines,  suggesting  that  RA  synovial  T  cells 
share  similarities  in  their  effector  function  to  Tck  cells  [308].  Subsequent 78 
phenotyping  of  this  Tck  cell  subset  has  revealed  that  they  are  a 
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high  population  of  T  cells.  After  IL-2,  IL-6  and  TNFα 
stimulation in culture these Tcks acquire an activated phenotype that resembles 
the  phenotype  of  RA  synovial  T  cells  including  the  selective  upregulation  of 
adhesion molecules and integrins such as very late antigen 4(VLA-4) [309]. In 
summary,  these  investigations  established  the  functional  and  phenotypic 
similarities between in vitro cytokine activated T cells (Tck) and RA synovial T 
cells and demonstrated the importance of the cell contact mediated activation 
of monocytes/macrophages as a surrogate model of RA. 
The modulation of T cell induced signalling in monocytes may be an important 
concept as it would maintain a low level of monocyte activation within the blood 
stream. Apolipoprotein (apo) A-I has been identified as a specific inhibitor of 
contact-mediated activation of monocytes [310]. Apo A-I is known as a negative 
acute phase protein and is one of the main proteins of high density lipoprotein 
(HDL). There have been several reports of variations of apo A-I concentration in 
inflammatory diseases [311] and in RA the levels of circulating apo A-I and HDL-
cholesterol  in  untreated  patients  were  lower  than  in  healthy  controls  [312]. 
Conversely, apo A-I levels were enhanced in the synovial fluid of RA patients 
[313]. 
This possible regulatory mechanism within the synovium may be overcome by a 
positive  acute-phase protein  which  can  displace apo  A-I  from  HDL,  known  as 
serum amyloid A (SAA)  [314]. SAA is produced in the liver but has also been 
detected  in  the  RA  synovium,  HDL-associated  SAA  is  a  pro-inflammatory 
molecule and the expression of SAA can be increased by cytokines such as TNFα 
and IL-1β. This could therefore lead to a positive feedback loop of inflammation 
within  the  synovium  as  the  cell  contact  dependent  activation  of  synovial 
macrophages  will  induce  the  production  of  pro-inflammatory  cytokines  which 
will therefore increase the levels of SAA and consequently decrease the levels of 
Apo  A-I.  The  decreased  level  of  Apo  A-I,  which  is  an  inhibitor  of  contact 
mediated monocyte activation, will thereby result in higher levels of monocyte 
activation and increased levels of pro-inflammatory molecules thus increasing 
the chronic synovial inflammation [314]. To try to further understand the role of 
HDL  within  T  cell  contact  activation  of  monocytes  Gruaz  et  al  performed  a 
microarray analysis of monocytes activated by the plasma membranes of fixed 79 
PHA/PMA stimulated T cells in the presence or absence of HDL. The results of 
this  study  demonstrated  that  T  cell  activation  of  monocytes  induced  the 
upregluation of 437 probe sets in the monocytes including genes associated with 
the inflammatory response and inflammatory diseases. It was also shown that 
the addition of HDL to the monocytes at the time of T cell membrane activation 
was  able  to  inhibit  the  expression  of  164  (38%)  of  these  probe  sets  which 
included probe sets specific for TNFα, IL-6, IL-1β, CCL4 and CCL3. Consequently 
this study substantiated the previous reports of the pro-inflammatory nature of T 
cell  contact  activation  of  human  monocytes  and  the  subsequent  anti-
inflammatory capacity of HDL upon this cell contact model [315]. 
In summary, these studies have demonstrated that stimulated T cells have the 
ability to active monocytes and macrophages in an antigen independent but cell 
contact  dependent  manner.  The  method  through  which  the  T  cells  are 
stimulated can vary (see Table 1.7) and this variation can affect the products 
secreted  by  the  monocytic  cell.  However  it  has  been  demonstrated  that  a 
particular  stimulus  consisting  of  a  cocktail  of  cytokines  can  induce  a  T  cell 
phenotype and activation pattern similar to that of RA synovial T cells. Due to 
the close proximity of T cells and macrophages within the RA synovium and the 
predominantly anti-inflammatory effect of T cell secreted cytokines the T cell – 
macrophage cell contact activation has been postulated to be a mechanism of 
increasing  the  pro-inflammatory  cytokine  and  chemokine  levels  within  the 
synovium. Therefore the cytokine cocktail method of T cell stimulation within 
the  cell  contact  model  has  become  an  established  in  vitro  method  of 
investigating the role T cell – macrophage activation within arthritis.  80 
1.3   Gene expression analyses in inflammatory 
arthritis 
As  described  in  1.1.1,  the  rheumatic  diseases  are  a  heterogenous  group  of 
disorders with a wide clinical spectrum and considerable variability in secondary 
organ involvement. Every aspect of this heterogenous disease phenotype should 
be represented in the pattern of genes and proteins which are expressed by the 
patient.  This  molecular  signature  will  represent  the  contribution  of  the 
interactions between specific molecules and the individual cell  types that are 
associated with disease characteristics and subtypes and thus will determine the 
samples‘  unique  molecular  biology.  A  powerful  way  to  gain  insight  into  the 
molecular signature contained within the cells and tissues of rheumatic diseases 
has  arisen  with  the  advent  of  DNA  microarray  technology,  which  can 
comprehensively identify the subset of genes which are differentially expressed 
among  patients  with  clinically  defined  disease.  There  were  initially  several 
problems  in  the  use  of  such  technology,  which  requires  highly  standardised 
conditions, such as the lack of consistent methods for blood and tissue handling 
or preparation or the use of different platforms and standardisation procedures. 
However,  after  a  decade  of  technical  improvement  the  technology  and 
standardisation procedures have been shown to be robust and allow comparison 
between properly designed and controlled experiments [316] thereby helping to 
unravel information that may aid in allowing clinicians to optimise treatment for 
and understanding further the complexity of rheumatic diseases. 
The  resultant  findings  of  microarray  analyses  performed  in  RA  and  PsA  are 
summarised in Table 1.8. 
1.3.1.1   Rheumatoid arthritis 
1.3.1.1.1  Genetic analysis of affected tissues  
One of the first gene expression profiling studies for RA was conducted on biopsy 
tissue using high density cDNA arrays [317]. This report identified an increased 
expression  of  inflammation  associated  genes,  such  as  HLA-DR,  in  the  RA 
synovium compared to normal synovium. However, due to the investigators using 
pooled samples from three patients with RA and three healthy controls it was 
impossible  to  study  the  individual  genetic  profiles  of  the  patients  or  the 
heterogeneity between samples. In contrast, a study set up by van der Pouw 81 
Kraan analysing the genetic expression of the synovial tissue from RA (n=21) and 
OA  (n=9)  patients  found  the  RA  patients  to  be  highly  heterogenous  in  their 
genetic  signatures  [318,  319].  Interestingly,  they  identified  two  molecularly 
distinct  forms  of  RA;  the  synovial  tissue  from  one  group  of  patients  had  an 
abundant expression of clusters of genes indicative of ongoing inflammation and 
involvement in the adaptive immune response. This subgroup was referred to as 
the  RA  high  inflammation  group.  The  second  group,  known  as  the  low 
inflammation  subgroup,  contained  expression  profiles  of  tissue  remodelling 
genes  such as  increased  expression  of  MMP-11  and  MMP-13  and low  levels  of 
inflammatory  genes  which  was  similar  to  the  patterns  seen  in  the  OA  tissue 
[318]. Analysis of the genes in the RA high inflammation subgroup indicated a 
prominent role of genes involved in activated IFN and the signal transducer and 
activator  of  transcription  (STAT)-1  pathway  [318].  It  was  determined  by 
histological analysis  that  the difference  obtained  in the  two  subgroups of  RA 
patients  were  related  to  differences  in  cell  distribution,  as  tissues  which 
contained  germinal  centre-like  structures  were  those  found  in  the  high 
inflammation subgroup. 
A further study performed by Devauchelle et al analysed the differences in gene 
expression between the synovial tissue of RA (n=5) and OA (n=10) patients [320]. 
A set of 63 genes were identified based on their over- or under-expression in RA 
tissue compared to the OA tissue, 15 of these genes had unknown function but 
the expression of the remaining 48 genes allowed the correct classification of 
additional  RA  or  OA  patients  therefore  the  authors  proposed  that  such 
information could aid in the diagnosis of RA. Of interest, 16 genes from this 
study overlapped between the microarray performed by van der Pouw Krann and 
seven  of  these  genes  including  the  type  I  IFN  regulated  GBP1  and  CTSL  had 
comparable gene expression profiles indicating the ability to reproduce genetic 
results between different patient samples and different groups of investigators.  
Additional  studies  have  also  demonstrated  that  RA  patients  have  significant 
tissue  heterogeneity  both  between  and  within  patient  samples.  A  study 
performed by Tsubaki and colleagues [321] showed that early RA patients were a 
heterogenous group in comparison to patients with longstanding RA as the early 
RA patients could be subdivided into at least two different subgroups depending 
on their gene expression profiles. A similar study was performed in 2009 [322], 82 
the synovium from 4 early RA patients, 4 treated longstanding RA patients and 7 
controls was analysed by microarray and it was found that distinct molecular 
signatures  were  expressed  during  early  or  longstanding  RA  suggesting  that 
increased understanding regarding the main biological processes and pathways 
involved at each stage of the disease may help to decide the most appropriate 
therapy  for  the  patients.  An  interesting  study  by  Lindberg  et  al  [323] 
investigated  the  variability  in  synovial  gene  expression  at  the  biopsy  site, 
between  different  sites  and  between  patients.  Multiple  biopsy  samples  were 
taken from 13 patients; 7 by orthopaedic surgery and 6 by rheumatic arthroscopy 
and  it  was  found that  the number  of  differentially  expressed  genes  between 
pairs  of  biopsies  from  the  same  knee  ranged  from  6  to  2,133  indicating  the 
considerable level of heterogeneity between biopsy samples. The methods by 
which these samples were taken had a significant effect on the results since the 
number  of  differentially  expressed  genes  between  biopsies  from  the  same 
patient was three times higher when the biopsies were taken by the orthopaedic 
method compared to the arthroscopic method which was thought to be due to 
sampling of non-inflamed tissue. Upon removal of biopsies which contained non-
inflamed  tissue  the  remaining  gene  expression  signatures  were  found  to  be 
unique to each patient but also contained groups of genes which belonged to 
gene ontology categories such as cell communication and immune response.  
Since  the  arrival  of  microarray  studies  which  have  analysed  the  diseased 
synovium of RA patients there has also been an increase in the number of studies 
which  analyse  the  gene  expression  changes  of  the  synovium  in  response  to 
patient  treatment.  Lindberg  and  colleagues  recently  investigated  the 
transcriptional profile of the synovium of RA patients treated with the anti-TNFα 
therapy infliximab in order to determine biomarkers which could be predictive 
of response to treatment  [324].  This study found that within the 62 patients 
analysed  no  significant  differences  in  genes  expression  could  be  detected 
between  responders  and  non-responders  to  the  infliximab  treatment  which 
therefore does not support the idea that microarray analysis of whole synovium 
biopsy specimens can be used to identify non-responders before the initiation of 
treatment.  
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1.3.1.1.2  Genetic analysis of blood derived cells  
Although the gene expression analysis of tissue samples of affected target organs 
offer  insight  into  the  genes  principally  involved  in  disease  progression  and 
activity, it may not be viable to use this approach to study all patients especially 
large  cohorts.  Consequently,  several  groups  began  to  analyse  the  gene 
expression profiles of whole blood or peripheral blood mononuclear cells (PBMCs) 
to obtain disease related gene expression profiles since the systemic nature of 
RA  allows  the  communication  between  systemic  and  organ  specific 
compartments  within  the  disease.  In  addition,  understanding  the  gene 
expression of blood cells may allow the use of such profiles for biomarker studies 
and could also improve diagnosis and personalised therapy. 
One of the first microarrays analysing RA PBMCs took place in 2004 by Bovin and 
colleagues who examined the PBMCs from eight RF-positive RA patients, six RF-
negative patients and seven healthy controls  [325].  No significant differences 
between  RF-positive  and  RF-negative  patients  were  detected.  However, 
comparison of the gene expression pattern from all fourteen patients and the 
healthy controls identified a subset of 25 discriminative genes which included 
genes  associated  with  the  inflammatory  response  such  as  defensin  alpha  and 
CD14  antigen  as  well  as  the  calcium  binding  proteins  S100A8  and  S100A12. 
Batliwalla and colleagues investigated the gene expression differences between 
PBMCs  from  RA  patients  (n=29)  and  those  from  healthy  donors  (n=21)  [326]. 
Using cluster analysis they identified a significant alteration in the expression of 
81 genes in the PBMCs of RA patients compared to controls. A large number of 
these genes correlated  with differences in the monocyte counts between the 
two study populations as many of the genes were known to be expressed at high 
levels in monocytes such as CD14 antigen. A logistic regression analysis revealed 
that  of  the  remaining  genes  IL-1RA,  S100A12,  glutaminyl  cyclase  and  Grb2-
associated  binding  protein  (GAB2)  were  the  top  discriminator  genes  in 
categorising RA patients from controls.  
A further study performed by Edwards and colleagues analysing the RNA from 
the PBMCs of nine RA patients and thirteen healthy controls found 330 genes 
differentially  expressed  in  RA  [327].  These  differentially  expressed  genes 
belonged to diverse functional classes and included genes involved in several 
biological groups such as transcription, signal transduction, extracellular matrix, 84 
cytokines,  enzymes  and  proteases.  Interestingly,  ten  genes  which  had  an 
increased expression in RA PBMCs compared to healthy controls mapped to an RA 
susceptibility  locus,  6p21.3  which  the  investigators  hypothesised  could  be  a 
mechanism contributing to the etiology of the disease through the coordinated 
transcription  of  specific  regions  of  a  chromosome  in  response  to  stress  or 
inflammation. A study performed by Junta et al evaluated the differential gene 
expression profile of PBMCs of RA patients and their association with the HLA 
shared  epitope  (HLA-SE),  anti-CCP  antibody  levels,  DAS-28  score  and  disease 
treatment  [328].  This  research  demonstrated  that  thirteen  genes  were 
exclusively associated with the presence of HLA-SE alleles whose major functions 
were related signal transduction, apoptosis and signal transduction. One hundred 
and one  genes  were associated  with  the  presence  of  anti-CCP  antibodies,  91 
genes  were  associated  with  disease  activity  including  genes  involved  in  DNA 
damage, signal transduction and response to stress and finally 28 genes were 
associated  with  TNF  blockade  treatment  which  included  genes  involved  in 
protein transport and intracellular signalling.  
In 2007, van der Pouw Krann and colleagues published a paper investigating the 
gene expression profiles of whole blood from RA patients (n=35)  and healthy 
controls (n=15) [329]. The microarray data confirmed previous observations of 
increased expression of genes such as the S100A8 and S100A12 calcium-binding 
proteins. Pathway analysis software identified the increased expression within 
RA patients of immune defense genes including the type I IFN response genes 
indicating that this pathway is activated systemically in RA. A separate study 
comparing RA PBMCs to those of controls identified a spectrum of genes involved 
in  immunity  and  defense  to  be  upregulated  in  the  RA  patients  once  again 
demonstrating that such immune pathways are upregulated systemically in RA 
[330]. 
In addition to microarray analyses being performed on synovial biopsies from 
patients  before  and  after  therapeutic  intervention  there  have  also  been  a 
number of recent studies evaluating the effect of different treatments on the 
gene profile of PBMCs. Since a significant percentage of patients fail to show a 
clinical  response  to  treatment,  designated  non-responders,  the  main  focus of 
such  microarray  studies  has  been  to  determine  molecular  discriminators  of 
response  in  patients.  One  study  which  obtained  blood  from  patients  before 85 
starting  the  TNFα  blockade  therapy  infliximab  identified  an  eight-gene 
expression profile that was able to predict the patient response to the treatment 
as either a responder or non-responder [331]. This profile, which included the 
genes  HLA-DRB3  and  TLR5,  was  able  to  predict  response  of  an  independent 
validation  set  of  RA  patients  with  85.7%  accuracy.  Another  study  looking  at 
molecular discriminators of response to the anti-TNFα therapy etanercept found 
certain genes which when expressed in groups of two or three could have 89-95% 
prediction accuracy [332]. Finally, a microarray analysis of  PBMCs taken from 
patients before the commencement of the IL-1Ra therapy anakinra identified 52 
genes which were expressed as a response to treatment [333]. Seven of these 
transcripts, as assessed by quantitative RT-PCR, were able to predict 15 of 18 
independent responder and non-responder patients with an accuracy of 87.5%. In 
conclusion, the emergence of such modelling systems could aid the clinician in 
the selection of the optimal treatment strategy for RA patients and has strong 
application potential within the clinical setting.  
1.3.1.1.3  Gene analysis within cell subsets 
The analysis of synovial biopsies and PBMCs from RA patients has been extremely 
useful  in  identifying  patterns  of  gene  expression  within  the  disease  and  the 
response of patient tissues to treatment. However, it has been suggested that 
some of the genetic signatures identified in such studies may be attributable to 
differences in the relative abundance of individual cell populations within the 
sample. In addition cell-specific changes may be missed when analysing a mixed 
population  of  cells.  Consequently,  several  groups  set  out  to  investigate  the 
genetic signatures of individual cell populations within RA patients.  
Fibroblast-like synoviocytes (FLS) are considered to play a major role in joint 
destruction in RA and also contribute to leukocyte migration into the joint. One 
of the first gene expression profiles of RA FLS revealed the over-expression of 
genes responsible for tumour like growth of rheumatoid synovium  [334].  This 
study used a cDNA array containing 588 cDNA-fragments of known cancer related 
genes to compare the gene expression of FLS from five RA patients and five 
traumatic control patients and found the increased expression of such cancer-
related genes in the RA FLS. An additional study analysing the genetic expression 
of  19  RA  FLS  samples  correlated  the  genetic  data  to  that  of  paired  synovial 
tissue samples and found that the heterogeneity at the synovial tissue level was 86 
associated with a specific FLS phenotype [335]. The high inflammation tissues 
were associated with an FLS subtype that exhibits similarity with a fibroblast cell 
called myofibroblasts. The myofibroblast cells are specialised cells that have a 
key role in connective tissue remodelling and cell infiltration. Addition studies in 
oncology have demonstrated that these cells play a crucial role in angiogenesis 
through  the  production  of  growth  factors  and  extracellular  matrix  proteins. 
Therefore these myofibroblast-like FLS in RA synovium are thought to contribute 
to the tissue destruction and angiogenesis which is often seen in this disease.   
Szodoray  and  colleagues  used  a  genome  scale  microarray  to  identify 
differentially regulated genes in peripheral blood B cells from eight RA patients 
with early disease compared to eight healthy controls  [336]. They discovered 
that  305  genes  were  overexpressed  in  RA  B  cells  and  231  genes  were 
underexpressed  compared  to  controls.  Clusters  of  functionally  associated 
networks were analysed and five biological classes were defined: autoimmunity; 
cytokines;  cell  activation  and  apoptosis;  neuro-immune  regulation  and 
angiogenesis. A microarray analysis has also been performed on isolated CD4
+ T 
cells, the study by Li et al analysed the microRNA (miRNA) profile of CD4
+ T cells 
isolated from the synovial fluid of RA patients compared to CD4
+ T cells isolated 
from healthy controls [337]. Analysis of the results demonstrated that miR-146a 
was  upregulated  in  SF  CD4
+  T  cells  whilst  miR-363  and  miR-498  were 
downregulated.  Subsequent  studies  indicated  that  miR-146a  overexpression 
suppressed  T  cell  apoptosis  since  one  of  the  genes  it  regulated  was  Fas 
associated  factor  1  (FAF1)  and  therefore  the  upregulation  of  this  miR  could 
promote the long-term survival of the pathogenic T cells.  
There  is also  one  microarray  gene  expression  study  that  has  been  performed 
specifically  on  monocytes  from  RA  patients,  Stuhlmüller  et  al  compared 
monocytes  from  the  first  leukapheresis  pool  (activated  cells)  and  third 
leukapheresis  pool  (nonactivated  cells)  of  26  RA  patients  undergoing 
leukapheresis  treatment  to  identify  known  and  novel  genes  in  the  activated 
monocytes  [338].  This  analysis  identified  482  differentially  expressed  genes 
between  the  first  and  third  pools,  the  activated  monocytes  were  found  to 
express inflammatory genes such as IL-1β, IL-6 and TNFα whilst the nonactivated 
monocytes expressed differentiation and transcription genes such as PU.1. 87 
Despite the enormous advances in the field of transcriptomics and microarray 
analyses there appears to be very few studies investigating the genetic signature 
of individual cell types within arthritis which could be masked in a full scale 
microarray of whole blood or synovium. Since individual cell types are known to 
play  diverse  roles  in  the  pathogenesis  of  arthritis  understanding  the  genetic 
signal of the different activated cell types may aid in unravelling the causes and 
different treatment mechanisms of this disease. 
1.3.1.2   Psoriatic arthritis  
In  comparison  to  the  vast  amount  of  microarray  analysis  that  has  been 
performed on RA patients there has been a paucity of research into the genetic 
signature  of  PsA.  In  addition,  there  has  been  a  great  deal  of  progress  into 
identifying the genetic phenotype of psoriasis but very few studies analysing the 
arthritis  that  will  often  accompany  or  follow  this  condition  have  been 
performed. One of the few microarray studies analysing PsA took place in 2002, 
Gu and colleagues investigated the genetic profiles of PBMCs from RA patients 
(n=6), spondyloarthropathy (SpA) patients (n=7) and PsA patients (n=6) compared 
to healthy controls (n=7). They established an upregulation of several genes in 
the three types of arthritis in comparison to healthy controls including those 
coding  for chemokine  receptors  (CCR1  and  CXCR4),  cytokines  (IL-1β)  and  the 
signalling  molecules  JAK3  and  MAP  kinase  p38  [339].  They  also  found  an 
upregluation of the chemokine receptor CXCR4 in the three arthritis groups, the 
ligand for CXCR4 is SDF-1 and levels of this chemokine were detected in the SF 
of the SpA and RA patients. Since SDF-1 is a chemokine for lymphocytes and 
monocytes  it  was  suggested  to  be  potentially  important  pro-inflammatory 
mediator within the pathogenesis of RA, SpA and PsA. 
Despite the interesting observations of the above study, due to the method by 
which  they  grouped  the  microarray  results  together  for  all  three  different 
arthritis subsets it proved difficult to discriminate the specific gene profile of 
the PsA patients. However, two subsequent studies used microarray technology 
to compare the PBMCs of PsA patients to those of healthy controls. The first 
study  performed  by  Batliwalla  and  colleagues  analysed  the  gene  expression 
signature of peripheral blood cells from 19 PsA patients compared to that of age 
and  sex  matched  healthy  donors  [340].  They  found  that  257  genes  were 88 
expressed at a lower level in PsA patients and 56 genes were expressed at a 
higher level in comparison to controls. The genes that were downregulated in 
the PsA patients were found to be involved in the suppression of innate and 
acquired  immune  mechanisms  suggesting  that  these  cells  favoured  a  pro-
inflammatory  response.  Pro-inflammatory  genes  such  as  S100A8  and  S100A12 
demonstrated  increased  expression  in  the  PsA  samples.  In  addition,  using  a 
dataset of RA samples for comparison it was found that the combination of two 
genes  MAP3K3  and  CACNA1S  could  correctly  classify  the  RA  patients  and  PsA 
patients. Therefore this gene expression profiling was able to differentiate PsA 
from  control  subjects  and  PsA  from  RA  patients  indicating  that  PsA  has  a 
distinctive blood cell gene expression pattern. Stoeckman et al also performed a 
similar microarray analysis comparing the PBMCs of PsA patients to those of age 
and  sex  matched  healthy  controls  and  discovered  that  310  genes  were 
differentially expressed with the majority being upregulated in PsA [341]. It was 
also  found  that  this  differential  gene  expression  profile  did  not  overlap  with 
those of RA or SLE patients and that individual genes, such as ZNF395, had high 
discriminatory potential for disease diagnosis indicating that PsA patients had a 
unique gene expression profile which could reveal novel disease markers. 
At present these three microarray analyses are the only studies to be performed 
investigating the gene expression pattern of PsA. There have been no studies 
into  the  gene  expression  of  synovial  tissue  or  individual  cell  subsets  and the 
effect of different drug therapies on the genetic signatures of diseased cells, 
which has been very informative in the field of RA, have not been performed. As 
a result very little is known about the transcriptomics of PsA and therefore more 
investigation is required in this field in order to gain more information into the 
pathogenesis of this disease and to aid clinicians in deciding the optimal therapy 
for the patients. 
See Table 1.8 for a summary of the gene expression studies performed in RA and 
PsA. 89 
 Table 1.8 Genomic studies in RA and PsA 
Disease  Tissue   Number of     Approx number  Comparison      Results          Ref. 
        samples    of genes on array 
 
RA    Synovium  21 RA and 9 OA  11,500 and 18,000  Within RA and versus   Evidence for the existence of  [318, 319] 
                    OA        multiple pathways for tissue 
                            destruction 
                               
RA    Synovium   5 RA and 10 OA    5,760    RA versus OA      Differentially expressed genes   [320] 
                            between RA and OA   
 
RA     Synovium   12 early and 4 late    23,040   Early versus longstanding  Early RA fell into two groups   [321]  
                    RA        dependent on the expression  
                            of genes critical for proliferate 
                            inflammation 
 
RA    Synovium  4 early untreated,    10,000   Early RA versus LS RA,  Early and LS RA have separate  [322] 
        4 treated          early RA versus healthy,  molecular signatures with distinct 
        longstanding, 7         LS RA versus healthy    biological processes participating  
        controls                  during the course of disease 
 
RA    Synovium  13 RA. 7 biopsies     46,000   Biopsies from the same  There is a substantial level of  [323]    
        obtained by          patient compared,     heterogeneity between pairs of   
        orthopaedic sampling,      orthopaedic versus    patient samples. Orthopaedic 
        6 by arthroscopy        arthroscopy      biopsies are unsuitable for gene 
expression analysis 
 
RA     Synovium  62 patients before    17,927   Treatment responders  No difference between responders  [324]   
infliximab treatment       versus non-responders  and non-responders was detected therefore  
synovial biopsy samples may not be  
appropriate to identify non-responders to 
infliximab treatment Chapter 1    90 
Table 1.8 continued                             
 
RA    PBMCs   8 RF
+, 6 RF
-, 7     10,000   RF
+ versus RF
- and    No differentially expressed genes   [325] 
        healthy controls        versus healthy control  between RF
+ and RF
- patients.  
                            Increased expression of  
immunoinflammatory response 
                            genes in RA 
 
RA    PBMCs   29 RA and 21      12,626   RA versus HC      Monocyte associated gene    [326] 
        healthy controls                signature increased in RA 
 
RA    PBMCs   9 RA and 13       6937    RA versus HC      Diverse functional subsets of   [327]   
        healthy controls                genes were differentially expressed  
                            between RA and HC samples. Ten  
                            genes with increased expression in  
RA PBMCs mapped to RA susceptibility  
locus 6p21.3 
 
RA    PBMCs   23 RA        4500    Comparison between   Different numbers of genes were  [328] 
                    patients according to   exclusively associated with each 
                    anti-CCP level, DAS-28,  disease variable  
                    HLA-shared epitope  
                    presence and treatment 
                    type 
 
RA    Whole blood  35 RA and 12      18,000   within RA and versus HC  Assignment of a type I IFN     [329] 
        healthy controls                signature in a subpopulation 
                            of patients 
 
RA    PBMCs   18 RA and 15      48,701   RA versus HC      Elevated expression of genes   [330] 
        healthy controls                associated with immunity and 
                            defense in RA patients 
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RA    Whole blood  44 RA before      47,000   treatment responders    An 8-gene expression profile   [331] 
        infliximab treatment       versus non-responders  was able to predict treatment response 
 
RA    PBMCs   19 RA        18,500   Before versus 72 hours  Gene pairs and triplets predictive   [332] 
                    after etanercept    for response to treatment at an 
                            early stage of treatment 
 
RA    PBMCs   32 RA before      12,000   treatment responders    A 52-gene expression profile   [333] 
        anakinra treatment        versus non-responders  was demonstrated to predict 
                            treatment response   
 
RA    FLS    5 RA and 5 HC     588    RA versus HC      Increased expression of genes   [334] 
                            responsible for tumour-like growth 
                            in RA FLS 
 
RA     FLS    19 RA        18,000   Within RA      The heterogeneity between    [335]   
                            synovial tissue is reflected in the FLS 
 
RA    B cells   8 RA and 8 HC     21,329   RA versus HC      B cell biology in RA is disregulated  [336] 
                            due to the differential expression of 
                            multiple biological pathways 
 
RA    CD4 T cells  2 RA and 1 HC     47,000   RA SF versus      RA CD4
+ cells overexpress    [337] 
                    HC PB CD4
+ cells    micro-RNA‘s which help promote the 
                            long term survival of the T cells 
 
RA    Monocytes   29 RA        482    Monocytes from first    Activated monocytes from first   [338] 
                    leukapheresis compared  leukapheresis pool had and increased 
                    to monocytes from third  expression of pro-inflammatory genes 
                    leukapheresis pool 
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PsA    PBMCs   6 RA, 7 SpA,      588    Three forms of arthritis  The three forms of arthritis similarly [339] 
        6 PsA, 7 HC          versus HC      upregulate pro-inflammatory 
                            molecules in comparsion to HC 
 
 
PsA    PBCs    19 PsA, 19 HC     22,215   PsA versus healthy    Downregulated genes in PsA    [340]  
                            compared to HC consisted of genes 
associated with suppression of 
                            immune mechanisms 
                             
PsA    PBMCs   16 PsA, 15 HC     54,000   PsA versus healthy    PsA genetic profiles showed no   [341] 
                            overlap with RA or SLE profiles 
                            and were distinct from control profiles 
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2.1  Patients and controls 
RA and PsA patients who fulfilled the American College of Rheumatology criteria 
for  RA  [6]  or  met  diagnostic  criteria  for  PsA  [8]  were  identified  from  the 
Rheumatology Clinics in Glasgow Royal Infirmary (GRI) and Glasgow Gartnavel 
Hospital  (GGH)  and  were  invited  to  take  part  in  the  study.  All  patients  and 
healthy donors gave informed consent and the study protocol was approved by 
the Ethical Committee, Glasgow Royal Infirmary, Scotland. 
2.2   Cell Culture 
2.2.1 Primary Human Cell Culture 
All tissue culture work was performed in laminar flow hoods and all cells were 
cultured  at  37
oC,  5%  CO2  in  RPMI-1640  medium  (Invitrogen)  containing  L-
glutamine  (2  mM),  penicillin  (100  IU/ml),  streptomycin  (100  μg/ml)  and  10% 
foetal calf serum (complete medium). 
2.2.2 Purification of mononuclear cells from buffy coats and 
peripheral blood 
Peripheral  blood  mononuclear cells  (PBMC)  were purified  by  standard  density 
gradient  centrifugation.  Briefly,  blood  was  obtained  from  either  single  donor 
plateletpheresis  residues  donated  by  Gartnavel  blood  bank  or  from  healthy 
donors.  The  blood  was  then  diluted  1:1  in  phosphate  buffered  saline  (PBS) 
(Invitrogen) and 10 mls were overlaid on 4 mls Histopaque®-1077 (Sigma) in 15 
ml centrifuge tubes. Tubes were centrifuged at 350 g for 20 minutes at room 
temperature. The mononuclear cells were then harvested from each tube and 
washed  three times  at  200  g  for  5  minutes  in  ice cold  PBS containing  2  mM 
ethylene diamine tetra-acetic acid (EDTA) and 0.5% human serum albumin, (PEA) 
before cell purification. 
2.2.3 Purification of mononuclear cells from synovial fluid  
Before the mononuclear cells were isolated from patient synovial fluid (SF) the 
fluid was centrifuged for at 350 g for 20 minutes in order to pellet the cells. The 
cell free synovial fluid  was collected and stored at  -70
0C. The pellet of cells 
from the synovial fluid was resuspended in PEA before being overlaid on 4 mls 
Histopaque®-1077 and centrifuged at  350 g for 20 minutes. The mononuclear 95 
cells  were  then  harvested  and  washed  three  times  in  PEA  before  cell 
purification. 
2.2.4 Isolation of CD3
+ T cells and CD14
+ monocytes 
CD3
+  T  cells  and  CD14
+  monocytes  were  purified  by  positive  selection  from 
mononuclear  cell  suspension  by  autoMACS,  according  to  the  manufacturer‘s 
instructions. Briefly, mononuclear cells were incubated in 90 μl/10
7 cells PBS/2 
mM EDTA/0.5% human serum albumin (PEA) containing 10 μl/10
7 cells anti-CD3-
conjugated magnetic microbeads (Miltenyi Biotec), or 10 μl/10
7 cells anti-CD14-
conjugated magnetic microbeads (Miltenyi Biotec) for 15 minutes at 4
oC. After 
washing in ice cold PEA by centrifugation at 200 g for 5 minutes CD3
+ T cells or 
CD14
+ monocytes were isolated by positive selection using the possel programme 
on  the  autoMACS  machine.  The  positive  cell  fraction  was  put  through  the 
machine  twice  on  possel  programme  to  ensure  a  higher  purity.  Purity  was 
assessed by flow cytometry and routinely >95%. 
2.2.5 CD3
+ T cell and CD14
+ monocyte stimulation 
CD3
+  T  cells  were  purified  by  positive  selection  from  peripheral  blood  and 
activated for 6 days in complete medium containing IL-2 (25 ng/ml), IL-6 (100 
ng/ml)  and  TNF-α  (25  ng/ml)  (all  from  Biosource),  in  order  to  produce  an 
activated phenotype similar to that displayed in the synovium [309]. CD14
+ cells 
were purified by positive selection from the same peripheral blood and cultured 
in 96, 24 or 12 well plates depending on the experiment at 5x10
5 cells/ml in 
complete medium supplemented with 50 ng/ml M-CSF (Biosource). These cells 
were then incubated for 6 days at 37
0C. 
2.2.6  T cell / macrophage cell contact 
After 6 days in culture the cytokine activated T cells (Tcks) were washed three 
times in PEA and either fixed in PBS/2% paraformaldehyde on ice for 2 hours, or 
not (as indicated), and added back to the macrophage culture at a ratio of 4:1. 
This culture was incubated at 37
0C for between 1 to 24 hours depending on the 
experiment. 96 
2.3  Flow cytometry 
2.3.1 Assessment of cell purity 
All samples which were isolated on the autoMACS were analysed for purity by 
Flow  cytometry.  After  positive  selection  cells  were  washed  in  PEA  and 
resuspended at a concentration of 1 x 10
6 cells/ml. 100 μl of cells was added to 
two  clean  FACS  tubes,  one  for  the  isotype  control  and  one  for  the  antibody 
staining.  For  purity  checks  the  following  antibodies  were  used  (all  from  BD 
biosciences): 
Tube 1. Isotype IgG FITC, IgG APC 
Tube 2. CD14 FITC, CD3 APC 
5 μl of each antibody was added to the tube and the cells were incubated at 
room temperature for 15 minutes in the dark. The cells were then washed with 
PEA and the supernatant discarded. If the cells were to be analysed immediately 
they were resuspended in 200 μl PEA or if they were to be analysed the following 
day they were resuspended in 200 μl FACS FIX (2% paraformaldehyde in PBS). The 
cells  were  analysed  on  a  FACS  Calibur  (BD  Biosciences)  using  Cell  Quest 
software™. When assessing the purity of the samples, an analysis gate was set to 
ensure that within the isotype control sample <2.5% of the cells were positive 
for FITC or APC staining. 
2.3.2 Semaphorin 6D staining 
Surface and intracellular semaphorin 6D staining was assessed on Tck cells and 
CD3/CD28 activated cells after 0, 3 and 6 days of activation. 
T cells were obtained from donor blood packs as described in 2.2.4 and half of 
the T cells were stimulated with IL-2, IL-6 and TNF-α as described in 2.2.5 for 3 
and 6 days to produce Tcks. The remainder of the T cells were stimulated with T 
cell activation expansion kit cytostim beads (Miltenyi Biotec) according to the 
protocol. Briefly, the MACSibead particles were loaded by pipetting 100 μl each 
of CD2-biotin, CD3-biotin and CD28-Biotin into a 1.5 ml eppindorf and mixing. 
500  μl  of  Anti-biotin  MACSibead  particles  (1  x  10
8  Anti-biotin  MACSibead 
Particles) were added to the antibody mix with 200 μl of PEA and the mixture 97 
was incubated for 2 hours at 4
0C under constant, gentle rotation. Once the Anti-
Biotin MACSibead particles were loaded they were stored at 4
0C until required. 
To activate the T cells with the Anti-Biotin MACSibead particles 25 μl of beads 
per 5 x 10
6 T cells were resuspended in 100 μl complete culture medium and 
centrifuged at 300 g for 5 minutes after which time the beads were resuspended 
in 100 μl complete medium. The T cells were resuspended at a density of 5 x 10
6 
cells per 900 μl of complete medium and the 100 μl of beads were added. The 
cells were cultured in 24 well plates at a concentration of 2.5 x 10
6 cells per 
well for 3 and 6 days. In order to remove the beads before the FACS staining 
commenced the T cells were extracted from the plate and washed before being 
resuspended in PEA and vortexed thoroughly. The cells were then placed in an 
easystep magnet (Stemcell) for 2 minutes and the supernatant containing the 
activated T cells was removed and the process was repeated again. Once all the 
beads had been removed from the cells they were washed twice in PEA buffer 
and stained for semaphorin 6D.  
The following protocol for intracellular and surface staining of semaphorin 6D 
was used to stain unactivated T cells at day 0 and the Tcks and CD3/CD28 Anti-
biotin MACSibead after 3 and 6 days of activation. 
2.3.2.1   Surface staining Semaphorin 6D 
T cells were washed and approximately 1 x 10
6 cells were put into each FACS 
tube. 10 μl of Fc block (Miltenyi Biotec) was added to each tube and the cells 
incubated for 5 minutes at 4
0C. The cells were washed in PEA at 200 g for 5 
minutes  and  5  μg  of  semaphorin  6D  antibody  (MAB2095,  R&D)  or  5  μg  of 
irrelevant  antibody  (CD68  mouse  anti  human  DAKO)  was  added  to  the  tubes 
before being incubated for 20 minutes at 4
0C. The cells were washed in PEA and 
6 μl of goat F(ab‘)2 anti-mouse IgG APC secondary antibody (F0101B, R&D) was 
added to the cells for 10 minutes at 4
0C before being washed again. CD4 FITC or 
isotype  FITC  (BD  bioscences)  was  added  to  the  relevant  FACS  tubes  for  15 
minutes at 4
0C and the cells were washed a final time before being resuspended 
in 300 μl PEA and analysed on the FACS Calibur. 
2.3.2.2   Intracellular staining of semaphorin 6D 
T cells were washed and approximately 1 x 10
6 cells were put into each FACS 
tube. 10 μl of Fc block (Miltenyi Biotec) was added to each tube and the cells 98 
incubated for 5 minutes at 4
0C. The cells were washed in PEA at 200 g and 100 μl 
of cytoperm (BD biosciences) was added for 20 minutes at 4
0C, after this time 50 
μl of permwash (BD Biosciences) was added to the cells which were then spun at 
200  g  for  5  minutes.  The  cells  were  then  resuspended  in  100  μl  of  2%  goat 
serum/perm wash and incubated at 4
0C for 20 minutes; 5 μg of semaphorin 6D, 
CD68 or mouse IgG1 was added directly to the cells in 2% goat serum/perm wash 
and incubated at 4
0C for 20 minutes. After this time 500 μl of permwash was 
added to the cells which were then spun at 200 g for 5 minutes. The cells were 
resuspended in 100 μl of permwash and 5 μl of goat anti-mouse APC (Invitrogen) 
was added before the cells were incubated at 4
0C for 10 minutes. For the final 
step the cells were washed in permwash and resuspended in 200 μl permwash 
before being analysed on the FACS Calibur. 
2.4  Enzyme-linked-immunosorbent assay (ELISA)  
ELISA was used to measure concentration of human IL-6 and TNFα in cell culture 
supernatants. The concentrations of antibodies and buffers used for each ELISA 
are shown in Table 2.1. 
96 well plates (Thermo Labsystems) were coated with detection antibody in PBS 
and  incubated  overnight  at  4
0C.  The  plates  were  then  washed  with  0.05% 
PBS/Tween followed by the addition of blocking buffer (0.5% BSA/PBS) to block 
non-specific binding and incubated at 37
0C for 1 hour. An eight point standard 
curve was made using recombinant human cytokine dissolved in complete media 
at a top standard of 2000 pg/ml and serially diluted 1:2. 100 μl of each standard 
was  added  in  duplicate  to  the  plate  along  with  two  wells  containing  only 
complete media. Samples were then diluted 1:2-4 with complete media (donor 
dependant) and 100 μl transferred to each well. The plates were covered and 
incubated for 2 hours at room temperature.  The plates were washed several 
times  in  0.05%  PBS/Tween  followed  by  addition  of  secondary  antibody  and 
incubated at 37
0C for 1 hour. After incubation the plates were washed and 100 μl 
TMB chromagen (Biosource) was added to each well. The reaction was stopped 
by addition of 100 μl stop solution (Biosource) and the intensity of the signal was 
read at 450 nm on a microplate reader (Dynex Technology). 99 
 
Cytokine  Concentration 
of primary 
antibody 
Concentration 
of  secondary 
antibody 
Streptavidin 
HRP dilution 
Kit supplier 
TNFα 
 
IL-6 
2 μg/ml (100 
μl/well) 
2 μg/ml (100 
μl/well) 
1.5 μg/ml 
(100 μl/well) 
1.5 μg/ml 
(100 μl/well) 
1:1250 
 
1:1250 
Invitrogen 
 
Invitrogen 
Table 2.1 Cytokine analysis by ELISA 
 
2.5  Microarray  
2.5.1 Collecting and preparing samples for microarray 
All CD14
+ blood and synovial fluid samples were collected by density gradient 
centrifugation and magnetic bead positive selection as described in 2.2.2 and 
2.2.3. An aliquot of each sample was taken to check for cell  purity  and the 
sample was lysed in trizol (Invitrogen) (2x10
6 cells/ml trizol) and stored at -70
0C.  
2.5.2 Isolating cells using the FACS ARIA 
For  the  cell  contact  activated  macrophages  the  following  protocol  was  used. 
Cytokine  activated  T  cells  (Tcks)  were  washed  three  times  in  PEA,  CFSE 
(Invitrogen)  dye  was  made  up  in  Hank‘s  buffered  salt  solution  (HBSS)  media 
(Invitrogen) at a concentration of 10 μM and 1 ml was added to the Tcks before 
incubating for 10 minutes at 37
0C. Tcks were washed three times in PEA and 
then  fixed  in  PBS/2%  paraformaldehyde  on  ice  for  two  hours.  After  washing 
three times in PEA the fixed CFSE stained Tcks were added to macrophages in a 
24 well plate at a 4:1 ratio and left in cell contact for 2 hours. Following the 2 
hour  cell  contact  the  supernatant  was  collected  and  retained  for  cytokine 
analysis by ELISA and 0.5 ml cell dissociation solution (Sigma) was added to each 
well. The plate was incubated for 15 minutes at 37
0C to remove the adherent 
macrophage cells. Any remaining cells that were seen to be still adhering to the 
plate  on  inspection  under  a  brightfield  microscope  were  incubated  with 
additional cell dissociation solution. All of the cell suspensions were washed in 100 
PEA and pooled together for isolating on the FACS ARIA. The two cell fractions of 
macrophages and fixed CFSE stained Tcks were separated on the basis of FITC 
positive and FITC negative therefore all the FITC negative cells were believed to 
be macrophages. Cells were counted as they were being separated on the FACS 
ARIA and cell fractions were lysed in Trizol (2 x 10
6 cells/ml Trizol) and stored at 
-70
0C. 
A small aliquot of each cell fraction was taken for cytospins to ensure we had 
collected the correct cell type in each fraction.  
2.5.2.1   Cytospins 
An  aliquot  of  cells  isolated  from  the  FACS  ARIA  were  resuspended  at  a 
concentration of 0.5 x 10
6 cell/ml in PEA. Glass slides were labelled and placed 
into the metal holders with a piece of filter paper and a cuvette, 200 μl of the 
cell suspension was loaded into the cuvette and the cells were spun at 350 rpm 
for  6  minutes.  The  slides  were  then  removed  and  the  cuvette  was  carefully 
detached  to  avoid  damaging  the  smear  of  cells.  The  cells  were  immediately 
stained with RAPI-DIFF reagents (Ready reagents). The slides were placed in a 
Coplin jar containing solution A for 15 seconds and then placed in a Coplin jar 
containing  solution  B  for  15  seconds  finally  the  slides  were  washed  twice  in 
Phosphate buffer pH 6.8 for 10 seconds and then left to dry before being imaged 
on a light microscope. 
2.5.3 Manual RNA Isolation from Trizol 
The cells isolated from the cell contact experiments and patient samples were 
stored in Trizol and transferred to GlaxoSmithKline (GSK) in Stevenage for mRNA 
extraction.  QIAgen  mini  columns  were  used  for  the  RNA  clean-up  with  an 
incorporated on column DNAse step. Briefly, 200 μl of chloroform was added to 
each epindorff of cells containing 1 ml of Trizol and centrifuged at 12,000 g for 3 
minutes.  The  aqueous  supernatant  was  removed  to  a  clean  epindorff  and  an 
equal  volume  of  70%  ethanol  added.  This  solution  was  applied  to  a  QIAgen 
RNeasy mini-column and the protocol supplied with the QIAgen kit was followed 
to extract the RNA. Briefly, the RNeasy column was centrifuged at 13,000 g for 
30 seconds at room temperature and the flow through discarded. The sample 
was then washed by adding 700 µl of solution RWT and the column was spun at 101 
13,000 g for 1 minute at room temperature and the flow through was discarded. 
A DNase-1 stock solution (Qiagen) was prepared in 550 µl RNase-free water and 
10 µl of this solution was added to 70 µl buffer RDD. 80 µl of DNase-1/RDD buffer 
was  pipetted  onto  each  column  and  incubated  at  room  temperature  for  15 
minutes. Following this step 500 µl of buffer RW1 was added to each column 
which was subsequently spun at 12,000 g for 1 minute.  The sample was then 
washed twice by adding 500 µl of solution RPE and spinning the column at 13,000 
g for 1 minute. The column was then transferred to an RNase-free microfuge 
tube and 35 µl of RNase-free water was added to the column making sure the 
liquid was centred on the membrane. The sample was allowed to stand for 1 
minute to allow the RNA to dissolve into the water and the microfige tube was 
spun for 1 minute at 13,000 g. The RNA sample was then re-pipetted onto the 
column membrane and allowed to stand for 1 minute in order to increase RNA 
yield before being centrifuged at 13,000 g for 1 minute. All RNA samples were 
subsequently stored at -70ºC. 
The  concentration  of  each  RNA  sample  was  measured  on  a  nanodrop 
spectrophotometer and the quality of the RNA was analysed on an Agilent 2100 
bioanlyser using the agilent RNA 6000 pico kit (Agilent Technologies). When using 
the  Agilent  bioanalyser  the  sample  RNA  was  diluted  to  5  ng/ml  in  deionised 
water before being put on the pico chip for analysis.  
RNA was then diluted to 10 ng/μl using water on a Beckman Coulter Biomek FX 
machine. 5 μl of this RNA was transferred to a 96 well cone plate (Greiner) for 
amplification. 
2.5.4 Single strand cDNA amplification 
Single  strand  amplification  was  performed  using  NuGEN  RNA  amplification 
system V2. 
2.5.4.1   First strand cDNA synthesis 
For the primer annealing stage 2.5 μl of A1 primer was added to each 5 μl RNA 
sample and the 96 well plate was placed in a thermal cycler for 5 minutes at 65 
ºC. After this time the samples were removed and snapcooled by placing them 
on ice. 102 
The first strand master mix was prepared as follows (volumes listed are for a 
single sample) 
First strand buffer mix     12 μl 
First strand enzyme mix     1 μl 
Total Volume       13 μl 
 
13 μl of the first stand master mix was added to each sample and the samples 
placed in a thermal cycler programmed to run as follows: 
Incubate at 48ºC for 60 minutes 
Heat at 70ºC for 15 minutes 
Cool to 4ºC  
Once the temperature had reached 4ºC the plate was removed from the thermal 
cycler and spun in a centrifuge to collect condensation before being placed on 
ice. 
2.5.4.2   Second strand cDNA synthesis 
The second strand mastermix was prepared as follows (volumes listed are for a 
single sample) 
Second strand buffer mix (B1)     18 μl 
Second strand enzyme mix (B2)    2 μl 
Total Volume         20 μl 
 
A multichannel pipette was used to add 20 μl of second strand master mix to 
each well containing the first strand reaction mixture in the 96 well plate. The 
plate was briefly centrifuged for 2 seconds to remove air bubbles before being 
placed in a pre-warmed thermal cycler set to the following programme: 
Incubate at 37ºC for 30 minutes 
Continue heating at 75ºC for 15 minutes 103 
Cool to 4ºC 
Once the programme had completed the plate was removed from the thermal 
cycler and spun briefly before being placed on ice. 
2.5.5 SPIA™ amplification 
The  SPIA  mastermix  was  prepared as  follows  (volumes  are  listed  for  a  single 
sample): 
SPIA buffer mix (C2)    72 μl  
SPIA primer mix (C1)     2 μl 
Water          4 μl 
SPIA enzyme mix (C3)    40 μl 
Total Volume       118 μl 
 
A multichannel pipette was used to add 118 μl of the SPIA mastermix to each 
well of the 96 well plate containing the second strand reaction mixture. The 
plate  was  briefly  centrifuged  before  being  placed  in  a  thermal  cycler 
programmed to incubate the samples at 48ºC for 30 minutes. After this time a 
further 6 μl of SPIA primer mix (C1) was added to each well of the 96 well plate 
containing the SPIA reaction mixture. The 96 well plate was centrifuged for 2 
seconds  and  placed  back  into  the  thermal  cycler  to  run  on  the  following 
programme: 
Incubate 48ºC for 30 minutes 
Continue heating at 95ºC for 5 minutes 
Cool to 4ºC 
The plate was removed from the thermal cycler and centrifuged for 2 seconds 
before being placed on ice. 104 
2.5.6 Purification of amplified cDNA 
Purification of the amplified cDNA is required if it is intended for fragmentation, 
labelling and GeneChip array analysis. All amplified cDNA was purified according 
to the Agencourt RNAClean magnetic beads protocol. 
The magnetic beads were resuspended by gently agitating the RNAClean bottle 
before  being  dispensed  into  a  clean  reagent  reservoir.  288  μl  of  beads  were 
added to one matrix tube per sample. The amplified cDNA sample (160 μl) was 
then  pipetted  into  a matrix  tube  and  incubated  at  room  temperature  for  10 
minutes to allow the cDNA to bind to the magnetic beads.  
A round bottomed 96 well plate was placed onto the plate magnet and for each 
sample half of the bead/cDNA mixture (220 μl) was added into each well and 
incubated for 10 minutes at room temperature. After this time the supernatant 
was carefully removed and discarded using a multichannel pipette.  
The remaining 220 μl of bead/cDNA mixture was added to the same wells and 
again  the  plate  was  incubated  for  10  minutes  at  room  temperature  before 
removing the supernatant from the wells.  
Each sample was washed by dispensing 200 μl of 80% ethanol to each well for 30 
seconds after which time the ethanol was removed and discarded. This step was 
repeated ensuring that all ethanol was removed before leaving the samples to 
air dry for 2 minutes.  
34 μl of water was added to each sample on the plate and the plate was left 
undisturbed for 5 minutes, after this time the plate was tapped gently to mix 
and left for another 5 minutes. The plate was then placed onto the magnet and 
incubated for 10 minutes.  
The  cDNA  concentration  of  each  sample  was  measured  on  a  nanodrop 
spectrophotometer and the quality of the cDNA was analysed on an Agilent 2100 
bioanlyser  using  the  agilent  RNA  6000  pico  kit.  When  using  the  Agilent 
bioanalyser the sample cDNA was diluted to 5 ng/ml in deionised water before 
being put on the pico chip for analysis. 105 
2.5.7 Fragmenting and biotin labelling of the amplified cDNA 
For fragmenting and labelling, 5 μg of cDNA in a total volume of 25 μl was used. 
Fragmenting  and  labelling  was  performed  using  the  FL-Ovation™  cDNA  Biotin 
Module V2 kit from Nugen. 
2.5.7.1   Fragmentation 
The fragmentation master mix was prepared as follows (volumes listed are for a 
single sample) 
FL1      5 μl 
FL2      2 μl 
Total Volume    7 μl 
 
7 μl of master mix was added to each cDNA sample in a 96 well plate and mixed 
by  pipetting  the  sample  several  times.  The  plate  was  centrifuged  briefly  to 
remove any air bubbles and then was placed into a thermal cycler set to the 
following programme: 
Incubate 37
0C for 30 minutes 
Incubate 95
0C for 2 minutes 
Cool to 4
0C. 
The plate was centrifuged briefly and placed on ice before proceeding with the 
labelling step. 
2.5.7.2   Labelling 
The  labelling  buffer  mix  (FL3),  labelling  reagent  (FL4)  and  labelling  enzyme 
(FL5) were obtained from the product box stored at -20
0C 15 minutes prior to 
completion of the fragmentation reaction to allow the products to thaw to room 
temperature.  
The labelling master mix was prepared as follows (volumes listed are for a single 
sample): 106 
FL3      15 μl 
FL4      1.5 μl 
FL5      1.5 μl 
Total Volume    18 μl 
 
18 μl of master mix was added to each cDNA sample in a 96 well plate and mixed 
by  pipetting  the  sample  several  times.  The  plate  was  centrifuged  briefly  to 
remove any air bubbles and was then placed into a thermal cycler set to the 
following programme: 
Incubate 37
0C for 60 minutes 
Incubate 70
0C for 10 minutes 
Cool to 4
0C  
After completion of the programme the plate was removed from the thermal 
cycler and centrifuged briefly before continuing with the hybridization step. 
2.5.8 Array hybridization 
Array hybridization was performed using the GeneChip Hybridization Control Kit 
(Affymetrix). The biotin-labelled cDNA was hybridized onto Human genome U133 
Plus 2.0 array cartridges (Affymetrix).  
The Affymetrix cartridges were removed from the refrigerator one hour before 
use to allow them to equilibrate to room temperature. 
The  hybridization  cocktail  was  prepared  as  follows  (volumes  listed  are  for  a 
single sample): 
2x hybridization buffer    110 μl 
Affymetrix B2      3.7 μl 
Affymetrix 20X controls    11 μl 
Invitrogen BSA      2.2 μl 
Invitrogen herring sperm DNA   2.2 μl 
DMSO          22 μl 
Water         19 μl 
Total volume       170.1 μl 
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170  μl  of  hybridization  cocktail  was  added  to  a  96  well  plate  (one  well  per 
sample)  into which 50 μl of fragmented and labelled cDNA was added.  After 
pipetting several times to mix the sample the 96 well plate was placed in a 
thermal cycler set to the following programme: 
Incubate 95
0C for 3 minutes 
Incubate 45
0C for 5 minutes 
Cool to 4
0C 
The plate was removed from the thermal cycler and centrifuged at 350 g for 5 
minutes. 
For each sample 200 μl of sample/hybridization cocktail was removed from the 
96 well plate and dispensed into an Affymetrix chip. The chips were secured in a 
45
0C hybridization oven and spun at 60 rpm for 16 hours. 
2.5.9 Staining and Scanning 
Genechip fluidic station 450 (Affymetrix) was used to wash and stain the probe 
chips. 
Wash buffers were made up the day prior to staining and scanning the chips. 
Wash buffer A was prepared as follows: 
20% SSPE     300 ml 
10% Tween     1 ml 
Water     699 ml 
Total volume   1000 ml 
 
150 ml of wash A was aliquoted into wash station bottles (one bottle per one 
Affymetrix chip). 
Wash buffer B was prepared as follows: 
MES buffer    83.2 ml 
NaCl      5.3 ml 108 
10% Tween    1 ml 
Water     910.5 ml 
Total Volume    1000 ml 
 
150 ml of wash buffer B was aliquoted into wash station bottles (one bottle per 
Affymetrix chip). 
The  fluidics  stations  were  primed  and  for  each  fluidic  station  three  bottles 
containing wash A buffer, wash B buffer and water were placed in the fluidic 
stations.  
The staining solutions to stain the chips were prepared as follows. 
Streptavidin  Phycoerythrin  (SAPE)  solution  (volumes  listed  are  for  a  single 
sample, 600 μl each for the first and third stain): 
2x stain buffer  600 μl 
BSA      48 μl 
SAPE      12 μl 
Water     540 μl 
Total Volume    1200 μl 
 
Antibody solution (volumes listed are for a single sample): 
2x stain buffer  300 μl 
BSA      24 μl 
Goat IgG    6 μl 
Antibody    3.6 μl 
Water     266.4 μl 
Total Volume   600 μl 
 
The empty vials on the fluidics station were replaced with 600 μl each of SAPE 
(first and third stain) and antibody (second stain).  
The  Affymetrix  chips  were  removed  from  the  hybridization  oven  and  the 
hybridization mix was extracted from the chip. Each chip was inserted into a 
fluidics station where they were washed and stained, after this time the chips 
were removed and checked for air bubbles. If air bubbles were found the chips 109 
were put back on the fluidic station to be re-filled with wash buffer, if no air 
bubbles were found the chips were then scanned. 
2.5.10  Scanning 
Tough-spot  (Cole-Parmer)  labels  were  used  to  cover  the  two  septa  on  the 
affymetrix  chip  to  prevent  leakage  of  wash  buffer.  Smudges  and  dust  were 
removed from the glass front of the chip and the chips were loaded into the chip 
carousel. The chips were scanned using GeneChip® Scanner 3000 and analysed 
using Affymetrix GeneChip Command Console software. 
2.6  PCR and SYBR green 
The primer sequences used for SYBR green are shown in Table 2.2. 
Table 2.2 Primer sequences used for RT-PCR 
 
 
Primer 
name 
 
Forward sequence 
 
Reverse sequence 
 
GAPDH 
β-actin 
Legumain 
Plexin A1 
Sema 3A 
Sema 3F 
Sema 6D 
 
TCG ACA GTC AGC CGC ATC TTC TTT 
AAT GTG GCC GAG GAC TTT GAT TGC 
CGC ACA CCA ACA CCA GCC AC 
AGG GAG AAC GGC TGC CTG GT 
TGG GGT TGC CCA GCT CCC TT 
GGA CAC AGC ATC GGC CCT CA 
GCC GTT CCA CCC ATT GCC GA 
 
ACC AAA TCC GTT GAC TCC GAC CTT 
AGG ATG GCA AGG GAC TTC CTG TAA 
AGG GGG ACG GGA GAA CTG GC 
AGC AGG GAG CGC ACG TTG TC 
TGT GCG TCT CTT TGC AGT GGG 
GAC GGG TCG TTC AGC CAC CG 
ACC ATG CCA GCT TCA GAG CCA 
 
RNA isolation was performed on samples as described in 2.5.3. 110 
2.6.1 cDNA preparation 
cDNA  was  prepared  from  RNA  samples  according  to  AffinityScript™  multiple 
temperature  cDNA  synthesis  kit.  Briefly  100-500  ng  of  RNA,  depending  on 
experiment,  was mixed with 3  μl random primers and RNase-free water to a 
total volume of 15.7 μl. The reaction was incubated at 65
0C for 5 minutes before 
being cooled to room temperature for 10 minutes to allow the primers to anneal 
to the RNA. The following components were then added to each sample for a 
total volume of 20 μl. 
2.0 μl of 10x AffinityScript RT buffer 
0.8 μl of dNTP mix 
0.5 μl of RNase Block Ribonuclease Inhibitor (40 U/μl) 
1 μl of AffinityScript Multiple Temperature Reverse Transcriptase (RT) 
A minus RT (-RT) control was also set up with each set of samples along with a 
water control. In the case of the -RT control 1 μl of RNase free water was added 
instead of the AffinityScript Multiple Temperature RT.  
The reaction was then incubated for 10 minutes at 25
0C to extend the primers 
prior to increasing the reaction temperature to 42
0C for 60 minutes for cDNA 
synthesis.  The  reaction  was  then  terminated  by  incubating  it  at  70
0C  for  15 
minutes. 
2.6.2 PCR  
2.6.3  SYBR green 
SYBR green was performed using SYBR green mastermix (Applied Biosystems). 
Prior to setting up the SYBR green the cDNA was diluted 1 in 5 using RNase-free 
water. The reaction mix was prepared as follows (volumes listed are for a single 
sample): 
Mastermix    10 μl  
Primer mix    0.8 μl 
Water     8 μl 111 
Total volume   18.8 μl 
  
Each sample was measured in triplicate therefore 3 lots of reaction mix were 
prepared for each cDNA sample. For the triplicate samples 54.5 μl reaction mix 
was mixed with 6 μl cDNA and 19.8 μl of this total mixture was added to each of 
the  three  wells  of  a  MicroAmp  fast  optical  96  well  reaction  plate  (Applied 
Biosystems). A non template control was added to the plate where 6 μl of water 
was mixed with the 56.4 μl reaction mix and a minus RT was also included in the 
plate using the –RT control cDNA.  
Once the plate had been loaded with the cDNA samples it was covered using a 
MicroAmp optical adhesive cover (Applied Biosystems) and spun at 200 g for 5 
minutes. The plate was then transferred to an ABI 7900 H7 Fast-real-time PCR 
machine (Applied Bioststems) where it was read on the following cycle: 
Incubate 48ºC for 30 minutes 
Incubate 95ºC for 10 minutes 
40 cycles of 95ºC for 15 seconds followed by 60ºC for 1 minute 
A dissociation curve was subsequently measures on the following cycle: 
Incubate 95ºC for 15 seconds 
Incubate 60ºC for 15 seconds 
Incubate 95ºC for 15 seconds 
Using the results of this analysis, the expression of target genes relative to the 
housekeeping gene was then quantified.  
2.7  Immunohistochemical methods 
2.7.1 Antibodies 
Table 2.3 Antibody source and concentration used for IHC 
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Antibody  Manufacturer  Source  Working concentration 
Legumain 
Plexin A1 
Prestige Antibodies 
Cell Signalling  
Rabbit 
Rabbit 
0.5 μg/ml 
1.02 μg/ml 
 
Table 2.3 shows the antibodies that were used for single immunohistochemical 
staining for light microscopy and the concentration of the antibody used. 
2.7.2 Single immunohistochemical staining 
Sections containing sections of RA synovial membrane were initially heated to 
65
0C  for  35  minutes  after  which  time  they  were  de-waxed  in  xylene  and 
rehydrated through an ethanol gradient to water/TBS Tween (TBST). To reduce 
non-specific  background  staining  endogenous  peroxidase  activity  was  blocked 
using hydrogen peroxide (H202) and methanol. Fixation of tissue specimens forms 
cross-links that mask the antigenic sites, thereby giving weak or false negative 
staining for immunohistochemical (IHC) detection of proteins. Antigen retrieval 
using citrate buffer is designed to break the cross-links thereby unmasking the 
antigens and epitopes in the tissue. Antigen retrieval was performed in 0.01 M 
citrate buffer pH 6.0, the buffer was heated in a microwave for 5 minutes then 
the sections were added to the buffer and were heated for 8 minutes before 
being left to cool for 15 minutes. The sections were then blocked for 1 hour at 
room temperature in 2.5% serum of the species in which the secondary antibody 
was raised. The relevant primary antibody or isotype antibody was applied to the 
sections which were left overnight at 4
0C.  
The following day the species specific reagent from the ImmPRESS kit (Vector) 
was  added  to  the  sections  for  30  minutes  before  being  washed  in  TBST  and 
developed  with  ImmPACT  DAB  (Vector)  for  up  to  2  minutes  until  a  brown 
reaction  product  appeared.  Sections  were  then  washed  in  water  and 
counterstained using hematoxylin. Finally sections were dehydrated in ethanol, 
cleared in xylene to remove fats and oils and then mounted in DPX (Cellpath Ltd) 
before being imaged on a light microscope. 113 
2.8  Western blotting 
2.8.1 Whole cell lysates 
CD14+  monocytes  from  the  peripheral  blood  or  synovial  fluid  of  patients and 
CD14+  monocytes  and  M-CSF  matured  macrophages  from  normal  donors  were 
washed  in  PBS.  Subsequently,  100  μl  of  M-PER  (Thermo  Scientific)  with  the 
addition of 1 μl Halt Protease Inhibitor Cocktail (Thermo Scientific) was added to 
the cells. The cells were solubilised for 30 minutes on ice before centrifugation 
of  the  lysates  at  16,000  g  for  15  minutes.  The  resulting  whole  cell  lysate 
supernatants were removed from the cell debris pellet and were stored at -20
0C 
before being used for Western blot anaylsis. 
2.8.2 BCA Assay 
To determine the protein concentration of the cell lysates a BCA assay (Thermo 
Scientific) was performed. For each sample 2.5 μl was added to 72.5 μl of BCA 
reagent in triplicate on a 96 well plate and left at room temperature for 30 
minutes.  A  standard  curve  was  also  set  up  on  the  plate  using  known 
concentrations (2000 µg/ml  – 25 µg/ml) of the protein bovine serum albumin 
(BSA). The plate was read on a plate reader at 502 nm. The amount of total 
protein  in  each  sample  was  determined  by  comparing  the  OD  value  of  each 
sample to a standard curve of values. 
2.8.3 SDS-PAGE gel electrophoresis 
5µg of protein from the whole cell lysates were incubated with the appropriate 
volume of 4x NuPAGE LDS sample buffer (Invitrogen) and 10 x NuPAGE reducing 
agent (Invitrogen) at 70
0C for 10 minutes. Samples and seeblue plus2 protein 
standard (Invitrogen) were run on NuPAGE Bis-Tris gels (4-12%) (Invitrogen) with 
NuPAGE MES running buffer (Invitrogen) at 100 V for 1 hour. The gel was then 
transferred  onto  a  nitrocellulose  membrane  using  the  i-blot  transfer  system 
(Invitrogen).  
2.8.4 Western blotting 
Following transfer, nitrocellulose membranes were washed in TBS/Tween (0.5 M 
NaCl and 20 mM Tris pH 7.0 with 0.1% (v/v) Tween-20) and blocked for 1 hour in 
TBS/Tween containing 5% non-fat milk protein. Membranes were then incubated 114 
with 0.2 μg/ml legumain primary antibody (R&D, AF2199) diluted in TBS/Tween 
containing 5% non-fat milk protein overnight at 4ºC. Following the incubation 
with  the  primary  antibody  the  nitrocellulose  membranes  were  washed  (5  x 
5mins)  with  TBS/Tween  and  incubated  in  the  an  anti-goat  HRP-conjugated 
antibody (abcam, ab6741) containing 5% non-fat milk containing protein for 1 
hour at room temperature. The membranes were then washed in TBS/Tween (5 
x 5 mins) and protein bands were visualised using the ECL detection system (GE 
Life Sciences). Nitrocellulose membranes were incubated in a mixture of equal 
volumes of ECL solution A (2.5 mM luminol, 0.4 mM p-coumaric acid and 100 mM 
Tris pH 8.5) and ECL solution B (0.002% hydrogen peroxide and 100 mM Tris pH 
8.5)  for  1  minute  before  exposing  the  membranes  to  Kodak  X-Ray  film. 
Nitrocellulose  membranes  were  then  stripped  and  re-probed  with  a  β-actin 
primary antibody (1/1000 dilution ab8229 Abcam). Membranes were stripped at 
room temperature for 1 hour with stripping buffer (100 mM 2-mercaptoethanol, 
2%  SDS  and  62.5  mM  Tris  pH  7).  Nitrocellulose  membranes  were  washed 
thoroughly in PBS/Tween and checked for residual signal before re-starting the 
western blotting protocol. 
2.9  Legumain activity assay 
To measure the activity of the enzyme legumain in our samples an activity assay 
was performed. The activity of legumain was measured on its ability to cleave a 
substrate Z-Ala-Ala-Asn-AMC (AnaSpec). Cleavage of this substrate releases the 
AMC (7-amino-4-methylcoumarin) flurophore which can be detected at 441 nm 
upon excitation at 342 nm. 
2.9.1 Collecting samples for activity assay 
M-CSF differentiated samples were washed in PEA prior to lysis. Patient synovial 
and blood CD14+ cells were isolated by magnetic bead separation and washed in 
PEA before lysis. All samples were lysed in lysis buffer containing 50 mM citrate, 
0.1% CHAPS (pH 5.5), 5 mM of DTT and 0.5% Triton-X 100 [342]. Cell lysates were 
collected and frozen at -70
0C.  
2.9.2 Setting up activity assay 
Human  recombinant  legumain  (rhLGM)  (R&D,  2199-CY-010)  was  used  as  a 
positive control and is supplied as the pro form of the enzyme. To activate the 115 
rhLGM it was diluted to 100 μg/ml in activation buffer containing 50 mM sodium 
acetate and 100 mM NaCl, pH 4.0 and incubated for 2 hours at 37
0C. After this 
time the rhLGM was diluted to 1 ng/μl in assay buffer containing 20 mM citric 
acid, 60 mM Na2HPO4, 0.1% CHAPS (pH 5.5), 1 mM EDTA, and 1 mM DTT. 50 μl of 
the rhLGM was loaded into a well of a black welled 96 well plate. 
Cell lysate samples were freeze thawed three times before being centrifuged at 
10,000 g for 5 minutes, 50 μl of each sample was loaded into a black welled 96 
well plate. 
The substrate Z-Ala-Ala-Asn-AMC was diluted to 200 μM in assay buffer and the 
reaction was started by adding 50 μl of substrate to all wells containing sample 
and rhLGM. A blank well containing 50 μl assay buffer and 50 μl substrate was 
also put on the plate.  
The plate was read on a fluorescent plate reader programmed to take readings 
at times 0, 5, 10, 15, 20, 25, 30, 60, 90, 120, 150, 180, 210 minutes, the plate 
was incubated at 37
0C for the duration of the readings. 
2.10  siRNA 
N-TER Nanoparticle siRNA transfection system (Sigma) was used to knockdown 
the plexin A1 gene in M-CSF derived macrophages using 4 Flexitube plexin A1 
siRNA‘s  (Qiagen).  To  check  the  transfection  system  was  working  in  the 
macrophage  cells  an  Allstars  negative  control  with  an  Alexa  Fluro  555 
modification (Qiagen) was used to visualise the cells after transfection. If the 
nanoparticle transfection system had worked and the siRNA negative control had 
entered the cells  then  the  cells  were  seen  to  be  fluorescing  orange  by  light 
microscope  or  by  FACS  analysis.  The  Allstars  negative  control  siRNA  is  a 
nonsilencing  siRNA  which  has  no  known  homology  to  any  known  mammalian 
gene; therefore it is used to check whether the transfection of the cells has any 
effect on the expression of the gene being investigated. 
To  set  up  the  siRNA transfection the target  (plexin  A1)  and  negative  control 
(Allstars negative control) siRNA were prepared as follows: 
5 μM target/control siRNA   13 μl 116 
siRNA dilution buffer    37 μl 
Total volume       50 μl 
 
The N-TER peptide was then prepared as follows (volumes listed are for each 
siRNA being tested) 
N-TER peptide       8 μl 
Water         42 μl 
Total Volume       50 μl 
 
The  50  μl  of  N-TER  peptide  was  added  to  each  50  μl  siRNA  preparation  and 
incubated at room temperature for 20 minutes; the concentration of siRNA at 
this point was 650 nM.  
To transfect the M-CSF differentiated macrophages the siRNA was diluted to a 
concentration of 5 – 30 nM in complete medium depending on the experiment. 
The  culture  medium was  then  removed  from  the  macrophages  and  500  μl  of 
diluted siRNA was added to macrophages. The cells were incubated for 24 hours 
at  37
0C  and  after  this  duration  the  supernatants  were  collected  for  cytokine 
analysis  and  the  cells  were  put  in  0.5  ml  trizol.  Alternatively  after  siRNA 
treatment,  the  macrophages  were  stimulated  with  Tcks  at  4:1  ratio  or  were 
stimulated  with  10  ng/ml  LPS  for  24  hours  at  37
0C.  After  this  period  of 
stimulation the supernatants were collected for cytokine analysis and the cells 
were put into 0.5 ml trizol.  
All 4 siRNA‘s were tested individually on the macrophages for knockdown of the 
plexin A1 gene, however in some experiments a mixture of 2 siRNA‘s were used 
to see their combined effect. In this case when preparing the siRNA 7.5 μl of 
each siRNA was added to the siRNA dilution buffer.  
2.11  Real time cell imaging 
Macrophages  and  T  cells  used  for  cell  imaging  were  autoMACS  purified  as 
described in section 2.2.4. 117 
2.11.1  Preparing macrophages for imaging 
AutoMACS purified CD14
+ monocytes were cultured in 24 well plates in complete 
medium supplemented with 50 ng/ml M-CSF (Biosource) for 5 days.  To remove 
the macrophages 0.5 ml of cell dissociation solution (Sigma) was added to each 
well and the plate was placed into a 37
0C incubator for 10 minutes. The wells 
were then washed with PEA and scraped to remove any remaining macrophages 
still adhering to the wells. Macrophages were washed, counted and resuspended 
in complete medium at concentrations between 2x10
5 and 6x10
5 depending on 
the experiment and plated out on either a 2-well or 4-well chamberslide (VWR). 
The macrophages were left to adhere overnight in a 37
0C incubator.  
2.11.2  Staining macrophages for imaging 
A  red  fluorochrome  called  CMTPX  (Invitrogen)  was  used  to  stain  the 
macrophages, the dye was diluted to a concentration of 2.5 μM in HBSS media 
(Invitrogen) and 1 ml was added to each chamberslide well of macrophages. The 
chamberslides were placed in a 37
0C incubator for 20 minutes. After this time 
the media was removed from each well and 1 ml of complete medium added, 
the  chamberslides  were  then  incubated  for  a  further  30  minutes  in  a  37
0C 
incubator to allow any excess CMTPX dye to be secreted from the cells. 
2.11.3  Staining T cells for imaging 
Depending on the experiment, either T cell purified from the blood of a healthy 
donor on the day of the imaging or Tcks that had been activated in a cytokine 
cocktail  for  6  days  were  used.  If  Tcks  were  to  be  used  they  were  washed 
thoroughly three times in PEA before being stained. The T cells/Tcks were dyed 
green  with  1  ml  of  10  μM  CFSE  (Invitrogen)  which  had  been  diluted  in  HBSS 
medium. The cells were incubated for 10 minutes at 37
0C, after this period the 
cells were washed three times in PEA to remove any excess CFSE. Tcks were 
either  fixed  in  PBS/2%  paraformaldehyde  on  ice  for  two  hours,  or  not  (as 
indicated) and the cells were added to the macrophages at a ratio of 1:1 or 4:1. 
2.11.4  Imaging cell contact on microscope 
The  T  cell  -  macrophage  cell  contact  was  left  for  varying  amounts  of  time 
depending on the experiment but was usually imaged after 2 hours on a  Carl 118 
Zeiss Axiovert S100 inverted microscope. An automated sequence of events using 
Openlab software was setup in order to record time lapse images of the cell 
contact.  The sequence of events consisted of an image taken in green, followed 
by a brightfield image followed by a red image. This series of pictures was taken 
every  12  seconds  for  up  to  1  hour  and  recorded  the  movement  of  the  T 
cells/Tcks along with their interactions with the macrophages. 
2.11.5  Analysis of real time images 
Analysis  of  the  movies  produced  from  the  time  lapse  images  was  done  on 
Volocity software (PerkinElmer).  Two different types of analysis were carried 
out measuring the number and duration of interactions and the co-localisation 
coefficient of interactions. 
2.12  Statistical analysis 
All microarray results were background corrected by the GC-RMA algorithm and 
analysed by paired T test or 1-way ANOVA unequal variance (Welsh ANOVA) using 
Genespring GX 11 software. In addition for specific comparisions both DAVID and 
IPA  software,  which  use  a  modified  version  of  Fisher‘s  exact  test,  were 
employed. The remaining results are displayed as mean ± standard deviation and 
statistical  analysis  was  done  by  students  T  test  or  1-way  ANOVA  test,  as 
indicated in figure legends, using the GraphPad Prism 4 software. A p value of < 
0.05 was considered statistically significant. 
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Chapter 3 Transcriptomic analyses of psoriatic and 
rheumatoid arthritis blood and synovial fluid CD14
+ 
cells 120 
3.1  Introduction and Aims 
Rheumatoid  arthritis  (RA)  and  Psoriatic  arthritis  (PsA)  are  both  chronic, 
autoimmune arthritides. The cause of neither disease is, at present, known with 
both  genetic  and  environmental  factors  thought  to  play  a  role  in  disease 
susceptibility and progression thereafter. The synovial tissue in both RA and PsA 
is  characterised  by  marked  cellular  infiltration,  pronounced  angiogenesis  and 
increased cytokine and protease expression [132, 343]. Therapies used clinically 
in both RA and PsA induce significant improvement in disease activity status but 
many patients do not respond to existing standard of care [132], consistent with 
the heterogeneous nature of the diseases: this in turn underlines the need for 
further research and better therapies specifically targeted at patients who are 
non-responders to current treatments. 
In order to address this gap in the knowledge and understanding of RA and PsA 
many  genome-wide  gene  expression  studies  have  been  undertaken  in  both 
diseases comparing the genetic profiles of patients to those of healthy controls 
in order to acquire a genetic signature unique to each disease [325-327, 329, 
330, 340, 341]. Gene expression studies have also been performed on patients 
undergoing various forms of therapy to identify discriminatory genetic markers 
which could predict the patient response to therapy [332]. Many of these genetic 
studies have been performed on peripheral blood mononuclear cells (PBMCs) or 
whole  synovial  tissue,  which  provides  interesting  information  on  the  genetic 
expression status of the diseased state as a whole but cellular heterogeneity 
contained  therein  may  be  masking  the  contribution  of  individual  cell  types. 
Recently  a  small  number  of  RA  gene  expression  studies  have  specifically 
examined B cells [336], CD4
+ T cells [337] and fibroblasts [334] from diseased 
patients in order to obtain an understanding of how these individual cell types 
are contributing to disease.  
There  is also  one  microarray  gene  expression  study  that  has  been  performed 
specifically  on  monocytes  from  RA  patients,  Stuhlmüller  et  al  compared 
monocytes  from  the  first  leukapheresis  pool  (activated  cells)  and  third 
leukapheresis  pool  (nonactivated  cells)  of  26  RA  patients  undergoing 
leukapheresis  treatment  to  identify  known  and  novel  genes  in  the  activated 
monocytes  [338].  However,  at  present  there  are  no  gene  expression  studies 121 
looking at CD14
+ cells in PsA and as yet there have been no studies performed on 
both  blood  and  synovial  CD14
+  monocyte/macrophage  cells  from  RA  or  PsA 
patients. These cells are known to play an important role in disease progression 
as they are a major source of proinflammatory cytokines in the joint [344] and 
the  number  of  synovial  macrophages  has  been  found  to  correlate  with  the 
degree of disease activity in RA [345]. The inflamed synovia in both RA and PsA 
have been found to contain similar numbers of macrophages upon comparison 
[243]  therefore elucidating the molecular signature of this cell type in both PsA 
and RA may lead to a better understanding of its critical role in disease activity. 
Due  to  the  lack  of  transcriptome  data  from  CD14
+  cells  from  PsA  and  RA  I 
therefore sought to determine the gene expression pattern of CD14
+ cells from 
the matched peripheral blood and synovial fluid of RA and PsA as well as CD14
+ 
cells isolated from healthy volunteer derived blood. A priori comparisons were 
set up between disease and non-diseased state (healthy versus diseased blood), 
the site of cell isolation (peripheral blood versus synovial fluid) and the two 
disease types (RA versus PsA). 122 
3.2  Patients and normal donors 
Inflammatory arthritis patients attending Gartnavel General Hospital (GGH) or 
Glasgow Royal Infirmary (GRI) fulfilled the American college of Rheumatology 
criteria for RA [6], or met diagnostic criteria for PsA [346]. Information regarding 
patient characteristics is shown in Table 3.1.  
Age-matched  normal  donors  were  recruited  from  the  Glasgow  Biomedical 
Research  Centre  (GBRC)  building  and  all  blood  samples  were  taken  with 
informed consent. 
Table 3.1 Patient characteristics 
 
Characteristic  RA patients  PsA patients 
Mean age (years) 
Female:Male 
Mean Disease duration (years) 
ESR mm/hr (mean) 
CRP  (mean) 
RF positive (%) 
% of patients using DMARDS 
Anti-TNF therapy (number of patients) 
68 
5:3 
12.2 
86 
107 
87.5 
62.5 
1* 
51 
4:4 
1.8 
37 
115 
0 
37.5 
1* 
 
*Anti-TNF therapy was stopped due to patients becoming anti-TNF resistant 123 
3.3  Collecting patient samples 
For  the  microarray  study,  matched  synovial  fluid  and  blood  samples  were 
collected  from  8  RA patients  and  8  PsA  patients.  CD14
+  cells  were  positively 
selected  from  the  samples  using  Miltenyi  beads  and  an  aliquot  of  cells  were 
tested by FACS analysis for purity before being put into Trizol. CD14
+ Miltenyi 
beads were used since the CD14 surface antigen is present on both monocytes 
and  macrophages  [190,  347]  therefore  these  beads  should  isolate  blood 
monocytes as well as the synovial fluid macrophages. Normal donors who were 
age  and  sex  matched  to  patients  (Table  3.2)  were  recruited  and  from  these 
donors  CD14
+  cells  were  positively  selected  from  the  blood  only  since  by 
definition no synovial compartment derived population cold be ethically derived. 
An aliquot of unactivated CD14
+ cells were put into Trizol and the remainder of 
the  monocytes  were  stimulated  with  M-CSF  for  6  days  and  then  cell  contact 
activated (see chapter 6). Once all the samples had been collected the RNA was 
extracted from all samples at GSK Stevenage and analysed for quality. 124 
Table 3.2 Patient and normal donor samples collected 
 
 
Patient 
 
Gender 
 
Age 
Age and sex 
matched normal 
donor 
PsA 1 
PsA 2 
PsA 3 
PsA 4 
PsA 5 
PsA 6 
PsA 7 
PsA 8 
RA 1 
RA 2 
RA 3 
RA 4 
RA 5 
RA 6 
RA 7 
RA 8 
Female 
Female 
Male 
Male 
Male 
Female 
Male 
Female 
Female 
Male 
Female 
Male 
Female 
Male 
Female 
Female 
53 
40 
34 
34 
80 
58 
54 
58 
71 
56 
62 
69 
78 
69 
69 
77 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
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3.3.1 Purity of monocyte samples 
The CD14
+ cells isolated from each patient blood and synovial fluid sample were 
analysed on a FACS Calibur to check that there were no other contaminating cell 
types that would affect the transcriptomic profile obtained. Figure 3.1 shows a 
purity check from one representative PsA patient (A) and one RA patient (B).  
3.3.2 RNA quality of patient samples 
The RNA quality of the samples was analysed on an Agilent 2100 Bioanalyser 
which  is  a  microfluidics  based  platform  that  analyses  RNA  qualitatively;  RNA 
samples and a standard (ladder) are loaded into wells on a specifically designed 
chip containing a fluorescent dye. The dye molecules become incorporated into 
the  RNA  and  a  voltage  gradient  is  applied  to  the  chip  allowing  the  RNA  to 
become separated by size. By comparing the separation of the RNA to that of 
the  ladder,  which  contains  components  of  known  size,  a  standard  curve  of 
migration time versus fluorescence units is plotted called an electropherogram. 
Viewing the electropherogram can give an indication of the integrity of the RNA 
sample. 
Figure 3.2 (A) is an electropherogram showing an example of good quality RNA. 
It is characterised by three clear peaks, a peak for the RNA marker (1) and a 
peak for the 18 S (2) and 28 S (3) ribosomal RNA subunits. There should be a 
relatively flat baseline between the two rRNA peaks and minimal low molecular 
weight noise adjacent to the RNA marker peak. Figure 3.2 also shows the RNA 
quality from the blood and synovial fluid CD14
+ cells of a representative PsA 
patient (B) and RA patient (C). All four of the samples show good quality RNA 
evident  by  the  two  clear  peaks  and  no  low  molecular  weight  noise.  After 
checking the RNA from each sample was of good quality, cDNA was generated 
from  each  RNA  sample  before  being  purified,  fragmented  and  labelled.  The 
labelled cDNA was then hybridised onto an Affymetrix GeneChip. 126 
 
Figure 3.1 Purity of CD14+ cells isolated from PsA and RA patient blood and synovial fluid 
samples 
These graphs are a representative of the CD14+ cells isolated from the 8 PsA and the 8 RA 
patients that were analysed on the microarray 127 
 
Figure 3.2 RNA quality of the CD14+ samples from two patients 
RNA was extracted and analysed for quality using an Agilent 2100 Bioanalyser. Figure (A) 
represents an example of good quality RNA. It is characterised by three clear peaks: a peak for the 
RNA marker (1) and a peak for the 18 S (2) and 28 S (3) ribosomal RNA subunits. The quality of 
representative PsA patient samples (B) and RA patient samples (C) are shown here and both 
demonstrate good quality RNA. 
 
(C) 
(B) 
PsA PB mo  PsA SF mo 
(A) 
1 
2 
3 
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3.4  Summary of samples analysed on microarray 
The  samples  that  were  examined  using  the  microarray  GeneChips  are 
summarised in Table 3.3. Eight matched PsA and RA blood and synovial fluid 
samples  were  obtained  along  with  6  age  and  sex  matched  healthy  controls, 
unactivated  blood  CD14
+  cells  were  not  collected  from  one  control  but 
macrophage cells before and after Tck cell contact activation were collected for 
all 6 healthy controls. These latter samples will be discussed and analysed in 
chapter 6. 
Table 3.3 Summary of microarray samples 
 
Monocyte/macrophage sample analysed     Number of samples 
 
PsA PB CD14
+               8 
PsA SF CD14
+               8 
RA PB CD14
+               8 
RA SF CD14
+                8 
Healthy control PB CD14
+            5 
Healthy control M-CSF activated Mø        6 
Tck cell contact activated Mø          6 
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3.5  Analysis of microarray results 
Affymetrix  GeneChip  microarrays  are  one  of  the  most  popular  high-density 
oligonucleotide (oligo) gene expression arrays currently available and have been 
widely validated for the purposes of the present study – this was therefore our 
selected  methodology  of  choice.  Each  gene  on  an  Affymetrix  GeneChip  is 
represented by a probe set consisting of 11 pairs of 25-bp oligos covering the 
transcribed region of the gene. Each probe set pair consists of a perfect match 
(PM) and a mismatch (MM) oligonucleotide. The PM probe matches exactly the 
sequence of the gene while the MM probe differs in a single substitution in the 
central 13
th base, the MM probe is designed to distinguish noise caused by non-
specific  hybridisation  from  the  actual  specific  hybridisation  signal  [348]. 
Affymetrix  GeneChips  have  many  sources  of  variation,  for  example  non-
biological variation can arise due to: differences in sample preparation, unequal 
quantities  of  starting  RNA,  differences  between  chips  or  differences  in 
hybridisation between chips [349], therefore pre-processing must take place to 
adjust for these sources of non-biological variation.  
Affymetrix microarrays are pre-processed in three steps: 
Background correction – this is to adjust for hybridisation effects that are not 
related to the interaction between probes and target DNA 
Normalisation – this is to remove systematic errors and bias, it is necessary as it 
allows multiple chips to be compared to each other and analysed together. It is 
performed  under  the  assumption  that  all  chips  have  approximately  the  same 
distribution of PM values. 
Summarisation – This is performed using the 11 individual probe intensities from 
a probe set, combined to yield a single value for each gene that best represents 
the expression level of the sample RNA transcript. 
There are many different algorithm tools that can be applied to the background 
correction  step  of  Affymetrix  data  pre-processing:  an  appropriate  choice  is 
dependent upon the experimental design and dataset. Each phase will now be 
described. 130 
3.5.1 Background correction of the Affymetrix chips 
At  present  there  are  several  different  algorithm  tools  that  are  used  to 
background  correct  Affymetrix  chips  such  as  MAS5  [350],  RMA  [351],  GC-RMA 
[352]  and  PLIER.  Upon  careful  consideration  it  was  decided  to  use  GC-RMA, 
which  is  a  modified  version  of  RMA,  as  the  background  correction  for  my 
experiment design and dataset. As mentioned above each gene is represented on 
the GeneChip by 11 probe pairs made up of a MM and a PM probe, the MM probe 
is  designed  to  distinguish  noise  and  non-specific  background  signal  from  the 
specific  hybridisation  signal.  However  a  problem  arises  when  using  MM  data 
because in approximately 1/3 of probes the MM intensity levels are higher than 
the  PM  intensity  levels.  This  suggests  that  the  MM  probes  are  detecting  real 
signal. In these cases subtracting the MM signal from the PM signal results in a 
negative signal value and the loss of interesting signal value for those probes. 
Due to this problem several pre-processing algorithms were designed which only 
took into account the PM values, an example of which is RMA. RMA excludes MM 
data completely which reduces noise but also loses information therefore GC-
RMA was designed which takes into account non-specific hybridisation using the 
signal intensity of representative MM probes possessing the same GC nucleotide 
content as the PM probe of interest. 
The background correction in GC-RMA consists of three sequential steps: 
1.  Optical background correction, this is an important step as the scanner 
measuring  the  hybridisation  strength  of  each  GeneChip  will  introduce 
optical noise 
2.  Probe intensity adjustment through non-specific binding (NSB) using the 
optical noise adjusted representative MM probe intensities 
3.  Probe intensity adjustment through gene-specific binding where the NSB 
adjusted PM intensities are corrected for the effect of PM probe affinities. 
GC-RMA is currently considered to be one of the best methods for estimating 
expression  values  of  genes.  A  recent  study  comparing  several  pre-processing 
algorithms found GC-RMA to be the algorithm of choice for detecting differential 
expression of genes and also the algorithm which produced gene expression data 131 
that was highly correlated to qRT-PCR validation data [353]. Hence, GC-RMA was 
chosen  for  pre-processing  the  Affymetrix  GeneChips  data  produced  in  the 
current study.  
3.5.2  Signal histogram of normalised data 
Once  the  data  normalisation  had  been  performed  and  prior  to  formal  data 
analysis,  all  the  GeneChips  must  be  analysed  to  check  for  outliers  that  may 
affect or skew the results interpretation. One method is to examine the signal 
histogram of the normalised data which plots a line for each of the GeneChips 
with the intensity of the probes contained on the chip on the x-axis and the 
frequency of the probe intensity on the y-axis. This then allows the visualisation 
of  the  distribution  of  the  signal  intensity  to  identify  any  outliers.  Figure  3.3 
illustrates the signal histogram of all the samples that were tested, each line 
represents  one  GeneChip  and  they  are  coloured  by  condition  with  blue 
representing  the  cell  contact  activated  macrophage  samples,  red  the  M-CSF 
treated macrophages, purple the healthy donor blood CD14
+, green the patient 
blood CD14
+ and gold represents the synovial fluid CD14
+ cells.  It can clearly 
been seen on the histogram that all the samples have a similar signal intensity 
expression apart from one sample which is a GeneChip containing a cell contact 
activated macrophage sample. The reasons for this outlying sample are unknown 
but since it is only one sample and the signal intensities of the other samples are 
relatively similar to each other it is unlikely to represent a problem with the 
hybridisation, washing or staining of the chips. As a result it is most likely to be 
due to a problem with the individual sample or the labelling of that particular 
sample.  Since  this  sample  is  an  outlier  and  may  potentially  skew  the  data 
interpretation it was removed from further data analysis. 132 
 
Figure 3.3 Signal histogram of normalised data 
This graph represents the signal intensity of all the GeneChips that were analysed in this 
experiment. It is used to identify outliers in the samples. Each line represents one GeneChip and 
the lines are coloured according to the monocyte sample that was loaded onto each GeneChip. A 
blue line represents a cell contact activated macrophage, green is CD14
+ cells from the patients, 
purple is healthy donor blood CD14
+, red is M-CSF activated macrophages and gold is synovial 
fluid CD14
+ cells.  
 
3.5.3 Principle component analysis 
Phenotypes  of  diseases  or  experimental  conditions  can  be  classified  using 
Principle  Components  Analysis  (PCA)  [354].  This  is  an  analytical  method  that 
identifies  distinct  patterns  in  the  observed  transcriptomic  differences  of 
samples.  It  transforms  multidimensional  data  into  a  lower  dimensional  space 
using as few variables as possible. The resultant PCA graph can be used to look 
for trends in the data and also identify samples which may be outliers as samples 
clustered  within  the  same  area  of  the  PCA  graph  are  considered  to  be 
genetically similar.  
All the samples from the microarray were analysed by PCA based on conditions 
applied  (Figure  3.4).  Each  circle  on  the  graph  represents  a  sample  and each 
colour  represents  a  condition.  Figure  (A)  shows  the  PCA  plot  of  all  samples 
including  the  outlier  sample  that  was  identified  in  the  signal  histogram  to 
illustrate how different the genetic profile of that sample was compared to all 
the  other  samples.  This  is  visualised  on  the  PCA  plot  by  the  one  blue  circle 133 
representing the outlier sample being isolated on the left hand side of the graph 
while  all  the  remaining  samples  are  clustered  on  the  right  hand  side  of  the 
graph. This graph provides further support for the removal of this one sample 
from the analysis as its genetic profile and signal intensity vary widely from the 
other samples. 
Figure 3.4 (B) demonstrates the PCA plot of the samples once the outlier had 
been removes. It can clearly been seen that SF CD14
+ cells (gold circles) from 
both disease types cluster tightly together indicating that CD14+ cells from RA 
and PsA SF share a similar expression transcriptomic profile. This same pattern 
can  also  been  seen  for  the  patient  blood  CD14
+  cells  (green  circles);  both 
diseases have similar genetic profiles as indicated by the clustering of the green 
circles. This cluster of patient blood samples is distinct from the synovial fluid 
cluster of samples and more ‗transcriptomically similar‘ to the healthy donor 
CD14
+ blood cells (purple circles) due to the healthy donor CD14
+ samples being 
located in the same area of the PCA graph as the diseased blood CD14
+ cells. The 
red  circles  and  blue  circles  represent  M-CSF  activated  macrophages  and  cell 
contact  activated  macrophages  respectively  and  will  be  fully  discussed  in 
chapter 6. 
This PCA analysis helped to visualise the trends in the data and these trends 
were used to determine further comparisons to be performed. These were:  
  comparing patient blood to normal blood 
  comparing diseased blood CD14
+ cells to synovial fluid CD14
+ cells of both 
RA and PsA to see if there are genes that are similar in both diseases and 
conversely if each disease also has a unique distinguishing genetic subset. 134 
 
 
Figure 3.4 Principle component analysis of all microarray samples 
PCA was performed on the microarray samples to try and identify trends in the data. Graph (A) 
indicates the normalised samples before the outlier was removed. The blue circle on the left hand 
side of the graph represents the outlying sample and it can been seen that all the other samples 
are clustered away from that area of the graph indicating that general genetic profile of the outlying 
sample does not match those of the remaining samples. Figure (B) shows PCA graph once the 
outlying cell contact sample had been removed. Each circle represents a sample and samples 
clustered in the same area of the graph are considered to be genetically similar. Each colour 
represents a sample condition; red is M-CSF treated macrophages, blue is cell contact activated 
macrophages, gold is synovial fluid derived CD14+ cells, green is patient blood CD14+ cells and 
purple is healthy blood CD14+ cells. 
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3.6  Comparing samples 
3.6.1 Comparison 1: Patient blood compared to normal blood 
Analysing the PCA graph indicated that the CD14
+ cells from both the 8 RA and 8 
PsA patients have a similar gene expression to the 5 healthy control CD14
+ cells. 
It was decided to analyse the genetic profiles of these samples further to see 
how similar they were and to determine if there were any disease-specific genes 
not detected in the healthy controls as has been found by many previous studies 
[325-327, 329, 330, 340, 341]. 
All samples were pre-processed by the GC-RMA algorithm and quality control on 
the entities was performed. To pass the quality control analysis each entity had 
to have a signal value between 20 and 100% in order to remove any background 
signal and each entity had to be expressed in all 21 samples (8 RA PB, 8 PsA PB 
and 5 healthy PB). This is due to the considerable heterogeneity in the patient 
samples  with  regards  to  treatment  and  disease  duration;  we  were  only 
interested in genes that had changed in all disease samples rather than genes 
that changed for example, only in response to a certain treatment type.  
41424 entities passed the quality control analysis that can be visualised as shown 
in Figure 3.5. The y value is the normalised signal intensity of the entity where 
the  signal  is  normalised  to  the  median  value  of  that  entity  across  all  the 
samples. It is a visualisation tool that allows entities with very high or very low 
signal values to be visualised on the same graph. The graph indicates that whilst 
there  are  many  entities  that  do  not  change  their  signal  expression  levels 
between  non-diseased  and  diseased  states  there  are  some  outliers  that  have 
varying levels of intensity in each of the three conditions.  136 
 
Figure 3.5 Profile plot of entities that passed the quality control filter. 
Each line represents an entity and this graph shows the change in the signal intensity value of each 
entity in all healthy samples (left hand side of the graph), PsA PB samples (middle of the graph) 
and RA PB samples (right had side of the graph). The colour of the line denotes the signal intensity 
of the entity in healthy peripheral blood; blue represents a signal intensity of -6 to -1, yellow -1 to 1 
and red 1 to 6. 
3.6.1.1   Statistical analysis of healthy and diseased blood CD14
+ 
cells 
During  microarray  data  analysis,  multiple  testing corrections  (MTC)  should be 
applied where possible to decrease the number of false positives. Any statistical 
tests (e.g. T test, ANOVA) that are performed on microarray data perform one 
test per gene therefore the number of false positives increases proportionally to 
the number of tests performed. For example analysing 10000 genes with a cut-
off p value of 0.05 will mean performing 10000 individual statistical tests and as 
a  result  500  genes  (0.05  x  10000)  are  likely  to  appear  significant  by  chance 
alone. The Benjamini and Hochberg (false discovery rate) MTC gives a corrected 
p value for each gene depending on the number of genes being tested [355]. 
A  one-way  ANOVA  unequal  variance  (Welch  ANOVA)  with  a  Student-Newman-
Keuls (SNK) post Hoc test was used to analyse the 3 microarray conditions of 137 
healthy blood, RA blood and PsA blood. A MTC was unable to be  used in this 
instance  as  when  the  Benjamini  and  Hochberg  MTC  was  used  there  were  no 
significantly changed genes between the three groups. Since a p value cut off of 
0.05 was used this means that 5% of the differentially expressed genes may be 
false positives and appearing by chance alone, a way to overcome this is to look 
at the p values of each gene as the higher the p value of the gene the less 
chance of it being a false positive.  
The one-way ANOVA with a p value cut off of 0.05 gave the following results: 
494 genes significantly changed between RA and PsA PB cells 
1457 genes significantly changed between healthy blood and RA blood 
1384 genes significantly changed between healthy blood and PsA blood 
These results indicate that although the PCA graph showed all of the blood CD14
+ 
samples to be genetically similar, there are groups of genes that are significantly 
changed between samples indicating that there are likely to be disease-specific 
genes being expressed.  
3.6.1.2   Fold change cut off analysis of healthy and diseased 
blood derived CD14
+ cells 
Since there were many genes that had significantly changed between groups a 
fold change analysis was performed to look at differential expression. A cut off 
value of 2 was chosen, consequently if a gene had a fold change difference in 
expression between two conditions that was ≥ 2 then it would be considered 
differentially expressed. The fold change cut off gave the following results: 
43 genes changed between RA and PsA blood CD14
+ cells (22 genes up-regulated 
in RA compared to PsA PB and 21 genes up-regulated in PsA compared to RA PB) 
239 genes changed between healthy blood and RA blood (158 genes up-regulated 
in RA compared to healthy PB and 81 genes down-regulated in RA compared to 
healthy PB) 138 
281  genes  changed  between  healthy  blood  and  PsA  blood  (153  genes  up-
regulated in PsA blood compared to healthy and 128 genes downregulated in PsA 
blood compared to healthy) 
These  results  demonstrate  that  of  the  54,000  probe  sets  on  the  Affymetrix 
GeneChips there are very few of these (43 probes/genes) that are differentially 
expressed  between  RA  blood  and  PsA  blood.  This  result  reinforces  the  PCA 
results  which  showed  the  RA  and  PsA  blood  samples  to  be  grouped  together 
therefore implying these samples were transciptionally similar. Hence from our 
data  it  appears  that  the  blood  monocytes  from  RA  and  PsA  have  similar 
transcriptomic profiles and there are very few genes that are expressed by these 
monocytes that could distinguish them as belonging to either disease. 
Nevertheless there are 43 genes that were distinguished by this analysis as being 
differentially expressed between RA and PsA PB CD14
+ cells with a fold change 
difference of ≥2. Of these 43 gene hits there were only 24 individual genes that 
had changed. This is because on the affymetrix GeneChips each gene can be 
represented by more than one probe set and one gene can be appear several 
times in the differentially changed gene list, also the gene lists often contain 
transcribed loci that have no known function or gene name and therefore cannot 
be analysed further. Of the 24 genes that were differentially expressed between 
RA and PsA blood CD14
+ cells 12 were upregulated in RA blood compared to PsA 
and 12 were upregulated in PsA blood compared to RA. 
Table 3.4 outlines the functions of the 12 genes upregulated in RA PB CD14
+ cells 
compared to PsA PB CD14
+ cells. 
Table 3.5 outlines the functions of the 12 genes upregulated in PsA PB CD14
+ 
cells compared to RA PB CD14
+ cells. 
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Table 3.4 A list of the 12 upregulated genes in RA PB CD14
+ cells compared to PsA PB CD14
+ cells  
Symbol    Gene Name        Fold change upregulation    Description of Gene 
              in RA PB compared to 
PsA PB (p value) 
 
NRP1    Neuropilin 1          5.1 (5.72 X 10
-5)  A single pass transmembrane protein which has various ligands including 
                       semaphorins and VEGF family members. They have principle functions  
in  cell  motility,  including  neural  growth  cone  collapse  mediated  by 
semaphorins, and vascular and lymphatic sprouting triggered by VEGFs 
[356].  NRP-1  is  the  major  VEGF  165  receptor  in  fibroblast  like 
synoviocytes in RA. It is also expressed in the lining layer, endothelial 
cells and infiltrating leukocytes in RA [357]. 
 
NCAM1   Neural cell adhesion molecule 1    3.8 (0.017)    A cell surface glycoprotein which mediates homotypic and heterotypic  
                      cell-cell adhesion through a homophilic binding mechanism. It is present  
                      in the nervous system where it participates in neural outgrowth and cell  
                      migration [358]. NCAM may also play a role in blood vessel stability as  
                      NCAM deficiency results in unstable endothelial cell – pericyte  
interaction and hence vessel stability [359]. 
 
CYB5R2  Cytochrome b5 reductase 2      3.5 (0.021)    Cytochrome b5 is an electron transfer component in oxidative reactions 
such  as  anabolic  metabolism  of  fats  and  steroids  [360].  The  CYB5R2 
isoform is a membrane bound form of cytochrome b5 reductase which 
partakes in fatty acid elongation and desaturation [361] and cholesterol 
biosynthesis. It may also play a role in mitochondrial respiration [362]. 
 
GPR34   G protein-coupled receptor 34    2.8 (0.048)    G protein-coupled receptors are the largest family of receptor proteins 
in mammals and are known to bind to a variety of extracellular ligands 
such  as  chemokines,  enzymes  and  hormones  [363].  GPR34  is  highly 
abundant  in  mast  cells  where  it  acts  as  the  functional  receptor  for 
lysophosphatidylserine which enhances mast cell degranulation [364]. 
 
HPGD    hydroxyprostaglandin dehydrogenase   2.4 (0.0062)    An enzyme responsible for the inactivation of prostaglandins and 
15-(NAD)                lipoxins by catalysing the oxidation of 15(S)-Hydroxyl group resulting 140 
in  metabolites  with  reduced  biological  activity  [365].  It  is 
downregulated  in  human  epithelial  tumours  and  shows  tumour 
suppressor activity [366]. 
 
PKP2    Plakophilin 2          2.3 (0.046)    A protein found co-localised to desmosomes, which are adhesive  
junctions  linking  intermediate  filament  networks  to  sites  of  strong 
intercellular  adhesion.  These  junctions  provide  strength  to  tissue 
undergoing  mechanical  stress  such  as  cardiac  and  epidermal  tissue 
[367].  Plakophilin  2  has  been  detected  in  the  adherens  junctions  of 
cardiomyocytes  [368]  and  can  co-localise  with  β-catenin  at  adherens 
junctions in epithelial cells [369]. 
 
CA5B    carbonic anhydrase VB, mitochondrial  2.2 (0.045)    A metalloenzyme expressed in mitochondria which is involved in several  
                      biosynthetic  processes and plays a key role in fatty acid biosynthesis 
[370]. 
 
IL7    Interleukin 7          2.1 (0.011)    A member of the IL-2 family expressed by epithelial cells in  
lymphopoietic  tissues,  epithelial  cells,  keratinocytes,  DCs  and 
monocytes [371]. IL-7 plays an important role in T cell homeostasis such 
as naïve T cell survival but has also been found to induce bone loss by 
inducing  osteoclast  formation  from  human  monocytes  in  a  T  cell 
dependent manner [372]. Serum levels of IL-7 are higher in RA patients 
compared  to  healthy  controls  and  correlate  with  markers  of 
inflammation [371]. IL-7
+ cells correlate with the number of CD68
+ cells 
in  RA  synovial  lining  and  sub-lining  layers  and  double  staining 
demonstrates that CD68
+ cells are a major producer of IL-7 [373]. 
 
LAMC1   Laminin, gamma 1        2.1 (0.016)    Laminins are extracellular matrix components and are a major  
constituent of basement membranes. Laminin and collagen provide the 
basic  scaffold  to  which  other  basement  membrane  proteins,  such  as 
proteoglycan, integrate [374]. Laminin is also expressed in the cerebal 
cortex and laminin γ1 has been shown to play a critical role in neuronal 
morphogenesis and migration [375]. Laminin γ1 is also required for the 
deposition of matrix molecules in cardiomyocytes [376]. 
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LYCAT   Lysocardiolipin acyltransferase    2.1 (0.011)    In embryonic stem cells (ESC) differentiation lysocardiolipin  
acyltransferase plays an essential role in hematopoietic and endothelial 
lineage development [377]. It is also involved in the remodelling of the 
phospholipid cardiolipin. Cardiolipin is sensitive to oxidative damage by 
reactive  oxygen  species  and  lysocardiolipin  acyltransferase  plays  a 
regulatory role in remodelling cardiolipin in response to stress [378]. 
 
LRP11    Low density lipoprotein receptor-related  2.1 (0.0077)    The LDL receptor related protein (LRP) is a heterodimeric endocytic 
protein 11                cell surface receptor which transports a variety of macromolecules 
into  cells  through  a  process  called  receptor  mediated  endocytosis. 
LRP11 is expressed mainly in the brain and it has been shown to play a 
role in cell-cell adhesion in neurons however it has also been shown to 
be present in vascular smooth muscle cells and can induce enhanced 
migration  and  invasion  activities  [379].  LRP11  may  play  a  role  in 
Alzheimer disease (AD) as its expression is significantly reduced in the 
brains of AD patients, in this setting LRP11 is thought to be a sorting 
protein that protects β-amyloid precursor protein (APP) processing into 
amyloid-β (Aβ) which is the peptide found accumulated within the brains 
of AD patients [380]. 
 
RNF34   Ring finger protein 34        2.0 (0.049)    Otherwise known as human ring finger homologous to inhibitor of  
apoptosis (hRFI). hRFI is an apoptosis regulator protein. Transfection of 
hRFI into HeLa cells resulted in an increase in cell survival after TNFα 
treatment [381] and transfection of hRFI into human colorectal cancer 
cells  significantly  inhibited  death  receptor  mediated  apoptosis  with 
decreased  caspase  activity  [382].  Thus  indicating  that  hRFI  has  anti-
apoptotic activity. 
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Table 3.5 A list of the 12 upregulated genes in PsA blood CD14
+ cells compared to RA blood CD14
+ cells 
 
Symbol    Gene Name        Fold change upregulation    Description of Gene 
              in PsA PB compared to 
RA PB (p value) 
 
GSTM2   glutathione S-transferase M2     3.0 (0.040)      Glutathione S-transferases (GSTs) are a broadly expressed family 
of enzymes which protect against endogenous oxidative stress as 
well as exogenous toxins. They detoxify a variety of electrophilic 
compounds including oxidised lipids and DNA products generated 
by reactive oxygen species damage to intracellular molecules 
[383]. Glutathione S-transferase M2 is a muscle specific enzyme. 
 
GSTM1   Gluthathione S-transferase M1    2.9 (0.035)      (See above for a description of GSTs). Allelic variant within the 
GSTM1 gene are associated with differences in detoxification 
efficiency, the GSTM1 gene has a non-functioning allele termed 
GSTM1-null. RA patients who carry this GSTM1-null polymorphism 
and are smokers are associated with worse disease severity 
[384]. A further study in a Korean population indicated that the 
GSTM1-null polymorphism is associated with increased 
susceptibility to RA [385]. 
 
PPP1R16B  protein phosphatase 1,      2.9 (0.036)      Protein phosphatase 1 (PP1) is a eukaryotic serine/threonine 
regulatory (inhibitor) subunit 16B             phosphatase which regulates a large variety of cellular functions 
through the interaction of its catalytic subunit with over 50 
different regulatory subunits [386]. The PPP1R16B gene encodes 
a protein called TGF-β-inhibited membrane-associated protein 
(TIMAP). TIMAP is expressed at high levels in endothelial cells, 
phosphorylation of TIMAP controls its association with PP1 which 
in turn regulates extension of filapodia within the endothelial 
cells [387]. 
 
 
VASH1   Vasohibin 1          2.9 (0.0088)      An angiogenesis inhibitor upregulated in endothelial cells [388]. 143 
Vasohibin-1 has also been detected in RA synovium in synovial 
lining  cells,  synovial  fibroblast  and  endothelial  cells.  In  vitro 
stimulation  of  RA  synovial  fibroblasts  with  inflammatory 
cytokines  induced  vasohibin-1  mRNA  expression  in  hypoxic 
conditions [388]. 
 
CHST13  Carbohydrate (chondroitin 4)     2.8 (0.013)      Chondroitin sulfotransferases synthesize the diverse sulphated 
sulfotransferase 13                 structures found in the glycosaminoglycans (GAGs) chondroitin  
sulphate [389].  As present there is no defining information on 
the specific role of carbohydrate sulfotransferase 13. 
 
FOXP1   forkhead box P1        2.7 (0.017)      A member of the FOX family of transcription factors. FOXP1 has a 
role in B cell development [390], thymocyte development [391] 
and  monocyte  differentiation  as  downregulation  of  FOXP1  is 
necessary  for  monocyte  differentiation  and  hence  macrophage 
function [392]. 
 
KLF9    Kruppel-like factor 9        2.3 (0.011)      The kruppel-like factor family are zinc finger transcription 
factors.  KLF9  regulates  estrogen  and  progesterone  action  by 
modulating the activity of the progesterone receptor (PGR). It 
directly interacts with PGR to mediate progesterone responsive 
genes [393] and acts as a transcriptional repressor of estrogen 
receptor signalling [394]. 
 
KIF1B    Kinesin family member 1B      2.3 (0.031)      The kinesin superfamily of proteins play a role in organelle  
transport  in  cells  such  as  neurons  and  epithelial  cells  [395]. 
KIF1B  is  a  plus  end  directed  motor  that  transports  synaptic 
vesicle precursors in the axon from the cell body to the synapse 
[396], it has also been shown to transport mitochondria in nerve 
cells [397]. 
 
BIN1    Bridging integrator 1        2.3 (0.035)      BIN1 contains a BAR domain that allows it to interact with  
cellular membranes and induce membrane curvature [398]. BIN1 
is a muscle specific isoform of BAR domain containing proteins. It 
is highly expressed during muscle development and helps 144 
generate the membrane curvature needed to form T-tubules 
[399].  
 
MED26   Mediator complex subunit 26     2.1 (8.6 X 10
-4)    Once of several subunits that comprise the Mediator complex. 
The Mediator complex forms a crucial part of the RNA 
polymerase II transcriptional machinery that is essential for the 
transcription of almost all protein coding genes [400]. 
 
ACSL3    Acyl-CoA synthetase long-chain    2.1 (0.039)      An enzyme isoform involved in lipid synthesis, fatty acid  
family member 3                catabolism and membrane remodelling [401]. 
 
EIF2AK3  Eukaryotic translation initiation factor  2.1 (0.022)      An ER transmembrane protein kinase which functions during 
2-alpha kinase 3                cellular stress as an unfolded protein response (UPR) sensor. It is  
activated by accumulated misfolded proteins in the ER and 
reduces cellular translation to allow the cell to correct for the 
misfolded proteins causing the ER stress before synthesising 
additional proteins [402]. 
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3.6.1.3   Database for annotation, visualisation and integrated 
discovery (DAVID) analysis of genes changed between 
healthy and patient CD14
+ cells 
Following on from the statistical and fold change analysis of the blood  CD14
+ 
samples an analysis of the groups of genes which were changed between healthy 
and patient samples took place. This analysis will identify the function of the 
expressed genes and subsequently group them according to their function. This 
may be more informative rather than studying each individual gene and could 
indicate the phenotype of the diseased CD14
+ cells.   
The  database  for  annotation,  visualisation  and  integrated  discovery  (DAVID) 
analysis was used to investigate the gene lists to see if there was a significant 
enrichment of group of genes required for a specific biological function. DAVID is 
a  publicly  available  software  that  can  systematically  map  a  large  number  of 
genes to their associated biological annotation and then statistically highlight 
the most overrepresented enriched biological processes [403].   
DAVID analyses gene lists in regard to the reference background, which in this 
analysis is all of the genes expressed on the Affymetrix GeneChip. To decide the 
degree of biological enrichment within the input gene list DAVID compares it to 
the reference background for example, if 10% of the gene list are kinases versus 
1% of the genes on the Affymetrix GeneChip then kinases would be classed as 
overrepresented  within  the  gene  list.  The  DAVID  software  uses  a  modified 
Fisher‘s  exact  test  to  measure  the  gene-enrichment  in the  biological  process 
groups  and  groups  with  a  p  value  <0.05  were  considered  to  be  specifically 
associated with the gene list. Each gene is represented by more than one probe 
on the Affymetrix GeneChip and therefore there may be several entities in the 
gene  list  which  correspond  to  the  same  gene,  DAVID  analysis  takes  this  into 
account and will only analyse each gene once irrespective of how many times it 
appears in the gene list.  
The  gene  lists  which  were  analysed  using  DAVID  were  the  up-  and  down-
regulated genes in RA blood CD14
+ compared to healthy blood CD14
+ and the up-
and  down-regulated  genes  in  PsA  blood  CD14
+  compared  to  healthy  blood. 
Related groups of genes with a p value <0.05 were considered to be significantly 
enriched within the gene list, if there were several gene groups associated with 146 
the gene list only the top 10 most significantly associated groups were analysed. 
Figure 3.6 shows the biological process gene groups which were expressed at a 
higher level in RA blood compared to healthy blood CD14
+ (A) and those that 
were  expressed  at  a  lower  level  in  RA  blood  (B).  The  upregulated  groups  of 
genes include genes associated with chemotaxis, which could be in preparation 
of  the  monocytes  extravasating  from  the  blood  into  the  diseased  joints,  and 
genes associated with response to external stimulus. This latter gene group may 
be  due  to  the  proinflammatory  stimuli  found  within  the  serum  of  arthritis 
patients but not healthy controls to which the RA blood monocytes are exposed 
[404, 405]. The downregulated groups of genes in RA PB monocytes include those 
that regulate intracellular protein complex localisation and negative regulation 
of cell migration which reinforces the results shown in graph (A) suggesting that 
RA blood monocytes are upregulating groups of genes which will enable the cell 
to migrate and respond to chemotaxis. 
Figure 3.7 indicates the biological process groups which were upregulated in PsA 
PB  CD14
+  compared  to  healthy  controls  (A)  and  downregulated  in  PsA  PB 
compared to healthy control blood (B). The results of this analysis indicate that 
in comparison to healthy control monocytes the PsA blood monocytes have an 
increased expression of genes involved in DNA packaging, chromatin assembly 
and nucleosome assembly suggesting an overall reduction of DNA transcription 
and  translation  within  these  cells.  The  PsA  blood  monocytes  are  also 
upregulating  genes  involved  in  chemotaxis,  which  was  also  shown  in  the  RA 
blood  monocytes  in  the  previous  figure,  and  may  be  due  to  an  increase  in 
chemokines within the serum of PsA patients in comparison to healthy controls 
[265,  406].  The  downregulated  genes  in  the  PsA  blood  samples  are  mainly 
involved  in  cell  projection,  morphogenesis,  differentiation  and  metabolic 
processes which all involve a large amount of energy expenditure therefore the 
cells could be trying to conserve energy and resources.  
In summary, the purpose of this healthy blood and diseased blood comparison 
was to determine if there were any disease-specific genes not detected in the 
healthy  controls  as  the  PCA  analysis  had  demonstrated  that  the  blood  CD14
+ 
samples in healthy and diseased patients had similar genetic profiles. Despite 
the possibility that 5% of the genes within the gene lists generated are false 
positives due to not being able to apply a multiple testing correction (MTC) to 147 
the  data  there  were a  considerable number  of  differentially  expressed  genes 
between the healthy blood samples and diseased samples. This indicates that 
there are disease specific genes being expressed in the monocytes which in the 
case of both RA and PsA included groups of genes required for chemotaxis and 
cell movement. This analysis also generated the surprising result that there are 
only 24 individual genes that are differentially expressed between RA and PsA 
blood monocytes, this would suggest that the blood monocytes are remarkably 
similar in the two forms of arthritis and may suggest that they play similar roles 
within the diseases.  
 
Figure 3.6 Up and downregulated groups of genes in RA blood compared to healthy blood 
DAVID analysis was used to discover the significantly up- and downregulated biological process 
gene groups as identified by gene ontology (GO). The 10 most significant biological process 
groups are shown which all have a p value <0.05 which is equivalent to a –log p value >1.30. 
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Figure 3.7 Up and downregulated groups of genes in PsA PB compared to healthy PB 
 DAVID analysis was used to discover the significantly up- and downregulated biological process 
gene groups as identified by gene ontology (GO). The 10 most significant biological process 
groups are shown which all have a p value <0.05 which is equivalent to a –log p value >1.30. 149 
3.6.2 Comparison 2: Analysis of microarray results comparing 
psoriatic and rheumatoid patient blood CD14
+ cells to 
synovial fluid CD14
+ cells 
My major questions concerned changes occuring in the genetic profile as the 
CD14
+  cells  of  PsA  and  RA  patients  move  from  the  blood  into  the  synovial 
compartment. The principle component analysis (PCA) plot of the RA and PsA PB 
and SF CD14
+ (Figure 3.8) illustrates that there are numerous genetic differences 
between the PB and SF of both diseases indicated by the PB samples (blue and 
red circles) occupying a separate area of the PCA graph as the SF samples (green 
and purple circles). However this graph also shows that the PB CD14
+ cells of 
both diseases and the SF CD14
+ of the two diseases are transcriptionally similar 
to each other. This observation indicates that there are large genetic differences 
between the site from which the CD14
+ were isolated (i.e. blood and synovial 
fluid) however the genetic differences between diseases at these sites  is small 
(i.e. RA and PsA SF CD14
+ cells are transcriptomically similar). 
3.6.2.1   Statistical analysis of peripheral blood CD14
+ compared to 
synovial fluid CD14
+ 
All samples were pre-processed with the GC-RMA algorithm and quality control 
was  performed  on  the  16  matched  RA  samples  (8  PB  and  8  SF)  and  then 
performed on the 16 matched PsA samples (8 PB and 8 SF). In order to pass the 
quality control filter each gene had to have a signal value between 20 and 100% 
and be expressed in all 16 samples. Again, this was selected due to the high 
heterogeneity of the 8 RA and 8 PsA patients with regard to disease duration and 
patient treatment. Ensuring that each gene was present in all of the 16 RA or 
PsA  samples  being  tested  meant  that  the  analysis  was  only  looking  at  genes 
changed  in  the  disease  condition  as  a  whole  and  was  not  affected  by  an 
individual treatment type.  
Once the quality control had been performed a paired T test was undertaken for 
each disease comparing the matched PB and SF samples of each patient. The p 
value  cut  off  was  0.05  and  the  Benjamini  and  Hochberg  multiple  testing 
correction was applied to the data which gives the genes a corrected p value. 
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Following this analysis there were:  
10763 significantly changed genes between RA PB CD14
+ cells and RA SF CD14
+ 
cells 
9533 significantly changed genes between PsA PB CD14
+ cells and PsA SF CD14
+ 
cells 
Figure 3.9 shows the profile plots of the significantly changed genes between RA 
PB and SF (A) and between PsA PB and SF (B). The profile plot is a visualisation 
tool  similar  to  a  heatmap  to  allow  trends  in  genetic  expression  data  to  be 
identified, however its benefit over a heatmap is that it allows thousands of 
genes to be analysed simultaneously. On these graphs each line represents one 
gene and the colour of the line denotes the median GeneChip intensity value of 
that gene from the 8 blood samples; with blue signifying a low intensity value, 
yellow denotes an intermediate value and red denotes a high level of intensity. 
The  profile  plots  indicate  that  there  are  a  large  number  of  genes  in  both 
diseases which are upregulated in the SF CD14
+ cells compared to PB CD14
+ cells; 
there are also a smaller number of genes which a downregulated in the SF cells 
compared to the PB CD14
+ cells. 
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Figure 3.8 PCA analysis of PB and SF from RA and PsA patients 
PCA analysis was performed on the 32 samples to try and discover trends in the data as samples 
in the same area of the graph are considered to be genetically similar. Each circle represents an 
individual sample and all samples are colour coded per condition, red corresponds to RA PB, blue 
to PsA PB, purple to RA SF and green to PsA SF. 
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Figure 3.9 Profile plots of entities that are significantly changed between PB and SF in RA 
and PsA 
Each line on the profile plot represents one gene and the graphs indicate how the normalised 
signal intensities of the gene change between the PB samples and the SF samples. The colour of 
the line represents the median signal intensity of each gene in the PB samples. A blue line 
indicates the gene was expressed at a low level in the PB, a yellow line indicates an intermediate 
level and a red line a high level of signal intensity. 153 
3.6.2.2   Fold change analysis and Ingenuity pathway analysis (IPA) 
of RA PB vs RA SF and PsA PB vs PsA SF 
The two gene lists which had been generated from the paired T test analysis 
were  subjected  to  fold  change  analysis.  Due  to  the  substantial  number  of 
significantly expressed genes in both diseases a fold change cut off of ≥ 4 was 
applied to the data. In microarray data analysis the fold change cut off value is 
arbitrary and we were interested in genes with a high fold change difference 
between PB and SF. 
The fold change analysis gave the following results: 
  1686 genes significantly changed between RA PB and RA SF with a fold 
change ≥ 4 
  1149 genes significantly changed between PsA PB and PsA SF with a fold 
change ≥ 4 
The varying expression levels of these genes is depicted in Figure 3.10 which is a 
heatmap of all the significantly changed genes between the PB and SF samples 
of  RA  and  PsA  with  a  fold  change  cut  off  of  4.  The  heatmap  displays  the 
normalised  signal  intensity  of  each  gene  within  the  blood  and  synovial  fluid 
samples of each patient. The range in colour represents the relative expression 
levels  of  the  genes  in  each  sample  with  green  representing  a  low  level  of 
expression and red representing a high level of relative expression. Heatmaps 
are used as a visualisation tool and this figure is demonstrating the there appear 
to be many genes which are upregulated in the synovial fluid of the patients in 
comparison  to  the  peripheral  blood  as  demonstrated  by  the  large  number  of 
genes which are green (low level of expression) in the peripheral blood cell but 
are red (high level of expression) in the synovial fluid cells.  
The  two  gene  lists  were  then  subjected  to  ingenuity  pathway  analysis  (IPA) 
which may be used to analyse complicated gene sets and identify genes that are 
part of a common regulatory network. This software has advantages over DAVID 
analysis in addition to identifying the overrepresented molecular and cellular 
functions within the gene list IPA can also identify the canonical pathways as 
well as the diseases and disorders associated with the genes. IPA is similar to 154 
DAVID analysis as it uses Fisher‘s exact test to determine whether an association 
of a biological process or a pathway with the dataset is due to random chance. 
The  smaller  the  p  value  of  the  process  or  pathway  the  less  likely  that  the 
association is random and the more significant the association, in this analysis p 
values less than 0.05 indicate a statistically significant non-random association. 
IPA determines the association of processes and pathways within the gene list by 
comparing  it  to  a  reference  gene  set,  which  in  this  case  are  all  the  genes 
expressed on the Affymetrix GeneChips, and calculating whether the pathways 
or processes are overrepresented in the gene list and whether this association is 
statistically significant using Fisher‘s exact test. 155 
 
Figure 3.10 Heatmap of significantly changed genes with a fold change cut off of 4 between 
the PB and SF of PsA and RA patients 
The normalised signal intensity of each differentially expressed gene with a fold change cut off of 4 
or above is shown. The degree of colour represent the relative level of expression for each gene in 
each sample ranging from green - low relative expression, to red - high relative expression (see 
legend). It can be visualised that there are genes which are expressed at a low level in the blood 
and therefore a high level in the synovial fluid and vice versa. 156 
3.6.2.3   IPA of RA blood vs RA synovial fluid CD14
+ 
The 1686 differentially expressed genes between the RA PB and RA SF CD14
+ 
samples with a fold change cut off of 4 were analysed using IPA. This analysis 
generated  three  sets  of  results  associated  with  the  gene  lists;  the  top  5 
canonical pathways, the top 5 diseases and disorders and the top 5 molecular 
and cellular functions. 
Table 3.6 indicates the top 5 canonical pathways associated with the up- and 
downregulated genes observed in the RA synovial fluid samples.  This analysis 
includes pathways which have previously been associated with RA such as the 
coagulation system and the role of macrophages in RA but also includes other 
pathways such as LXR/RXR activation.  
Figure 3.11 outlines the canonical pathway of LXR/RXR activation which was the 
most significant pathway associated with the RA PB vs SF gene list. All of the 
genes highlighted in the pathway are the 17 genes from the gene list associated 
with the RA comparison; all of these genes are highlighted in red which indicates 
that these genes were upregulated in the synovial fluid CD14
+ cells compared to 
the PB CD14
+ cells. These genes range from pro-inflammatory chemokines such 
as MCP-1 to the cholesterol efflux genes ApoE and ApoC1. The relevance of these 
genes to RA pathogenesis will be analysed in detail in the discussion section of 
this chapter. 
Table 3.7 outlines the diseases and disorders associated with the up- and down-
regulated genes expressed in RA SF CD14
+ compared to RA PB CD14
+. As would be 
expected all the diseases and disorders are related to or involve RA. The range 
of p values shown determines the significance of the gene list to different terms 
encompassed by the diseases and disorders. For example the term inflammatory 
disease includes more specific terms such as inflammatory disorder of the joint, 
arthritis or multiple sclerosis so depending on the association of the gene list 
with each term tested an individual p value is given. Due to the large number of 
terms that can be significant within one category a range of p values is outlined 
in the table. 157 
Table 3.8 outlines the top 5 cellular functions associated with the gene list. The 
gene list comprises genes that are differentially expressed within the RA synovial 
fluid CD14
+ cells and the cellular functions significantly overrepresented in this 
gene list are those which we would expect to be upregulated within the RA SF 
cells in comparison to the PB cells. Two of the cellular functions are cellular 
movement and immune cell trafficking which could be upregulated as a result of 
the CD14
+ transendothelial migration from the blood vessels into the synovium 
[258, 407]. Since macrophages within the synovial compartment are known to 
participate  in  cellular  interactions  with  several  cell  types  such  as  fibroblasts 
[249], T cells [269, 314, 408], endothelial cells [407] and natural killer (NK) cells 
[251] it is no surprise that one of the top cellular functions associated with the 
RA SF CD14
+ cells is cell-to-cell signalling and interaction. The final two cellular 
functions associated with RA SF CD14
+ compared to PB cells are cellular growth 
and  proliferation  and  cellular  development  which  is  logical  due  to  the 
maturation that the CD14
+ cells undergo into fully activated macrophages once 
they are within the synovium and exposed to the pro-inflammatory and hypoxic 
environment [409, 410]. 158 
Table 3.6 The top 5 canonical pathways associated with the RA PB vs RA SF CD14+ 
comparision 
 
Canonical pathway 
p value (number of 
associated 
genes/total number 
of genes in pathway) 
 
LXR/RXR activation 
Hepatic fibrosis/ hepatic stellate cell activation 
Role of mø, fibroblasts and endothelial cells in RA 
LPS/IL-1 mediated inhibition of RXR function 
Coagulation system 
 
3.96 x 10
-7 (17/86) 
2.27 x 10
-5 (21/131) 
7.20 x 10
-5 (36/366) 
1.07 x 10
-4 (25/205) 
1.98 x 10
-4 (9/37) 
 
Table 3.7 The top 5 diseases and disorders associated with the RA PB vs RA SF CD14
+ 
comparison 
 
Diseases and Disorders 
 
p value 
 
Connective Tissue Disorders  
Inflammatory Diseases 
Skeletal and Muscular Disorders 
Immunological Diseases 
Inflammatory Response 
 
4.68x10
-15 – 4.77x10
-4 
4.68x10
-15 – 5.90 x 10
-4 
4.68x10
-15 – 4.77x10
-4 
9.70x10
-14 – 4.43x10
-5 
2.79x10
-13 – 7.03x10
-4 
 
Table 3.8 Top 5 molecular and cellular functions associated with the RA PB vs RA SF CD14
+ 
comparison 
 
Molecular and Cellular Functions 
 
p value 
 
Cellular movement 
Cell-to-cell signalling and interaction 
Cellular growth and proliferation 
Immune cell trafficking 
Cellular development  
 
1.00x10
-23 – 5.90x10
-4 
1.40x10
-17 – 7.03x10
-4 
9.08x10
-17 – 7.05x10
-4 
1.72x10
-15 – 1.35x10
-4 
7.08x10
-13 – 6.89x10
-4 
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Figure 3.11 LXR/RXR activation canonical pathway associated with the RA PB vs SF 
comparison 
This diagram outlines the genes involved in LXR and RXR activation which were differentially 
expressed in the RA PB vs RA SF comparison. The genes which are coloured red are those which 
were expressed at a higher level in the RA SF cells and therefore are genes which are upregulated 
once the blood CD14
+ cells enter the synovial environment. 160 
3.6.2.4   IPA analysis of PsA blood vs PsA synovial fluid CD14
+ 
The  1149  genes  differentially  expressed  with  a  fold  change  ≥  4  in  the  PsA 
synovial fluid compared to the PsA blood CD14
+ were analysed using IPA. As with 
the RA blood vs synovial fluid investigation this analysis yielded three sets of 
results associated with the gene list: the top 5 canonical pathways, the top 5 
diseases and disorders and the top 5 molecular and cellular functions. 
Table  3.9  demonstrates  the  top  5  canonical  pathways  associated  with  the 
differentially expressed genes in the PsA SF CD14
+ samples compared to the PsA 
CD14
+ blood samples. Three of the pathways overlap with the results of RA SF 
associated  pathways  once  again  emphasizing  the  similarities  between  the 
synovial fluid macrophages of both RA and PsA. The PsA SF specific canonical 
pathways included the complement system and intriguingly the pathogenesis of 
multiple sclerosis. The elements of this canonical pathway along with the PsA 
genes  associated  with  it  can  be  visualised  in  Figure  3.12.  This  diagram 
demonstrates that the PsA SF differentially expressed genes associated with the 
pathogenesis of multiple sclerosis pathway are all chemokines and emphasises 
the  overlap  in  inflammatory  gene  expression  between  immune  mediated 
diseases. 161 
Table 3.10 outlines the diseases and disorders associated with the differentially 
expressed genes in PsA SF CD14
+ cells compared to PsA PB CD14
+ cells. As was 
observed with the RA SF gene set in Table 3.7 all of the diseases and disorders 
associated with immunological disease and the inflammatory response. 
Table 3.11 outlines the cellular functions associated with PsA SF CD14
+ cell gene 
expression.  There  is  considerable  overlap  between  the  cellular  functions 
associated with PsA SF and RA SF CD14
+ cells as four of the top five functions 
associated with RA are also associated with PsA. All of the five cellular functions 
would be expected to be differentially expressed in PsA SF CD14
+ cells compared 
to the matched peripheral blood cells. In PsA, monocytes are known to migrate 
from the blood into the inflamed joint [254, 411] (demonstrated by the functions 
cellular movement and immune cell trafficking) where they interact with other 
cell types and illicit an immune response [412] (demonstrated by the functions 
cell-to-cell signalling and interactions and cell mediated immune response), the 
pro-inflammatory  environment  also  enables  the  differentiation  of  these  cells 
into activated macrophages (demonstrated by the function cellular growth and 
proliferation).  Hence,  the  cellular  functions  being  undertaken  by  the  PsA  SF 
CD14
+ cells as they move from the blood into the synovium are the functions 
needed  to  transform  them  into  an  activated,  pro-inflammatory  immune  cell 
capable of sustaining the chronic inflammation seen in psoriatic arthritis. 162 
Table 3.9 Canonical pathways associated with the PsA PB vs PsA SF CD14
+ comparison 
Canonical pathway  p value (number of 
associated genes/total 
genes in pathway) 
LXR/RXR activation  
Complement system 
LPS/IL-1 mediated inhibition of RXR function 
Pathogenesis of multiple sclerosis 
Hepatic fibrosis/hepatic stellate cell activation 
8.52 x 10
-6 (13/86) 
7.12 x 10
-5 (8/35) 
2.09 x 10
-4 (20/205) 
4.50 x 10
-4 (4/9) 
1.67 x 10
-3 (14/131) 
 
Figure 3.12 Pathogenesis of multiple sclerosis canonical pathway associated with the PsA 
PB vs PsA SF CD14+ cell comparison. 
Component of the pathway coloured red are genes that are upregulated in the PsA SF CD14+ 
cells. Four of the nine pathway components are upregulated in PsA SF macrophages. 163 
Table 3.10 Diseases and disorders associated with the PsA PB vs PsA SF CD14
+ 
comparison 
 
Diseases and Disorders 
 
p value 
 
Inflammatory Disease 
Connective Tissue Disorder 
Skeletal and Muscular Disorders 
Immunological Disease 
Inflammatory Response 
 
2.58x10
-15 – 2.21x10
-3 
2.76x10
-15 – 2.08x10
-3 
2.76x10
-15 – 1.70x10
-3 
6.64x10
-14 – 2.08x10
-3 
4.83x10
-10 – 2.21x10
-3 
 
Table 3.11 Molecular and cellular functions associated with the PsA PB vs PsA SF CD14
+ 
comparison 
 
Molecular and Cellular Function 
 
p value 
 
Cellular Movement 
Cell-to-cell signalling and interaction 
Cellular Growth and Proliferation 
Immune Cell Trafficking 
Cell Mediated Immune Response 
 
2.98x10
-20 – 2.31x10
-3 
1.51x10
-16 – 2.15x10
-3 
3.41x10
-13 – 2.21x10
-3 
1.18x10
-13 – 1.14x10
-3 
7.86x10
-9 – 2.15x10
-3 
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3.6.2.5   Depicting RA and PsA differentially expressed genes 
Analysis of the foregoing results identified the interesting observation that the 
synovial fluid CD14
+  cells of both the RA and PsA patients shared substantial 
similarity in gene expression. This observation was first identified by examining 
the PCA plot (Figure 3.8) depicting the SF samples of both diseases were co-
localised indicating a similarity in the overall transcriptomes of the two diseases. 
The subsequent IPA analysis then identified that many of the same canonical 
pathways and cellular functions appeared in both diseases therefore signifying a 
similarity in gene expression. Consequently, it was decided to further analyse 
the  genes  that  had  changed  in  the  RA  and  PsA  PB  and  SF  samples  as  we 
hypothesized  that  there  would  be  a  subset  of  genes  that  changed  in  both 
diseases as well as subsets of genes that had only changed in RA or PsA. To 
answer this hypothesis a Venn diagram was constructed (Figure 3.13) using the 
following gene lists: 
All entities (shown in blue), which is the list of genes that had a positive signal 
on the GeneChip in any of the samples. This is the starting list of genes before 
any quality control analysis has been done.  
PsA PB vs PsA SF (shown in green), these are the differentially expressed genes 
between PsA PB and PsA SF. According to a paired T test and Benjamini and 
Hochberg MTC each gene has a corrected p value ≤ 0.05. 
RA PB vs RA SF (shown in red), this list represents the differentially expressed 
genes  between  RA  PB  and  RA  SF.  The p  values  were  calculated  in  the  same 
manner as those for the PsA comparsion. 
Figure  3.13  indicates  the  Venn  diagram,  analysing  the  results  proved  our 
hypothesis to be correct as the diagram produced three gene lists: 
1.  Genes that are specifically changed in only the RA PB vs RA SF analysis 
(5158 genes) 
2.  Genes that are specifically changed only in the PsA PB vs PsA SF analysis 
(3928 genes) 165 
3.  Genes that are changed in both diseases (5605 genes) 
These gene lists also demonstrate that 58% (5605 of 9533 total genes) of the PsA 
SF CD14
+ differentially expressed genes and 52% (5605 of 10763 total genes) of 
the  RA  SF  CD14
+  differentially  expressed  genes  are  present  in  both  of  the 
diseases.  This  indicates  that  there  is  a  significant  and  substantial  amount  of 
overlap between the transcriptomes of the synovial fluid CD14
+ cells of the two 
diseases. 
 
 
 
Figure 3.13 Venn diagram of the differentially expressed genes between RA PB and SF and 
between PsA PB and SF 
Gene lists were applied to the Venn diagram in order to distinguish genes that were changed in 
both RA and PsA and genes that were changed in only one of the diseases. The blue circle 
represents all of the genes which were expressed on the Affymetrix GeneChips. The red circle 
represents differentially expressed genes between RA PB and RA SF which had a p value ≤ 0.05. 
The green circle represents the differentially expressed genes between the PsA PB and PsA SF 
which had a p value ≤ 0.05. The regions where these three circles overlap represent genes which 
are expressed in both RA and PsA (5605 genes), in RA only (5158 genes) and in PsA only (3928 
genes). 166 
Prior to any further analysis a fold change cut off of 4 was applied to the data. 
Since the fold change cut off in microarray data analysis is arbitrary we decided 
a  high  fold  change  cut  off  to  specifically  focus  on  the  genes  that  were 
differentially  expressed  to  a  large  extent.  The  fold  change  cut  off  gave  the 
following three gene lists: 
1.  Up-  and  downregulated  genes  that  are  changed  in  both  diseases  (873 
genes) 
2.  Up- and downregulated genes that are changed in the PsA PB vs PsA SF  
analysis only (154 genes) 
3.  Up- and downregulated genes that are changed in the RA PB vs RA SF 
analysis only (348 genes) 
IPA analysis was subsequently performed on these three gene lists to determine 
the  canonical  pathways  associated  with  both  diseases  and  each  disease 
individually.  Specifically  the  genes  that  were  up-  and  down-regulated  in  the 
synovial fluid compared to the peripheral blood CD14
+ cells of the diseases were 
analysed to try to determine what pathways were activated within the synovial 
fluid macrophages once they were exposed to the proinflammatory environment 
of the joint. The diseases and disorders analyses in the previous IPA comparisons 
were not very informative as they highlighted that the diseases associated with 
our gene lists were related to arthritic and inflammatory disorders. Therefore in 
this IPA analysis only the canonical pathways and molecular functions associated 
with the genes lists were investigated. 167 
Table  3.12  shows  the  canonical  pathways  associated  with  the  differentially 
expressed genes that were similarly expressed in both RA and PsA synovial fluid. 
These pathways are the same as those that were identified in the IPA analysis of 
the  RA  PB  vs  SF  and  PsA  PB  vs  SF  comparison  (Table  3.6  and  Table  3.9 
respectively).  Table  3.13  demonstrates  the  molecular  and  cellular  functions 
associated with the gene list which was differentially expressed in both RA and 
PsA synovial macrophages.  These functions have previously been identified in 
the RA PB vs SF and the PsA PB vs SF comparisons and demonstrate the shared 
macrophage functions between the two diseases. 168 
Table 3.14 identified the canonical pathways that are significantly associated 
with the subset of genes which are differentially expressed specifically in the 
synovial fluid CD14
+ cells of the PsA patients but not the RA patients. It outlines 
pathways that would not usually be associated with macrophages such as B cell 
development  and  altered  B  and  T  cell  signalling  in  RA.  Investigating  the 
differentially expressed genes from the gene list which are associated with these 
pathways identifies genes that are expressed in both macrophages and B cells/T 
cells such as CD40, MHC II and TLR3. This result is highlighted in  Figure 3.14 
which  demonstrates  that  the  two  genes  within  B  cell  development  canonical 
pathway associated with the PsA only gene list, are MHC II and CD40 which are 
two genes that are known to be expressed in both B cell and macrophages. 
Table  3.15  outlines  the  molecular  and  cellular  functions  associated  with  the 
differentially  expressed  genes  found  specifically  in  the  PsA  SF  CD14
+  cells 
compared to the PsA PB CD14
+ cells. Two of these functions, cellular movement 
and cell-to-cell signalling and interaction, were previously associated with the 
broad PsA PB vs SF CD14
+ comparison, however the other three functions which 
consist of DNA replication, cell cycle and cell death are unique to the PsA SF 
CD14
+ expressed genes and demonstrate the disease specific cellular functions. 
Table  3.16  outlines  the  canonical  pathways  significantly  associated  with  the 
subset of genes differentially expressed specifically within the RA synovial fluid 
CD14
+  cells.  The  top  two  pathways  were  previously  associated  with  the 
differentially  expressed  genes  in  RA  PB  vs  SF  (see  Table  3.6)  however  this 
analysis  of  the  unique  genes  expressed  in  RA  SF  cells  identifies  three  other 
pathways  involving  intracellular  signalling  within  the  macrophages  including 
atherosclerotic,  p38  and  ERK5  signalling.  Figure  3.15  demonstrates  the  ERK5 
canonical pathway and outlines the five genes from the RA gene list which were 
associated  with  the  pathway.  In  this  figure,  genes  highlighted  in  green  were 
expressed at a higher level in the RA PB CD14
+ cells compared to the SF cells 
whereas genes highlighted in red denote the genes which were expressed at a 
higher level in the RA SF CD14
+ cells compared to RA PB CD14
+ cells. Table 3.17 
outlines  the  molecular  and  cellular  functions  associated  with  the  gene  list 
expressed  by  RA  SF  CD14
+  cells  only.  All  of  these  functions  were  previously 
associated with the broad analysis of RA PB vs SF CD14
+ apart from the function 169 
of cell morphology. Hence cell morphology is a disease specific function and is 
only associated with RA SF CD14
+ cells. 170 
Table 3.12 Canonical pathways associated with the differentially expressed genes in BOTH 
RA and PsA synovial fluid 
 
Canonical Pathways expressed in BOTH RA and 
PsA synovial fluid CD14
+ 
P value (number of associated 
genes/total number of genes 
in pathway) 
LXR/RXR activation 
LPS/IL-1 mediated inhibition of RXR function 
Complement system 
Hepatic fibrosis/Hepatic stellate cell activation 
Pathogenesis of Multiple Sclerosis  
3.28x10-6 (12/76) 
7.07x10-5 (18/197) 
1.00x10-4 (7/34) 
1.52x10-3 (12/128) 
3.11x10-3 (3/9) 
 
Table 3.13 Molecular and cellular functions associated with the differentially expressed 
genes in BOTH RA and PsA synovial fluid 
 
Molecular and cellular functions associated 
with BOTH RA and PsA synovial fluid CD14
+ 
P value 
Cellular movement 
Cellular growth and proliferation 
Cell-to-cell signalling and interaction 
Cellular development 
Cellular function and maintenance  
9.80x10-17 – 1.15x10-2 
3.51x10-12 – 1.15x10-2 
1.09x10-11 – 1.15x10-2 
3.96x10-7 – 1.15x10-2 
5.32x10-7 – 1.15x10-2 
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Table 3.14 Canonical pathways associated with the differentially expressed genes in PsA 
only 
 
 
Canonical pathways expressed in PsA synovial fluid 
CD14
+ only 
P Value (number of 
associated genes/total 
number of genes in 
pathway) 
B cell development  
Allograft rejection signalling  
Pathogenesis of Multiple Sclerosis 
Autoimmune Thyroid disease signalling  
Altered T and B cell signalling in Rheumatoid Arthritis 
8.08x10-4 (3/30) 
1.53x10-3 (3/51) 
1.75x10-3 (2/9) 
1.79x10-3 (3/53) 
2x10-3 (4/85) 
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Figure 3.14 B cell development canonical pathway associated with the genes expressed in 
PsA synovial fluid only 
The two genes highlighted within this pathway (MHC II, CD40) are expressed in the PsA only gene 
list and are associated with this pathway. These genes are highlighted in red which indicates that 
they were upregulated in the PsA SF compared to PsA PB. 
 
Table 3.15 Molecular and cellular functions associated with the differentially expressed 
genes in PsA only 
Molecular  and  cellular  functions  associated  with 
PsA synovial fluid CD14
+ only 
P value 
Cellular movement  
DNA replication, recombination and repair 
Cell-to-cell signalling and interaction 
Cell cycle 
Cell death 
3.34x10
-7 – 2.16x10
-2 
1.08x10
-5 – 1.91x10
-2 
1.74x10
-5 – 2.16x10
-2 
2.46x10
-5 – 2.16x10
-2 
3.47x10
-5 – 2.16x10
-2 
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Table 3.16 Canonical pathways associated with the differentially expressed genes in RA 
only 
 
Canonical  pathways  expressed  in  RA  synovial 
fluid CD14
+ only 
p value (number of 
associated genes/total 
number of genes in 
pathway) 
Heptatic fibrosis/hepatic stellate cell activation 
Role of mø/fibroblasts and endothelial cells in RA 
Atherosclerosis signalling 
p38 MAPK signalling 
ERK5 signalling 
5.27x10
-5 (9/128) 
2.19x10
-4 (13/329) 
2.95x10
-4 (7/107) 
1.52x10
-3 (6/96) 
1.54x10
-3 (5/69) 
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Figure 3.15 ERK5 signalling canonical pathway associated with the genes expressed in RA 
synovial fluid only 
The highlighted genes are those that were differentially expressed only in the RA PB vs RA SF 
comparison. Genes highlighted in green indicate genes which were downregulated in RA SF 
CD14
+ cells and therefore were expressed at a higher level in RA PB CD14
+ cells. Genes which 
are highlighted in red demonstrate genes which were expressed at a higher level in RA SF CD14
+ 
cells compared to the RA PB CD14
+ cells. 175 
Table 3.17 Molecular and cellular functions associated with the differentially expressed 
genes in RA only 
Molecular and cellular functions associated with 
RA synovial fluid CD14
+ only 
P value 
Cellular movement  
Cellular growth and proliferation 
Cellular development 
Cell-to-cell signalling and interaction 
Cell morphology 
1.09x10
-14 – 4.09x10
-3 
3.19x10
-11 – 3.75x10
-3 
1.38x10
-9 – 4.12x10
-3 
4.87x10
-9 – 3.57x10
-3 
9.64x10
-8 – 4.90x10
-3 
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3.6.2.6   Table of genes highly upregulated in both RA and PsA SF 
samples 
The IPA analysis was very informative in defining the groups of genes and the 
pathways  involved  in  the  RA  and  PsA  synovial  CD14
+  cells  however  we  also 
wanted to study individual genes and their expression within each disease to try 
and identify novel pathways of arthritis pathogenesis. The aim of the subsequent 
analysis therefore was to locate novel genes that were increased in the CD14
+ SF 
samples of both diseases. The list of genes upregulated in both RA and PsA SF 
cells  compared  to  their  matched  blood  cells  was  obtained  from  the  Venn 
diagram analysis and analysed in order of descending fold change. Starting from 
the  most highly  expressed  genes  in  both RA  and  PsA  synovial fluid  literature 
searches were performed on genes to determine their function and expression. 
Unsurprisingly, many genes had been previously associated with or found to be 
highly expressed in either RA or PsA; however some novel genes were also found. 
Table 3.18 lists several of the genes that were analysed. 
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  Table 3.18 Gene upregulated in BOTH RA and PsA synovial fluid CD14+ cells 
 
Symbol  Gene Name        Fold change    Fold change      Description of Gene 
              upregulation    upregulation 
in RA SF (p value)  in PsA SF (p value) 
 
SPP1    Secreted phosphoprotein 1    1762 (3.8x10
-4)  484 (3.2x10
-4)   An extracellular matrix glycoprotein expressed  
(osteopontin)                    by many inflammatory cells. It is up-regulated  
in response to injury and inflammation  [413]. 
Thrombin cleaved OPN is found in RA SF at a 
                          30 times higher concentration compared to OA 
                          SF [414]. 
 
CCL18   Chemokine ligand 18     326 (6.4x10
-5)   375 (2.7x10
-4)   A T cell attracting chemokine expressed by 
                          monocytes/macrophages and DCs [415]. Levels  
of CCL18 in RA were higher than in OA in serum, 
synovial fluid, cartilage and synovial tissue. These 
levels were positively correlated with disease activity 
and rheumatoid factor levels [416, 417]. 
 
APOCI   Apolipoprotein C-I      482 (3.3x10
-4)   344 (5.4x10
-4)   Apo C-I along with Apo C-II are constituents of  
high-density lipoprotein (HDL) that slows the clearance 
of triglyceride-rich lipoproteins [418]. 
 
PLTP    Phospholipid transfer protein   98 (8.9x10
-4)    246 (2.7x10
-4)   PLTP facilitates the transfer of phospholipids  
from triglyceride-rich lipoproteins to HDL via an enzyme 
lipoprotein lipase (LPL) [419]. PLTP may play a role in 
atherosclerosis depending on its expression. Systemic 
over-expression of PLTP is associated with increased 
atherosclerosis susceptibility [420] whereas in an LDLr
-
/- mouse model, which is susceptible to atherosclerosis, 
macrophage derived PTLP was found to be 
atheroprotective [421]. 
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AXL    AXL receptor tyrosine kinase   72 (0.002)    203 (2.4x10
-4)   AXL subfamily is involved in cell adhesion,  
motility, angiogenesis and signal transduction. It may 
play a role in the invasiveness of cancers [422]. 
 
FN1    Fibronectin 1        263 (8.1x10
-4)   172 (5.6x10
-4)   A glycoprotein that has roles in adhesion of  
multiple cell types to the extracellular matrix (ECM), 
migration, proliferation, matrix remodelling and tissue 
repair [423]. Activated T cells and macrophages 
secrete fibronectin [424] and RA SF contains 2 to 3 
times more fibronectin than RA plasma [425]. 
Fibronectin is present in the SF, synovial membrane 
and plasma of PsA patients [426-428]. 
 
LGM    Legumain        167 (1.7x10
-4)   164 (2.7x10
-4)   A lysomal cysteine proteinase that is specific  
for the hydrolysis of asparaginyl bonds [429]. It can 
cleave and activate MMP2 [429]; α-thymosin [430]; 
fibronectin [431] and cathepsin B, H and L [432]. It is 
over-expressed in tumour associated macrophages in 
breast cancer tumours [433]; unstable atherosclerotic 
plaque macrophages [434]; and lesional atopic 
dermatitis and psoriasis [435]. 
 
AQP3    Aquaporin 3        62 (5.5x10
-4)    30 (4.4x10
-4)    A small hydrophobic membrane protein  
involved in the transport of water and glycerol across 
the cell membrane [436]. AQP3 is expressed in the 
basal layer of keratinocytes mammalian skin [437, 438]. 
AQP3 has been found in OA cartilage [439] and in 
PBMCs from RA patients where it was associated with 
DAS28-CRP levels [440]. 
 
NRP1    Neuropilin 1        11 (0.002)    40 (7.0x10
-4)    Single pass transmembrane glycoprotein  
involved in cell motility and whose ligands include 
semaphorins and VEGF family members [356]. 
Neuropilin 1 is the VEGF 165 receptor in fibroblast like 179 
synoviocytes in RA and is also expressed on infiltrating 
leukocytes [357]. Neuropilin 1 mRNA has also been 
detected in OA but not healthy cartilage samples [441].  
 
PLXNA1  Plexin A1        26 (4.9x10
-4)    27 (9.9x10
-4)    Single membrane spanning proteins which,  
along with neuropilins, are receptors for semaphorins 
[442]. Plexin A1 expression is increased during M-CSF 
differentiation [443] and it is thought to be important for 
T cell – DC interactions as plexin A1 deficient DCs 
Induced 50% less T cell proliferation than control DCs 
[444]. 
 
PDPN    Podoplanin        6 (0.02)    22 (0.001)    A mucin-type transmembrane glycoprotein that  
is involved in lymphatic vessel formation. It is a specific 
marker for lymphatic endothelium and is not expressed 
in blood vessels [445]. TNFα blockade therapy 
promotes the proliferation of lymphatic vessels, the 
inflamed synovium of RA and SpA patients receiving 
TNF blockade therapy stained for podoplanin [446]. 
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Table  3.18  demonstrates  the  subset  of  genes  that  were  explored  in  silico  in 
depth from the list of genes upregulated in SF CD14
+ cells of both diseases. They 
were analysed based on their large fold change increased in the SF; this analysis 
was set up to try and discover novel genes that as yet had not been analysed in 
the context of RA and PsA arthritis. Several novel genes were found but after 
performing comprehensive literature searches two of these genes, an enzyme 
called  legumain  and  a  surface  receptor  called  plexin  A1,  appeared  to  be 
candidate genes which may have particular relevance to the pathogenesis of the 
synovial macrophage in both PsA and RA. It was decided to concentrate further 
research  on  these  two  genes  to  try  and  discover  why  they  were  highly 
upregulated in the SF CD14
+ cells of both RA and PsA. The following two chapters 
demonstrate the experimental work performed to try and understand the role of 
these genes within the synovial environment. 181 
3.7  Discussion 
Microarrays have become a standard method to investigate differential disease 
states  on  the  basis  of  genome-wide  expression.  Previously,  there  have  been 
numerous microarray studies analysing the two diseases RA and PsA. However, 
these studies mainly focused on the gene expression of PBMCs or whole synovial 
tissue and as yet very few studies have measured the gene expression within 
individual immune cell types. Macrophages are an essential component of the 
inflammatory  cell  influx  into  the  joint,  being  one  of  the  major  cell  types 
producing the pro-inflammatory cytokines, chemokines and extracellular matrix 
components  which  all  contribute  to  the  destruction  and  degradation  of  the 
arthritic joint [258]. Since very little is known about the transcriptomic profile 
of this cell type within RA or PsA we decided to microarray chip analyse several 
different samples to try and elucidate which genes were being expressed in (1) 
diseased blood monocytes compared to healthy controls, and (2) synovial fluid 
macrophages compared to blood monocytes. 
Once  all  the  patient  and  normal  samples  had  been  collected,  prepared  and 
individually hybridized onto Affymetrix GeneChips the results were subjected to 
quality control to detect any outliers. Quality control must take place during 
microarray  analysis  to  ensure  that:  i)  the  data  is  suitable  to  answer  the 
experimenter‘s  question  and  ii)  the  data  is  suitable  for  subsequent  analysis 
[447]. For the current analysis quality control consisted of examining the signal 
intensity of the GeneChips on a signal histogram which resulted in the detection 
of a GeneChip which had an abnormal signal intensity. This outlier was further 
confirmed by analysing the principle component analysis (PCA) plot which graphs 
the overall transcriptomic signature of each sample. Quality control problems 
can come from several sources; for example the hybridisation step can cause 
uneven  fluorescence on  the  chip  and  differences  in  RNA  quality  can produce 
variable signal intensity and reports have shown that removing outlier GeneChips 
can improve the detection of differentially expressed genes [447], therefore the 
outlier sample identified in this study was removed from further analysis. 
Once the outlier was removed a PCA plot of the samples was setup to identify 
trends  in  the  data  since  samples  clustered  within  the  same  area  of  the  PCA 
graph are considered to be genetically similar [354]. This analysis identified that 182 
the blood CD14
+ cells from both RA and PsA were genetically similar and also the 
synovial fluid CD14
+ cells from both diseases had similar genetic profiles, which 
was a surprising result as previous studies had identified differential subsets of 
macrophages in RA compared to PsA [253, 255]. On the basis of the PCA plot and 
the original hypotheses we decided to perform two main comparisons:  i)  the 
differentially  expressed  genes  in  the  patient  blood  CD14
+  cells  compared  to 
those of the healthy blood CD14
+ cells, and ii) the differentially expressed genes 
in the patient synovial fluid CD14
+ compared to the matched blood CD14
+ cells. 
3.7.1 Comparison 1: Healthy blood versus diseased blood  
The first data comparison to take place was analysing CD14
+ cells isolated from 
the blood of diseased patients and healthy controls. Previously there have been 
several  microarray  analyses  comparing  peripheral  blood  mononuclear  cells 
(PBMCs) or peripheral blood cells (PBCs) of healthy donors to those of patients 
with rheumatic diseases such as RA, PsA and JIA [325-327, 329, 330, 340, 341]. 
These  studies  have  been  very  informative  in  distinguishing  disease  specific 
expression profiles such as the microarray analysis work by van der Pouw Krann 
et  al  which  discovered  a  type  I  IFN  subpopulation  of  RA  patients  who  had  a 
higher  expression  of  type  I  IFN  specific  genes  and  a  distinct  biomolecular 
phenotype  compared  to  healthy  controls  [329].  Batliwalla  et  al  performed  a 
similar  microarray  analysis  comparing  the  PBCs  of  PsA  patients  to  those  of 
healthy controls and identified specific genes that could discriminate healthy 
controls  from  PsA  patients,  which  they  suggested  could  act  as  diagnostic 
biomarkers for PsA [340]. Consequently, microarray analysis comparing healthy 
and diseased peripheral blood cells have provided a wealth of information for 
rheumatic  disease  and  identified  many  disease  specific  genes  and  biological 
processes.  
However, this type of analysis is not without problems and several analyses have 
reported  skewing  of  the  overall  data  and  gene  expression  due  to  differing 
numbers of cell subtypes within the whole blood. Batliwalla et al came across 
this  problem  when  examining  the  gene  expression  profiles  of  PBCs  from  RA 
patients to those isolated from healthy controls. They found 40% of the genes 
differentially upregulated in the RA cells were classed as ―monocyte enriched‖ 
which  they  later  discovered  was  due  to  significantly  higher  numbers  of 183 
monocytes in the RA patient PBCs compared to those of healthy controls [326]. 
Thus whilst microarray analysis on whole blood cells is informative, difficulties 
can arise when trying to account for differences in the number of cell subtypes 
which can cause complications when trying to compare and verify work between 
groups.  
Whole blood microarray profiling may also be masking the individual contribution 
of cell subtypes to the disease therefore microarray analysis of individual cell 
types  from  diseased  patients  may  be  a  useful  strategy  in  understanding  the 
genetic makeup of these cells. Recently, a small number of studies have been 
performed looking at the gene expression profiles of specific  cell types in RA 
such  as  B  cells  [336],  CD4
+  T  cells  [337]  and  fibroblasts  [334].  One  study 
performed  by  Stuhlmuller  et  al  has  also  analysed  the  gene  expression  of  RA 
blood monocytes isolated during the course of leukapheresis treatment  [338]. 
However, at present there have been no studies analysing the blood monocytes 
of  RA  and  PsA  compared  to  healthy  donor  blood  monocytes.  Given  the 
importance of the monocyte/macrophage in the pathogenesis of RA and PsA we 
hypothesised  that analysing  the  gene  expression  profile  of  this  cell  subset  in 
comparison to healthy controls may elucidate disease specific genes and also 
discriminate differences in gene expression between the two diseases. 
Peripheral blood isolated CD14
+ cells were analysed from 8 RA patients, 8 PsA 
patients and 5 healthy controls. When these samples were analysed on the PCA 
plot (Figure 3.4) we discovered the intriguing result that all of the peripheral 
blood  samples  were  clustered  together  indicating  a  similar  gene  expression 
profile expressed by the healthy and diseased sample conditions. Since most of 
the  previous  microarray  experiments  of  healthy  vs  diseased  PBMCs  have 
demonstrated  a  significant  difference  in  the  genetic  profiles  of  the  two 
conditions  this  result  may  suggest  that  the  large  genetic  differences  seen  in 
these experiments are not the result of differences in the monocytes but may be 
due to large genetic differences between other cell subtypes. 
Of the 12 genes which are upregulated in RA blood monocytes compared to PsA 
monocytes three (NCAM1, PKP2 and LAMC1) are associated with cell adhesion 
and interaction. Neural cell adhesion molecule 1 (NCAM1) otherwise known as 
CD56 is usually expressed on cytotoxic cells such as natural killer (NK) cells and 184 
NK-T  cells.  However,  a  small  population  of  CD56
+  monocytes  have  been 
identified in healthy individuals which can present antigen and produce a variety 
of monocyte cytokines in response to LPS stimulation [448]. CD56
+ NK cells are 
enriched at the inflammatory sites in RA where they have been found to interact 
with monocytes and induce TNFα expression in a cell contact dependent manner 
[251,  449].  Conversely,  CD56
+  CD8
+  CD28
-  T  cells  displayed  strong  anti-
inflammatory  properties  in  a  SCID  mouse  chimera  model  of  human  RA  by 
interacting with APCs and causing the subsequent down-regulation of CD80 and 
CD86 [450]. NCAM1 is known to mediate cell-cell adhesion and the data above 
suggests that it plays a role in cell adhesion and interaction therefore we can 
hypothesise that NCAM1 expression in RA blood monocytes may be playing a role 
in cell-cell interaction.  
PKP2  and  LAMC1  are  two  novel  genes  not  previously  associated  with  RA. 
Plakophilin 2 (PKP2) is normally found co-localised with adhesive junctions in 
cardiomyocytes and epithelial cells [368, 369] therefore its possible role in RA 
blood monocytes is unclear at present. LAMC1 (laminin gamma 1) is a subunit of 
all laminin molecules which are major constituents of basement membranes and, 
along  with  collagen,  provide  the  basic  scaffold  to  which  other  basement 
membrane  proteins,  such  as  proteoglycan,  integrate  [374].  Laminins  have 
structural, adhesive and cell signalling functions and are able to modulate cell 
signalling  behaviour  and  migration  by  interacting  with  cell  surface  integrin 
receptors  [451].  Laminin  has  also  previously  been  found  to  affect  monocyte 
phagocytosis, and play a role in monocyte migration by inhibiting their adhesion 
to basement membranes thereby assisting their migration across the membrane 
and also by inducing spontaneous migration within the cells [452-455].  LAMC1 
has previously been detected in healthy blood monocytes, which was used to 
produce the molecule laminin-8, monocyte adhesion to laminin-8 also produced 
spontaneous and chemokines-induced migration [455]. Hence, the upregulation 
of LAMC1 in RA blood monocytes could help play a role in the migration of these 
cells across the basement membrane of the blood vessels thereby assisting their 
infiltration into the joint. 
Two genes which were upregulated in RA PB compared to PsA PB have previously 
been shown to be associated with RA. These genes are NRP1 (neuropilin-1) and 
IL7  (Interleukin  7).  Neuropilin-1  is a  receptor  for  vascular  endothelial  growth 185 
factor  (VEGF)  and  is  expressed  in  the  synovium  of  RA  patients  where  it  was 
specifically  associated  with  the  lining  layer,  infiltrating  leukocytes  and 
endothelial  cells  [357].  Recent  work  has  shown  that  the  interaction  of 
neuropilin-1  with  VEGF  prevented  apoptosis  and  was  therefore  crucial  to 
rheumatoid synovial cell survival  [357].  VEGF is detected in the serum of RA 
patients  [456]  and  has  been  found  to  correlate  with  the  development  of 
radiographic  damage  and  CRP  level  [457].  Since  neuropilin-1  interaction  with 
VEGF has been shown to prevent apoptosis in synoviocytes we hypothesis that 
neuropilin-1  is  playing  the  same  role  in  the  blood  monocytes  and  the 
upregulation of NRP1 in the RA monocytes could be a mechanism to prolong their 
survival.  
IL-7 has also previously been described in RA, serum levels of the cytokine are 
higher in RA patients compared to healthy controls and correlate with markers 
of inflammation [371]. IL-7
+ cells correlate with the numbers of CD68
+ cells in RA 
synovial lining and double staining has demonstrated that CD68
+ cells are the 
major producer of IL-7 [371]. In RA blood and synovial fluid IL-7R is primarily 
expressed  on  T  cells,  with  the  highest  expression  on  CD4
+  cells.  Numerous 
studies have focused on the role of IL-7 in RA, synovial fluid isolated CD4
+ T cells 
are hyperresponsive to IL-7 and IL-7 enhanced cell-contact dependent activation 
of  T  cells  and  macrophages  resulting  in  TNFα  production  [373].  IL-7  also 
enhances IFNγ and TNFα production from T cells  [458].  Hence, the RA blood 
monocytes positive for the IL7 mRNA in this present study may be a source of the 
increased  RA  serum  IL-7  levels  and  due  to  the  cytokine‘s  pro-inflammatory 
properties  could  be  contributing  to  increased  inflammation  seen  in  these 
patients. 
Analysing  the  group  of  12  genes  that  are  upregulated  in  PsA  PB  monocytes 
compared  to  RA  PB  monocytes  two  groups  of  genes  emerge,  genes  that  are 
associated with response to stress and toxins (GSTM1, GSTM2 and EIF2AK3) and 
genes  involved  in  transcription  and  its  initiation  (FOXP1,  KLF9  and  MED26). 
Glutathione S-transferase M1 and M2 (GSTM1 and GSTM2 respectively) are part of 
a  broadly  expressed  family  of  enzymes  which  catalyse  the  conjugation  of 
glutathione and are involved in the detoxification of cytotoxic carcinogens and 
metabolites.  Glutathione  is  an  intracellular  antioxidant  and  is  a  prominent 
defence against reactive oxygen species, it acts as a radical quencher in cells by 186 
removing superoxide anions and hydrogen peroxide and works to maintain the 
equilibrium between free radical production and antioxidant defence thereby 
reducing  oxidative  stress  damage  [383].  Oxidative  stress  has  previously  been 
shown to be implicated in the pathogenesis of RA and PsA where an excess of 
free radicals causes oxidation and subsequent damage to cartilage, extracellular 
matrix and DNA [459] and markers of oxidation have been found in the serum 
and synovial fluid of patients [460, 461]. Hassan et al measured the level of the 
antioxidant glutathione in RA serum compared to healthy controls and found it 
to  be  decreased  whereas  the  levels  of  the  enzyme  glutathione  S-transferase 
(GST)  were  increased,  which  the authors suggested  could  be  a  compensatory 
mechanism in the absence of its substrate glutathione [462]. Since our data has 
shown an increase in the levels of two GST proteins, GSTM1 and GSTM2, in PsA 
blood monocytes compared to RA blood monocytes these PsA patients may also 
be increasing their levels of these enzymes to due to the increased oxidative 
stress associated with this disease and the decrease in antioxidant glutathione. 
Of  interest,  polymorphisms  in  GST  genes  have  been  associated  with  RA 
susceptibility, these genes include GST Theta (GSTT1), GST Pi (GSTP1) and in 
particular  one  of  our  genes  of  interest  GST  Mu  (GSTM1)  [385].  Some  of  the 
polymorphisms also show an additive effect with smoking and patients carrying 
the polymorphisms who also smoke were found to be at an increased risk of 
disease  with  higher  disease  severity  [463].  Despite  no  susceptibility  being 
reported  for  PsA  these  findings  highlight  the  potential  importance  of  GST 
enzymes within the pathogenesis of psoriatic arthritis. 
Eukaryotic  translation  initiation  factor  2-alpha  kinase  3  (EIF2AK3)  otherwise 
known as PERK is an endoplasmic reticulum (ER) transmembrane protein kinase. 
The  function  of  the  ER  is  to  correctly  fold  and  process  proteins  which  are 
intended for the secretory pathway before they are transported to the Golgi 
apparatus. If the secretory demand exceeds the folding capacity of the ER, the 
accumulated  mis-  or  unfolded  proteins,  often  called  ER  stress,  activates  the 
unfolded  protein  response  (UPR).  The  UPR  aims  to  enhance  the  processing, 
assembly and transport of secretory proteins. PERK is a UPR sensor, its role is to 
reduce global translation thereby allowing the cell to correct for the impaired 
protein folding resulting from the ER stress before allowing additional secretory 
proteins to be synthesised [402]. PERK does this by phosphorylating eIF2 which 187 
prevents the release of the translation factor from the ribosomal machinery and 
thus reduces translation [464]. At present there have been no studies performed 
on  the  role  of  the  UPR  in  psoriatic  arthritis,  however  another 
spondyloarthropathy ankylosing spondylitis (AS) has shown associations between 
the molecule HLA-B27, which is present in up to 96% of patients [465], and the 
UPR. Research into AS in HLA-B27 transgenic rats has shown that HLA-B27 has 
the propensity to mis-fold resulting in ER stress and the activation of the UPR 
[466]. Consequently, the upregulation of the UPR sensor PERK in PsA compared 
to RA blood monocytes may be an indication that the PsA monocytes are more 
exposed  to  mediators  of  ER  stress  such  as  metabolic  stress  or  mutant/over 
expression of secreted proteins as is seen in the spondyloarthropathy AS which 
shares some clinical features with PsA. 
As mentioned above there are also a group of genes upregulated in PsA blood 
monocytes  which  are  associated  with  transcription  initiation  namely  FOXP1, 
KFL9 and MED26. Forkhead box P1 (FOXP1) is a member of the FOX family of 
transcription  factors  and  is  involved  in  B  cell  development  [390],  thymocyte 
development [391] and monocyte differentiation in vitro and in vivo [392, 467]. 
FOXP1  must  be  downregulated  by  the  monocyte  in  order  for  it  to  fully 
differentiate into a macrophage, because mice which are transgenic for FOXP1 
have  reduced  M-CSF  receptor  expression,  impaired  migratory  capacity  and 
diminished macrophage function such as cytokine production  [392]. Since PsA 
monocytes  expressed  FOXP1  as  2.7  fold  change  increase  compared  to  RA 
monocytes this could suggest that at the time of the samples being taken the RA 
monocytes  were  more  differentiated  towards  a  macrophage  phenotype 
compared to the PsA monocytes. 
Kruppel-like factor 9 (KLF9) is a member of the Kruppel-like family (KLF) of zinc 
finger transcription factors. There are 25 KLFs proteins known at present, which 
bind to GC/GT boxes found in promoter regions and enhancer/silencer regions of 
multiple  chromosomal  genes  [468].  KLF9  has  been  identified  as  having  a 
stimulatory role in neuronal cell process formation and differentiation [469] and 
endometrial cell proliferation [470]. A recent study has also shown that mice 
lacking KLF9 have disregulated intestinal crypt cell proliferation and villus cell 
migration [471]. The exact role of KLF9 within PsA blood monocytes is unclear at 
present but it could play a role in monocyte migration into the diseased joint. 188 
Mediator complex subunit 26 (MED26) is one of at least 30 subunits that make up 
the  mediator  complex.  The  mediator  complex  is  a  required  part  of 
transcriptional activation and serves as an adaptor between the transcription 
factors bound at the regulatory elements on the DNA and both RNA polymerase II 
and the general transcription factors [472]. At present the exact role of MED26 
within the mediator complex is unknown therefore it is difficult to speculate on 
the role of MED26 on PsA blood monocytes however it could indicate an increase 
in the amount of general transcription taking place within the monocytes. 
Database for annotation, visualisation and integrated discovery (DAVID) software 
was used in this analysis to determine if there is a significant enrichment of 
different  biological  processes  within  the  two  remaining  gene  lists:  (1) 
differentially  expressed  genes  between  RA  PB  monocytes  and  healthy  blood 
monocytes  (2)  differentially  expressed  genes  between  PsA  PB  monocytes  and 
healthy blood monocytes.  
The DAVID analysis of the genes which were expressed at a higher level in RA 
blood  compared  to  healthy  blood  monocytes  (Figure  3.6)  demonstrated  two 
distinct groups of genes, response to stimulus (indicated by the three biological 
processes  response  to  external  stimulus,  response  to  chemical  stimulus  and 
response to wounding) and cellular movement (indicated by the three biological 
processes  chemotaxis,  taxis  and  locomotion).  The  other  biological  processes 
associated with this RA gene list were negative regulation of cellular process and 
positive regulation of cellular process,  which both contain many of the same 
genes. Since these biological processes conflict highly with each other they were 
not analysed further.  
The RA blood monocytes may be up-regulating genes associated with response to 
stimulus function due to the pro-inflammatory stimuli present in the serum of RA 
patients which are not found in healthy controls. The three biological process 
groups:  response  to  stimulus,  response  to  chemical  stimulus  and  response  to 
wounding contain many of the same genes including; TSP1 (thrombospondin-1), 
SOCS3 (suppressor of cytokine signalling 3) and CLU (clusterin). Thrombospondin-
1 has previously been associated with RA [473] and a recent study indicated that 
serum  thrombospondin-1  levels  were  increased  in  RA  patients  compared  to 
healthy controls and correlated with increased serum levels of pro-inflammatory 189 
cytokines [474]. This study validates the data found in this experiment which 
indicates thrombospondin-1 is expressed at a higher level in RA PB monocytes 
compared  to  healthy  controls  and  is  significantly  associated  with  biological 
processes involving response to environmental stimuli. 
Another  gene  associated  with  all  three  response  to  stimuli  related  biological 
processes is suppressor of cytokine signalling 3 (SOCS3). The SOCS family consists 
of  SOCS1–SOCS7  and  cytokine-inducible  SH2  (CIS)  and  their  role  is  to  tightly 
regulate the activity of the JAK-STAT pathway [475]. They are not constitutively 
expressed in cells but their expression is induced by a range of cytokines via 
activated STATs [476]. Once expressed they inhibit the JAK-STAT pathway by 
several  mechanisms  such  as  prevention  of  STAT  recruitment  to  activated 
cytokine receptors, induction of substrate degradation and suppression of JAK 
catalytic  activity  [477].  SOCS3  levels  are  significantly  higher  in  RA  PBMCs 
compared to healthy controls, which was found to be due to the upregulation of 
SOCS3  specifically  in  the  RA  blood  monocytes  [478].  SOCS3  overexpression  is 
effective  in  preventing  the  development  of  murine  collagen  induced  arthritis 
(CIA) [479] and SOCS3 knockout mice, which have a constitutive lack of SOCS3 in 
hematopoetic and endothelial cells, developed a more severe form of acute IL-1 
dependent  inflammatory  arthritis  [480].  Taken  together  these  results  suggest 
that SOCS3 is a critical negative regulator in inflammatory arthritis. Our data 
indicate  that  SOCS3  is  upregulated  in  RA  PB  compared  to  healthy  control 
monocytes which was also found by Isomaki et al [478]. This upregulation is no 
doubt caused by the increased pro-inflammatory environment to which the RA 
monocytes are exposed to within the blood and may be a regulatory mechanism 
of the cells to try and reduce the overactive inflammatory response. However, 
SOCS expression is known to alter cellular responsiveness to cytokines therefore 
up-regulation  of  SOCS3  may  be  involved  in  disease  progression  by  causing 
unresponsiveness to anti-inflammatory genes.  
Clusterin  (CLU)  was  another  gene  associated  with  the  response  to  stimulus 
processes outlined in the DAVID analysis. It was the most differentially expressed 
genes in the RA PB vs healthy blood monocyte comparison with a fold change 
increase in RA PB of 40 it also had the second highest p value of 1.80 x10
-4. Since 
a multiple testing correction was unable to be used in the analysis a high p value 
indicates  that  this  change  is  more  likely  to  be  a  true  result  and  not  a  false 190 
positive. CLU is a secreted heterodimeric protein which was initially described as 
a  complement  inhibitor  protein,  where  its  role  is  to  protect  cells  from  the 
membrane  attack  complex  (MAC)  by  binding  to  the  MAC  and  rendering  it 
physiologically inactive [481]. It has since been found to interact with a variety 
of molecules including lipids, amyloid proteins, and Igs. However, unravelling 
the  function  of  CLU  is  complicated  by  its  ability  to  interact  with  several 
molecules  and  its  differential  expression  in  many  diseased  states  such  as 
neurodegenerative disease and cancer [482, 483]. Recently it became apparent 
that  different  functions  of  CLU  might  depend  on  its  final  maturation  and 
localisation, and whilst its predominant form is a secreted 80 kDa heterodimeric 
protein  (sCLU)  a  nuclear  form  of  the  protein  (nCLU)  has  also  been  reported 
which is thought to be responsible for its functions involving NF-κB and apoptosis 
[484]. This suggests that CLU can have different functions depending on whether 
it is expressed inside or outside of the cell. 
Santilli et al reported that the intracellular level of nCLU could be essential for 
regulation of NF-κB activity through its ability to stabilise inhibitors of NF-κB 
(IκB)  [485].  Consequently,  Devauchelle  et  al  further  demonstrated  that  nCLU 
interacts with phosphorylated IκB and prevented it from being degraded by the 
E3  ubiquitin  ligase  βTrCP  and  therefore  blocking  NF-κB  activation  [486].  This 
latter study was based on the result of a previous microarray experiment which 
demonstrated significantly lower amounts of CLU in the synovial membrane of 
RA patients compared to OA [320]. Subsequently it was concluded that the lack 
of CLU within the RA synovium would result in enhanced IκB degradation and 
therefore a greater activation status of NF-κB enabling pro-inflammatory gene 
expression.  This  finding  was  also  supported  by  their  observation  that  siRNA 
induced knockdown of CLU in cultured fibroblast-like synoviocytes (FLS) resulted 
in increased production of IL-8 and IL-6 cytokines which are regulated by NF-κB 
[486]. 
Numerous studies have analysed the role of CLU in the apoptosis of cancer cells 
but once again the function of CLU may depend on its form and localisation. 
sCLU inhibits apoptosis in human cancer cells by interfering with Bax activation 
in  mitochondria  [487]  however,  nCLU  has  been  found  to  be  pro-apoptotic  as 
overexpression of nCLU resulted in cell death in both the presence or absence of 
ionizing radiation [488]. It is now accepted that a shift from the cell producing 191 
sCLU to nCLU would result in cell death as nCLU has been found to induce cell 
death in many experimental conditions [489]. 
The finding that RA blood monocytes highly upregulate CLU compared to healthy 
blood monocytes is a significant one and has not been demonstrated previously. 
Of note the same pattern of upregulated CLU expression is also seen in PsA blood 
monocytes compared to healthy controls. Many reports conclude that CLU is an 
anti-inflammatory molecule in arthritis as CLU has been found at a reduced level 
in RA synovium compared to OA synovium [320] and CLU knockout mice induced 
with the K/BN model of arthritis developed arthritis faster which also lasted for 
longer  compared  to  the  control  mice  [490].  Hence  the  reasons  for  the  large 
upregulation  of  CLU  in  RA  PB  (40  fold  change  increase)  and  PsA  PB  (20  fold 
change increase) compared to healthy controls are unknown. Since most reports 
demonstrate that CLU is anti-inflammatory the monocytes may be upregulating 
CLU  as  a  counteractive  mechanism  as  a  result  of  the  pro-inflammatory 
environment. Two of the most studied functions of CLU are inhibition of the NF-
κB  pathway  and  induction  of  apoptosis.  However,  since  several  of  the  NF-κB 
target  genes,  such  as  IL-6,  are  consistently  upregulated  in  the  serum  of  RA 
patients and there have been no reports of increased apoptosis levels in PsA or 
RA PB monocytes, to the contrary the antiapoptotic molecule Mcl-1 has been 
found to be increased in CD14
+ cells isolated from RA SF [491], this may suggest 
that CLU may have a different function within arthritic blood monocytes. CLU is 
a heterogenous molecule with many differing, often conflicting, functions and 
further work into the expression of this molecule within the cells and serum of 
RA and PsA patients is necessary. 
The  second  group  of  biological  processes  upregulated  in  RA  PB  monocytes 
compared to healthy controls were associated with cellular movement, indicated 
by the three biological processes chemotaxis, taxis and locomotion. This group 
of biological processes in significant for the pathogenesis of RA as one of the 
earliest  events  in  RA  is  the  ingress  of  leukocytes  into  the  inflamed  synovial 
tissue. In order for the cells to enter the synovium from the blood they must 
adhere  to  the  endothelial  cells  and  then  migrate  into  the  interstitial  matrix 
which is aided by the upregulation of chemokines and chemokines receptor on 
the  leukocytes  and  the  endothelial  cells  [136].  Once  again  due  to  the 
heterogeneous nature of genes and their various functions many of the same 192 
genes  were  significantly  associated  with  all  three  chemotaxis  associated 
biological processes which indicate the importance of cellular movement to the 
RA PB monocytes. Some of the genes associated with these biological processes 
are LAMC1, FPR1, FPR2 and PPBP. 
Laminin gamma 1 (LAMC1) has been described earlier on in this discussion as it 
was significantly upregulated in RA PB compared to PsA PB. It is a basement 
membrane molecule and may be helping the RA monocytes migration across the 
basement  membrane  of  the  blood  vessels  thereby  allowing  their  subsequent 
infiltration into the joint. The two genes formyl peptide receptor 1 (FPR1) and 
formyl peptide receptor 2 (FPR2) were also both included in the chemotaxis, 
taxis and locomotion biological process groups. The protein product of FPR1 is 
known  as  formyl  peptide  receptor  (FPR)  and  the  protein  product  of  FPR2  is 
denoted as formyl peptide receptor-like 1 (FPRL-1) which both belong to the 
seven transmembrane domain Gi-protein-coupled receptor (GPCR) family. Two 
of the main sources of ligands for this family of receptors are bacterial [492] and 
mitochondrial proteins [493] therefore the main function of these receptors is 
thought to be to mediate trafficking of phagocytes to sites of bacterial invasion, 
tissue  damage  or  cell  necrosis,  although  anti-inflammatory  functions  of  some 
ligands  has  also  been  proposed  [494].  FPR  and  FPRL-1  are  detected  on 
phagocytic  leukocytes  especially  monocytes  and  neutrophils  and  activation  of 
these  receptors  by  their  agonists  results  in  Ca
2+  mobilisation  and  cellular 
migration [495].  
There are numerous ligands for FPR and FPRL-1 and several of them have been 
previously found in the serum and synovial fluid of RA, one such ligand is soluble 
form of the urokinase-type plasminogen activator receptor (suPAR). suPAR is a 
ligand  for  FPRL-1  and  has  been  demonstrated  to  be  released  by  neutrophils 
isolated from the PB and SF of RA patients. Cell lines expressing FPRL-1 migrated 
towards the supernatants harvested from RA neutrophils thereby suggesting that 
neutrophils may be involved in the recruitment of FPRL-1 expressing cells into 
the diseased synovium [496]. Consequently, the upregulation of FPR and FPRL-1 
in RA blood monocytes in comparison to healthy control blood may be due to 
pro-inflammatory  environment  that  the  RA  blood  monocytes  are  exposed  to 
which has been shown to contain the ligands for these receptors. Activation of 
FPR and FPRL-1 has been demonstrated to induce monocyte migration therefore 193 
the  upregulation  of  these  genes  may  be  a  mechanism  to  induce  monocyte 
recruitment into the synovial joint. 
Pro-platelet basic protein (PPBP) otherwise known as CXCL7 is the third gene 
associated with the cell migration group of biological processes upregulated in 
RA monocytes. It is translated as a 14 kDa propeptide called PPBP or leukocyte 
derived growth factor (LDGF) which can then be cleaved into several smaller 
forms called platelet basic protein (PBP), β-thromboglobulin (β-TG) connective 
tissue activating protein-3 (CTAP-III) and neutrophil activating peptide-2 (NAP-2) 
[497]. Peptidases such as cathepsin G, are known to play a role in the post-
transcriptional  modifications  of  PPBP  [498].  The  derivatives  of  PPBP  have 
amazing  functional  diversity:  NAP-2  is  a  potent  neutrophil  chemoattractant 
[497]; PBP and CTAP-III have antimicrobial activity and LDGF itself is a fibroblast 
mitogen [497]. PBP was originally thought to be expressed only by cells of the 
megakaryocyte  lineage  but  it  has  since  been  shown  to  be  expressed  by 
monocytes  in  response  to  various  stimuli  such  as  exposure  to  microbial 
components  LPS  or  zymosan  [499].  CTAP-III  has  previously  been  found in  the 
blood  circulation  of  RA  patients,  deposition  of  CTAP-III  was  found  in  the 
synovium and is associated with a partial processing to NAP-2 isoforms [500]. It is 
difficult to speculate on the importance of the upregulation of PPBP in RA blood 
monocytes due to its ability to be cleaved into several smaller forms which all 
have differing functions especially since cathepsin G, which can cleave PPBP, is 
present  in  RA  serum  [501].  Its  main  function  may  be  to  act  as  a  neutrophil 
chemoattractant however further investigations are needed. 
The biological processes downregulated in RA PB compared to healthy control PB 
monocytes  display  three  main  functions:  protein  complex  localisation 
(demonstrated  by  the  two  biological  processes  cellular  protein  complex 
localisation  and  protein  complex  localisation),  selenocysteine  incorporation 
(translational  readthrough  and  selenocysteine  incorporation)  and  negative 
regulation  of  cell  movement  (demonstrated  by  the  three  biological  processes 
negative  regulation  of  cell  migration,  locomotion  and  cell  motion).  A 
downregulation in protein complex localisation was indicated by the decrease in 
expression  of  SMAD7  (SMAD  family  member  7)  and  TMEM48  (transmembrane 
protein 48). SMAD7 is an inhibitor of TGF-β signalling, TGF-β is a multifunctional 
cytokine which regulates cell growth, adhesion and differentiation in a variety of 194 
cell  types  and  it  is  also  a  potent  immunosuppressor.  Therefore  the  RA  PB 
monocytes  downregulating  SMAD7,  the  inhibitor  of  TGF-β,  may  be  an 
autoregulatory  mechanism  to  compensate  for  the  increased  inflammatory 
processes  taking  place.  However  SMAD7  had  also  been  demonstrated  to 
negatively  regulate  signalling  intermediaries  in  pro-inflammatory  signalling 
pathways such as NF-κB, in this pathway SMAD7 plays a role in increasing IκB 
expression  [502].  Consequently  the  downregulation  of  SMAD7  by  the  RA  PB 
monocytes may conversely enable NF-κB signalling and increase the production 
of  pro-inflammatory  cytokines  therefore  contributing  to  the  increased  pro-
inflammatory cytokines detected within RA serum. The other gene associated 
with  protein  complex  localisation  is  TMEM48  that  codes  for  the  protein 
nucleoporin NDC1. This protein is required for nuclear pore complex assembly 
which are large multiprotein complexes that span the nuclear envelope forming 
a selective channel between the cytoplasm and the nucleus. There is very little 
information regarding nucleoporin NDC1 therefore at present the relevance of 
the downregulation of this gene in RA blood monocytes is unclear. 
Selenocysteine  incorporation  was  also  process  downregulated  by  the  RA  PB 
monocytes  indicated  by  the  downregulation  of  the  genes  SEPSECS  (Sep  (O-
phosphoserine)  tRNA:Sec  (selenocysteine)  tRNA  synthase)  and  TRSPAP1  (tRNA 
selenocyteine  associated  protein  1).  Selenocysteine  incorporation  it  is  an 
essential  process  required  for  the  production  of  at  least  25  selenoproteins. 
Selenocysteine  is  comprised  of  the  trace  element  selenium  which  is  an 
antioxidant,  deficiency  of  this  element  results  in  increase  reactive  oxygen 
species (ROS) [503]. Selenium levels are reduced in the serum and synovial fluid 
of RA patients compared to controls and this reduced selenium is associated with 
increased risk of the disease [504]. Hence, a reduction in the selenium levels in 
the  serum of the  RA  patients could  be  the  reason  for  the  downregulation  of 
genes associated with selenocysteine incorporation in RA PB monocytes. Of note, 
selenium  deficiency  in  RAW  264.7  macrophages  had  significantly  increased 
inducible nitric oxide synthase activity (iNOS) and subsequent nitric oxide (NO) 
production after stimulation with LPS [505] therefore a reduction in selenium 
and selenocysteine incorporation in RA PB monocytes may be one mechanism 
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The third group of biological processes downregulated in RA PB monocytes was 
negative regulation of cell movement which again emphasises the importance of 
the process of chemotaxis and extravasation for the diseased monocytes. The 
downregulated  RA  genes  associated  with  this  biological  process  are  SMAD7, 
which has been previously discussed, and VASH1 (vasohibin 1). Vasohibin 1 is a 
negative feedback regulator of angiogenesis which was originally identified in a 
microarray  analysis  designed  to  analyse  the  upregulated  genes  induced  by 
vascular endothelial growth factor (VEGF) stimulation in endothelial cells [388]. 
Subsequent  immunohistochemistry  analysis  has  identified  vasohibin  1  in  the 
synovium of RA patients associated with synovial lining cells, endothelial cells 
and  synovial  fibroblasts  [507].  At  present  there  has  been  no  vasohibin  1 
identified specifically in monocytes therefore our observation may represents a 
novel one. Inflammatory cytokines were shown to induce vasohibin 1 expression 
in RA synovial fibroblasts [507] and its expression is thought to help co-ordinate 
the formation of blood vessels and angiogenesis in the synovium. Consequently, 
the downregulation of vasohibin 1 in RA blood monocytes could be due to it not 
being  required  by  the  blood  cells  and  may  be  upregulated  again  once  the 
monocytes  enter  the  inflamed  synovium.  Analysing  the  RA  SF  macrophage 
samples  (which  will  be  discussed  thoroughly  in  the  next  comparison  of  this 
chapter)  this  hypothesis  is  correct.  The  RA  PB  CD14
+  express  a  low  level  of 
vasohibin 1 compared to healthy controls and this expression is increased by a 
fold  change  of  13  in  the  patient  matched  RA  SF  macrophages.  This  result 
indicates  that  the  monocytic  cells  downregulate  their  vasohibin  1  expression 
until they migrate into the synovial fluid of RA patients where its anti-angiogenic 
properties  are  needed  to  regulate  and  co-ordinate  the  formation  of  blood 
vessels.  
DAVID  analysis  was  also  performed  on  the  differentially  expressed  genes 
between PsA PB monocytes and healthy blood monocytes. After removal of gene 
repeats in the list and genes with no designated function the list of 154 genes 
upregulated in PsA blood monocytes was reduced to 92 and the list of 129 genes 
downregulated  in  PsA  blood  monocytes  was  reduced  to  66  genes.  The  two 
biological processes associated with the 92 upregulated genes in PsA were DNA 
packaging  (demonstrated  by  the  groups  nucelosome  assembly,  chromatin 
assembly,  protein-DNA  complex  assembly,  DNA  packaging  and  chromatin 196 
assembly  and  disassembly)  and  chemotaxis  (demonstrated  by  the  groups 
chemotaxis and taxis). Again because genes can be part of several biological 
process groups each of the six biological process groups which had the shared 
general function of DNA packaging all had the same six genes from the PsA gene 
list  associated  with  them.  These  genes  were  HIST1H2BK  (histone  cluster  1, 
H2bk),  TSPYL5  (TSPY-like  5),  HIST1H2AC  (histone  cluster  1,  H2ac),  HIST3H2A 
(histone cluster 3, H2a), NAP1L5 (nucleosome assembly protein 1-like 5) and a 
probe  on  the  Affymetrix  GeneChip  which targets  six  histone  cluster  1  genes. 
Surprisingly there is very little to no information on the function or role of any of 
these  genes  particularly  the  histone  genes.  The  function  of  NAP1L5  is  also 
unknown  but  its  shows  homology  to  nucleosome  assembly  protein  1  which  is 
involved in the translocation of histones from the cytoplasm into the nucleus 
[508]. Given that the role of histones is to provide a core around which DNA is 
packaged  to  form  a  nucleosome,  the  basic  unit  of  chromatin,  it  could  be 
suggested that the PsA blood monocytes upregulating genes responsible for DNA 
packaging would therefore prevent any further gene transcription. However, the 
importance of this observation cannot be fully understood until the roles of the 
upregulated genes are discovered. 
The second group of biological processes associated with the genes upregulated 
in PsA PB monocytes had the general function of chemotaxis. This result is the 
same as that seen in the upregulated genes in RA PB monocytes, and the same 
genes such as FRP1, FRP2 and PPBP are upregulated in both cell subsets. Once 
again this highlights importance of chemotaxis to the arthritic blood monocyte 
as  it  is  via  chemotaxis  that  the  cell  will  move  into  the  diseased  joint.  The 
increased levels of chemokines and pro-inflammatory mediators detected in the 
serum of PsA patients compared to healthy controls may be one of the triggers 
causing the upregulation of chemotaxis related genes in the PsA monocytes [406, 
509]. 
The two main biological processes associated with the downregulated genes in 
the  PsA  blood  monocytes  have  the  main  functions  of  cell  morphogenesis 
(demonstrated by the biological processes cell projection morphogenesis, cell 
part  morphogenesis,  cell  morphogenesis,  cell  projection  organisation  and 
cellular  component  organisation)  and  osteoclast  differentiation  (demonstrated 
by the biological processes regulation of osteoclast differentiation, regulation of 197 
myeloid  leukocyte  differentiation  and  positive  regulation  of  osteoclast 
differentiation).  Downregulated  PsA  genes  associated  with  the  cell 
morphogenesis  biological  processes  include  DYNC1I2  (dynein,  cytoplasmic  1, 
intermediate chain 2) and DST (dystonin). Dynein is an energy dependent motor 
protein found to be associated with microtubules which moves cellular cargo, 
such  as  organelles,  vesicles  and  RNA,  towards  the  minus  end  of  the 
microtubules.  DYNC1I2 is one of two intermediate chains which are involved in 
intracelluar  dynein  cargo  transport  by  binding  to  specific  cargo  although  the 
mechanisms  of  this are  not  fully  understood  [510].  Dystonin is  a cytoskeletal 
interacting  protein  which  is  known  to  play  important  roles  in  maintaining 
cytoarchitecture integrity in skin and in the neuromuscular system, it is thought 
to act as a ―linker‖ protein linking elements of the cytoskeleton to each other or 
to subcellular components such as adhesion structures [511]. Since there are no 
reports  of  disregulated  cytoskeletal  or  microtubule  transport  in  PsA  the 
importance of these downregulated genes in PsA is yet to be understood. 
Downregulated genes associated with the osteoclast differentiation include GNAS 
(GNAS complex locus) and KLF10 (Kruppel-like factor 10). GNAS codes for the 
protein  Gs  α-subunit  (Gsα)  which  is  a  subunit  of  G  proteins.  G  proteins  are 
membrane associated complexes that are primarily involved in signalling at the 
plasma  membrane.  Gsα  plays  a  central  role  in  receptor  mediated  signal 
transduction, coupling receptor activation with the production of cAMP [512]. It 
is well known that G-protein coupled receptors play a substantial role in arthritis 
as  the  signal  transducing  receptors  for  many  molecules  such  as  MMPs  and 
chemokines  [513,  514].  However,  the  GNAS  complex  locus  has  recently  been 
identified as an incredibly complex gene which encodes multiple gene products 
through the use of alternative promoters and first exons  [515] such as extra-
large isoform Gsα, which is thought to be localised to the Golgi apparatus, and 
NESP55  amongst  others  [512].  Consequently,  this  multiple  gene  product 
complexity renders it impossible to try and understand the significance of the 
down-regulation  of  this  gene  in  PsA  blood  monocytes  since  we  do  not  know 
which end product of the gene the PsA and healthy monocytes are translating 
and producing. 
KLF10 otherwise known as TGFβ early gene-1 (TIEG) is a zinc finger transcription 
factor  which  plays  an  important  role  in  mediating  the  TGFβ  Smad  signalling 198 
pathway. TIEG overexpression enhances Smad 4 activity and the induction of 
TGFβ  target  genes  [516].  Overexpression  of  TIEG  in  an  epithelial  cell  line 
induced apoptosis [517] and reduced cell proliferation in a human osteosarcoma 
cell line which was also seen in control cells stimulated with TGFβ [518]. Hence 
the PsA monocytes may be downregulating the TIEG gene in order to avoid TGFβ 
mediated apoptosis and suppression of cellular activation and proliferation. Of 
note, this mechanism is seen in cancer cells which are known to downregulate 
their TIEG expression at the protein and mRNA level in order to avoid cell death 
and reduced proliferation [519].  
In  conclusion  the  diseased  and  healthy  blood  comparison  has  been  very 
informative in defining the biological functions of the groups of genes up- or 
downregulated by each monocyte subset as well and allowing the investigation 
of individual genes. The PCA analysis performed on the entire set of microarray 
samples indicated the surprising result that the peripheral blood monocytes from 
healthy  donors,  RA  patients  and  PsA  patients  all  had  a  very  similar  genetic 
profile. In addition, performing statistical and fold change analyses on the data 
did  result  in  the  identification  of  just  24  genes  which  were  differentially 
expressed  between  the  RA  and  PsA  blood  monocytes.  This  low  result 
demonstrates  that  within  the  blood  the  monocyte  may  not  a  cell  type 
responsible for the differing clinical features seen in both diseases since this cell 
subset is showing a similar genetic profile in both diseases. 
The  12  genes  which  were  upregulated  in  RA  blood  compared  to  PsA  blood 
monocytes  contained  a  group  of  genes  which  had  roles  in  cell  adhesion  and 
interaction, such as the laminin subunit LAMC1, as well as genes that had been 
previously  associated  with  RA  including  the  IL-7  gene.  This  latter  result  is 
encouraging  as  the  presence  of  differential  expression  in  genes  previously 
associated with RA validates this dataset. The 12 genes which were upregulated 
in PsA blood compared to RA blood monocytes contained two groups of genes, 
one group had functions involved in the response to stress and toxins such as 
EIF2AK3/PERK and the other group of genes were involved in transcription and 
its initiation. It would be interesting to perform validation experiments on some 
of these genes especially those which have not been previously associated with 
monocytes  in  inflammatory  disease.  Laminin  and  its  receptor  expression  has 
previously been associated with synovial fibroblasts in RA [520] but we believe 199 
this is the first time the expression of a laminin subunit (LAMC1) has been found 
in RA blood monocytes and further experiments are needed in order to elucidate 
the  function  of  LAMC1  in  particular  whether  the  monocyte  is  producing  and 
releasing laminin molecules. The upregulated expression of EIF2AK3/PERK in PsA 
monocytes  is  another  novel  and  interesting  finding  since  this  molecule  is 
involved in the ER stress induced unfolded protein response (UPR). The UPR has 
not previously been implicated in the pathogenesis of PsA but has been well 
researched in another spondyloarthropathy ankylosing spondylitis (AS) [466, 521] 
which  shares  some  clinical  features  with  PsA.  Unfortunately  time  restrictions 
meant  that  no  further  experimental  or  validation  assays  were  able  to  be 
performed on these genes. 
The  RA  PB  vs  healthy  PB  monocyte  comparison  was  also  very  revealing  in 
illustrating  the  overall  functions  of  the  differentially  expressed  genes.  In 
comparison to healthy blood monocytes the RA PB cells showed an upregulation 
of  genes  involved in response to  stimulus such as  CLU  and  genes  involved in 
cellular movement such as CXCL7. These two groups of genes are not surprising 
given that it is well known that the RA serum contains many pro-inflammatory 
mediators compared to healthy control serum which will be partly responsible 
for the upregulation of the response to stimulus genes. It is also known that the 
monocyte  cells  in  RA  need  to  undergo  chemotaxis  and  migration  in  order  to 
transmigrate  from  the  blood  vessels  into  the  synovial  joint  where  they 
accumulate and play a role in the damage and destruction of the joint.  
The  downregulated  genes  in  RA  PB  had  functions  in  complex  localisation, 
selanocysteine  incorporation  and  negative  regulation  of  cell  movement.  The 
down-regulation  of  two  genes  involved  in  selanocysteine  incorporation  was 
interesting as selenium, the main component of selanocysteine, is decreased in 
the serum and synovial fluid of RA patients but also  selenium deficiency has 
been  shown  to  induce  increased  iNOS  and  subsequent  nitric  oxide  (NO) 
production in RAW 264.7 macrophages. Therefore a lack of serum selenium may 
directly be contributing to the increased NO and NO-induced damage seen in RA. 
Down-regulation  of  genes  associated  with  the  negative  regulation  of  cell 
movement also reinforces the importance of the ability of the RA monocytes to 
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The  upregulated  genes  in  PsA  blood  monocytes  compared  to  healthy  blood 
monocytes had roles in DNA packaging and chemotaxis. An upregulation of genes 
associated  with  DNA  packaging  could  suggest  that  the  PsA  monocytes  are 
reducing their overall transcription levels by packing their DNA into nucleosomes 
and chromatin. However, since there is little to no information on any of the six 
upregulated genes associated with the DNA packaging function it is difficult to 
speculate  further  on  the  reasons  for  their  increased  expression  compared  to 
healthy  controls.  The  upregulated  genes  associated  with  chemotaxis  are  the 
same genes upregulated in RA PB monocytes such as CXCL7, FPR1 and FPR2. The 
increased expression of these genes in PsA blood compared to healthy control 
demonstrates  the  importance  of  the  arthritis  specific  requirement  for  the 
monocyte  to  migrate  out  of  the  blood  and  into  the  diseased  joint.  The 
downregulated  genes  in  PsA  monocytes  identified  an  interesting  transcription 
factor TIEG which is known to induce apoptosis; therefore the PsA monocytes 
may be down-regulating molecules like TIEG in order to maintain and prolong 
cell survival as has been seen in cancer cells. 
Due to time restrictions only 5 healthy control blood monocyte samples were 
obtained  which  mainly  were  age-  and  sex-matched  to  the  PsA  patients.  It  is 
recognised  that  obtaining  additional  healthy  donor  samples  which  were  age-
matched to the RA patients would have been advantageous and allowed us to 
investigate  the  age  specific  genes  that  may  have  changed  in  the  monocytes. 
Nevertheless, the analysis performed with the 5 healthy donors has been very 
informative in identifying the differentially regulated genes in the monocytes 
including novel genes not previously associated with inflammatory arthritis. This 
analysis has also identified that the blood monocytes in RA and PsA have very 
similar genetic profiles which was also previously unknown. 201 
3.7.2 Comparison 2: RA and PsA blood versus matched synovial 
fluid 
Given the important role of synovial macrophages in the pathogenesis of both RA 
and PsA one important question to be answered by this microarray analysis was 
what changes occur in the arthritic monocyte as it exits the blood and enters the 
synovium?  This  is  an  important  question  as  it  aims  to  identify  not  only  the 
monocyte  differentiation  markers  as  it  changes  from  a  monocyte  into  an 
inflammatory macrophage but it will also identify the inflammatory genes that 
are upregulated once the monocyte is exposed to the pro-inflammatory synovial 
environment.  
In order to answer this question paired T tests were performed between the 
matched RA blood and synovial fluid samples and a separate set of paired T tests 
were performed between the matched PsA blood and synovial fluid samples in 
order  to  determine  the  up-  and  down-regulated  genes  in  the  synovial 
macrophages compared to the blood monocytes. Due to the substantial amount 
of differentially expressed genes between the PB and SF of each disease (10763 
in RA and 9533 in PsA) we applied a fold change cut off of 4 to the data since 
fold change values in microarray analysis are arbitrary and we were interested in 
genes  with  a  high  fold  change  difference  between  the  blood  and  the  SF. 
Ingenuity  pathway  analysis  (IPA)  was  then  used  to  determine  the  canonical 
pathways and molecular functions significantly associated with the differentially 
expressed genes in the RA SF compared RA PB CD14
+ cells and those significantly 
associated with the differentially expressed gene in the PsA SF compared to the 
PB CD14
+.  
3.7.2.1   RA PB CD14
+ versus RA SF CD14
+ 
Table 3.6 shows the top 5 canonical pathways significantly associated with the 
differentially expressed genes in the RA SF macrophages compared to the RA PB 
monocytes.  The  most  significantly  associated  pathway  is  LXR/RXR  activation 
pathway. LXR is a nuclear receptor ligand-activated transcription factor, it forms 
heterodimers  with  RXR  before  binding  to  the  DNA  sequences  of  target  genes 
[522]. Analysing the list of RA SF differentially expressed genes associated with 
this pathway demonstrates the novel finding that one of the LXR isoforms LXRα 
which  has  been  previously  been  shown  to  be  expressed  in 202 
monocytes/macrophages [523] is upregulated in RA SF macrophages compared to 
RA PB. Other RA SF upregulated genes associated with this pathway include the 
a range of LXR target genes such as ABCA1,  ABCG1,  lipoprotein lipase (LPL), 
ApoE, ApoC1 and ApoC2 which are all involved in reverse cholesterol transport 
and cholesterol efflux [524, 525]. This process ensures the efflux of cholesterol 
from peripheral cells and its transport to the liver for metabolism and biliary 
excretion  hence  the  LXR  activation  pathway  is  considered  to  be  central  in 
maintaining  cholesterol  homeostasis  and  is  considered  protective  against 
atheroscleosis.  
However,  LXR  agonism  has  also  been  considered  pro-inflammatory  since  LPS-
stimulated  human  macrophages  treated  with  two  synthetic  LXR  agonists 
increased  TNFα  expression  though  the  ability  of  LXRs  to  increase  Toll-like 
receptor  4  (TLR4)  expression;  this  agonism  also  increased  reactive  oxygen 
species  generation  from  the  macrophages  [526].  LXR  agonism  has  also  been 
demonstrated by our group to exacerbate articular damage in a murine model of 
arthritis suggesting LXRs have a pro-inflammatory role in arthritis [527]. In this 
study, LXR agonism induced a dose-dependent enhancement of the prevalence, 
incidence and severity of the collagen induced arthritis (CIA) mouse model. Ex 
vivo culture of RA PB derived monocytes which were LPS stimulated and treated 
with  two  LXR  agonists  showed  an  increase  in  IL-6  and  TNFα  production. 
Macrophages stimulated in the in vitro inflammatory model of arthritis by direct 
cell  contact  with  Tcks  also  demonstrated  an  increase  in  pro-inflammatory 
cytokine  and  chemokine  production  in  response  to  LXR  agonism.  Low  density 
lipoprotein (LDL) is a natural agonists for LXR activation and has been found in 
the synovial fluid of RA patients [528] therefore the up-regulation of the LXR 
pathway  in  RA  SF  macrophages  compared  to  PB  monocytes  along  with  the 
presence of its agonist in the synovial fluid indicates that this pathway may be 
promoting  articular  destruction  through  inducing  the  increased  production  of 
pro-inflammatory  cytokines  and  chemokines  from  the  synovial  macrophages. 
However  more  work  on  the  role  of  LXR  activation  in  RA  SF  macrophages  is 
required to test this hypothesis. 
The  hepatic  stellate  cell  activation  canonical  pathway  is  the  second  most 
significant pathway differentially expressed in RA SF CD14
+ cells. This is due to 
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implicated  in  both  hepatic  stellate  activation  and  synovial  macrophage 
activation.  For  example  platelet-derived  growth  factor  alpha  polypeptide 
(PDGFA) and PDGFB were both upregulated in the RA SF macrophages and these 
genes have also been implicated in hepatic stellate cell induced hepatic fibrosis 
[529,  530].  PDGF  is  a  potent  mitogen,  chemoattractant  and  angiogenesis 
promoter [531] and the level of this growth factor is increased in RA synovial 
tissue and fluid [532, 533]. PDGF has been implicated in RA through its function 
as  a  growth  factor  for  fibroblast-like  synoviocytes  (FLS)  [532,  533].  It  has 
recently been shown that in combination with TGF-β, PDGF augmented TNFα or 
IL-1β induced MMP3, IL-6,  IL-8 and macrophage inflammatory protein 1 alpha 
(MIP1α)  secretion  by  FLS  suggesting  PDGF  induces  a  more  pro-inflammatory, 
aggressive phenotype in the FLS in response to TNFα [534]. Consequently, the 
increased  expression  and  possible  secretion  of  PDGFA  and  PDGFB  by  RA  SF 
macrophages may be contributing to articular damage by activating synovial FLS.  
The remaining genes differentially expressed in RA SF macrophages which were 
associated with the hepatic stellate cell activation canonical pathway consist of 
many  inflammatory  cytokines,  chemokines  and  growth  factors  which  have 
previously been connected with RA. These genes include FN1 (fibronectin) which 
is  detected  in  the  synovial  fluid  of  RA  and  can  induce  MMP  expression  from 
fibroblasts [425]; the gelatinases MMP2 and MM9 (matrix metalloproteinase 2 and 
9) which are both upregulated in the synovium of RA patients [535] and their 
levels  are  associated  with  increased  joint  erosions  [536];  CCL2  (monocyte 
chemoattractant protein  1,  MCP1)  is  also  increased  in  the  synovium  and  is a 
potent chemoattractant for immune cells [537]; and CSF1 (macrophage colony 
stimulation  factor,  M-CSF).  M-CSF  is  a  growth  factor  which  controls  the 
proliferation,  survival  and  differentiation  of  mononuclear  phagocytes,  it  is 
normally expressed by the tissue environment however macrophages can also 
produce and secrete M-CSF if the tissue cells are unable to supply large amounts 
of the growth factor [538]. In conclusion, the association of the hepatic stellate 
cell  activation  pathway  with  the  genes  differentially  expressed  in  the  RA  SF 
macrophages compared to RA PB monocytes has highlighted the upregulation of 
several important inflammatory genes discussed above. However not only do the 
SF macrophages up-regulate genes which will contribute to the pro-inflammatory 
environment but they also demonstrate increased expression of the macrophage 204 
differentiation  and  survival  factor  M-CSF  which  could  help  differentiate 
monocytes infiltrating into the joint into pro-inflammatory macrophages.  
The third canonical pathway is defined as the role of macrophages, fibroblasts 
and endothelial cells in RA. The association of this canonical pathway validates 
the genes that are differentially expressed by the RA SF macrophages as many of 
these  genes  are  known  to  be  expressed  in  the  RA  synovium.  This  pathway 
contains many of the upregulated genes which were associated with the hepatic 
stellate cell activation pathway such as fibronectin, MMP2, MMP9 and the two 
PDGFs as well as other genes such as TRAF5 (TNF receptor-associated factor 5), 
WNT5A  (wingless  type  MMTV  integration  site  family  member  5A)  and  FZD7 
(frizzled homolg 7). 
TRAFs  are  cytoplasmic  adaptor  proteins  for  the  TNF/IL-1/TLR  receptor 
superfamily, they are responsible for transducing extracellular signals from cell 
surface receptors and activating intracellular signalling cascades such as the NF-
κB and the JNK signalling pathways [539]. The RA SF macrophages demonstrated 
a 5 fold increase in TRAF5 expression compared to matched blood monocytes 
and  interestingly  a  SNP  upstream  of  TRAF5  has  been  identified  as  an  RA 
susceptibility gene [540]. TRAF5 interacts with lymphotoxin  β receptor (LTβR) 
and CD40 and has shown functional redundancy with TRAF2 [541].  Both TRAF2 
and TRAF5 can mediate TNF-induced NF-κB activation and protection from cell 
death [539].  Hence, an upregulation of TRAF5 in the RA SF macrophage may 
imply that it plays a proinflammatory role such as increased cellular activation 
and transcription of other proinflammatory cytokines. However, a recent study 
into  the  role  of  macrophage  TRAF5  in  atherosclerosis  found  it  to  be  anti-
inflammatory  as  murine  monocytes  deficient  for  TRAF5  demonstrated  an 
upregulation of cell adhesion molecules implicated in cell adhesion and rolling 
and also enhanced migration and chemokine production [542]. Since macrophage 
TRAF5 has not been examined in RA at present further studies are required to 
distinguish whether TRAF5 plays a pro- or anti-inflammatory role in this disease. 
WNT5A was also upregulated in the RA SF macrophages compared to the blood 
monocytes, Wnt-5a is one of 19 Wnt proteins which are a family of secreted 
lipid-modified glycoproteins that display a highly regulated pattern of expression 
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importance  of  Wnt-5a  in  various  developmental  pathways  is  demonstrated  in 
Wnt-5a knockout mice which die at birth and display many defective features 
such as facial abnormalities, truncated bodies and shortened limbs [543]. Wnt 
signalling pathways are activated by the binding of secreted Wnt to the cystolic 
domain  of  a  family  of  transmembrane  receptors  called  the  Frizzled  receptor 
proteins (Fz) [544]. The binding of Wnts to their receptors determines the type 
of  downstream  signalling  pathway  either  canonical,  which  involves  the 
transcriptional activation of β-catenin, or non-canonical which does not involve 
β-catenin.  Wnt-5a  is  classed  as  a  non-canoical  Wnt  which  are  generally 
considered to control morphogenic movement. In RA Wnt-5a has been shown to 
be upregulated in synovial fibroblasts where it binds to frizzled 5 (Fz5), and the 
downregulation of Wnt-5A or Fz5 both resulted in inhibition of synovial fibroblast 
activation [545]. 
Wnt-5a has also been demonstrated to be upregulated in human macrophages 
stimulated  with  bacterial  pathogens  in  vitro  as  it  was  demonstrated  that 
activation  of  TLR4  signalling  cascade  induced  Wnt-5a  expression.  These 
macrophages also expressed Fz5 and it was demonstrated that Wnt-5a and Fz5 
regulated the microbially induced IL-12 release from these cells [546]. Wnt-5a 
has been demonstrated to be expressed in macrophages of murine and human 
atherosclerotic  plaques  associated  with  TLR4  [547]  and  has  also  been 
demonstrated  to  be  critical  for  invasion  and  MMP7  and  TNFα  release  from 
tumour  associated  macrophages  which  were  found  to  be  positive  for  Wnt-5a 
[548]. Consequently the upregulation of Wnt-5a in the RA SF macrophages may 
be as a result of increased TLR4 signalling since TLR4 ligands are present in the 
RA  synovium  [549].  Both  synovial  fibroblasts  and  macrophages  have  been 
demonstrated to express a Wnt-5a receptor Fz5 therefore the secretion of Wnt-
5a by synovial macrophages could be acting in an autocrine or paracrine manner 
by  stimulating  surrounding  cells.  This  activation  by  Wnt-5a  could  cause 
inflammatory  cytokine  and  proteinase  secretion  by  synovial  fibroblasts  or 
macrophages thereby contributing to the synovial joint damage. 
FZD7  (frizzled  homolog  7)  was  another  gene  upregulated  by  the  RA  SF 
macrophages which was associated with role of macrophages and fibroblasts in 
RA  canonical  pathway.  As  mentioned  above  frizzled  molecules  are  the  cell 
surface  receptors  for  Wnt  proteins  and  the  subsequent  binding  of  these  two 206 
molecules activates the Wnt signalling pathways. Frizzled 7 (Fz7) has previously 
been detected in RA synovial tissue [550] and a recent paper has demonstrated 
the Fz7 can associate with Ror2 to form a receptor complex to mediate Wnt-5a 
signalling and activation of the JNK signalling pathway [551]. Put together this 
novel data demonstrates the upregulation of a Wnt protein (Wnt-5a) and part of 
its receptor complex (Fz7) specifically in RA synovial macrophages, further work 
is required to elucidate the importance of these molecules in RA pathogenesis 
however they could play a role in the invasive potential, inflammatory mediator 
secretion and sustained activation of these cells. 
The differentially associated genes with the role of macrophages and fibroblasts 
in  RA  canonical  pathway  was  also  associated  with  genes  that  were 
downregulated in RA SF macrophages compared to their matched PB monocytes. 
Two of these downregulated RA SF macrophage genes were TLR5 and TLR7. The 
activation of TLRs by pathogen-associated molecular patterns (PAMPs) alters the 
host to presence of infection and triggers a variety of defense mechanisms, such 
as the production of pro-inflammatory cytokines and chemokines, depending on 
the receptor and cell type. Several TLRs have been detected in RA synovium as 
well  as  candidate  endogenous  TLR  ligands  [552]  therefore  the  perpetual 
activation of TLR signalling has been identified as a potential mechanism for the 
maintenance of the chronic inflammation seen in RA. TLR5 has not previously 
been identified in the synovium of RA however stimulation of FLS from RA and 
JIA  patients  with  the  TLR5  ligand  flagellin  did  induce  IL-6,  MMP1  and  MMP3 
production suggesting that these FLS expressed TLR5 [553]. 
TLR7  has  been  demonstrated  to  be  expressed  within  the  RA  synovium  [554]. 
However, when DCs isolated from RA patients were stimulated with TLR7 ligands 
the level of cytokine production was similar between DCs from RA and those 
from healthy patients. This was in marked contrast to TLR2 or TLR4 stimulation 
which induces a much higher production of inflammatory mediators for RA DCs 
compared to healthy controls [554]. This result suggests that TLR7 may not as 
essential  to the  perpetuation of arthritis as  TLR2  and  TLR4,  which  is  further 
verified by the observation that TLR2 and TLR4 deficient mice do not develop 
serum  transfer  or  streptococcal  cell  wall-induced  arthritis  [555,  556]. 
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may be due to these receptors not being as vital in the pathogenesis of RA as 
some of the other Toll-like receptor members such as TLR2/TLR4. 
The  LPS/IL-1  mediated  inhibition  of  RXR  was  the  fourth  most  significant 
canonical pathway associated with the RA SF differentially expressed genes. The 
associated genes include many of the same genes which were included in the 
LXR  activation  pathway  such  as  APOC1,  APOC2  and  APOE.  All  three  of  these 
apolipoprotein molecules are constituents of the anti-inflammatory and athero-
protective high density lipoprotein (HDL) [418]. ApoE and another apolipoprotein 
ApoA1  have  been  detected  at  an  increased  level  in  the  synovial  fluid  of  RA 
patients compared to serum levels and total cholesterol was also at an increased 
level in the synovial fluid [557]. Accumulation of HDL particles in the inflamed 
joint has anti-inflammatory effects since HDL can block the pro-inflammatory 
cytokine production from monocytes induced by T cell contact through binding 
to the T cell surface activating factors [558]. However, it has also been proposed 
that the accumulation of HDL within the synovium of RA patients and thereby 
reducing  the  amount  of  circulating  HDL  may  contribute  to  the  increased 
cardiovascular risk seen in these patients [559]. Consequently, the upregulation 
of these genes in the RA SF macrophages as well as the lipid transporter ABCA1 
needed to assemble the HDL particles may be as a result of the activation of the 
LXR/RXR pathway, as indicated by the canonical pathway analysis, or it may be 
as a result of the macrophage trying to dampen down the immune response by 
producing anti-inflammatory HDL particles which will inhibit the local production 
of inflammatory cytokines.  
The presence of the LPS/IL-1 mediated inhibition of RXR canonical pathway also 
indicates that the LPS pathway may play a role in the RA SF CD14
+. LPS is one of 
the ligands for TLR4 which is a protein expressed on the surface of immune cells 
such as monocytes and its activation triggers signalling pathways which in turn 
lead to the induction of inflammatory cytokines such as TNF-α [560]. TLR4 has 
been  detected  in  the  RA  synovium  [549]  and  a  TLR4  agonist  has  shown 
therapeutic effect in two murine models of arthritis [561] indicating that it may 
play a role in pathogenesis. Therefore the association of this canonical pathway 
with RA SF CD14
+ is unsurprising since many TLR4 agonists such as hyaluronan, 
fibrinogen and heat shock proteins have been detected in the RA synovium. 208 
The  coagulation  system  is  the  fifth  canonical  pathway  that  is  significantly 
associated with the differentially expressed genes in the RA SF CD14
+ cells due 
to  the  upregulation  of  genes  such  as  coagulation  factors  and  plasminogen 
activators  such  as  UPA  (plasminogen  activator,  urokinase).  UPA  can  convert 
plasminogen into the less specific plasmin which has various substrates including 
fibrin, cytokines and proMMPs, and also has a role in matrix degradation [562]. It 
has been demonstrated that systemic inflammation in arthritis can activate the 
coagulation cascade [563]. Levels of UPA are increased in RA [564] and induction 
of CIA in UPA
-/- mice resulted in a mild disease indicating a pro-inflammatory 
role for UPA in RA [565]. Therefore these results indicate that RA synovial fluid 
macrophages  are  expressing  genes  which  are  contributing  to  the  increased 
coagulation cascade seen in RA as well as the increased matrix degradation and 
inflammation.  
The diseases and disorders associated with the differentially expressed genes in 
RA SF macrophages compared to their matched PB monocytes are all related to 
rheumatoid  arthritis  such  as  inflammatory  disease  and  skeletal  and  muscular 
disorders.  The  presence  of  these  diseases  significantly  associated  with  the 
differentially expressed gene list validates this dataset as they are all related to 
our disease of interest. 
The top 5 cellular functions significantly overrepresented in the RA SF gene list 
comprise  functions  which  we  would  expect  to  upregulated  in  the  monocytes 
once they move from the blood into the synovium. This is exemplified by two of 
the  cellular  functions  being  cellular  movement  and  immune  cell  trafficking 
which  would  be  expected  to  be  upregulated  as  a  result  of  the  CD14
+ 
transendothelial migration from the blood vessels into the synovium [258, 407]. 
Transendothelial migration is the mechanism via which leukocytes infiltrate into 
the RA joint and several adhesion molecules which assist in this process have 
been identified in RA [179]. Another cellular functions significantly associated 
with the up- and down-regulated genes in the RA SF gene list was cell-to-cell 
signalling  and  interaction  which  is  unsurprising  since  it  has  been  well 
documented that macrophages within the synovial compartment are known to 
participate  in  cellular  interactions  with  several  cell  types  such  as  fibroblasts 
[249], T cells [269, 314, 408], endothelial cells [407] and natural killer (NK) cells 
[251]. The final two cellular functions associated with RA SF CD14
+ compared to 209 
PB cells are cellular growth and proliferation and cellular development which is 
logical due to the maturation that the CD14
+ cells undergo into fully activated 
macrophages  once  they  are  within  the  synovium  and  exposed  to  the  pro-
inflammatory and hypoxic environment [409, 410]. An upregulation of genes such 
as  CSF1  (M-CSF)  which  was  previously  discussed  will  be  contributing  to  the 
maturation of the blood monocytes into synovial macrophages. 
In conclusion the RA PB versus RA SF analysis to determine the effect of the 
migration of the monocytes from the blood into the synovial fluid has been very 
informative. The IPA analysis demonstrated the association of the differentially 
expressed genes with several pathways such as the LXR/RXR activation pathway. 
This pathway could be contributing towards an anti-inflammatory effect, though 
the production of HDL, or a pro-inflammatory effect since research by our group 
has demonstrated LXR activation is pro-inflammatory in a murine arthritis model 
[527].  Further  analysis  of  the  IPA  canonical  pathways  also  demonstrated  the 
upregulation of novel receptor ligand complexes in the RA SF macrophages such 
as  Fz7  and  Wnt-5a  which  warrant  further  investigation.  The  cellular  and 
molecular  functions  associated  with  the  RA  SF  gene  list  consisted  of  cellular 
migration,  cell-to-cell  interaction  and  cellular  development.  This  result 
demonstrates  that  once  the  RA  PB  monocytes  migrate  into  the  synovial 
compartment  they  are  expressing  transcripts  of  genes  involved  in  cellular 
interactions,  which  are  know  to  promote  the  production  of  pro-inflammatory 
mediators,  and  also  genes  associated  with  monocyte  maturation  into  a  fully 
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3.7.2.2   PsA PB CD14
+ versus PsA SF CD14
+ 
The IPA analysis of the differentially expressed genes in the PsA SF CD14
+ cells 
compared to the PB CD14
+ cells resulted in remarkably similar results to those 
obtained  from  the  IPA  analysis  of  the  RA  SF  gene  list.  Three  of  the  five 
significantly  associated  canonical  pathways  were  the  same  pathways  found 
associated  with  RA  SF  macrophages:  LXR/RXR  activation,  LPS/IL-1  mediated 
inhibition  of  RXR  function  and  hepatic  stellate  cell  activation.  Many  of  the 
individual genes associated with these pathways were the same in the PsA and 
RA gene lists indicating similarities between the two types of arthritic synovial 
macrophages.  LXR  activation  has  not  previously  been  demonstrated  to  be 
associated with PsA therefore this finding is a novel one.  The LXR activation 
pathway could be playing one of two roles; it could be an anti-inflammatory 
pathway  in  PsA  by  producing  components  of  HDL  which  prevents  cytokine 
secretion  from  monocytes  [558]  or  it  is  more  likely  to  be  playing  a  pro-
inflammatory role in PsA. As discussed in the previous section LXR agonism in 
LPS-stimulated  monocytes  resulted  in  increased  TNFα  production  and  LXR 
agonism  also  exacerbates  a  murine  model  of  arthritis  possibly  through  the 
increased cytokine and chemokine production [526, 527]. A natural agonist of 
the LXR activation pathway is LDL, which has been detected in the plasma of PsA 
patients  therefore  indicating  a  mechanism  for  the  LXR  activation  [566].  The 
association  of  the  LPS/IL-1  mediated  inhibition  of  RXR  pathway  with  the 
differentially expressed PsA SF macrophage genes is due to the upregulation of 
the same apoplipoproteins and lipid transporter genes which were upregulated 
in the RA SF macrophages including APOE, APOC1, APOC2, ABCA1 and ABCG1. As 
discussed for the RA SF CD14
+ cells the upregulation of these genes would result 
in an increase in HDL which prevents monocyte cytokine secretion and therefore 
mediate an anti-inflammatory effect from the PsA SF macrophage. 
The association of the hepatic stellate cell activation canonical pathway with 
the  PsA  gene  list  is  due  the  upregulation  of  growth  factors,  MMPs  and 
chemokines which are also involved in hepatic stellate cell activation. It includes 
genes  which  have  been  previously  associated  with  PsA  such  as  MMP2,  MMP9 
[567], fibronectin [426] and CCL2 [509] but also novel genes such as SMAD7 and 
TGFB2 (transforming growth factor beta 2). TGFβ exists in three isoforms TGFβ1, 
TGFβ2 and TGFβ3, it is a multifunctional cytokine which regulates cell growth, 211 
adhesion  and  differentiation  in  a  variety  of  cell  types,  it  is  a  potent 
immunosuppressor but also helps to drive the differentiation of Th17 which can 
promote inflammation and augment autoimmune conditions [568]. Of note there 
are increased levels of circulating Th17 cells in the blood of PsA patients [569]. 
TGFβ has not previously been associated with PsA but one of its isoforms TGFβ1 
is present in the epidermis and serum of psoriasis patients and correlates with 
the psoriasis area and severity index (PASI), although the same study found no 
correlation  between  PASI  and  our  TGF  isoform  of  interest  TGFβ2  [570]. 
Overexpression studies of TGFβ1 in keratinocytes of mice induces a psoriasis-like 
skin  inflammation  suggesting  TGFβ  is  pro-inflammatory  [571]  however  the 
mechanisms  for  this  are  not  understood.  In  addition  to  an  upregulation  of 
TGFβ2, the PsA SF macrophages also upregulated SMAD7 which paradoxically is a 
negative  regulator  of  TGFβ2  [572].  SMAD7  had  also  been  demonstrated  to 
negatively  regulate  signalling  intermediaries  in  pro-inflammatory  signalling 
pathways such as NF-κB, in this pathway SMAD7 plays a role in increasing IκB 
expression [502]. Therefore the upregulation of SMAD7 in the PsA macrophages 
may be as an auto-regulatory anti-inflammatory mechanism in order to decrease 
the  amount  of  NF-κB  pro-inflammatory  gene  transcription.  TGFβ2  and  SMAD7 
expression have not been analysed in PsA previously therefore our observation is 
an  interesting  one.  It  is  difficult  to  determine  the  overall  net  effect  of  the 
upregulation of the potential pro- and anti-inflammatory molecule TGFβ2 along 
with  its  intracellular  inhibitor  SMAD7  therefore  further  expressional  and 
functional studies would be required. 
The two canonical pathways which are specifically associated with the PsA SF 
macrophage  differentially  expressed  gene  list  are  pathogenesis  of  multiple 
sclerosis  and  the  complement  system.  Numerous  studies  have  implicated  the 
complement system within rheumatoid arthritis; elevated levels of complement 
activation  products  have  been  detected  within  RA  synovial  fluid  [573]  and 
several  animals  models  have  provided  evidence  for  the  involvement  of 
complement in arthritis such as C5
-/- and C3
-/- mice being resistant to CIA [574, 
575].  In  comparison  there  are  very  few  studies  implicating  the  complement 
system  in  PsA,  one  study  has  found  the  presence  of  terminal  complement 
complex in PsA serum [576] and another study indicated that erythrocytes from 
psoriatic patients had reduced expression of surface CD59 compared to healthy 212 
controls and it was hypothesised that this may be an indicator of low tissue CD59 
expression  [577].  CD59  (protectin)  is  an  inhibitor  of  the  membrane  attack 
complex  (MAC)  therefore  a  reduction  in  its  expression  could  result  in  the 
perpetual  activation  of  the  complement  system  and  increased  lysis  of 
erythrocytes and synovial cells through the MAC. Contrary to this observation the 
data generated by our microarray indicates that the PsA SF actually have an 
increased level of CD59 expression compared to PB monocytes which may due to 
the macrophage trying to regulate the amount of complement activation taking 
place  in  order  to  prevent  perpetual  activation.  Brought  together  these  data 
suggest that the complement system may be involved in PsA as well as RA and 
the synovial macrophage could be a key cell type producing complement system 
components. 
The  pathogenesis  of  multiple  sclerosis  canonical  pathway  is  significantly 
associated with the differentially expressed genes in PsA SF CD14
+ due to four 
chemokines  which  play  a  role  in  this  small  nine  component  pathway  being 
present in the gene list (see Figure 3.12). The four chemokines involved in this 
pathway  are  CCL4,  CCR5,  CXCL9  and  CXCL11.  CCL4  otherwise  known  as 
macrophage-inflammatory  protein-1  beta  (MIP-1β)  is  produced  by  activated 
macrophages  [578].  CCL4  has  been  identified  as  one  of  the  chemokines 
significantly  upregulated  in  the  serum  of  PsA  patients  compared  to  healthy 
controls and it is significantly associated with cellular synovial tissue markers in 
PsA  [237].  Studies  performed  in  RA  have  demonstrated  that  mediators  found 
within RA synovial fluid, such as osteopontin, can induce CCL4 production from 
monocytes [241] and there is also evidence that the interaction between CCL4 
and its receptor CCR5 plays a crucial role for trafficking Th1 and other immune 
cells into the RA joint [235, 579]. Apart from the identification of CCL4 within 
PsA serum and synovial fluid there is little known about the role of CCL4 within 
PsA; however it could be hypothesised that this chemokine plays a similar role in 
inflammatory cell recruitment that has been described for RA. 
CCR5 otherwise known as CC-CKR5 is a receptor found on macrophages and T 
cells which binds RANTES, MIP-1α and MIP-1β (CCL4) with high affinity [580]. As 
has been illustrated above it has been implicated in Th1 cell trafficking into the 
RA joint and its expression has been determined within the RA synovial tissue 
and  on  synovial  fluid  monocytes  and  T  cells  [581].  At  present  there  is  no 213 
evidence for the presence of CCR5 within the PsA synovial compartment apart 
from the data presented here, however since its high affinity ligand CCL4 has 
been demonstrated to be present in the synovial fluid we can hypothesise that 
CCR5 is also present also and contributing to the inflammatory cell influx into 
the diseased joint. 
The third gene upregulated in PsA SF CD14
+ cells and associated with pathogensis 
of MS pathway was CXCL9 otherwise known as monokine induced by IFN-γ (Mig). 
CXCL9  is  produced  by  activated  monocytes  [582]  and  mRNA  levels  of  this 
chemokines have previously been detected in the synovium of PsA [238] where it 
is thought to help regulate the influx of inflammatory cells. CXCL11 otherwise 
known  as  IFN-inducible  T-cell  alpha  chemoattractant  (I-TAC)  was  the  fourth 
chemokine upregulated in PsA SF CD14
+ cells, this chemokines is upregulated by 
LPS stimulated macrophages [583] and had been detected in PsA synovial fluid 
[584]. Consequently, from this result it is not assumed that the pathogenesis of 
multiple sclerosis (MS) plays a role in PsA only that several of the chemokines 
which are involved in the pathogenesis of MS are also upregulated in PsA synovial 
fluid macrophages. 
The diseases and disorders correlated with the PsA SF macrophage differentially 
expressed  genes  are  the  same  as  those  found  associated  with  the  RA  SF 
macrophage genes and are all related to arthritic disease such as inflammatory 
diseases and inflammatory response. Again the significant association of these 
disorders with the gene list validates our PsA dataset. 
The molecular and cellular functions associated with the up- and down-regulated 
PsA  SF  macrophages  are  highly  similar  to  those  correlated  with  the  RA  SF 
macrophage genes as 4 of the 5 associated functions are the same in RA and PsA. 
This data further substantiates the finding that the RA and PsA macrophages 
have  very  similar  genetic  profiles  and  upregulate  analogous  genes  once  the 
monocytes migrate out of the blood and into the synovial fluid. The molecular 
and cellular functions which were significantly associated with the PsA genes 
included cell movement and immune cell trafficking which will be due to the 
presence of up- and downregulated genes involved in transendothelial migration 
and movement of the cells into the synovial joint. The synovium of PsA patients 
is characterised by an inflammatory cell influx [7] and monocytes isolated from 214 
PsA patients have been demonstrated to interact with cultured endothelial cells 
whilst  down-regulating  adhesion  molecules  which  is  thought  to  aid  in  their 
migration [411]. PBMCs from PsA patients are also have a significant increase in 
their adhesion to endothelial cells compared to healthy PBMCs  [585] and the 
level of chemokines is significantly increased in the serum and synovium of PsA 
patients  [259,  406,  509].  These  data  emphasize  the  importance  of 
transendothelial migration in the pathogenesis of PsA and also emphasises why 
the  PsA  SF  have  a  significant  change  in  their  migratory  associated  genes 
compared to PB monocytes. 
Another molecular and cellular function associated with the PsA SF macrophage 
expressed genes was cell-to-cell signalling and interaction. In comparison to RA 
there have been only two studies into the role of macrophage direct cell contact 
in  PsA.  These  studies  demonstrated  that  direct  cell  contact  between  PsA 
monocytes and NK cells was able to differentiate the monocytes into DCs [586] 
and direct  interaction  of PsA  monocytes with endothelial  cells  aided  in  their 
transendothelial migration [411]. Despite the lack of information regarding the 
role  of direct macrophage cell contact in PsA,  due to the close proximity of 
macrophages to other immune cells in the synovium [124] we can hypothesise 
that  direct  cell  interaction  is  one  method  through  which  macrophages  exert 
their pro-inflammatory potential as has been extensively demonstrated in RA. 
The  two  other  molecular  and  cellular  functions  associated  with  the  PsA  SF 
macrophage gene list are cellular growth and proliferation and cell mediated 
immune response. A reason for genes associated with both of these functions 
being differentially expressed in the synovial macrophages could be due the pro-
inflammatory environment into which the cells migrate. Previous studies have 
demonstrated the PsA synovium to be a hypoxic environment [587] containing 
many cytokines, chemokines and inflammatory mediators [237, 259] which would 
in  turn  cause  the  monocytes  to  differentiate  into  macrophages  and  illicit  an 
immune response. 
In summary the PsA PB versus PsA SF microarray comparison to establish the 
effect  of  the  PB  monocyte  migration  into  the  synovium  has  identified  the 
activation of novel pathways in the macrophages such as LXR/RXR activation as 
well  as  the  identification  of  novel  genes  which  have  not  previously  been 
associated with PsA such as TGFβ2 and its inhibitor SMAD7. Nevertheless, the 215 
most  interesting  observation  to  come  out  of  this  analysis  is  the  similarity 
between the transcriptomes of the RA and PsA synovial macrophages which is 
investigated further in the following comparison. 
3.7.2.3   Identification of genes expressed in: both RA and PsA 
synovial fluid macrophages, only in RA macrophages or 
only in PsA macrophages  
The  similarity  between  the  transcriptomes  of  the  RA  and  PsA  samples  first 
became apparent during the PCA comparison which indicated that the synovial 
fluid samples of both PsA and RA were clustered in the same area of the graph 
indicating that these samples had similar genetic expression. Investigating the 
two diseases individually during IPA analysis then demonstrated that the synovial 
macrophages in both RA and PsA shared many of the same canonical pathways 
and molecular functions. These results let us to hypothesise that the synovial 
fluid macrophages of PsA and RA shared many of the same genes. To investigate 
this hypothesis the differentially expressed genes from both disease PB versus SF 
comparison were subjected to a Venn diagram comparison to determine genes 
which were expressed in both diseases and also genes which were specific to the 
synovial fluid macrophages of each disease. 
Interestingly the Venn diagram demonstrated that 58% of the PsA differentially 
expressed genes and 52% of the RA differentially expressed genes were present 
in both diseases indicating that just under half of the genes expressed in the RA 
or PsA synovial fluid cell were disease specific. This result is in contrast to those 
of Dominique Baeten and his group who have previously described a differential 
macrophage phenotype in SpA (including PsA) compared to RA patients through 
revealing an increased number of CD163
+ cells in the synovium of SpA patients 
[255] and demonstrating that the synovial fluid of SpA but not RA was able to 
polarise  blood  monocytes  to  express  CD163  [253].  CD163  is  a  cell  surface 
glycoprotein which is classed as a marker of alternatively activated macrophages 
(M2), M2 macrophages have been implicated in tissue remodelling and immune 
regulation and are in stark contrast to classically activated macrophages (M1) 
which are thought to be the main source of pro-inflammatory cytokines which 
are associated with tissue damage [185]. Consequently, Baeten et al suggest that 
the macrophage phenotype in RA and SpA are significantly different due to the 
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diseased  synovial  fluid  to  induce  these  macrophage  phenotypes.  Our  venn 
diagram data illustrates that in contrast to results of Baeten et al the genetic 
profile and therefore the phenotype of both RA and PsA macrophages are very 
similar and over 50% of the genes expressed by each diseased macrophage are 
shared  between  the  diseases.  This  observation  is  further  exemplified  by 
analysing for the presence of genes associated with M1 and M2 phenotypes in the 
macrophage gene lists from both diseases. As although CD163 is not present in 
either the PsA or RA SF macrophages, possibly due to the strict inclusion criteria 
for the microarray analysis, other markers of M2 phenotype such as the mannose 
receptor  (MRC1  and  MRC2)  and  macrophage  scavenger  receptor  (CD204)  are 
upregulated by a similar fold change in both RA and PsA. MRC1 has a fold change 
(FC) increase of 73 in PsA and 61 in RA, MRC2 (FC 32 PsA, 32 RA) and CD204 (FC 
10 PsA,  8 RA). However, analysis of markers of M1 polarisation demonstrates 
that these markers are also upregulated to similar levels of magnitude in both 
RA and PsA SF macrophages such as CD86 (FC 11 PsA, 15 RA) and MHC class II 
molecules HLA-DOA (FC 7 PsA, 4 RA). Our results would suggest that rather than 
the RA and PsA SF macrophages being two separate phenotypes, as implicated by 
work of Beaten et al, they are both similar cell types and at the RNA transcript 
level appear to have no preferential expression of an M1 or M2 phenotype. This 
could be an indication of the high level of plasticity of macrophage cells and 
their  ability  to  constantly  change  their  phenotype  in  response  to  their 
environment.  Despite  there  being  very  little  differences  in  the  expression  of 
several M1 and M2 macrophage markers the results of the venn diagram did also 
demonstrate that both the RA and PsA have a subset of genes that were disease 
specific  which  could  account  for  some  of  the  differences  in  seen  in  the 
pathogenesis and cytokine profiles of the two diseases.  
The results of the Venn diagram were saved as three individual datasets; i) genes 
which  were  differentially  expressed  in  both  diseases,  ii)  genes  which  were 
expressed only in PsA and iii) genes which were expressed only in RA. These 
gene lists were then analysed by IPA to identify the canonical pathways and the 
molecular and cellular functions which were significantly associated with them. 
The canonical pathways associated with the gene list expressed by both PsA and 
RA consisted of pathways which had already been discovered from the previous 
IPA analyses of RA PB vs RA SF and PsA PB vs PsA SF. These five pathways were: 217 
LXR activation which has been previously been described as being a potential 
pathogenic pathway in RA [527] but as yet no association has been demonstrated 
for PsA; LPS/IL-1 inhibition of RXR function is also associated with the gene list 
due to an upregulation of HDL constituents in both RA and PsA macrophages, the 
significance  of  this  pathway  is  not  fully  understood  but  since  HDL  had  been 
demonstrated to prevent monocytes from releasing pro-inflammatory mediators 
[315, 558] this pathway may be an anti-inflammatory mechanism through which 
the  macrophages  counter-balance  their  disproportionate  pro-inflammatory 
response. The complement system was the third pathway associated with the 
genes expressed in both diseases, complement components have been detected 
in the serum and synovial fluid of RA and PsA patients [573, 576] and several 
animals  models  have  already  provided  evidence  for  the  involvement  of 
complement in arthritis such as C5
-/- and C3
-/- mice being resistant to CIA [574, 
575]. Therefore the combination of this data with our microarray data indicate 
that synovial macrophages may be a specific cell type in both RA and PsA to be 
involved in the activation of the complement pathway. 
The hepatic stellate cell activation was the fourth associated canonical pathway, 
as described previously the presence of this pathway is due to the occurrence of 
pro-inflammatory chemokines, cytokines and growth factors that are expressed 
in  both  hepatic  stellate  cells  and  synovial  macrophages  during  cellular 
activation.  The  final  canonical  pathway  was  the  pathogenesis  of  multiple 
sclerosis, the association of this pathway to the gene list is due to the presence 
of three chemokines which play a role in both multiple sclerosis as well as RA 
and  PsA  pathogenesis.  The  three  chemokines  were  CCL4  (MIP-1β)  and  its 
receptor CCR5 which are both associated with macrophages and play a role in 
trafficking immune cells into the arthritic joint [235, 579], and CXCL11 which 
has been previously detected in RA synovium [588] and PsA synovial fluid [584]. 
The molecular and cellular functions associated with the gene list expressed in 
both RA and PsA SF CD14
+ cells had all previously been associated with the SF 
macrophages such as cell-to-cell signalling and interaction, cellular development 
and  cellular  movement.  The  one  function  which  had  not  previously  been 
correlated to the SF macrophages was cellular function and maintenance which 
may be due to genes associated with cellular homeostasis being expressed by the 
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The canonical pathways associated with the genes specifically expressed in PsA 
SF macrophages were: B cell development, pathogenesis of multiple sclerosis, 
autoimmune  thyroid  disease  signalling,  altered  T  and  B  cell  signalling  in 
rheumatoid  arthritis,  and  allograph  rejection  signalling.  The  pathogenesis  of 
multiple sclerosis was previously associated with the PsA PB vs SF comparison 
but the four other canonical pathways are unique to the PsA SF macrophage 
gene list. All four of these novel canonical pathways appear to be specifically T 
and B cell related, however they are associated with the PsA SF specific gene list 
due to the presence of three genes within the gene list. These genes are CD40, 
HLA-DQA1  and  HLA-DOA  which  were  all  upregulated  in  PsA  SF  macrophages 
compared  to  PB  monocytes  and  these  genes  are  found  in  all  four  canonical 
pathways. 
CD40 is a cell surface receptor found on macrophages/monocytes, B cells and 
myeloid DCs and it is activated by ligation with CD154 found on CD4
+ T cells, 
platelets, mast cells and basophils  [589].  Ligation of CD40 on monocytes and 
macrophages  results  in  the  induction  of  pro-inflammatory  cytokine  and 
chemokine synthesis such as IL-1α, TNFα, IL-6, IL-8, CCL2 and CCL4 [589]. CD40 
ligation on monocytes or macrophages also upregulates the expression of MHC 
class  II  and  co-stimulatory  molecules  CD80  and  CD86,  as  well  as  CD40  itself 
[590].  CD40  has  previously  been  demonstrated  to  play  a  role  in  arthritis  as 
blockade of the CD40:CD154 interaction inhibited the onset of collagen induced 
arthritis  (CIA)  [591].  Once  again,  in  comparison  to  RA  there  have  been  few 
studies analysing the role of CD40 in PsA. However, soluble CD40 ligand (sCD40L) 
is present in the serum of PsA patients [592] and interestingly Stoeckman et al 
discovered that CD40 and its signalling intermediates were downregulated in PsA 
PBMCs compared to healthy controls which they suggested could be due to the 
migration of CD40-expressing cells out of the blood and into the synovium. Our 
data agrees with this hypothesis as we demonstrate that in comparison to PsA PB 
CD14
+ cells there is an upregulation of CD40 gene expression in PsA SF CD14
+ 
cells. The presence of CD40 on PsA synovial macrophages will be contributing to 
the  inflammatory  milieu  within  the  synovium  through  its  ligation  with  CD154 
present on the synovial T cells and sCD40L present within PsA patients. 
The remaining two genes associated with the four canonical pathways specific to 
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Human  leukocyte  antigen  (HLA)  is  coded  for  by  the  major  histocompatibility 
complex (MHC) gene region and HLA molecules are critical for distinguishing self 
from  non-self.  Cell-surface  HLA  molecules  function  to  present  processed 
antigenic peptide, which is held within a groove in the HLA molecule, to T cell 
receptor molecules expressed on the surface of T cells. HLA class II DR, DQ and 
DP molecules are found on B cells and professional antigen presenting cells and 
present  processed  peptides  derived  from  exogenous  antigens  to  CD4
+  T  cells 
[593]. An increased expression of HLA genes within the PsA SF macrophage could 
indicate an increase in the amount of antigen presentation taking place within 
the synovium and is also a marker of increased cellular activation. HLA-DQA1 
alleles  have  been  associated  with  susceptibility  to  a  wide  variety  of 
inflammatory  conditions  such  as  multiple  sclerosis  [594]  and  coeliac  disease 
[595].  The  expression  of  this  molecule  has  also  been  upregulated  in 
oligoarticular JIA [596] and different alleles have been demonstrated to be a risk 
factor for susceptibility to RA [597] and susceptibility to psoriasis [598]. These 
results  indicate  that  HLA-DQA1  has  a  role  in  immune  disease  and  arthritis 
pathogenesis and despite there being no direct link to PsA increased levels of 
HLA-DQA1 in PsA macrophages may be playing a role in disease susceptibility and 
antigen presentation. The other gene associated with the PsA specific canonical 
pathways  is  HLA-DOA  which  is  another  HLA  molecule  involved  in  antigen 
presentation  and  is  upregulated  at  the  RNA  and  protein  level  in  monocytes 
treated with GM-CSF [599]. A single nucleotide polymorphism (SNP) in HLA-DOA 
which  is  significantly  associated  with  RA  susceptibility  has  recently  been 
identified [600] again emphasising the importance of antigen presentation in the 
pathogenesis of arthritic disease. 
The  cellular  and  molecular  functions  specifically  associated  with  PsA  SF 
macrophages  included  two  functions,  cellular  movement  and  cell-to-cell 
signalling and interaction, which have been previously discussed. However, the 
other three pathways: DNA replication, recombination and repair; cell cycle and 
cell death represent functions which are specific to PsA SF macrophages. Despite 
there being no direct link of DNA replication, recombination and repair to PsA 
pathogenesis this molecular function is associated with the PsA macrophages due 
to an increase in the expression of genes such as TOP2A (topoisomerase (DNA) II 
alpha 170kDa). TOP2A is an enzyme which transiently breaks and rejoins double 220 
stranded DNA in order to resolve topological problems which arise as a result of 
supercoiling or knotting which can occur naturally in the DNA [601]. 
The molecular function of cell cycle is associated with the PsA gene list due to 
the upregulation of genes such as TOP2A (described above) and CDK1 (cyclin-
dependent  kinase  1)  which  regulates  cell  division  and  controls  cell-cycle 
transitions by associating with different cell-cycle stage specific cyclins [602]. 
The association of the cell death function with the PsA gene list is due to the 
differential expression of apoptosis related genes including the down-regulation 
of clusterin (CLU) in SF macrophages. Clusterin was discussed previously in this 
chapter as a protein which was highly upregulated in RA PB monocytes compared 
to  healthy  controls.  Clusterin‘s  cellular  functions  are  context  dependent  and 
nuclear associated clusterin (nCLU) is a pro-apoptotic factor [489]. Hence the 
down-regulation of this gene within the SF macrophages may be a mechanism 
through which these cells evade apoptosis. This data demonstrates that as well 
as the proinflammatory pathways which are being upregulated in the synovial 
macrophages,  as  demonstrates  by  the  pathways  correlated  with  the  genes 
expressed in both RA and PsA SF macrophages, the PsA macrophages are also up-
regulating  cellular  functions  associated  with  the  maintenance  of  homeostasis 
such as cell cycle and DNA replication as well as pro-survival factors.  
The canonical pathways associated with the gene list expressed specifically in RA 
SF  macrophages  compared  to  the  PB  monocytes  consisted  of  two  pathways, 
hepatic stellate cell activation and the role of macrophages, endothelial cells 
and fibroblasts in RA, which were previously associated with the primary RA PB 
vs RA SF comparison. This is due to the differential expression of genes such as 
CSF1  (M-CSF)  and  VEGFA  which  play  a  role  in  these  pathways  and  the 
pathogenesis of RA. However, the IPA analysis of the genes expressed only in RA 
SF  macrophages  also  revealed  three  RA  specific  pathways:  atherosclerosis 
signalling,  ERK5  signalling  and  p38  MAPK  signalling.  The  presence  of  the 
atherosclerosis signalling pathway within the IPA analysis of the RA SF specific 
genes  is  interesting  as  inflammatory  pathways  have  been  implicated  in  both 
atherosclerosis  and  RA  and  this  result  emphasises  the  overlap  in  immune 
disregulation which exists in both diseases. RA patients also have a 30-60% higher 
risk  of  cardiovascular  events  compared  to  osteoarthritis  patients  or  patients 
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being  exposed  to  chronic  inflammation  which  is  known  to  be  a  driver  of 
atherosclerosis. 
One of the RA SF macrophage genes correlated to this atherosclerosis signalling 
pathway was TNFRSF12A (tumour necrosis factor receptor superfamily, member 
12A) which codes for the TWEAK (TNF-like weak inducer of apoptosis) receptor 
otherwise  known  as  fibroblast  growth  factor  inducible  14  (Fn14).  TWEAK  has 
been demonstrated to induce proliferation as well as cell adhesion molecule and 
cytokine expression in human umbilical vein endothelial cells (HUVECs) [604] and 
has also been implicated in angiogenesis in vivo. Recently, studies using an anti-
human  Fn14  monoclonal  antibody  have  demonstrated  that  TWEAK-induced 
proliferation and migration is solely mediated by its Fn14 receptor  [604]. The 
TWEAK/Fn14 interaction has been implicated in the pathogenesis of arthritis as 
serum levels of TWEAK were elevated in murine CIA and neutralising TWEAK in 
this  model  significantly  reduced  the  clinical  severity,  paw  swelling  and 
infiltration of inflammatory cells [605, 606]. Recently, Fn14 has been detected 
in the RA synovium and on synovial fibroblasts where its ligation with TWEAK 
induced  the  production  of  pro-inflammatory  cytokines  and  the  expression  of 
intracellular adhesion molecule (ICAM-1) [607]. This pro-inflammatory cytokine 
release has since been demonstrated to be mediated through the activation of 
the NF-κB pathway [608]. Fn14 is detected within the synovium of both RA and 
PsA  where  it  has  been  demonstrated  to  be  specifically  expressed  on 
macrophages and fibroblasts [609] and its ligand TWEAK is present in the serum 
of  RA  patients  and  correlates  with  disease  activity  [610].  Consequently,  the 
upregulation of the Fn14 gene TNFRSF12A by the RA SF macrophages in our study 
demonstrates a mechanism through which these macrophages can contribute to 
the inflammatory environment in RA synovium. The TWEAK/Fn14 has been shown 
to play a role in the pathogenesis of atherosclerosis and cardiac dysfunction due 
to its ability to induce angiogenesis, exacerbate vascular damage and mediate 
lipid uptake by macrophages [611-613] and therefore may be a pathway causing 
the increased risk of cardiovascular events seen in RA. 
The remaining two canonical pathways associated with the RA specific gene list 
were ERK5 signalling pathway and p38 MAPK pathway, both of these pathways 
are  members  of  the  MAPK  signalling  family  and  their  association  with  RA  SF 
macrophages is due to the up- and down-regulation of genes coding for signalling 222 
intermediates  and  transcription  factors  involved  in  these  pathways.  ERK5 
signalling pathway has not previously been associated with RA pathogenesis but 
some of its signalling components which were differentially expressed in the RA 
SF macrophages have been demonstrated to play a role. For example, FOSL1 is 
upregulated in the RA SF macrophages and this gene codes for the Fra-1 protein 
which dimerises with c-Jun to form the AP-1 transcription factor. AP-1 has been 
demonstrated  to  be  constitutively  active  in  rheumatoid  synovium  [614]  and 
treatment of rheumatoid synoviocytes with TNFα and IL-1β induced the nuclear 
translocation of Fra-1 and induction of AP-1 transcription [615]. Consequently, 
despite  no  evidence  for  the  ERK5  pathway  being  implicated  in  RA  the 
components  of  this  pathway  have  been  demonstrated  to  play  a  role  in  the 
pathogenic phenotype of synovial cells.  
The p38 MAPK pathway is also correlated to the RA SF macrophages which is due 
to the upregulation of genes coding for IL-1 receptor type I, IL-1 receptor type II, 
IL-1 receptor-associated kinase 2 (IRAK2) and the anti-inflammatory molecule IL-
1 receptor antagonist. The ligation of  IL-1α or IL-1β to the IL-1 receptor type I 
on  the  cell  surface  activates  IRAK  and  commences  the  activation  of  the  p38 
MAPK signalling pathway and the subsequent translation of genes coding for pro-
inflammatory mediators such as IL-6, IL-8, CCL2 (MCP-1), IL-1α and IL-1β [616]. 
Interestingly  the  RA  SF  macrophages  have  also  upregulated  levels  of  IL-1 
receptor  antagonist  (IL-RA)  and  the  decoy  receptor  IL-1  receptor  II  (IL-1R2) 
which are inducible negative regulators of IL-1 signalling and can terminate or 
limit  IL-1  effects.  Hence  the  RA  SF  macrophages  are  not  only  up-regulating 
activator components of the p38 MAPK pathway but also negative regulators of 
this pathway, the net effect of this gene expression is not known since IL-1RA 
binds IL-1R1 with a similar specificity and affinity as IL-1α and IL-1β [616]. Of 
interest, a recombinant version of human IL-1RA designated anakinra is used as a 
therapy for RA demonstrating the significant anti-inflammatory properties of IL-
1RA [266]. 
The molecular and cellular functions of the RA SF specific gene list highlight the 
same group of functions which were associated with the previous RA PB vs RA SF 
comparison  such  as  cellular  movement,  cell-to-cell  signalling  and  cellular 
growth. As discussed previously the differential expression of genes associated 
with these functions demonstrates the increased cellular migration undertaken 223 
by the macrophages as well as the physiological growth and development which 
the PB monocytes undergo to mature into the synovial macrophages.  
In summary, the analysis of the genes similarly expressed in both RA and PsA SF 
macrophages as well as the genes expressed specifically in PsA SF macrophages 
or RA SF macrophages has been crucial in defining groups of genes specifically 
expressed  in  each  disease.  The  Venn  diagram  analysis  also  revealed  the 
significant  similarity  in  gene  expression  in  both  RA  and  PsA  macrophages 
compared to their matched disease blood monocytes with over 50% of the genes 
being shared in each disease. 
Apart  from  the  identification  of  the  shared  expression  of  the  LXR  activation 
pathway  which  was  an  interesting  finding  this  analysis  unfortunately  did  not 
reveal any novel genes which change in expression as the RA monocytes move 
from the blood into the synovial fluid. For that reason it was decided to analyse 
the  differentially  expressed  genes  that  changed  in  both  RA  and  PsA  SF 
macrophages  to  try  and  detect  novel  genes  that  had  not  previously  been 
associated  with  arthritis.  This  was  in  the  hope  of  finding  novel  pathways 
regulating  the  pathogenesis  of  the  arthritic  synovial  macrophage.  The  genes 
which had been upregulated in the synovial macrophages compared to the blood 
monocytes were analysed starting with those that had the largest fold change 
difference. Analysing the genes using this method unsurprisingly resulted in the 
identification  of  genes  coding  for  molecules  which  have  previously  been 
associated  with  arthritis  such  as  FN1  (fibronectin),  SPP1  (osteopontin)  and 
CCL18. However, through this analysis we also discovered two novel genes; LGM 
which codes for the enzyme legumain and PLXA1 which codes for the cell surface 
receptor plexin A1. These two candidate genes were subsequently validated and 
further analysis was performed to determine their function within the arthritic 
synovium. These results are discussed in full detail in the following chapters. 
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Chapter 4 Investigation into the expression and 
function of the novel gene plexin A1 in rheumatoid 
and psoriatic arthritis patients  225 
4.1  Introduction  
Plexin A1 is one of the genes found to be upregulated in RA and PsA SF CD14
+ 
cells  in  the  preceding  microarray  experiment;  it  has  not  been  previously 
associated with arthritis and is one of the two genes that I selected for intensive 
investigation in the context of rheumatoid and psoriatic arthritis pathogenesis. 
Plexins are a homogenous family of proteins, which when first identified were 
shown to be neuronal cell surface molecules with a function in cell adhesion 
[442].  They  are  grouped  into  four  categories  (A-D)  based  on  their  overall 
homology, there are 4 type-A, three type-B, one type-C and one type D found in 
vertebrates and two plexins found in invertebrates (A and B) [617].  
Plexins  are  the  receptors  for  semaphorins,  which  are  both  secreted  and 
membrane associated proteins named for their properties which are analogous 
to the system of flags and lights used in rail and maritime communication for the 
direction  of  movement.  Semaphorins  were  originally  characterised  in  the 
developing nervous system as chemorepellent molecules which acted to initiate 
axonal  collapse  in  areas  where  they  were  found  in  high  concentration,  thus 
resulting in axonal guidance [618, 619]. However, more recently they have been 
shown  to  have  diverse  functions  in  several  physiological  processes  such  as 
angiogenesis  [620],  tumor metastasis  [621, 622],  osteoclastogenesis  [623] and 
immune  regulation  [624].  More  than  20  types  of  semaphorins  have  been 
identified  and  are  grouped  into  eight  classes  on  the  basis  of  their  structural 
elements and amino acid sequence similarity [619]. The semaphorins found in 
invertebrates  are  grouped  into  classes  1  and  2,  classes  3-7  are  vertebrate 
semaphorins and the final group, group V, are viral semaphorins. Proteins in the 
semaphorin classes 1, 4, 5, 6 and 7 are membrane associated whereas those in 
classes  2,  3  and  the  viral  semaphorins  are  secreted  [617].  All  semaphorins 
contain  a  conserved  ~500  amino  acid  extracellular  domain  termed  a  sema 
(semaphorin) domain and a class specific C terminus. 
Plexins are single membrane spanning proteins that have an extracellular domain 
consisting  of  a  ~500  amino  acid  sema  domain,  that  is  conserved  among  all 
semaphorin  family  members,  followed  by  a  cysteine-rich  motif  and  several 
glycine-proline  rich  motifs  [442].  Most  plexin-semaphorin  interactions  are 
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semaphorins,  which,  with  the  exception  of  sema  3E,  bind  to  neuropillin-1  or 
neuropilin-2 along with plexin in a co-receptor complex [625-627]. Neuropilins 
have a very short cytoplasmic domain that cannot transduce intracellular signals, 
therefore the plexin receptor must act as the signal transducing components of 
the semaphorin-neuropilin-plexin complex [628]. Plexin A family members are 
the main receptors for the secreted class 3 semaphorins as shown in Figure 4.1, 
semaphorin  3A  will  only  bind  neuropilin-1  (NRP-1)  in  the  plexin-neuropilin 
receptor complex whereas semaphorin 3C and 3F bind both NRP-1 and NRP-2 
[443]. 
 
Figure 4.1 Semaphorin ligands for type A plexin family members 
There are four members of the plexin A family which interact primarily with two classes of 
semaphorins, class 3 and class 6. Both plexins and semaphorins are characterised by a sema 
domain shown in red for the plexins and blue for the semaphorins. Arrows indicate binding 
interactions detected between semaphorins and plexins. Labels on the arrows indicate which 
specific semaphorins have been shown to interact with which plexin [443, 444, 617, 629-632]. Blue 
labels of semaphorin names indicate the necessity for neuropilin-1 (dark blue) or neuropilin-
1/neuropilin-2 (green). 227 
Plexin A1 is the only receptor in the type A family of plexins that interacts with 
two different classes of semaphorins, class 3 and class 6 (Figure 4.1). It is our 
gene  of  interest  based  on  the results  of  the  microarray and it  is  one of  the 
semaphorin receptors whose function has been widely investigated. It is known 
to be expressed in the heart, liver, brain, kidney, spleen and lung of 4 week old 
mice  [623]  and  is  specifically  expressed  on  plasmacytoid  DCs  [633],  mature 
dendritic cells [444] and at low levels on T and B cells [623]. Recently plexin A1 
has also been shown to increase in expression during M-CSF differentiation of 
human  monocytes  into  macrophages  [443],  the  same  group  also  showed  LPS 
stimulation suppressed plexin A1 expression in macrophages. Toyofuku et al first 
identified semaphorin 6D (sema 6D) as one of plexin A1‘s ligands during chick 
cardiac  development.  Plexin  A1  was  found  to  form  site  specific  receptor 
complex with vascular endothelial receptor type 2 (VEGFR2) in the conotruncal 
segment or with Off-track in the ventricle segment. These specific complexes 
bound to sema 6D and were responsible for its specific effects in these regions 
[631].  It is thought that semaphorin binding relieves plexin autoinhibition, as 
plexin A1 lacking its sema domain is constitutively active [634]. 
Plexin A1 has been previously shown to play a role in axonal guidance in the 
developing nervous system by acting as a co-receptor with neuropilin-1 to bind 
sema  3A  resulting  in  a  chemorepulsive  signal  [635].  It  also  has  a  role  in 
chemotaxis of carcinoma cells as expression of constitutively active plexin A1 in 
breast carcinoma cells impaired their ability to chemotax [636]. However, the 
first report of plexin A1 in immune cell function came as a result of a microarray 
that identified plexin A1 as a gene down regulated in CIITA-deficient DCs to 5% 
of  that  found  in  wild  type  cells  [444].  CIITA  (class  II  transactivator)  is  a 
transcription factor that controls MHC class II expression [637], it functions as a 
transcriptional  scaffold  to  coordinate  NF-Y  and  RFX5  transcription  factors  in 
binding the conserved promoter regions found in MHC class II promoters. The 
same group found plexin A1 to be highly expressed in mature DCs from wild type 
mice and it was established that depletion of plexin A1 in mature DCs by RNA 
interference led to a 50% reduction in T cell stimulation  in vitro and in vivo 
indicating that plexin A1 expression is important for T cell-DC interactions. This 
reduced proliferation could not be attributed to decreased antigen processing, 
MHC expression or peptide loading; however a suggested function for plexin A1 228 
on the DCs was to serve as a co-stimulatory marker that binds its partner ligand 
on the T cells therefore enhancing the T cell-DC interaction.  
A  further  study,  [623],  into  plexin  A1‘s  role  in immune responses  found  that 
plexin A1
-/- DCs had an impaired ability to stimulate antigen-specific T cells as 
they  had  reduced  proliferative  responses  and  cytokine  production,  consistent 
with  the  previous  work  performed  by  Wong  et  al.  The  plexin  A1
-/-  mice  had 
reduced cellularity in their long bones compared to wild type litter mates and it 
was revealed that plexin A1 deficiency resulted in increased bone mass and the 
development  of  osteopetrosis.  It  was  also  shown  that  plexin  A1
-/-  mice  had 
decreased  osteoclast  numbers,  lower  osteoclast  surface  to  bone  ratio  and 
reduced osteoclast bone turnover therefore implicating a role for plexin A1 in 
bone homeostasis. This group had previously identified sema 6D as the ligand for 
plexin A1 in chick cardiac development [631] and found sema 6D to be highly 
expressed  in  T  cells,  therefore  they  incubated  DCs  with  soluble  recombinant 
sema 6D and showed that it induced IL-12 production and upregulation of MHC 
class II suggesting that sema 6D is the ligand for plexin A1 in T cell- DC cellular 
interactions. Sema 6D was also found to be expressed on osteoclasts and soluble 
recombinant sema 6D promoted osteoclast differentiation again suggesting that 
sema  6D  is  the  ligand  for  plexin  A1  in  bone  homeostasis.  To  try  and  further 
understand  the  plexin  receptor  complex,  the  group  screened  molecules 
associated with plexin A1 in DCs and osteoclasts and identified TREM-2. Previous 
studies have indicated that TREM-2 forms a receptor complex with DAP12, an 
ITAM-bearing activating adaptor protein, through a positively charged amino acid 
in its transmembrane domain [638]. Several experiments using RNA interference 
and DAP12
-/- cells suggested that plexin A1, DAP-12 and TREM-2 are the sema 6D 
functional  receptor  components  on  DCs  and  osteoclasts  [623].  Interestingly, 
genetic mutations in TREM-2 or DAP12 result in a bone fracture syndrome called 
Nasu-Hakola disease further underscoring the importance of the association of 
plexin A1 with DAP12 and TREM-2 in bone homology [639]. 
Further studies into the localisation of plexin A1 in DCs found it to be associated 
with the DC-T cell immune synapse in approximately 70% of T cell- DC cellular 
conjugates  where  it  was  found  to  regulate  actin  polarisation  in  the  DCs  via 
activation  of  the  small  GTPase  Rho  [640].  Plexin  A1  has  also  been  found  to 
associate with DAP12 and another TREM family member found specifically on 229 
pDCs designated PDC-TREM. Sema 6D binding to the plexin A1-DAP12-PDC-TREM 
complex on pDCs induced the production of type I IFN [633]. 
Plexin A1 has recently been shown to play a crucial role in allowing murine DCs 
to enter the lymphatic system and track to the lymph node. This migration is 
dependent  on  the  presence  of  semaphorin  3A  (sema  3A),  one  of  plexin  A1‘s 
ligands,  in  the  lymphatic  system.  Sema  3A  is  thought  to  promote  DC 
transmigration  by  inducing  actomyosin  contraction,  which  allows  the  cells  to 
pass  through  constricted  areas,  by  regulating  myosin  II  activity  and 
phosphorylation. This was demonstrated by treating the DCs with the myosin II 
inhibitor blebbistatin or the Rho kinase ROCK inhibitor Y-27632 which abolished 
sema  3A  induced  transmigration  across  lymphatic  endothelial  cell  monolayers 
[632]. 
Due to the identification of a novel gene, plexin A1, expressed in RA and PsA SF 
CD14
+ cells, and its plausible biologic profile, I therefore sought to validate this 
expression  by  RT-PCR  in  the  microarray  samples  and  samples  from  other 
patients. I then sought to identify its potential function in macrophage cells by 
siRNA and to investigate the expression of its semaphorin ligands on stimulated 
T cells and synovial membrane. 230 
4.2  Validation of plexin A1 in microarray samples 
Plexin A1 was one of the genes identified when the group of genes upregulated 
in both RA and PsA SF were analysed. It had a fold change increase from the PB 
to the SF of 26 in RA patients and 27 in PsA patients. Figure 4.2 (A) demonstrates 
the  raw  fluorescent  data  signals  of  plexin  A1  obtained  from  the  Affymetrix 
GeneChips. The PB samples from both disease groups have very low levels of 
signal intensity indicating that these samples had low levels of plexin A1 mRNA. 
In contrast the patient synovial fluid samples have much higher levels of signal 
intensity and therefore contained higher levels of plexin A1 mRNA. The reason 
for the variable levels of the mRNA expression may be due to different disease 
duration in the patients or differences in disease therapy. To verify and validate 
this expression qRT-PCR was used to analyse the expression of plexin A1 in the 8 
RA and 8 PsA matched PB and SF CD14
+ samples. All of the samples were able to 
be analysed apart from one RA PB sample which consistently produced unusual 
results which could not be included in the analysis. This may have been due to a 
problem with the RNA sample therefore that PB sample and its matched SF were 
not analysed. Figure 4.2 (B) shows the results of qRT-PCR, the fold change values 
were calculated by comparing the level of plexin A1 expression in the synovial 
fluid compared to the PB. Each circle represents one patient and the line is the 
mean fold change, the RA samples had a mean fold change increase of 8 from 
the PB to the SF and the PsA samples had a mean fold change increase of 13.  
The results demonstrate that there was an increase in plexin A1 expression in all 
of  the  synovial  fluid  samples  compared  to  their  matched  peripheral  blood 
samples which agree with the results obtained from the microarray.  231 
 
Figure 4.2 Plexin A1 expression in microarray samples 
(A) Demonstrates the raw signal intensities of the plexin A1 gene locus on the Affymetrix 
GeneChips. Each circle represents one patient sample which was hybridised to one genechip and 
the line represents the mean signal intensity. Plexin A1 mRNA levels were then measured in the 
RA and PsA paired PB and SF microarray samples by qRT-PCR. (B) The fold change of plexin 
expression in the SF samples was normalised to the matched patient PB sample, each circle 
represents one patient and the line the mean fold change  
 
4.3  Expression of plexin A1 in other patient samples 
Once the expression of plexin A1 had been validated in the microarray patient 
samples we then analysed the expression of plexin A1 in CD14
+ of other arthritic 
patients to check that the increase in plexin A1 expression was generalizable. 
Figure 4.3 shows the results of this analysis, graph (A) indicated all the CD14
+ 
cells that were obtained and tested for relative expression plexin A1 which was 
normalised  to  the  housekeeping  gene  GAPDH.  PsA  SF  cells  have  varying 
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expressions  of  plexin  A1  depending  on  the  individual  patient  but  the  mean 
relative expression is higher than the mean relative expression of the PsA PB 
samples. The RA SF samples also have variable amount of plexin A1 but the mean 
expression is similar to that seen in PsA SF.  An inflammatory polyarthritis and a 
juvenile idiopathic arthritis (JIA) SF sample were also obtained for this analysis 
and both samples contain plexin A1 RNA, unfortunately no matched peripheral 
blood  CD14
+  cells  were  acquired  for  either  patient  so  we  cannot  determine 
whether the plexin A1 expression increases in the SF cells compared to the PB 
cells as is seen with RA and PsA patients. However, matched PB and SF CD14
+ 
cells from a patient with osteoarthritis (OA) were also analysed and shows that, 
as with the RA and PsA from the microarray, plexin A1 expression is higher in the 
SF compared to the PB. This indicates that expression of plexin A1 on CD14
+ cells 
is not confined to PsA and RA SF and could also be expressed in other arthritic 
diseases.  These  analyses  should  however  be  considered  anecdotal  and  are 
included here for completeness at this stage. Five of the PsA patients analysed 
had matched SF and PB CD14
+ cells therefore the fold change increase of plexin 
A1  from  the  PB  samples  to  the  SF  samples  was  determined  (graph  B).  In 
summary,  these  data  indicate  that in the  majority, but  not  all,  PsA  patients 
plexin A1 RNA levels are higher in the SF compared to the PB CD14
+ cells as was 
seen in the microarray experiment. 233 
 
Figure 4.3 Plexin A1 expression in CD14
+ cells from arthritic patients 
To verify the microarray results plexin A1 RNA levels were measured in CD14
+ cells from several 
other arthritic patients (A). Five of the PsA patients analysed in (A) had matched PB and SF 
samples therefore the fold change increase of plexin A1 expression from the PB sample to the SF 
sample was measured for each of these patients and is shown in (B) each square represents one 
patient. Lines on each graph indicate the mean. 
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4.4  Immunohistochemistry of plexin A1 
Once plexin A1 expression had been validated as being present in the microarray 
samples and other patient samples by RT-PCR, immunohistochemistry (IHC) was 
used to investigate the presence of plexin A1 protein in RA synovial membrane 
tissue. Five RA membranes stained positively for plexin A1; Figure 4.4 shows the 
pattern of staining seen in a representative membrane. Panel (B) shows an area 
of the membrane at x10 magnification on the left and x40 magnification on the 
right. The synovial membrane can be seen to be positively stained (indicated by 
brown  staining)  around  vascular  structures  and  within  cells  in  the  area 
surrounding the vasculature possibly indicative of infiltrating cells (indicated by 
black  arrows).  Panel  (C)  indicates  two  more  images  taken  from  the  same 
membrane and again demonstrates that the areas staining positively for plexin 
A1 are those surrounding blood vessels and in cells around vasculature area but 
there are also cells within the synovial membrane structure that have stained for 
plexin A1. The staining appears to be present in both the cytoplasm and the 
nucleus of the cells. The positive staining surrounding the vasculature could be 
indicative of endothelial cells but the identity of the positive cells within the 
membrane require double staining of plexin A1 and other cellular markers. Such 
experiments would be the focus of future analysis in order to confirm the extent 
of plexin A1 expression. 235 
 
Figure 4.4 Plexin A1 staining in RA synovial membrane 
Five RA synovial membrane tissues were stained for the presence of plexin A1. This figure 
indicates the staining pattern seen in one of these membranes. Panel (A) indicates the isotype 
control at x 10 and x 40 magnification. Panel (B) and (C) show the positive plexin A1 staining 
(shown in brown) of two areas within the membrane (arrows identify infiltrating cells), the staining is 
shown at x 10 magnification on the left and x 40 magnification on the right. 
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4.5  siRNA knockdown of plexin A1 in M-CSF derived 
macrophages 
I next decided to establish the role of plexin A1 in macrophage biology using RNA 
interference (RNAi). RNAi is a pathway in eukaryotic cells by which sequence 
specific small interfering RNA (siRNA) is able to find and cleave complementary 
mRNA [641]. An enzyme known as Dicer can cleave double stranded RNA into 
siRNA fragments [642]. Once siRNA is present in the cell it is incorporated into a 
protein complex called the RNA induced silencing complex  (RISC) [643] where 
argonaute-2  unwinds  the  siRNA.  The  activated  RISC  complex  containing  the 
antisense  strand  of  siRNA  will  then  find  and  degrade  mRNA  that  is 
complementary  to  this  strand  resulting  in  specific  gene  silencing.  Synthetic 
siRNA specific to a gene can be directly introduced into a cell allowing gene 
silencing of almost any mammalian gene thereby allowing analysis of specific 
gene function.  
So far most experimental work on plexin A1 has looked at plexin A1 expression 
and function in DCs, since our results showed that plexin A1 is upregulated in 
monocytes/macrophages in the arthritic synovial fluid we wanted to determine 
the role of plexin A1 in this cell type with the use of siRNA. M-CSF differentiated 
macrophages  were  used  to  work  up  the  siRNA  experiments  as  these  are  a 
relatively  accessible  cell  source  compared  to  the  limited  number  of  synovial 
fluid patient samples we obtain in the lab. 
4.5.1 Expression of plexin A1 in macrophages after 6 days of M-
CSF differentiation 
A preliminary experiment before starting the siRNA knockdown of plexin A1 was 
to first determine that macrophages expressed plexin A1 mRNA. A previous study 
had demonstrated that plexin A1 was upregulated in macrophages differentiated 
in  M-CSF  for  2  days  [443].  In  our  experimental  setup  monocytes  were 
differentiated with 50 ng/ml M-CSF for 6 days and analysed at day 0 and 6 for 
plexin A1 expression. Figure 4.5 shows the fold change in plexin A1 expression in 
day  6  differentiated  macrophages  compared  to  day  0.  Once  the  presence  of 
plexin A1 had been determined in these cells we could then set up the siRNA 
experiments. 237 
 
Figure 4.5 Plexin A1 in M-CSF differentiated macrophages  
Monocytes were differentiated with 50 ng/ml M-CSF for 6 days. Fold change in plexin A1 mRNA 
expression was measured by qPCR. 
4.5.2 Transfection efficiency of N-TER reagent 
An N-TER nanoparticle transfection system was used to knockdown the plexin A1 
gene. In this transfection system the N-TER peptide binds siRNA non-covalently 
forming a nanoparticle. The nanoparticle then interacts with the lipids on the 
surface of the plasma membrane thus allowing the nanoparticle to diffuse across 
the cell membrane and delivering the siRNA to the cytoplasm.  
To test the efficiency of this transfection system a negative control siRNA with 
an Alexa Fluro 555 modification was used. The negative control siRNA will not 
knockdown any genes in the cell since it is a non-silencing siRNA with no known 
homology to any known mammalian gene. Since it is modified with a fluorescent 
tag it can be used to measure the transfection efficiency of the N-TER peptide as 
any cell that has been successfully transfected will fluoresce. To determine the 
concentration at which the N-TER peptide worked most effectively, cells were 
transfected  with  the  negative  control  siRNA  and  analysed  on  a  fluorescent 
microscope and by FACS.  
4.5.2.1   Inverted microscope images 
Day  6  M-CSF  differentiated  macrophages  were  transfected  with  varying 
concentrations of negative control siRNA for 24 hours in the presence or absence 
of fetal calf serum (FCS) as FCS can sometimes affect siRNA transfection. The 238 
cells were then imaged on a fluorescent inverted microscope as seen in Figure 
4.6. In the cells transfected in medium plus FCS all concentrations of siRNA have 
resulted  in  positively  transfected  cells  as  shown  by  the  orange  fluorescence. 
However, the cells did not transfect as well at the 5 nM concentration of siRNA 
indicated  by  the  less  intense  fluorescent  staining  of  those  macrophages.  A 
similar staining pattern can be seen in the cells which were transfected without 
serum  in  the  medium  as  all  the  concentrations  of  siRNA  show  positive 
transfection  and  fluorescent  cells  but  some  cells  in  the  10  nM  and  5  nM 
concentrations are not stained as brightly as the cells in the 30 nM and 20 nM 
concentrations. The cells that were incubated without serum contained lots of 
cellular debris as can be seen in the 30 nM image indicating that this could be 
detrimental to the cells.  Therefore,  siRNA transfection was performed in the 
presence of FCS. 
 
 
Figure 4.6 siRNA transfection efficiency by imaging fluorescence on the microscope 
Macrophages were treated with M-CSF for 6 days and transfected with varying concentrations (30 - 
5 nM) of negative control siRNA for 24 hours in the presence or absence of fetal calf serum (FCS). 
The negative control siRNA has a fluorescent tag therefore cells that been successfully transfected 
cells will fluoresce. 
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4.5.2.2   FACS plots 
To  quantify  the  amount  of  positive  transfection  with  the  N-TER  transfection 
system macrophages were treated with the negative control siRNA for 24 hours 
in serum-containing media, the cells were then collected and analysed on the 
FACS for Alexa Fluro-555 fluorescence compared to untransfected cells. Figure 
4.7 shows the results of this FACS analysis and demonstrates that at least 93% of 
macrophages  were  positive  for  negative  control  siRNA  in  all  of  the 
concentrations tested. This indicates that the N-TER transfection system allows 
siRNA  to  successfully  enter  the  macrophage  cells  even  at  5  nM 
concentration.
 
Figure 4.7 FACS analysis siRNA transfected macrophages 
Monocytes were differentiated with M-CSF for 6 days and transfected with varying concentrations 
of a fluorescent tagged negative control siRNA for 24 hours in complete medium. Cells were then 
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collected and analysed by FACS for fluorescence which was indicative of positive siRNA 
transfection. 
4.5.3 Testing siRNA 1-4 at 3 concentrations 
Once the transfection system had been validated in macrophage cells the plexin 
A1 siRNA was tested in the macrophage cells to see if it changed the expression 
of  plexin  A1.  The  plexin  A1  siRNA  received  from  Qiagen  consisted  of  four 
individual  siRNA‘s  designated  1-4.  Each  individual  siRNA  was  tested  on  the 
macrophages at three concentrations 10, 20 and 30 nM. It was decided not to 
test  the  siRNA  at  5  nM  as  from  the  fluorescent  microscope  experiment  the 
macrophages did not appear to be as intensely stained at the 5 nM concentration 
as they did at the other concentrations. 
4.5.3.1   PLX1- 4 at 30, 20, 10 nM 
Macrophages  were  M-CSF  treated  for  6  days  and  then  treated  with  negative 
control siRNA (designated control) and the four plexin siRNA (designated PLX 1-
4) at 10, 20 and 30 nM concentrations for 24 hours. After this time the cells were 
collected and put into trizol and the qRT-PCR was performed on the samples to 
determine  whether  the  siRNA  had  decreased  the  amount  of  plexin  A1  siRNA 
being expressed by the cells. Since the negative control siRNA is a non-silencing 
siRNA it should not affect the amount of plexin A1 expression and therefore the 
plexin A1 mRNA levels in the samples treated with siRNA PLX 1-4 were compared 
back to the negative control siRNA to look for a relative increase or decrease in 
expression.  Figure  4.8  shows  the  results  of  this  experiment;  graph  (A) 
demonstrates the expression of plexin A1 as a result of siRNA treatment. The 
values of the negative control siRNA are 1 and the line drawn on the graph is set 
at 1. It can be seen that at 30 nM concentration PLX 1,  -2 and -3 siRNAs are 
causing an increase in Plexin A1 expression rather than knocking it down and at 
the 10 nM concentration PLX 2 and 3 siRNA are also causing an increase in plexin 
A1 expression in the cells compared to the control. 
 Figure 4.8 (B) shows the percentage inhibition of plexin A1 as a result of adding 
the 4 different siRNAs. The percentage inhibition was calculated relative to the 
negative  control  and  a  negative  value  indicates  an  increase  in  plexin  A1 
expression whereas a positive value indicates a decrease in plexin A1 expression. 
At the 30 nM concentration PLX 1, PLX 2 and PLX 3 siRNA induced an increase in 241 
plexin  A1  expression  of  89,  83  and  84%  respectively.  Also  at  the  10  nM 
concentration PLX 2 and PLX 3 siRNA increased the amount of plexin A1 mRNA by 
100 and 67% respectively. The reason for these siRNAs increasing the amount of 
expression is unknown. A recent study has shown when an siRNA sequence is 
complementary to the promoter region of a gene it can increase transcription of 
that gene [644]. However, the siRNAs used in this study are unlikely to target 
the promoter region of plexin A1 as the phenomenon of the PLX siRNA inducing 
expression of plexin A1 does not occur at all of the concentrations tested and 
only occurs at 30 nM and 10 nM concentrations.  
Due to the PLX 2 and PLX 3 siRNA producing an increase in plexin A1 levels at 30 
and 10 nM concentrations they were omitted from further experiments. PLX 1 
siRNA induced an increase of plexin A1 at the 30 nM concentration but otherwise 
induced a high amount (75%) of inhibition at the 20 nM concentration and also 
decreased plexin A1 levels at the 10 nM concentration. PLX 4 siRNA was the only 
siRNA to consistently decrease the level of plexin A1 mRNA. Consequently only 
PLX 1 and 4 were used in additional experiments. 242 
 
Figure 4.8 Testing siRNA PLX 1-4 in M-CSF differentiated macrophages 
M-CSF differentiated macrophages were treated with 4 siRNAs PLX 1-4 and a negative control 
siRNA that should not affect the expression of plexin A1 at 3 different concentrations 10, 20 and 30 
nM for 24 hours. Using qRT-PCR the amount of expression of plexin A1 in the cells relative to the 
negative control, which is set at 1, was determined in graph (A). The line on the graph is set at 1 
therefore any bars above the line are showing an increase in plexin A1 expression and any lines 
below are a decrease in plexin A1 expression. The percentage inhibition of plexin A1 was also 
determined for this experiment as can be seen in graph (B). Positive values for the percentage 
inhibition indicate that there was a decease in plexin A1 expression compared to the negative 
control. 
4.5.3.2   PLX 1 and 4 at 30, 20, 10 nM 
To check the level of plexin A1 inhibition by the two siRNAs PLX 1 and PLX 4, M-
CSF  derived  macrophages  were  treated  with  10,  20  and  30  nM  siRNA  for  24 
hours. Figure 4.9 (A) indicates that both PLX 1 and PLX 4 decreased the amount 
of  plexin  A1  mRNA  expression  in  the  macrophages  compared  to  the  negative 
control in all of the three conditions. The percentage inhibition of plexin A1, 
graph (B), ranged from 14% to 54%. The concentration at which the percentage 
inhibition was greatest was 20 nM, at this concentration PLX 1 and PLX 4 induced 
49 and 54% inhibition respectively compared to the negative control. Hence the 
20 nM concentration of PLX 1 and PLX 4 was used in the further experiments, a 
mixture of both siRNAs was also used to determine if combining the two siRNAs 
results in a greater amount of gene silencing. 
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Figure 4.9 Testing PLX 1 and PLX 4 siRNA in macrophages 
PLX 1 and PLX 4 siRNA were tested again to ensure that they were decreasing the amount of 
plexin A1 expression in M-CSF derived macrophages. The relative expression compared to the 
negative control is shown (A) as well as the percentage inhibition of plexin A1 expression (B). 
 
4.5.4 Effect of plexin A1 knockdown in M-CSF derived 
macrophages stimulated with LPS or Tck 
I next examined the effect of plexin A1 knockdown on macrophage activation. 
M-CSF derived macrophages were treated with 20 nM PLX 1, PLX 4 and PLX 1 + 
PLX 4 for 24 hours, the transfection media was then removed and the cells were 
either left unstimulated or stimulated with 10 ng/ml LPS or Tcks at a ratio of 4:1 
for 24 hours. The supernatants were then removed for cytokine analysis and the 
cells were analysed by qRT-PCR. This experiment was repeated three times and 
the following results are a representative example of the results achieved. 
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4.5.4.1   qRT-PCR data 
Prior to analysing the TNF ELISA data it was necessary to check that the plexin 
A1 expression had decreased as a result of treating the cells with siRNA. Figure 
4.10  shows  the  relative  expression  of  plexin  A1  in  the  macrophage  samples 
relative to the negative control. In the unstimulated macrophages which were 
incubated  with  media  after  the  siRNA  treatment  there  is  a  decrease  in  the 
amount of plexin A1 being expressed by the cells which were treated with PLX 1 
siRNA. The amount of plexin A1 expression in macrophages treated with PLX 4 
siRNA is also decreased compared to control but the siRNA treatment producing 
the highest amount of gene silencing is the combined treatment of PLX 1+4. This 
same pattern is seen with the macrophages which were stimulated with LPS, 
where  the  greatest  level  of  gene  silencing  is  seen  when  the  combination  of 
PLX1+4 were used. The percentage inhibition of plexin A1 in the macrophages 
treated with PLX 1+4 siRNA was 43% and 55% for the macrophage samples which 
were subsequently incubated with media or LPS respectively. Despite this being 
a large percentage inhibition in the context of the experiment it indicates that 
there is still over 50% or just under 50% of the total amount of plexin A1 being 
expressed in the macrophages, which will therefore bias the results when trying 
to  determine  effect  of  silencing  the  plexin  A1  gene  in  macrophages.  It  also 
indicates  that  there  is  a  discrepancy  of  over  10%  in  the  amount  of  gene 
knockdown obtained each time the macrophages are treated with PLX siRNA; 
this variability will also bias the results of the siRNA experiment. 
In  Figure  4.10  the  results  from  the  macrophages  which  were  subsequently 
stimulated with Tcks in a cell contact (c.c) indicate that there was very little 
gene silencing of plexin A1 in these cells since the level of plexin A1 relative 
expression in the cells treated with siRNA is similar to the level of plexin A1 in 
the  cells  treated  with  the  negative  control  siRNA.  This  may  be  due  to 
contaminating Tcks in the sample with the macrophages as although every effort 
was made to remove the Tcks before putting the cells in trizol some may have 
remained. T cells have been shown to express plexin A1 [623] and the presence 
of  contaminating  Tcks  in  the  macrophage  sample  could  have  diluted  out  the 
effect of the siRNA gene silencing therefore producing the result of little or no 
plexin A1 gene knockdown in these samples. 245 
Once the result of 43% and 55% gene knockdown in the macrophage samples had 
been  determined,  the  pro-inflammatory  output  from  these  stimulated 
macrophages could be analysed. 
 
Figure 4.10 RT-PCR of plexin A1 knockdown in activated macrophages 
PLX 1, 4 or 1+4 siRNA were used to silence the plexin A1 gene in macrophages that were 
subsequently stimulated with LPS or Tcks. 
4.5.4.2   TNFα ELISA data 
To  establish  whether  the  plexin  A1  knockdown  had  any  effect  on  the  pro-
inflammatory output of the macrophages stimulated with LPS or Tcks a TNFα 
ELISA was performed on the cell supernatants. Figure 4.11 shows the results of 
the  ELISA,  while  there  were  small  amounts  of  TNFα  produced  by  the 
macrophages incubated for 24 hours in media alone the stimulated macrophages 
both produced elevated quantities of TNFα. The LPS stimulated macrophages 
produced  less  TNFα  in  the  samples  which  had  been  treated  with  PLX  siRNA 
compared  to  the  samples  which  had  been  treated  with  the  negative  control 
siRNA. The lowest amount of TNFα produced is from the macrophage sample 
that  was  treated  with  PLX  4  which  from  the  previous  figure  induced  31% 
inhibition  of  plexin  A1  therefore  inhibiting  a  relatively  small  percentage  of 
plexin A1 in macrophages may be enough to change its pro-inflammatory profile. 
This  decrease  in  TNFα  using  PLX  4  siRNA  compared  to  the  negative  control 
sample is statistically significant using a 1 way ANOVA and a Turky‘s multiple 
comparison test. 246 
The Tck cell contact activated macrophages do not appear to have changed their 
proinflammatory  output  as  a  result  of  siRNA  silencing  of  plexin  A1  since  the 
amount of TNF produced by the cells treated with PLX siRNA is not significantly 
different to the TNF production from the negative control treated macrophages. 
This could indicate that plexin A1 may not be involved in the cellular cross talk 
between macrophages and T cells however plexin A1 was not fully silenced with 
the PLX siRNA and it is possible that in order to elucidate the role plexin A1 
plays in the cellular contact between macrophages and T cells the plexin A1 
gene must be fully knocked down. 
Figure 4.11 TNFα ELISA of siRNA treated macrophages 
A TNFα ELISA was performed on macrophages that had been treated with various siRNAs before 
being incubated with media alone, 10 ng/ml LPS or Tcks (c.c). Error bars are mean ±SEM. This is 
a representative of three individual experiments. Using a 1 way ANOVA with Tukey’s multiple 
comparison test on the LPS treated group there is a statistically significant difference between the 
–ve control LPS group and the PLX 4 LPS group in addition to a statistically significant difference 
between –ve control LPS and PLX1+4 LPS group (p<0.05). 
 
4.6   Investigation into the expression of the Plexin A1 
ligand semaphorin 6D on T cells 
Plexin A1 is known to have several semaphorin ligands including semaphorin 6D. 
In the context of the immune system semaphorin 6D is the most well studied 
plexin  A1  ligand  to  date  and  several  studies  have  indicated  that  plexin  A1 
expressed on DCs may interact with T cells expressing semaphorin 6D [623]. A 
recent study investigated the regulation of semaphorin 6D expression on T cells 
and found that in vitro activation of murine CD4
+ T cells using plate-bound anti-
CD3 and anti–CD28 antibody increased mRNA levels of sema 6D by 24 hours and 247 
after 5 days induced 71% surface expression of sema 6D compared to control 
during the late phase of activation [645].  
Since  plexin  A1  is  upregulated  in  RA  and  PsA  synovial  fluid  CD14
+  cells  and 
macrophages are known to interact with T cells in the arthritic joint [408] we 
hypothesised  that  semaphorin  6D,  one  of  plexin  A1‘s  specific  ligands,  is 
expressed  on  arthritic  T  cells  and  is  one  of  the  receptor-ligand  interactions 
taking place within the synovium of diseased patients. It was decided to first 
test for the presence of sema 6D on cytokine activated T cells (Tcks) since these 
are  an  in  vitro  model  of  activated  synovial  T  cells  [298,  309].  As  a  positive 
control  human  T  cells  were  also  activated  with  anti-CD3  and  anti-CD28 
antibodies as a previous study had shown 71% of murine cells stimulated in this 
manner were found to express semaphorin 6D after 5 days [645]. 
4.6.1 Semaphorin 6D FACS analysis 
T  cells  were  isolated  from  normal  donors  and  stimulated  for  6  days  with  a 
cytokine cocktail to produce Tcks or CD3/CD28 microbeads to produce activated 
T  cells.  T  cells  were  analysed  for  semaphorin  6D  expression  at  day  0 
(unactivated T cells), day 3 and day 6. Since the semaphorin 6D antibody was 
unconjugated a secondary APC antibody was incubated with the cells to detect 
whether sema 6D had bound to the cells. As a control, an irrelevant antibody 
(CD68) that should not have bound to the T cells was incubated with the cells 
before  adding  the  secondary  antibody  in  order  to  detect  any  non-specific 
staining of the secondary antibody. 
4.6.1.1   Semaphorin 6D expression on CD3/CD28 stimulated T   
cells 
Figure 4.12 demonstrates representative results of the FACS staining for the T 
cells stimulated for 0, 3 and 6 day with anti-CD3, anti-CD28 microbeads. Isotype 
control is shown as the grey histogram, semaphorin 6D surface and intracellular 
staining  is  shown  in  blue  on  the  left  hand  histograms.  Irrelevant  antibody 
staining is shown in red on the right hand panel of histograms. 
Unstimulated T cells on day 0 appear to have approximately 3.5% semaphorin 6D 
surface staining however upon comparison to the irrelevant antibody, which has 248 
3.16% positive staining, it appears  that the majority of the staining seen at day 
0 is non-specific secondary antibody staining. The same pattern is seen at day 3 
where there is 3.5% positive surface staining from the irrelevant antibody which 
indicates that the 4.39% positive semaphorin 6D staining is unlikely to be a valid 
observation. The same observation is seen within the day 6 activated T cells.. 
The intracellular staining at day 6 is also negative for both semaphorin 6D and 
irrelevant antibody. However, the intracellular staining in the T cells at day 3 
appears  to  show  a  small  increase  in  semaphorin  6D  expression  compared  to 
isotype  control  as  9%  of  cells  are  positive  for  semaphorin  6D.  The  irrelevant 
antibody staining at this timepoint is 1.9% indicating that the semaphorin 6D 
expression could be valid observation. 
Consequently,  day  3  intracellular  staining  is  the  only  timepoint  which  shows 
expression of semaphorin 6D, the intracellular levels are negative at day 6 and 
there is no surface expression of semaphorin 6D at any of the three timepoints 
examined. These observations conflict with the results shown by O‘Connor et al 
[645]  who  demonstrated  that  over  70%  of  murine  CD4
+  T  cells  express 
semaphorin 6D on the surface after 5 days of stimulation with anti-CD3 and anti–
CD28 antibodies. 249 
 
Figure 4.12 Surface and intracellular semaphorin 6D staining of CD3/CD28 stimulated T cells 
T cells were analysed at day 0, day 3 and day 6 after stimulation for surface and intracellular 
staining of semaphorin 6D (blue lines). The semaphorin 6D was not a directly conjugated FACS 
antibody therefore a secondary APC conjugated antibody was incubated with the cells after 
semaphorin 6D staining to detect the presence of the surface ligand. As a control an irrelevant 
antibody (CD68) was incubated with the cells before adding the secondary antibody in order to 
check for non-specific staining of the secondary antibody (red lines). Isotype control is shown as 
the grey histograms. The surface staining is a representative of n=6 experiments and the 
intracellular staining is a representative of n=2 experiments. 
4.6.1.2   Semaphorin 6D expression in cytokine stimulated T cell 
(Tcks) 
Tcks were also analysed for semaphorin 6D expression after 0, 3 and 6 days of 
activation (Figure 4.13). Semaphorin 6D staining is shown by the blue lines on 
the left hand panel of histograms and irrelevant antibody staining is shown by 
the red lines on the right hand panel of histograms. Since the same unactivated 
T  cells  were  used  as  a  control  for  both  CD3/CD28  and  Tck  activated  T  cells 
before the cells were activated with either stimulus,  day 0 T cells  show the 
same  results  as  in  the  previous  figure.  There  is  no  surface  semaphorin  6D 
expression  due  to  a similar  percentage  of  positive  staining  for  the  irrelevant 
antibody,  indicating  that  the  secondary  antibody  is  binding  non-specifically. 
There was no induction of surface semaphorin 6D expression after 3 and 6 days 
of cytokine activation (2.1% and 2.5% positive respectively) considering that the 250 
secondary antibody was also positive (0.68% and 1.7% respectively) indicating 
non-specific staining. There was also no intracellular semaphorin 6D expression 
at day 6 since the percentage of positive cells for semaphorin 6D and irrelevant 
antibody were almost identical (3.93% and 3.75%). However, as was seen with 
the CD3/CD28 activated T cells the intracellular expression of semaphorin 6D in 
Tcks was increased at day 3, 17.1% of Tcks were positive for semaphorin 6D. The 
irrelevant antibody had a considerably lower expression at this timepoint (3.97%) 
suggesting that the semaphorin 6D staining was specific. 
As  was  seen  with  the  CD3/CD28  activated  T  cells  semaphorin  6D  is  only 
expressed in Tcks intracellularly after 3 days of activation but is not expressed 
on the surface of the cells during the 6 days of activation.  
 
Figure 4.13 Surface and intracellular semaphorin 6D staining of Tcks 
T cells were analysed at day 0, 3 and 6 after cytokine stimulation for surface and intracellular 
expression of semaphorin 6D (blue lines). Since the semaphorin 6D was not a conjugated FACS 
antibody a secondary APC conjugated antibody was incubated with the cells after semaphorin 6D 
staining to detect the presence of the ligand. As a control an irrelevant antibody (CD68) was 
incubated with the cells before adding the secondary antibody in order to check for non-specific 
staining of the secondary antibody (red lines). Isotype control is shown as the grey histograms. The 
surface staining is a representative of n=6 experiments and the intracellular staining is a 
representative of n=2 experiments. 251 
4.6.2  Investigation into the level of semaphorin 6D mRNA in T 
cell samples 
Due to problems with repeated non-specific staining of the secondary antibody 
during  the  FACS  analysis  we  therefore  went  on  to  analyse  the  levels  of 
semaphorin 6D mRNA in cytokine- and CD3/CD28-activated T cells. A PCR was 
set up with these samples and no detectable bands could be observed (data not 
shown) therefore to verify this result the samples were analysed by qRT-PCR. 
4.6.2.1   qRT-PCR of T cell samples 
T cells were isolated from 2 donors and activated with cytokines or CD3/CD28 
for 6 days. CD3
+ cells were also isolated from 3 PsA synovial fluids. The relative 
expression of semaphorin 6D compared to the GADPH of each sample is shown in 
graph (A) of Figure 4.14. All Tck and CD3/CD28 samples have very low relative 
expression values indicating that semaphorin 6D is almost certainly not being 
expressed. The Tck day 6 sample of one of the donors has a much higher relative 
expression compared to all of the other samples which could suggest semaphorin 
6D mRNA is being expressed. The three PsA synovial fluid CD3
+ samples have 
varying  levels  of  semaphorin  6D  relative  expression  but  the  levels  are  still 
relatively low, again indicating that semaphorin 6D is unlikely to be expressed in 
these cells.  
The fold change of semaphorin 6D expression in the Tck and CD3/CD28 activated 
cells  can  be  determined  by  comparing  the  semaphorin  6D  expression  of  the 
activated samples to that of the corresponding inactivated day 0 T cell sample. 
Graph  (B)  of  Figure  4.14  illustrates  the  fold  change in  semaphorin  6D  in  the 
activated  T  cell  samples  compared  to  inactivated  T  cells.  The  Tcks  and 
CD3/CD28 T cells activated after 3 days in both donors demonstrated a decrease 
in the amount of semaphorin 6D compared to inactivated T cells. The day 6 Tcks 
and  CD3/CD28  T  cells  had  a  decrease  in the  amount  of  semaphorin  6D  (fold 
change of -141 and -28 respectively) in donor 1 and a slight increase in donor 2 
(fold change 11 and 1.9 respectively).  
The combined FACS and qRT-PCR data suggest that in the activated T cells there 
are donor specific variances in the mRNA level of semaphorin 6D, however these 
expression levels are very low and on the whole demonstrate a decrease in the 252 
amount of semaphorin 6D mRNA compared to inactivated T cells. The levels of 
semaphorin 6D expression within CD3
+ cells from PsA synovial fluid are also very 
low. Semaphorin 6D protein appears to be transiently expressed within the T cell 
during activation. Plexin A1 is a receptor for semaphorin 6D and can only form 
an  interaction  if  its  ligand  is  present  on  the  cell  surface.  During  the  FACS 
analysis surface semaphorin 6D could not be detected in the Tck samples that 
have been previously demonstrated to be an in vitro model of synovial T cells 
[298, 309]. This data combined with the very low levels of semaphorin 6D mRNA 
in the CD3
+ synovial fluid samples suggests that T cells within the arthritic joint 
may not be the source of plexin A1‘s ligand semaphorin 6D. 253 
 
Figure  4.14  qRT-PCR  of  semaphorin  6D  expression  in  T  cell  samples  and  patient  CD3
+ 
samples 
T cells from two donors were stimulated for 3 and 6 days with cytokines (Tcks) or CD3/CD28 
microbeads. These activated T cells and inactivated T cell were then analysed for semaphorin 6D 
expression by qRT-PCR. T cells were also isolated from 3 PsA synovial fluids and analysed for 
semaphorin 6D. Graph (A) shows the relative expression of semaphorin 6D compared to the 
GAPDH levels in each sample. Graph (B) shows the fold change in expression in the Tck or 
CD3/CD28 activated T cells compared to the inactivated T cells (T cells d=0). 254 
4.7  Investigation into the expression of other plexin A1 
ligands semaphorin 3A, 3F, 6D on RA synovial 
membrane 
The previous results suggested that semaphorin 6D is unlikely to be expressed on 
the T cells in the arthritic joint therefore it was decided to analyse the synovial 
membrane of RA patients for semaphorin 6D. If the membrane was positive for 
semaphorin  6D  expression,  this  would  imply  that  plexin  A1‘s  ligand  is  being 
expressed by other cell types rather than T cells. 
Plexin A1 is also known to interact with class 3 semaphorins namely semaphorin 
3A  and  semaphorin  3F  [617].  As  mentioned  in  the  introduction  class  3 
semaphorins will only bind plexin A1 if neuropilin is present as a co-receptor, 
semaphorin 3A will specifically bind neuropilin-1 (NRP-1) and semaphorin 3F will 
bind NRP-1 and NRP-2 [443]. Analysing the microarray data (presented in chapter 
4) for genes that are upregulated in addition to plexin A1 in the RA and PsA SF 
CD14
+ cells reveals that these cells have upregulated NRP-1 with a fold change 
increase of 40 in PsA SF and 11 in RA SF and NRP-2 with a fold change increase of 
24 in PsA SF and 31 in RA SF. Since these cells had upregulated plexin A1 and the 
two co-receptors needed for semaphorin 3A and 3F signalling it was possible that 
plexin  A1  could  be  binding  to  either  of  these  ligands  hence  the  presence  of 
semaphorin 3A and 3F were also analysed in the RA synovial membrane. 
4.7.1 qRT-PCR on RA synovial membrane 
SYBR green analysis was performed on 10 RA synovial membranes to investigate 
the presence of three plexin A1 ligands. The results are shown in Figure 4.15 and 
indicate that all three semaphorins are expressed in the RA membranes however 
semaphorin 3A has the greatest relative expression in the samples compared to 
its housekeeping gene. Semaphorin 6D is also expressed in the RA membranes 
indicating that although we could not detect it on T cells it may be present on 
other  cell  types  within  the  membrane.  Consequently  the  level  of  these 
semaphorins on another cell type known to be present in the RA synovium was 
investigated. 255 
 
Figure 4.15 Semaphorin 3A, 3F, 6D expression in RA synovial membrane 
qRT-PCR was used to determine the relative expression of 3 of plexin A1’s ligands in 10 RA 
synovial membranes. Each dot represents one patient sample and the line indicates the mean 
expression. 
4.7.2 SYBR green of RA synovial fibroblasts 
Given  that  it  had  been  determined  that three of  the  plexin  A1  ligands  were 
expressed in the RA synovial membrane it was hypothesised that fibroblasts may 
be a cell type expressing these semaphorins since macrophages and fibroblasts 
are known to interact in the inflamed synovial joint [646]. Consequently, the 
relative  expression  of  semaphorin  3A,  3F  and  6D  compared  to  GAPDH  was 
determined for RA synovial fibroblasts from 5 patients. Figure 4.16 outlines the 
results  and  reveals  that  semaphorin  3F  was  the  most  highly  expressed 
semaphorin and all five samples expressed it at a similar level. Semaphorin 3A 
was also expressed but the levels varied between samples with 3 samples having 
a high level of expression comparable to semaphorin 3F samples whereas the 
remaining  2  samples having  a  low  level of  expression.  The  five  RA  fibroblast 
samples expressed semaphorin 6D but at a lower level compared to the other 
semaphorin‘s  examined.  The  overall  expression  of  the  three  semaphorin 
molecules is very low with all of the relative expression values being lower than 
0.02.  Further  analysis  with  more  samples  would  need  to  be  performed  to 
determine  whether  synovial  fibroblasts  could  be  expressing  the  plexin  A1 
ligands.  256 
 
Figure 4.16 Semaphorin 3A, 3F and 6D expression in RA synovial fibroblasts 
Synovial fibroblasts from 5 RA patients were analysed for semaphorin (sema) 3A, 3F and 6D. qRT-
PCR was used to determine the relative expression of the semaphorins which were then 
normalised to GAPDH levels of each sample. The line represents the mean value. 257 
4.8  Discussion 
Plexin  A1  is  a  semaphorin  receptor  known  to  participate  in  axonal  guidance 
[635],  chick  cardiac  development  [631],  bone  homeostasis  [623],  T  cell-DC 
interactions [444, 623] and DC trafficking to the lymph node [632]. Plexin A1 had 
been  previously  shown  to  be  expressed  on  human  M-CSF  differentiated 
macrophages [443] but has not been shown to be present or play a role in PsA or 
RA. After discovering plexin A1 to be a highly upregulated gene in RA and PsA 
CD14
+ cells, showing a fold change increase of 26 and 27 respectively, we were 
interested  in  its  previously  identified  role  in  T  cell-DC  interactions.  In  this 
setting  plexin  A1  is  expressed  on  the  DCs  and  is  thought  to  act  as  a  co-
stimulatory marker for a T cell ligand because plexin A1
-/- DCs have a reduced 
ability to stimulate T cells [623] and plexin A1 has been shown to be localised at 
the T cell-DC interface [640]. Since macrophages have been demonstrated to 
interact with many cellular subtypes within the synovium of arthritis patients 
[249,  408,  646]  we  hypothesized  that  the  increased  levels  of  plexin  A1  on 
synovial  fluid  CD14
+  cells  may  play  a  role  in  enhancing  cellular  interactions 
within the diseased joint. In order to investigate this hypothesis we needed to 
demonstrate that plexin A1 was present within the synovial fluid cells and the 
synovium of arthritis patients, determine which plexin A1 ligands were present 
within the joint and investigate the effects of silencing plexin A1 on the pro-
inflammatory cytokine level obtained from activated macrophages. 
Plexin A1 was expressed at the mRNA level in all of the CD14
+ cells isolated from 
the synovial fluid of RA and PsA examined which included the samples that had 
been analysed on the microarray and other patient samples. Plexin A1 mRNA was 
also  detected  in  the  CD14
+  synovial  fluid  cells  of  a  JIA,  an  inflammatory 
polyarthritis and an OA patient indicating that this cell surface molecule may 
also be playing a role in other arthritic diseases, although more patients would 
have to be analysed to verify this. In the patients where a matched synovial fluid 
and blood sample were available the mRNA level of plexin A1 was consistently 
increased in the synovial fluid CD14
+ cells compared to the blood CD14
+ cells 
verifying  the  microarray  results  and  suggesting  the  pro-inflammatory 
environment  within  the  diseased  joint  causes  the  CD14
+  cells  to  upregulate 
plexin A1 once they exit the blood and enter the synovium. 258 
We observed the presence of plexin A1 in five RA synovial membranes where it 
was mainly located in cells outlining vascular structures, possibly indicative of 
endothelial cells, and within cells surrounding the vasculature structures which 
could  represent  cells  infiltrating  into  the  membrane  via  the  blood  vessels. 
However, due to a lack of PsA synovial membrane this disease was unable to be 
analysed for plexin A1 staining.  
Plexin A1 is a receptor molecule for semaphorin ligands and previous work has 
indicated that the specific ligands which interact with plexin A1 are semaphorin 
3A, 3F and 6D [624]. The main focus of research involving plexin A1‘s role in the 
immune response has been its interaction with semaphorin 6D on T cells [623, 
640].  O‘Connor  et al  demonstrated  that  CD3/CD28  activation of  murine  CD4
+ 
cells  induced  the  surface  expression  of  semaphorin  6D  [645]  therefore  we 
investigated whether an in vitro system of cytokine activation previously shown 
to induce a T cell phenotype similar to that of synovial T cells [298, 309] could 
induce the expression of semaphorin 6D. The interaction of macrophages and T 
cells  in  the  arthritic  joint  has  been  well  documented  [314,  408]  therefore  a 
plexin  A1  –  semaphorin  6D  receptor  ligand  complex  could  be  one  of  the 
interactions taking place. We observed no surface semaphorin 6D expression on 
the cytokine activated or CD3/CD28 activated T cells and no mRNA expression of 
semaphorin 6D in these cells or synovial fluid CD3
+ T cells. The lack of surface 
semaphorin 6D on CD3/CD28 activated T cells conflicted with the results of the 
O‘Connor paper  which demonstrated CD3/CD28 antibody stimulation induced 
semaphorin  6D  expression  in  70%  of  T  cells  after  5  day  [645].  However,  this 
discrepancy may be explained by a species specific response as the O‘Connor 
paper analysed murine T cells whereas we investigated semaphorin 6D in human 
T cells.  
Despite semaphorin 6D being undetected in cytokine activated and synovial T 
cells  there  was  a  possibility  that  semaphorin  6D  was  being  expressed  in  the 
synovium on other cell types. There was also the prospect of the macrophage 
plexin  A1  interacting  with  one  of  its  other  ligands  in  the  synovium  such  as 
semaphorin 3A or 3F. However, both of these semaphorins only interact with 
plexin A1 in the presence of neuropilin-1 or -2 acting as a co-receptor [647]. 
Analysis of the microarray study data indicated that compared to blood CD14
+ 
cells RA and PsA SF CD14
+ had increased levels of neuropilin-1 and -2 as well as 259 
plexin A1 indicating that binding of semaphorin 3A or 3F would be possible in 
these  synovial  macrophages.  We  observed  that  10  RA  synovial  membranes 
expressed semaphorin 3A mRNA at a higher level than that of semaphorin 3F or 
6D and so it appeared that semaphorin 3A could be the main receptor for plexin 
A1 in the synovial compartment. To try and elucidate which cell type expressed 
the plexin A1 ligands we investigated five RA synovial fibroblasts samples since 
synovial  macrophages  have  been  demonstrated  to  interact  with  synovial 
fibroblasts [249]. In these cells semaphorin 3F mRNA was expressed at a higher 
level compared to semaphorin 3A and 6D. However, the relative expression of 
these semaphorins were very low and further studies to analyse protein levels of 
expression  should  be  conducted  before  a  definitive  conclusion  can  be  made 
about the presence of semaphorins on synovial cell types. 
Despite being unable to define which cells were expressing the plexin A1 ligands 
we had shown that these ligands were present in the synovium of RA patients 
and therefore could hypothesize that the upregulation of plexin A1 in synovial 
macrophages was significant and may be playing a role in the progression of 
disease in RA and PsA. To try and elucidate the function of plexin A1, small 
interfering  (siRNA)  was  used  to  silence  the  plexin  A1  gene  in  M-CSF  derived 
macrophages which had been shown to upregulate plexin A1 mRNA during their 
differentiation.  The  transfection  efficiency  was  over  90%  indicating  that  the 
siRNA  was  effectively  entering  the  cells  using  the  nanoparticle  transfection 
system. Unexpectedly, two of the four siRNA induced an increase in plexin A1 
expression rather than knocking it down. siRNA‘s are known to have off-target 
effects as a result of a lack of specificity and can therefore silence other genes 
within the cell if the siRNA imperfectly pairs with sequence motifs residing in 
the  3‘  UTR  of  cellular  mRNA  [648].  There  has  been  one  report  of  siRNA 
treatment resulting in the upregulation of mRNA within cells. This was thought 
to  be  due  to  competition  between  the  transfected  siRNA  and  the  cell‘s  own 
endogenous miRNA. Hence the mRNAs targeted by the endogenous miRNA are 
not degraded and the cell demonstrates an upreglulation of these mRNA‘s [649]. 
However, despite this report of upregulation of mRNA levels occurring as a result 
of siRNA treatment there has been no report of upregulation of the siRNA target 
gene which is what occurred during the plexin A1 knockdown experiments. The 
reason for the observed upregulation of plexin A1 mRNA is unknown but could 260 
have been due to badly designed siRNA which did not target the plexin A1 mRNA 
for degradation. As a result the two PLX siRNA which demonstrated increased 
plexin A1 expression were not used in further experiments. 
The  TNFα  cytokine  profile  of  siRNA  treated  macrophages  subsequently 
stimulated with 10 ng/ml of LPS or cell contact activated with Tcks for 24 hours 
were analysed. It was thought that these two treatments may mimic the pro-
inflammatory environment to which synovial macrophages may be exposed as 
TLR  signalling  may  play  a  role  in  arthritis  [650]  and  cellular  contact  with 
activated T cells is known to take place within the joint.  
In the experiment shown, treating macrophages with 20 nM PLX 1+PLX 4 resulted 
in a 43% inhibition of plexin A1 in the cells which were subsequently cultured 
with  media  alone  and  55%  inhibition  in  the  macrophages  which  were 
subsequently stimulated with LPS. This discrepancy of over 10% in the amount 
gene silencing demonstrated the large variability of the siRNA treatment which 
was seen throughout all three siRNA experiments.  The small amount of gene 
silencing also indicated that potentially there could be as much as 50% of the 
total amount of plexin A1 mRNA still present in the macrophage cells before 
activation which could therefore bias the results of the cytokine analysis. In the 
siRNA treated macrophages which were activated with Tcks there appeared to 
be little to no gene silencing with the maximal amount of inhibition being 10% 
with PLX 4 treatment. This observation could be the result of contaminating Tcks 
remaining in the culture wells as T cells have been shown to express plexin A1 
[623]. Consequently, contaminating T cells in the macrophage sample may have 
diluted out any effect of the siRNA treatment which resulted in the appearance 
of no plexin A1 knockdown. Due to this discrepancy we must assume that the 
level of gene silencing in the Tck-stimulated was at a similar level to the gene 
silencing seen in the other macrophage samples i.e. around 43 – 55% inhibition. 
The subsequent TNFα analysis of the macrophage samples demonstrated that the 
cytokine  level did  not  change  in  the  macrophages  incubated in  media alone, 
indicating that the siRNA treatment did not adversely activate the macrophages. 
The LPS stimulated macrophages produced less TNFα in the samples which had 
been  treated  with  siRNA  compared  to  the  negative  control.  The  sample 
producing  the  lowest  amount  of  TNFα  was  the  sample  which  had  a  31% 261 
knockdown of the plexin A1 gene suggesting that even a small decrease in the 
amount of plexin A1 may be enough to change the pro-inflammatory cytokine 
profile of the macrophage. This result would imply that plexin A1 is playing a 
pro-inflammatory  role  within  the  macrophage  as  a  decrease  in  plexin  A1 
expression  causes  less  TNFα  to  be  released  by  the  cell  as  a  result  of  TLR4 
stimulation.  This  observation  is  in  contrast  to  that  of  Ji  et  al  [443]  who 
previously demonstrated that LPS stimulation of human monocytes alongside M-
CSF  stimulation  for  24  hours  resulted  in  the  inhibition  of  plexin  A1  mRNA 
expression. The inconsistency could be due to the stage of monocyte activation 
as the Ji et al paper investigated day 0 monocytes which were M-CSF and LPS 
stimulated at the same time for 24 hours while our investigation analysed the 
effect of plexin A1 silencing in macrophages that had been treated with M-CSF 
for 6 days and therefore would have a more activated phenotype. It must also be 
noted that the plexin A1 inhibition in the macrophages of this experiment was 
55%  therefore  there  is  still  45%  of  the  total  plexin  A1  mRNA  level  being 
expressed  within  these  cells.  Subsequently,  it  is  difficult  to  draw  definitive 
conclusions about the role of plexin A1 with regards to TLR-4 stimulation until 
complete knockdown of the plexin A1 gene is established. 
The TNFα levels measured in the siRNA treated macrophage activated with Tcks 
did not appear to have changed significantly in comparison to siRNA negative 
control macrophages. This result could indicate plexin A1 on the macrophages is 
not  involved  in  the  cellular  cross  talk  which  occurs  between  Tcks  and 
macrophages since its knockdown did not affect the pro-inflammatory output of 
the macrophages. This conclusion is supported by our  finding that semaphorin 
6D, one of plexin A1‘s most studied ligands, is not present on Tcks or synovial 
CD3
+ cells at the surface protein or mRNA level. However, as with the siRNA-
treated LPS stimulated macrophages it is difficult to draw conclusions about the 
role of plexin A1 within the macrophage - Tck cell contact when the plexin A1 
gene is incompletely silenced. The true function of plexin A1 may only become 
apparent once macrophage cells with 100% knockdown of plexin A1 are studied. 
In conclusion, the plexin A1 investigation has demonstrated that plexin A1 mRNA 
is highly upregulated in synovial fluid macrophage cells of PsA and RA and is also 
upregulated in synovial CD14
+ cells of other arthritic conditions such as OA, JIA 
and inflammatory polyarthritis. It is present within the synovial membrane of all 262 
5 RA patients examined although double staining is necessary to determine if the 
plexin  A1  positive  cells  are  predominantly  macrophages.  One  of  plexin  A1‘s 
ligands  semaphorin  6D  could  not  be  measured  on  cytokine  activated  T  cells 
(Tcks) or CD3/CD28 activated T cells as had been previously described [645] and 
its mRNA levels could not be determined in the above cell types or synovial fluid 
CD3
+ cells suggesting that macrophage plexin A1 was not interacting with T cells 
in the synovium. However, another of plexin A1‘s ligands, semaphorin 3A, was 
found to be highly expressed at the mRNA level in 10 RA synovial membranes 
indicating that this could be plexin A1‘s main ligand within the arthritic joint. At 
present the cell type expressing this semaphorin has not been discovered and 
analysis of RA synovial fibroblasts indicated that they expressed low levels of 
semaphorin. Investigation into the function of plexin A1 using siRNA has hinted 
at  a  possible  pro-inflammatory  role  in  macrophages  as  LPS  induced  TNFα 
secretion decreased in siRNA treated cells. However further investigations are 
needed to fully confirm this observation. 
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Chapter 5 Investigation into the expression and 
function of the novel gene legumain in rheumatoid 
and psoriatic arthritis patients 264 
5.1  Introduction 
The second ‗novel articular‘ gene to be discovered during the analysis of the 
upregulated  genes  in  RA  and  PsA  SF  CD14
+  cells  was  legumain.  Legumain, 
otherwise  known  as  asparagine  endopeptidase  (AEP),  is  a  lysosomal  cysteine 
protease that specifically cleaves protein substrates on the C-terminal side of 
asparagine [651]. The mammalian form was cloned and sequenced in 1997 [651] 
after being described in leguminous plants [652] and the blood fluke Schistosoma 
mansoni  [653].  There  are  four  families  of  cysteine  endopeptidases  found  in 
mammals, the most numerous of those belong to the papain family (C1), which 
are predominantly lysosomal enzymes and include cathepsin S, L, F, B, K and C 
[654]. These enzymes are responsible for proteolysis in the lysosomal/endosomal 
system and can also be secreted to act extracellularly. The other families of 
cysteine endopeptidases consist of calpain (family C2), caspase and legumain 
(family C13) [655]. 
Legumain is produced as an inactive zymogen that requires proteolytic cleavage 
to gain activity. Legumain activates itself autocatalytically which requires the 
sequential cleavage of a C-terminal 110-residue propeptide and then a shorter 
N-terminal  8-residue  propeptide,  this  activation  is  pH  dependent  occurring 
optimally between pH 4.0-4.5 [656]. Initial studies of legumain found it to have 
the highest activity in the kidney of rat, rabbit and pig [651]. However, further 
studies  of  mouse  legumain  found  it  be  expressed  in  all  samples  examined 
including placenta, spleen, kidney, heart, lung, liver, testis and thymus but the 
active  legumain  was  particularly  abundant  in  the  kidney  and  placenta  [657]. 
Legumain deficient mice have enlarged proximal renal tubule cells suggesting 
that  material  to  be  degraded  is  accumulating  in  the  lysosomes;  previous 
hypotheses proposed that legumain has a role in the biosynthesis of lysosomal 
enzymes [432]. Legumain has since been shown to be ubiquitously expressed in a 
large panel of human tissue at mRNA level [435] and is constitutively expressed 
in most cells types including macrophages and DCs [658]. 
Legumain  is  known  to  cleave  and  activate  several  substrates  such  as  MMP-2 
[429]; fibronectin [431]; α-thymosin [430]; cathepsin B, H and L [432]; TLR9 in 
DCs [658] and it also processes microbial tetanus toxin antigen [659]. Due to this 
wide  variety  of  substrates,  the  functional  role  of  legumain  is  cell  and  tissue 265 
context dependent. Manoury et al [659] first described a role for legumain as the 
enzyme  which  processes  microbial  tetanus  toxin  antigen  (TTCF)  for  antigen 
presentation; legumain was isolated from disrupted lysosomes of the human B 
cell line EDR and exposed to TTCF in vitro. Peptide inhibitors to legumain slowed 
TTCF presentation to T cells while pre-processing of the peptide with legumain 
accelerated its presentation. The same group later showed that T cell responses 
to TTCF were still mounted in legumain-deficient mice but the in vivo kinetics of 
TTCF  presentation  was  slower.  Boosting  legumain  levels  in  the  primary  APCs 
accelerated TTCF processing and presentation in vitro indicating that legumain 
is  the  most  efficient  protease  for  TTCF  processing  but  in  its  absence  other 
enzymes can substitute to enable a slower immune response  [660]. Recently, 
Sepulveda et al [658] showed that legumain plays a role in the processing of 
TLR9  in  DCs  as  legumain  deficiency  resulted  in  decreased  secretion  of 
proinflammatory cytokines in response to umCpG DNA. They also showed that 
transfection  of  TLR9  deficient  DCs  with  a  mutant  TLR9  lacking  a  legumain 
cleavage site did not restore TLR9 signalling, suggesting that TLR9 is a direct 
substrate for legumain.  
As well as its roles in antigen processing and TLR9 cleavage, legumain has also 
been shown to directly degrade fibronectin in vitro and in cultured mouse renal 
proximal  tubular  cells  [431].  The  processing  of  fibronectin  was  abrogated  by 
chloroquine, an inhibitor of lysosomal degradation, and was enhanced by the 
overexpression of legumain revealing that fibronectin degradation occurs in the 
presence of legumain in the lysosomes of renal proximal tubular cells. Similarly, 
legumain-deficient  mice  exhibit  renal  injury  induced  protein  accumulation  of 
fibronectin and enhanced renal interstitial fibrosis which led to the hypothesis 
that renal proximal tubular cells take up and degrade fibronectin intracellularly 
thereby linking legumain to extracellular matrix remodelling. Legumain may also 
play an indirect role in matrix remodelling as it can cleave pro-MMP-2 into active 
MMP-2 [429]. MMP-2 is known to degrade the extracellular matrix due its wide 
variety  of  substrates  including  fibronectin,  several  MMPs  and  collagen  types 
[661]. 
Despite playing an important role in extracellular matrix turnover and antigen 
processing  legumain  is  also  linked  to  various  pathological  conditions  such  as 
cancer,  atherosclerosis  and  skin  barrier  function.  Legumain  was  first 266 
demonstrated  to  be  involved  in  cancer  when  Liu  et  al  showed  that  it  was 
overexpressed in a panel of human solid tumours including breast, colon, lung, 
prostate  and  ovarian  carcinoma  [662].  The  same  study  used  fluorescent 
microscopy  in  tumour  cells  to  show  legumain  expression  associated  with 
intracellular membranous vesicles, consistent with its function as a lysosomal 
protease,  as  well  as  on  the  cell  surface  and  in  membranous  vesicles 
concentrated  at  the  invadopodia  of  the  tumour  cell.  HEK  293  cells  stably 
expressing  legumain  were  found  to  have  increased  migration  and  invasion  in 
vitro  and  legumain  expression  was  correlated  with  tumour  invasion  and 
metastasis in vivo [662]. Legumain was also found to be expressed specifically in 
tissue sections of a mouse tumour line CT26 where it was detected in vascular 
endothelial cells, macrophages and in the extracellular matrix associated with 
collagen I [663]. Cystatin E/M is a cysteine protease inhibitor and its relationship 
with legumain was investigated in human melanoma, legumain was expressed 
and active in most of the cell lines but was absent or at low levels in cell lines 
secreting  cystatin  E/M.  When  melanoma  lines  lacking  cystatin  E/M  secretion 
were  transfected  with  a  plasmid  containing  full  length  cystatin  E/M  their 
intracellular  legumain  activity  was  inhibited,  suggesting  that  it  regulates 
legumain activity and hence its invasive potential [664]. 
Legumain  was  first  associated  with  atherosclerosis  when  a  microarray  study 
comparing stable and unstable atherosclerotic plaques found legumain to be one 
of the genes upregulated in the unstable areas of plaques [434]. The same group 
demonstrated legumain mRNA to be co-localised with CD68 macrophages in the 
shoulder region of the plaque by in situ hybridisation and IHC. Another group 
followed on from this initial observation by using a microarray to study the aorta 
of aging Apolipoprotein E deficient mice with developed atherosclerosis, they 
found  that  legumain  mRNA  expression  increased  with  the  development  of 
atherosclerosis while its expression remained at low unchanged levels in aged 
matched C57BL/6 control mice [665]. In both Apolipoprotein E deficient mouse 
arteries  and  human  advanced  atherosclerotic  plaques  legumain  was 
predominantly  expressed  in  macrophages.  It  was  also  shown  to  induce 
chemotaxis of primary human monocytes and human umbilical vein endothelial 
cells (HUVECs). The macrophage-specific expression of legumain in vivo as well 
as  the  ability  of  legumain  to  induce  chemotaxis  of  cells  in  vitro  suggests 267 
legumain could play a functional role in atherogenesis. It has also subsequently 
been shown that human unstable plaques express twice the amount of legumain 
as stable plaques [666]. 
Cystatin C and cystatin E/M both bind to legumain with high affinity  in vitro 
thereby inhibiting its activation [667]. Since cystatin E/M plays a regulatory role 
in epidermal differentiation, misregulation of this pathway leads to abnormal 
stratum corneum and hair follicle formation as well as severe disturbances of 
skin  barrier  formation  [668].  Legumain  is  found  in  the  epidermis  and  hair 
follicles  of  wild  type  and  Cystatin  E/M  null  mice  (ichq  mouse)  but  active 
legumain is only found in the epidermis of the ichq mouse suggesting that a role 
for  cystatin  E/M  in  vivo  is  to  regulate  legumain  activity  [669].  Regulation  of 
legumain activity is important as it cleaves and activates cathepsin L which in 
turn  activates  transglutaminase  3  (TGM3).  Active  TGM3  was  detected  in  skin 
extracts of cystatin E/M null mice at a time where skin lesions developed and 
caused abnormal cornification [669], therefore unrestricted legumain activation 
could play a role in irregular skin barrier formation. Ichq mice are a model of the 
human disorder type 2 harlequin ichthyosis which is a severe type of skin disease 
and as yet the presence of legumain in this disorder has not been determined. 
However, legumain mRNA has been detected in atopic dermatitis and psoriasis 
suggesting  it  may  be  contributing  to  the abnormal  skin  barrier  seen in  these 
conditions [435]. 
Since  legumain  was  expressed  at  high  levels  in  the  SF  of  RA  and  PsA  in  my 
microarray  samples  and  it  is  has  been  demonstrated  to  cleave  and  activate 
several  substrates  found  in  the  arthritic  joint,  such  as  fibronectin  [425-428], 
MMP-2 [670] and cathepsin B and L [671-673], it was decided to analyse legumain 
and its expression and activity in RA and PsA samples.  
Due to identification of a novel gene legumain which was highly upregulated in 
RA and PsA CD14
+ SF cells I therefore sought to validate this expression in the 
microarray samples and samples from other patients. I also sought to determine 
the  level  of  protein  expression  of  legumain  in  the  synovial  membrane  of 
diseased patients and in the CD14
+ cells of diseased patients by IHC and western 
blot. Once the presence of legumain had been verified I sought to determine 268 
whether  the  legumain  that  was  present  was  active  and  still  able  to  cleave 
substrates. 269 
5.2  Validation of legumain expression in microarray 
samples 
Legumain had a fold change increase from PB CD14
+ samples to the matched SF 
CD14
+ samples of 167 in RA and 164 in PsA. However, since microarray results 
require validation and verification by an alternative and complementary gene 
expression profiling method qRT-PCR was used to determine  the expression of 
legumain in the 8 RA and 8 PsA pairs of samples that had been used for the 
microarray study. Figure 5.1 (A) shows the raw data signals of legumain on the 
affymetrix GeneChips for each patient sample. The signal values of legumain in 
the synovial fluid of both sets are considerably higher than those of the blood 
samples however the signal intensity varies between the synovial fluid samples 
of each patient indicating that the levels of legumain in the synovial fluid CD14
+ 
cells  are  not  consistent  possibly  due  to  differences  in  disease  duration  and 
treatment type of the patients. 
To  validate  these  results  qRT-PCR  was  used  to  determine  the  fold  change  in 
legumain  expression in  the  SF  samples  compared  to  the PB  samples.  One  RA 
patient was unable to be analysed due to a problem with the peripheral blood 
sample,  as  repeated  measurements  gave  unusual  results  which  could  not  be 
analysed. This could have been due to a problem with the RNA for that sample 
therefore the matched PB and SF samples from that particular patient were not 
analysed.  Figure  5.1  (B)  shows  the  results  of  the  qRT-PCR  and  clearly 
demonstrates that legumain expression increases from the PB to the SF of each 
patient which reflects the results obtained from the microarray.  
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Figure 5.1 Legumain expression in microarray samples 
(A) Demonstrates the raw signal intensities of the legumain gene locus on the Affymetrix 
GeneChips. Each circle represents one patient sample and the line represents the mean signal 
intensity. Legumain mRNA levels were then measured in the RA and PsA paired PB and SF 
microarray samples by qRT-PCR. (B) The fold change of legumain expression in the SF samples 
was normalised to the matched patient PB sample, each circle represents one patient and the line 
the mean fold change. 
5.3  Expression of legumain in other patient samples 
Once it had been verified that legumain was expressed in the samples used in 
the microarray we then analysed legumain expression in more patient samples to 
check that increased legumain expression in the SF of RA and PsA occurred in 
other patients and not just the 16 who were examined on the microarray. Figure 
5.2 shows the legumain expression in all of the CD14
+ samples tested. In graph A 
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it can been seen that there are varying levels of legumain in the PsA CD14
+ SF 
samples but the mean level of expression is higher than that seen in PsA PB 
CD14
+. Five of these PsA patients tested had matched PB and SF CD14
+ cells and 
therefore the fold change increase in legumain expression from the PB to the SF 
was  able  to  be  measured  as  seen  in  Figure  5.2  (B).  As  was  observed  in  the 
microarray  samples  some  of  the  patients  had  a  substantial  fold  change 
differences but the mean fold change difference in legumain expression was 133 
which is similar to the mean fold difference of 138 seen from the microarray 
samples.  We  were unable  to obtain  matched  PB  samples  for the  RA  patients 
analysed however, in part (A) of Figure 5.2 the RA SF CD14
+ and PsA SF CD14
+ 
samples both have a similar mean relative expression of legumain which concurs 
with the results observed in the microarray samples. 
Graph (A) of Figure 5.2 also demonstrates the other arthritic patient samples 
from  which  we obtained  CD14
+  cells  to  analyse  for  legumain expression.  The 
inflammatory arthritis and JIA CD14
+ samples both appear to have lower levels of 
legumain expression compared to the RA and PsA SF samples however legumain 
is present in the samples. Unfortunately we were not able to obtain PB CD14
+ 
samples from each patient to distinguish whether the legumain expression level 
increased from PB to SF CD14
+ as has been seen with the RA and PsA patients. 
Matched OA PB and SF CD14
+ cells from the same patient were measured for 
legumain expression and as with the RA and PsA microarray samples the level of 
mRNA expression increased from the PB to the SF. These data demonstrate that 
legumain is not specific to RA and PsA but is also expressed in other arthritic 
diseases. 272 
 
Figure 5.2 Legumain expression in CD14
+ cells from arthritic patients 
Legumain RNA expression was measured in the CD14+ cells from the PB or SF of arthritic 
patients. (A) Expression was measured relative to GAPDH. Five of the PsA patients had matched 
PB and SF samples, in these patients the fold change increase of legumain expression was 
measured and plotted in graph (B). 
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5.4  Immunohistochemistry 
Next immunohistochemistry (IHC) was performed  to detect the enzyme in RA 
synovial membrane. The antibody staining was first optimised on tonsil sections 
before the RA synovial membranes were stained for legumain (data not shown). 
Five  individual  RA  membranes  were  stained  and  they  all  displayed  specific 
positive staining of legumain. Figure 5.3 shows representative staining from one 
of the RA synovial membranes. The x10 and x40 magnification isotype controls 
are shown in panel (A). Positive legumain staining at x10 and x40 magnification 
from two different areas of the same RA synovial membrane are shown in panel 
(B) and (C). The isotype controls show no non-specific staining indicating the 
antibody is specific for legumain. In panel (B) legumain staining is seen to be 
constitutively  expressed  throughout  the  membrane  and  analysing  the  x40 
magnification  the  staining  is  cytoplasmic  with  no  nuclear  staining  and  within 
some cells the staining is granular indicative of lysosomal staining.  
Panel (C) shows staining from the same tissue and demonstrates that positive 
legumain staining is seen on the edge of the membrane where it is contained 
within the cytoplasm of cells. Positive staining can also been seen in cells within 
follicular regions of the tissue (indicated by arrows). The staining appears to be 
present in macrophage-like cells but this cannot be verified until the membrane 
is double stained for legumain and CD68. 274 
 
Figure 5.3 Immunohistochemistry staining of legumain in RA synovial membrane 
Five individual membranes were stained for legumain; this figure shows the results from one 
membrane that represents the staining pattern of legumain seen in the membranes. The isotype 
controls are shown in (A) at the x10 and x40 magnification. Images (B) and (C) define the positive 
legumain staining (shown in brown) seen in the RA membrane. Arrows in panel C denote positive 
follicular staining. The x10 magnification is shown on the left and the x40 magnification of an area 
of the x10 image defined by the box is shown on the right. 275 
5.5  Western blot for legumain  
Since we had determined that legumain RNA was expressed in synovial CD14
+ 
cells and IHC had indicated that legumain was present in RA synovial membrane 
we wanted to determine if arthritic synovial CD14
+ cells were expressing the 
legumain enzyme at the protein level. Legumain has already been demonstrated 
to  be  upregulated  in  M-CSF  macrophages  [665,  674]  therefore  M-CSF  treated 
macrophages were also analysed as a positive control. 
5.5.1 Legumain in M-CSF derived macrophages by RT-PCR 
To determine whether the presence of legumain increased as a result of M-CSF 
treatment,  day  6  M-CSF  treated  macrophages  from  5  individual  donors  were 
analysed by RT-PCR. As can be seen from Figure 5.4, M-CSF treatment induced 
legumain mRNA production in all 5 donors. The fold change difference between 
untreated monocytes and treated macrophages is donor dependent and varies 
between the lowest fold change of 26 and the highest fold change of 3567. 
 
Figure 5.4 Legumain expression in M-CSF treated macrophages for 6 days 
Monocytes were obtained from 5 healthy donors and treated with M-CSF for 6 days. Monocyte 
samples were taken at day 0 and compared to the M-CSF treated macrophages for legumain 
expression by RT-PCR. The graph shows the relative fold change in legumain expression from day 
0 monocytes to day 6 treated macrophages. 276 
5.5.2 Legumain in M-CSF macrophages by western blot 
Once we had shown that legumain is present in M-CSF derived macrophages at 
the  mRNA  level  we  next  wanted  to  verify  expression  at  the  protein  level. 
Monocytes were isolated from three individual donors and analysed at day 0, 3 
and 6 days after M-CSF treatment for legumain and also for β-actin as a loading 
control (Figure 5.5). As described in the introduction legumain can exist in two 
forms, a pro form and an active form, to convert to the active form legumain 
must autocatalytically cleave itself in a pH dependent process [656]. In Figure 
5.5  the  upper  panel  indicates  the  presence  or  absence  of  legumain  in  each 
sample. There appears to be no legumain in any of the day 0 - monocyte samples 
however day 3 M-CSF treated monocytes exhibit two bands representing pro-
legumain at 52 kDa and active legumain at 36 kDa. At day 6 in all three donors 
the  amount  of  pro-legumain  is  reduced  as  well  as  the  amount  of  active 
legumain.  The  lower  panel  of  Figure  5.5  demonstrates  the  β-actin  loading 
control of each macrophage sample. Despite the samples being analysed by BCA 
for protein concentration and 5 μg of protein being loaded to each well, the β-
actin blot indicates that the amount of protein loaded into each well varies due 
to the different intensity of the β-actin band in each sample. Also, there appears 
to be very little sample in day 0 monocytes of donor 1 due to a lack of a band for 
the  β-actin  control.  However,  regardless  of  the  loading  control  we  have 
demonstrated that macrophages express the pro- and active form of legumain 
when induced via M-CSF differentiation of monocytes. 277 
 
Figure 5.5 Legumain western blot of M-CSF treated macrophages 
Three donors were analysed after day 0, 3 and 6 of M-CSF treatment for the presence of legumain 
(top blot) or β-actin as a loading control (bottom blot). Both pro- and active legumain were present 
at day 3 in all three donors whereas by day 6 the pro-legumain levels had decreased. 
5.5.3 Legumain in patient CD14
+ samples by western blot 
We  next  wished  to  detect  legumain  by  western  blotting  in  RA  synovial  CD14 
cells.  The western blot assay had already been optimised for the detection of 
legumain  using  M-CSF  derived  macrophages  as  a  control.  CD14
+  cells  were 
isolated from five individual RA bloods, one PsA blood, two PsA synovial fluids 
and one RA synovial fluid and run on a western blot to detect legumain and the 
loading control β-actin.  
The upper panel in Figure 5.6 illustrates the presence of active legumain in 4 of 
the 5 RA bloods and in the PsA blood CD14
+ cells which was not seen in the CD14
+ 
cells at day 0 of the normal donors in Figure 5.5. Large amounts of pro- and 
active  legumain  were  present  in  both  of  the  PsA  synovial  fluid  macrophage 278 
samples however, there does not appear to be any legumain in the RA synovial 
fluid CD14
+ cells. The lower panel of Figure 5.6 demonstrates the β-actin loading 
control  of  the  samples  as  observed  in  the  M-CSF  macrophage  western  blot 
despite 5 μg of protein being added to each well there appears to be varying 
levels of protein in each well as indicated by the difference in intensity of the β-
actin bands. Also the two samples which appeared to contain no legumain in the 
upper panel, the RA PB sample and the RA SF sample, do not have a β-actin band 
suggesting  that  not  enough  of  sample  was  loaded  into  these  wells.  These 
samples would have to be repeated to determine if they do contain the enzyme 
legumain. We have therefore demonstrated that active legumain is present in 
the  peripheral  blood  CD14
+  cells  of  arthritic  patients  which  was  not  seen  in 
normal donors day 0 CD14
+ cells (Figure 5.5). We have also demonstrated that 
pro- and active legumain is expressed in the PsA synovial fluid CD14
+ cells.  
 
Figure 5.6 Legumain western blot of patient CD14
+ cells 
CD14
+ cells from five RA bloods, one PsA blood, two PsA synovial fluids and one RA synovial fluid 
were analysed by western blot for the presence of legumain (upper panel) and β-actin control 
(lower panel). 
5.6  Legumain activity assay 
Legumain  is  a  lysosomal  enzyme  that  in  its  active  form  specifically  cleaves 
protein substrates after an asparagine residue [651], despite showing that M-CSF 
derived macrophages and synovial fluid derived CD14
+ cell express the active 279 
form  of  legumain  it  was  necessary  to  establish  that  this  enzyme  was  still 
physiologically active and could still cleave its substrates. A legumain activity 
assay  was  therefore  employed  which  uses  a  substrate  Z-Ala-Ala-Asn-AMC. 
Incubating active legumain with this substrate results in its cleavage after the 
asparagine residue (Asn) thereby releasing the AMC (7-amino-4-methylcoumarin) 
flurophore.  The  amount  of  flurophore  released  can  be  detected  on  a 
luminescence reader.  
To determine the presence of active legumain in M-CSF derived macrophages 
and patient derived CD14
+ samples, cells were resuspended in lysis buffer and 
then  freeze  thawed  three  times  to  disrupt  the  lysosomes  where  legumain  is 
thought to reside [432]. 
5.6.1 Legumain activity assay of M-CSF derived macrophages 
Given that large amounts of the active form of legumain were visualised in the 
M-CSF  derived  macrophages  by  western  blot  it  was  decided  to  analyse  these 
samples to determine if the legumain in these samples was physiologically active 
and still able to cleave its substrate. Clerin et al [665] previously demonstrated 
that  legumain  is  more  active  and  can  cleave  its  substrate  in  day  3  M-CSF 
differentiated  macrophages  compared  to monocytes  however  a  timecourse  of 
day 0, 3 and 6 activated macrophages has not been reported to my knowledge. 
Day 0, 3 and 6 M-CSF treated macrophages from two donors were analysed using 
the  activity  assay;  the  same  number  of  cells  (1  x  10
6)  were  examined  per 
condition. Recombinant human (rh) legumain was also analysed on the assay as a 
positive control. Figure 5.7 illustrates the results of the activity assay; the rh 
legumain  (black  line)  shows  an  increase  in  fluorescence  units  (FU)  over  time 
indicating that the legumain is active. The two donors tested are shown by the 
red line for donor 1 and blue line for donor 2 with the triangle symbol indicating 
day 0 monocytes, the square symbol indicating macrophages treated with M-CSF 
for 3 days and the diamond symbol indicates day 6 M-CSF treated macrophages. 
In both donors a similar pattern in legumain activity can be observed. The day 0 
monocytes have little or no legumain activity for the duration of the assay as the 
FU  detected  were  less  than  the  background  fluorescence  of  the  assay.  This 
corroborates the legumain western blot of M-CSF macrophages (Figure 5.5) as 280 
there was no legumain detected in the day 0 monocytes. The fluorescence units 
of day 3 M-CSF activated macrophages in both donors is high and increases over 
time  to  a  maximum  of  670  FU  and  592  FU  in  donors  1  and  2  respectively 
indicating a high level of legumain activity. This discrepancy in the amount of 
legumain  activity  in  these  samples  despite  having  the  same  number  of 
macrophages may be due to donor specific variability or it is possible that the 
macrophages from donor 1 contain more legumain. 
In both day 6 activated macrophage samples the amount of fluorescence and 
therefore  legumain  activity  is  lower  compared  to  the  day  3  activated 
macrophages. The FU from donor one decreases by almost two thirds from 670 
to 177 FU at the 210 minute timepoint and the FU from donor two decreases 
from 592 to 346. This indicates that there could be less legumain present in 
these cells and therefore legumain may undergo a cyclic form of expression with 
no  active  legumain  present  in  day  0  monocytes,  a  high  level  of  activity  and 
expression in 3 day differentiated macrophages which then decreases to a lower 
level  at  day  6.  This  observation  agrees  with  the  western  blot  of  the  M-CSF 
differentiated macrophages as there was a greater amount of active legumain 
expressed  in  the  day  3  macrophages  compared  to  the  day  6  macrophages. 
Overall it has been demonstrated that legumain is expressed at varying levels in 
M-CSF  activated  macrophages  depending  on  the  duration  of  activation,  this 
legumain is the active form of the enzyme and as a result is able to fulfil its 
physiological role and cleave its endogenous substrate.  281 
 
Figure 5.7 Legumain activity assay in M-CSF derived macrophages 
M-CSF activated macrophages for 0, 3 and 6 days from two separate donors were analysed using 
a legumain activity assay to determine whether the legumain detected in these samples was active 
could cleave a substrate. Once the substrate is cleaved it releases a fluorophore which can be 
detected on a luminescence plate reader. The assay is incubated at 37ºC for 3.5 hours and the 
amount of fluorescence (measured in fluorescent units) is measured at set time points. Human 
recombinant legumain was used as a positive control and is indicated by the black line. Cells from 
donor 1 are shown by the red line and cells from donor 2 are shown by the blue line with the 
triangle symbol indicating day 0 monocytes, square symbol indicating M-CSF treated macrophages 
for 3 days and diamond symbol indicating M-CSF macrophages treated for 6 days. Each donor 
sample contained 1 x 10
6 cells. 
5.6.2 Legumain activity assay of patient CD14
+ samples 
Once we had determined that legumain was present and active in the M-CSF 
macrophage samples we then went on to establish whether the large amounts of 
legumain present in the CD14
+ patient samples as seen on the western blot was 
active and able to cleave its substrate. Two RA synovial fluid samples, one with 
a matched blood, were obtained and CD14
+ cells were isolated from each. Due 
to differences in the amount of synovial fluid obtained and donor variation there 
were slight differences in the total number of cells, analysed, RA patient 1 had 
7.2 x 10
5 SF CD14
+ cells whereas RA patient 2 had 8.8 x 10
5 SF CD14
+ cells. 
The results for the patient legumain activity assay are shown in Figure 5.8. As in 
the  previous  experiment  rh  legumain  was  used  as  a  positive  control.  Despite 
having the lowest total cell number RA patient 1 SF (red line)  exhibited the 
largest amount of legumain activity shown by the steady increase over time of 282 
FU up to a maximum of 830 FU. However, the PB sample (red line) from the 
same  patient  contained  a  much  lower  amount  of  legumain;  the  fluorescence 
level of this sample was very low and did not increase above the background 
level  of  fluorescence  indicated  by  the  negative  FU  values.  Nevertheless,  it 
appears that this sample did contain a small amount of legumain as the FU can 
be  seen  to  slowly  increase  towards  the  baseline  which  would  suggest  that 
legumain  is  present  but  there  is  not  enough  enzyme  to  create  a  strong 
fluorescent signal. This same pattern of activity can be visualised in the patient 
2 RA SF sample (blue line) where the fluorescence unit increase from -30 to -1 
FU over the duration of the assay indicating that active legumain is present in 
this sample but in small amounts. 
Synovial fluid from several patients including six RA, six PsA, one OA, one JIA 
and  one  inflammatory  polyarthritis  were  analysed  using  the  activity  assay  to 
investigate  whether  these  samples  contained  active  legumain  that  may  have 
been excreted from the synovial cells. However, no activity was determined for 
any of the samples (data not shown). 
 
Figure 5.8 Legumain activity assay in CD14
+ patient samples 
CD14
+ cells isolated from patient blood or synovial fluid samples were analysed using a legumain 
activity assay to determine whether the legumain that was present in these cells was active and 
able to cleave a fluorescent substrate. The assay is incubated at 37ºC and the amount of 
fluorescence measured in fluorescence units (FU) is quantified at set time points. Human 
recombinant legumain (black line) was also assayed as a positive control. RA patient 1 is shown in 
red with the upwards facing triangle indicating blood CD14
+ cells and the downwards facing triangle 
indicating synovial fluid CD14
+ cells. RA patient 2 is shown by the blue line indicating synovial fluid 
CD14
+ cells. 283 
5.7   Analysing legumain expression under normoxic 
and hypoxic conditions 
Once  we  had  established  that  legumain  was  present  in  RA  synovial  fluid 
macrophages and was physiologically active we decided to try and determine 
what  potential  factors  could  be inducing  legumain  expression.  To  do  this  we 
cultured healthy donor M-CSF differentiated macrophages in complete media or 
in complete media supplemented with 10% RA or PsA synovial fluid for 24 hours 
under  normoxic  (24%  oxygen)  or  hypoxic  (1%  oxygen)  conditions.  This  was  in 
order to represent the conditions that the arthritic macrophages may be exposed 
to once they exit blood and enter the synovial compartment. The synovium has 
been shown to be a hypoxic environment [409] and the synovial fluid of arthritic 
patients  contains  many  cytokines,  chemokines,  antibodies  and  extracellular 
matrix proteins [410, 537] which could interact with and induce differential gene 
expression  in  the  macrophages.  Therefore,  we  hypothesized  that  exposing 
macrophages to patient synovial fluid under hypoxic conditions may induce the 
expression of legumain within these cells. Three RA and three PsA synovial fluids 
were tested on the macrophages and the experiment was repeated three times. 
Figure 5.9 shows the fold change in legumain mRNA expression relative to the 
macrophage  in  complete  media  alone  control.  Graph  (A)  demonstrates  those 
cells  which  were  incubated  with  the  six  synovial  fluids  for  24  hours  under 
normoxic conditions. The fold change in legumain expression increases with 2 of 
the RA synovial fluids but the addition of RA SF 2 seems to decrease the amount 
of legumain expression resulting in a negative fold change. In contrast, only one 
PsA SF appeared to increase the amount of legumain expression under normoxic 
conditions  while  PsA  SF  1  and  PsA  SF  3  decreased  the  amount  of  legumain 
expression.  
On  the  other  hand,  culturing  macrophages  with  synovial  fluid  under  hypoxic 
condition increased legumain expression in all synovial fluid conditions relative 
to  the  macrophages  incubated  with  media  alone.  The  hypoxic  conditions  are 
shown in graph (B) of  Figure  5.9;  the three RA synovial fluids and three PsA 
synovial  fluids  all  induced  an  increase  in  legumain  expression  compared  to 
control indicated by the positive fold change values.  284 
These results suggest that the combination of both synovial fluid and hypoxia are 
needed in order to induce legumain expression in macrophages. As the addition 
of synovial fluid under normoxic conditions induces both up and down regulation 
of  legumain expression  compared to control  whilst  the  macrophages  cultured 
under hypoxic conditions show an increase in legumain expression with all of the 
six synovial fluids examined. 
 
Figure  5.9  Legumain  expression  in  the  presence  of  synovial  fluid  under  hypoxic  and 
normoxic conditions 
M-CSF differentiated macrophages were cultured individually with three different RA synovial fluids 
or three PsA synovial fluids for 24 hours under normoxic (24% oxygen) (A) or hypoxic (1% oxygen) 
(B) conditions. The fold change in legumain expression is shown relative to the mo alone control for 
either the hypoxic or normoxic condition. This is a representative of three independent 
experiments.  285 
5.8   Discussion 
The  second  gene  identified  from  the  microarray  experiment  as  being  highly 
expressed in both RA and PsA synovial macrophages was the enzyme legumain. It 
is an enzyme that specifically cleaves its substrates after an asparagine residue 
and has a role in the cleavage and activation of several substrates as well as in 
the processing of microbial antigen for MHC II presentation [659]. Legumain is 
known to be disregulated in several inflammatory conditions and diseased states 
such  as  breast  cancer  where  it  is  specifically  overexpressed  on  tumour 
associated  macrophages  [433];  atherosclerosis  where  it  is  upregulated  in 
macrophages in unstable areas of plaques [434] and in inflamed skin where it is 
highly  upregulated  in  lesional  atopic  dermatitis  and  psoriasis  compared  to 
normal skin [435].  
Legumain  has  not  been  previously  associated  with  inflammatory  arthritis 
however several of its substrates that it can cleave and activate are present 
within the synovium of arthritis patients. These substrates include fibronectin 
[431] a glycoprotein that has been found in the synovia of RA and PsA patients 
[426] whose cleaved fragments acquire catalytic activities which can stimulate 
cartilage chrondrolysis [675]; legumain can activate gelatinase A (MMP2) [429] 
which has been found a higher levels in RA patient blood compared to controls 
[670] and is also upregulated in the RA and PsA SF CD14
+ cells in my microarray 
experiment  (see chapter  3).  Legumain  has  also  been  demonstrated  to  cleave 
several  cathepsins  including  cathepsin  B  and  L  which  are  upregulated  in  RA 
synovial fluid [671]. Since active fibronectin, gelatinase A, cathepsin B and L are 
all known to degrade collagen and other components of the extracellular matrix 
we hypothesised that legumain is upregulated by synovial fluid macrophages as a 
result  of  the  pro-inflammatory  environment  to  function  as  an  extracellular 
matrix degradation enzyme and therefore may be contributing to the cartilage 
and bone degradation that is often seen in these two diseases.  
These are the first data to investigate legumain expression in RA and PsA and 
using qRT-PCR we observed that all of the RA and PsA synovial fluid samples 
analysed were expressing legumain at varying levels and the amount of synovial 
fluid  CD14
+  legumain  was  always  elevated  in  comparison  to  the  CD14
+  blood 
cells. We also demonstrated that legumain was expressed in the synovial fluid 286 
CD14
+ cells of an OA patient, a JIA patient and an inflammatory polyarthritis 
patient indicating that this enzyme was not exclusively expressed in RA and PsA 
and appeared to be a marker of other arthritic synovial macrophages. Research 
into  the  control  of  mRNA  expression  has  uncovered  small  non-coding  RNAs 
termed microRNAs (miRNA) that target and degrade mRNA thereby suppressing 
proteins synthesis [676] therefore observing mRNA expression of a gene such as 
legumain  does  not  imply  that  it  will  be  expressed  at  the  protein  level. 
Consequently,  further  studies  took  place  to  investigate  the  expression  of 
legumain.  Immunohistochemistry  revealed  a  novel  observation  that  legumain 
was  consitutively  expressed  in  five  RA  synovial  membranes.  At  a  higher 
magnification legumain was observed specifically in the cytoplasm of the cells in 
a granular pattern which is indicative of its role as a lysomomal enzyme [432] 
and cell surface staining was also observed. Legumain has previously been shown 
to  be  expressed  on  the  cell  surface  and  along  the  invadapodia  of  invading 
tumour cells where it correlated with increased tumour invasion and metastasis 
[662].  Further  double  staining  of  legumain  and  the  plasma  membrane  would 
need to be carried out to verify legumain cell surface expression on synovial 
arthritic cells but a role for this surface expression could be to help invading 
synovial cells to further degrade the cartilage and extracellular matrix. Positive 
staining was also observed within follicular regions of the membrane and within 
cells  on  the  outside  edge  of  the  synovium.  We  propose  that  the  legumain 
positive cells  on the outside of  the  membrane  are  well  positioned  to  uptake 
substrates from the synovial fluid, such as fibronectin, in order to cleave them 
intracellularly. To establish whether this synovial legumain was present mainly 
in  macrophages  double  staining  would  need  to  be  performed  but  time 
restrictions meant this could not be performed. 
It had been observed that synovial fluid CD14
+ macrophages expressed legumain 
at the mRNA level and arthritic synovial membrane expressed legumain at the 
protein  level  therefore  we  wanted  to  determine  whether  synovial  fluid 
macrophages expressed legumain at the protein level by western blot. Legumain 
has  been  previously  shown  to  be  upregulated  in  M-CSF  differentiated 
macrophages [665, 674] therefore these cells were used as a positive control for 
the  western  blot.  We  confirmed  that  M-CSF  differentiated  monocytes  had 
increased  legumain  mRNA  expression,  the  fold  change  increase  in  legumain 287 
ranged from 26 to 3573 indicative of donor specific variability. A western blot 
was performed on 3 donors consisting of monocyte samples which were treated 
for 0, 3 and 6 days with M-CSF. We observed no legumain in the day 0 CD14
+ 
monocytes but pro- and active legumain were visible at day 3 and 6 of all three 
donors analysed. There appeared to be more active legumain in all of the day 3 
samples but it is difficult to remark on levels of the enzyme since the β-actin 
loading control was not consistent among all samples despite the same amount 
of protein (5 μg) being loaded onto the assay. Repetition of these experiments 
would be helpful to formally define this issue – time precluded this analysis. 
Once we had validated the western blot assay, we analysed CD14
+ cells from the 
blood and synovial fluid of RA and PsA patients. There has been no previous work 
illustrating  legumain‘s  presence  in  PB  monocytes,  however  it  has  been 
demonstrated  that  other  cysteine  proteases  are  upregulated  in  monocytes  in 
response to pro-inflammatory cytokines  [677, 678]. The serum of PsA and RA 
patients is known to contain pro-inflammatory cytokines, growth factors, MMPs 
and adhesion molecules [679-681] which could be inducing active legumain in 
diseased  blood  monocytes,  a  phenomenon  that  is  not  seen  in  healthy  donor 
blood  monocytes.  The  two  PsA  synovial  fluid  CD14
+  samples  tested  on  the 
western blot were positive for high levels of pro- and active legumain but the RA 
SF CD14
+ tested did not develop any protein bands. This result indicates that the 
legumain  positive  cells  detected  by  IHC  in  the  synovium  are  likely  to  be 
macrophages however the possibility that other cells express legumain cannot be 
discounted. The two RA PB and SF samples which did not develop a legumain 
band were also negative for a β-actin loading control band indicating either a 
problem with the samples or that perhaps not enough sample was loaded onto 
the  western  blot.  Further  analysis  of  the  presence  of  legumain  within  RA  SF 
CD14
+ samples would be useful to verify that these cells express legumain at the 
protein level but time restrictions meant this was not possible.  
An activity assay was set-up to determine if the legumain protein detected in 
the  samples  was  active.  Clerin  et  al  [665]  had  previously  demonstrated  that 
monocytes  treated  with  M-CSF  for  3  days  contained  physiologically  active 
legumain  however  a  timecourse  of  M-CSF  treated  monocytes  had  not  been 
examined. The results of the western blot were replicated in the activity assay 
as  day  0  monocytes  showed  no  activity  on  the  assay  and  no  protein  on  the 288 
western  blot.  Day  3  activated  monocytes  had  high  levels  of  active  legumain 
which  decreased  in  the  day  6  activated  macrophages.  These  observations 
demonstrate  that  legumain  may  undergo  a  cyclic  form  of  expression  with  no 
active  legumain  present  in  day  0  monocytes,  a  high  level  of  activity  and 
expression in 3 day differentiated macrophages which then decreases to a lower 
level  at  day  6.  At  present  there  have  been  no  other  reports  of  legumain 
undergoing cyclic expression dependent on macrophage maturation as all other 
studies  have  analysed  legumain  levels  at  one  timepoint.  Further  studies  are 
required to understand the significance of this observation. 
Patient  derived  CD14
+  cells  were  analysed  on  the  activity  assay  to  ascertain 
whether  these  cells  contained  physiologically  active  legumain.  We  examined 
matched RA PB and SF CD14
+ samples and a RA SF CD14
+ sample due to the 
variation  in  isolated  cell  numbers  in  patient  samples  the  number  of  cells 
analysed  in  each  sample  was  slightly  different.  Nevertheless,  the  SF  patient 
sample containing the least number of cells had the highest amount of active 
legumain illustrating that individual macrophage cells may contain varying levels 
of legumain. The matched PB sample from this patient showed a low level of 
active legumain as did the other RA SF sample analysed again indicating that the 
level of legumain varies between patients. It would be interesting to determine 
if treatment type or disease duration was a factor determining how much active 
legumain  was  present  within  the  synovial  macrophages  of  arthritic  patients. 
Unfortunately we did not receive any PsA patient samples to assay and time 
restrictions meant we could not continue collecting samples. 
The inflammatory synovium is known to be a hypoxic environment [409] and the 
synovial fluid of RA patients contains many cytokines, chemokines, antibodies 
and extracellular matrix proteins [410, 537, 682-685] which could interact with 
and  induce  differential  gene  expression  in  the  cells  entering  the  synovium. 
Establishing what factors could be causing the upregulation of active legumain in 
macrophages  once  they  have  transmigrated  from  the  blood  system  into  the 
diseased  joint  is  vital  in  understanding  legumain‘s  role  in  disease  pathology. 
Proinflammatory cytokines have been previously shown to induce expression of 
other cysteine proteases in monocytes [677, 678] therefore we hypothesised that 
the proinflammatory mediators and environmental stresses within the synovial 
environment  may  be  inducing  the  large  upregulation  of  legumain  once  the 289 
macrophages entered the synovial compartment.  To  address this question we 
differentiated healthy monocytes with M-CSF for 6 days and cultured them in the 
presence of three RA synovial fluids and three PsA synovial fluids for 24 hours in 
hypoxic  or  normoxic  conditions.  We  observed  that  under  normoxic  conditions 
macrophages had increased legumain mRNA expression when incubated with two 
of the three RA synovial fluids and one of the three PsA synovial fluids compared 
to macrophages incubated alone. However, under hypoxic conditions legumain 
mRNA  expression  increased  in  all  of  the  macrophages  incubated  with  the  six 
synovial fluids indicating that a combination of the hypoxic environment with 
the proinflammatory mediators contained within the synovial fluid is necessary 
to induce upregulation of legumain. 
In  summary,  legumain  is  an  enzyme  which  plays  a  physiological  role  in  the 
biosynthesis  of  lysosomal  enzymes  in  the proximal  tubule  cells  of  the  kidney 
[431] and is expressed in macrophages and DCs where it is thought to play a role 
in cleaving peptides for antigen presentation  [658, 659]. However it has now 
become apparent that legumain is involved in many inflammatory diseases and 
conditions  including  arthritis.  We  propose  that  legumain  is  a  marker  for  cell 
activation  demonstrated  by  its  upregulation  in  macrophages  but  it  is  also  an 
inflammatory  enzyme  induced  and  deregulated  during  inflammation.  The 
perpetual inflammation that occurs during arthritis causes the upregulation of 
this enzyme. Legumain is induced in the arthritic blood monocytes by the pro-
inflammatory mediators contained within the serum and is also induced within 
the synovial fluid macrophages by the hypoxic inflammatory milieu found within 
the  joint.  Once  upregulated  within  the  synovial  macrophages  legumain  is 
expressed  on  the  cell  surface  and  may  be  assisting  the  cells  to  invade  and 
degrade the surrounding joint cartilage and extracellular matrix. Pro- legumain 
has recently been found to be excreted from macrophages and has been shown 
to  induce  chemotaxis  of  primary  monocytes  [665],  therefore  if  the  legumain 
positive  macrophages  visualised  within  the  synovium  were  also  excreting 
legumain this could be playing a role in increasing the number of infiltrating 
monocytes into the arthritic joint.  
Legumain is also expressed within the lysosomal compartment of the cells where 
it may cleave and active glycoproteins such as fibronectin either being produced 
by the cell or which have been taken up by the cell. One of legumain‘s primary 290 
roles during homeostasis is to cleave microbial antigen for MHC II presentation 
and  to  activate  several  cathepsins  which  are  also  involved  in  antigen 
presentation [432, 686]. T cells specific to autoantigens such as collagen type II 
have  been  found  within  the  arthritic  joint  [687]  therefore  an  increase  of 
legumain within synovial macrophages may play a role in the presentation of 
autoantigens to these T cells thereby aiding the perpetuation inflammation and 
destruction seen in RA and PsA. Figure 5.10 summaries these findings. 
 
 
Figure 5.10 Overview of legumain's expression and proposed role in arthritis 
A summary of legumain’s expression in patient blood monocytes and synovial fluid macrophages, 
the factors that could be inducing its expression and its proposed role in the synovium. 
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Chapter 6 Microarray analysis of cell contact 
activated macrophages 292 
6.1  Introduction 
One  critical  mechanism  whereby  macrophages  are  thought  exert  their 
proinflammatory potential in the synovium is by direct cell-cell interaction with 
T cells. We and other groups have investigated this interaction in an  in vitro 
model system of inflammatory arthritis. In order to set up this model monocytes 
and  T  cells  are  isolated  from  normal  donors  before activating  T  cells  with  a 
cytokine  cocktail  (IL-2,  IL-6,  TNFα)  and  maturing  the  monocytes  into 
macrophages with M-CSF for 6 days each.  After this time the two cells types are 
put into direct contact for a period of 24 hours after which the supernatants are 
collected and analysed for cytokine release. Several groups have investigated 
this in vitro system and found it to be a robust model of inflammatory arthritis 
since both cytokine activated T cells (Tcks) and RA synovial T cells can induce 
production of TNFα and several CC and CXC chemokines in resting M-CSF treated 
macrophages in a cell contact dependent manner [269, 298, 308]. Also Brennan 
et al found that after 8 days of stimulation Tcks acquire an activated phenotype 
resembling RA synovial T cells, such as upregulation of adhesion molecules and 
activation markers. Neutralising these markers in both T cell types abolished the 
cell  contact  dependent  TNFα  production  from  resting  macrophages  [309]. 
However, apart from cytokine and chemokine production little is known about 
the effects of Tck direct cellular contact activation on the macrophages. 
Due  to  the  lack  of  transcriptomic  information  of  the  cell  contact  activated 
macrophages it was decided to collect normal donor samples, which were age 
and  sex  matched  to  the  RA  and  PsA  patient  samples  collected  for  the 
microarray,  and  activate  these  using  the  cell  contact  model  of  inflammatory 
arthritis.  These  macrophages  were  then  analysed  on  the  microarray  and  the 
results  were  compared  to  the  synovial  CD14
+  cell  samples  to  determine  how 
similar these Tck activated macrophages were to the synovial macrophages. The 
results  should  inform  us  how  comparable  the  macrophages  from  the  in  vitro 
model of inflammatory arthritis are to synovial macrophages from RA and PsA 
patients. 
6.2  Patients and normal donors 
As  described  previously,  inflammatory  arthritis  patients  attending  Gartnavel 
General Hospital (GGH) or Glasgow Royal Infirmary (GRI) fulfilled the American 293 
college of Rheumatology criteria for RA [6], or met diagnostic criteria for PsA 
[346].  
Age-matched  normal  donors  were  recruited  from  the  Glasgow  Biomedical 
Research  Centre  (GBRC)  building  and  all  blood  samples  were  taken  with 
informed consent. 
6.3  Separating macrophages from the cell contact 
In order to analyse the transcriptomic profile of the activated macrophages after 
they had been in contact with the Tcks we had to first gain a pure population of 
macrophages that did not have any contaminating Tcks which would affect the 
results of the microarray. 
6.3.1 Live cell contact 
The  in  vitro  cell  contact  model  of inflammatory arthritis  can be  set  up in  a 
number of ways including using T cell membranes [294], fixed Tcks or live Tcks 
to  activate  the  macrophages.  For  the  microarray  experiment  we  wanted  to 
compare cell contact activated macrophages with patient derived SF CD14
+ cells 
and therefore decided to set up the cell contact experiment with live Tcks. This 
would  allow  us  to  see  the  effects  of  direct  cellular  contact  along  with  the 
soluble mediators that the Tcks released upon the activation of macrophages. 
The cell contact was set up at a ratio of 4 Tcks to 1 macrophage for 24 hours, 
the cells were separated by washing off the non-adherent Tcks (Tck fraction) 
and scraping the adherent macrophages from the wells (macrophage fraction). 
However, when the two cell fractions were analysed on the FACS for cell purity 
(Figure 6.1) the macrophage fraction (A) was 91% positive for CD3 cells and had 
no CD14 positive cells but a very small percentage (3.7%) of CD3 negative cells. 
This  experiment  was  repeated  n=5  times  with  the  same  or  similar  results 
occurring each time. The same experiment was set up with fixed Tcks as it was 
thought that fixed cells may be less likely to stick to the macrophages, however 
we  obtained  similar  Tck  contamination  in  the  macrophage  fraction  in  these 
experiments (data not shown). 294 
 
 
Figure 6.1 Separation of cells from a live cell contact 
Cells were separated by washing the non-adherent Tcks from the wells designated Tck fraction (B) 
and scraping the adherent macrophages from the wells designated macrophage fraction (A). This 
is a representative FACS plot from n=5 experiments 
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6.3.2 FACS ARIA sorting of macrophages 
Due to the problem of being unable to fully separate the macrophages from the 
Tcks using the method of washing and scraping the wells, it was decided to try 
and separate the two cell fractions from the cell contact using the FACS ARIA.  
The  Tcks  were  stained  with  carboxyfluorescein  succinimidyl  ester  (CFSE)  and 
fixed before being put into cell contact with the macrophages. After incubating 
the  cell  contact  all  the  cells  were  collected  and  put  through  the  FACS  ARIA 
machine,  separating  the  cells  based  on  FITC-positive  cells  (Tcks)  and  FITC-
negative cells (presumably macrophages). Figure 6.2 shows the plots from one 
FACS ARIA experiment; figure A shows all the cells that were isolated from the 
cell contact experiment and the histogram shows the counts of cells that were 
FITC positive and FITC negative. On the histogram the gates p1 and p2 indicate 
the gates that were used to differentiate and collect FITC-negative (macrophage 
cells) and FITC-positive (Tck cells) respectively. The two gates did not overlap 
and a substantial gap was left between them, cells included in this area were 
not collected as it was important for the purpose of the microarray to be able to 
collect a pure population of macrophages with no contaminating Tcks. Figure B 
and C show the plots and histograms of the two separated cell fractions, Tcks 
and macrophages respectively. The cells collected in the Tck fraction (B) were 
all FITC-positive, as indicated by the histogram, and the forward and side scatter 
plot  indicates  the  cells  collected  in this  fraction are of  the  correct  size and 
granularity for activated T lymphocytes. As expected all cells collected in the 
macrophage fraction (C) were FITC-negative and on the forward and side scatter 
plots show the cellular size and granularity of macrophage like cells. However, it 
must  be  noted  from  panel  (C)  that  a  large  proportion  of  the  events  on  the 
forward side scatter graph are in the bottom left hand corner which is indicative 
of  cellular  debris.  This  debris  may  be  as  a  result  of  the  removal  of  the 
macrophages  from  the  culture  wells  after  cell  contact  activation  and  the 
presence of this debris may ultimately affect the purity of the macrophages used 
for the microarray.  
Subsequently an aliquot of the FACS ARIA separated cells was used for cytospins 
which  were  stained  with  RAPI-DIFF  reagents  to  check  for  cell  purity  and 
morphology.  As  can  been  seen  in  figure  (D)  the  cells  from  the  macrophage 
fraction  had  the  correct  shape  and  morphology  of  macrophage  cells  with  no 296 
visible contaminating Tck cells whereas the cells from the Tck fraction (E) were 
the morphology and size of T lymphocytes. 
It was decided therefore that using the FACS ARIA to gain a pure population of 
cell contact activated macrophages was the optimal method of separation for 
the normal donor samples that would be age and sex matched to the patient 
samples.  297 
 
Figure 6.2 Separating the macrophages and Tcks from cell contact using the FACS ARIA 
The FACS ARIA was used to separate fixed CFSE stained Tcks from the macrophages after cell 
contact. (A) All cells from the cell contact experiment showing the forward and side scatter plot of 
the cells and the histogram plot with the gates used to separate the cells, gate p1 (FITC negative 
cells) and gate p2 (FITC positive cells). (B) Tck cell fraction after separation and (C) macrophage 
cell fraction. An aliquot of the two cell fractions from the macrophage fraction (D) and the Tck 
fraction (E) was stained with RAPI-DIFF to check for cell morphology. 298 
6.4  Analysing cell contact RNA yield and quality 
Microarray  experiments  demand  a  high  quality  of  RNA  in  order  for  correct 
interpretation of results and the amount of RNA obtained from the cells should 
be  consistent  between  samples.  Therefore  before  the  cell  contact  activated 
cells  are  analysed  on  a  microarray  the  RNA  quality  and  yield  from  the 
macrophage cells must be examined (described in detail in chapter 3). 
 
6.4.1  Cell contact activated macrophages have variable RNA 
quality after 24 hours 
Fixing the Tcks before putting them into cell contact was found to help recover 
a more pure population of macrophages after FACS ARIA separation thus it was 
decided that fixed Tcks should be used in all cell contact experiments. Three 
independent macrophage – Tck cell contact experiments were set up at a 4:1 
ratio of fixed Tcks to macrophages, after 24 hours the Tcks and macrophages 
were separated and both cell types were put into Trizol reagent. The RNA was 
isolated  from  the  cells  and  the  quality  was  analysed  on  an  Agilent  2100 
Bioanalyser.  The  principles  of  the  agilent  2100  bioanalyser  are  described  in 
section 3.3.2 of chapter 3, but briefly this equipment is used to ascertain the 
quality  of  the  RNA  and  allows  the  user  to  obtain  a  plot  indicating  the  RNA 
integrity.  Figure  6.3  (A)  shows  an  example  of  good  quality  RNA.  It  is 
characterised by three clear peaks, a peak for the RNA marker (1) and a peak for 
the 18 S (2) and 28 S (3) ribosomal RNA subunits. There should be a relatively 
flat baseline between the two rRNA peaks and minimal low molecular weight 
noise adjacent to the RNA marker peak. 
Figure  6.3  (B)  shows  the  electropherogram  of  the  three  fixed  Tck  and 
macrophage  samples  after  24  hours  of  cell  contact.  The  Tcks  in  all  three 
experiments had degraded RNA indicated by the low molecular weight noise and 
the absence of 18 S and 28 S peaks. The degraded RNA for the Tcks was thought 
to be a consequence of fixing the Tcks with paraformaldehyde. However, the 
RNA from the macrophages was of poor quality in two of the three experiments. 
The macrophage RNA from experiment 2 shows good quality RNA with two sharp 
rRNA peaks and no low molecular weight noise but the RNA from experiment 1 
and 3 is of poor integrity with the complete absence of rRNA peaks. Due to the 299 
large  variability  in  quality  of  the  macrophages  RNA  it  was  decided  that  a 
timepoint cell contact should be set up to try and discover why the macrophage 
RNA is degraded after 24 hours of cell contact. 
 
Figure 6.3 RNA integrity of macrophages and Tcks after 24 hours of cell contact 
An Agilent 2100 Bioanalyser was used to analyse the quality of the RNA from 3 macrophage and 3 
Tck samples after 24 hours of cell contact. (A) an example of good quality RNA (B) the agilent 
profile electropherograms of the three cell contact experiments. 300 
6.4.2 Cell contact activated macrophage RNA quality over time  
A timecourse cell contact was set up three times and the macrophages were 
activated with Tcks for between 1 and 48 hours. Figure 6.4 shows the results of 
one timecourse experiment and consist of RNA electropherograms for the fixed 
Tcks,  unactivated  macrophages  (Mø)  and  macrophages  that  have  been  cell 
contact activated for varying amounts of time. The fixed Tck RNA is once again 
badly degraded due to the paraformaldehye fixation process. The RNA from the 
macrophages that had not been cell contact activated (Mø) was of good integrity 
as indicated by the two sharp rRNA peaks and the absence of low molecular 
weight noise. The RNA from the macrophages that had been in cell contact for 1 
hour up until 8 hours is also of good quality showing similar electropherogram 
plots to the one for the inactivated macrophages. With the exception of 28 hr 
cell contact activated macrophages (t=28hrs)  the plots for RNA isolated from 
macrophages after 8 hours of cell contact all showed blank electrophreogram 
plots,  apart  from  the  RNA  marker  peak,  indicating  that  the  RNA  was  either 
degraded or in such low concentration that the Agilent machine could not detect 
it. t=28 hrs RNA was the only exception to this observation as that sample was of 
high quality with no degradation. 301 
 
Figure 6.4 Macrophage RNA quality after different durations of cell contact 
Macrophages were exposed to direct cellular contact with fixed Tcks for between 1 and 48 hours. 
The Tcks were removed from the macrophages and the quality of the Tck and macrophage RNA 
were analysed on an Agilent 2100 Bioanalyser 
 
6.4.3 RNA yield decreases after prolonged cell contact activation 
The total amount of RNA that was being recovered from the macrophages during 
the timecourse cell contact experiments was also investigated and measured on 
a  nanodrop.  Figure  6.5  shows  a  representative  experiment  from  the  three 
experiments that were set up, for comparison the amount of RNA from the fixed 
Tcks  and  macrophages  alone  (t=0)  was  also  measured.  It  can  be  seen  that 
compared to the unstimulated macrophages, designated t=0, the total amount of 
RNA  decreases  with increasing duration of  cell  contact activation.  This  trend 
continues until 26 hours of cell contact where the total amount of RNA increases 
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from 202 ng at cell contact t=26 hrs to 608 ng at cell contact t=28 hrs, however 
after this one timepoint cell contact the amount of RNA recovered from the 
sample decreases to 252 ng at t=48hrs. This trend of decreasing total yield of 
RNA  from  cell  contact  activated  macrophages  compared  to  the  unstimulated 
macrophages was seen in the two other timecourse experiments set up (data not 
shown). Based upon the preceding results it was decided to analyse macrophages 
which had been cell contact activated for 2 hours on the microarray as well as 
unactivated macrophages from the same donor. The reasons for this were due to 
the large variability in the yield and quality of macrophage RNA after 8 hours 
and also because we were interesting in the early response genes that changed 
in a macrophage after Tck contact. 
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Figure 6.5 Total RNA yield from macrophages after increasing duration of cell contact 
activation by Tcks 
A fixed 4:1 cell contact between Tcks and macrophages was set up for varying amounts of time 
between 1 and 48 hours. Each cell contact was set up in an individual well of a culture plate. After 
the specified time the macrophages and Tcks were separated and the macrophages placed into 
Trizol reagent. RNA was extracted from all samples and the total yield measured. RNA was also 
extracted from Tcks (fixed Tcks) and macrophages alone (t=0). This graph is a representative of 
n=3 experiments. 303 
6.5  Collecting patient samples 
Normal  donors  who  were  age  and  sex  matched  to  patients  (Table  3.2)  were 
recruited and from these donors CD14
+ cells were positively selected from the 
blood. An aliquot of unactivated CD14
+ cells were put into trizol and the rest of 
the  cells  were  differentiated  with  M-CSF  for  6  days.  After  this  duration  the 
macrophages were cell contact activated for 2 hours with fixed Tcks that had 
been obtained from the same donor. The cell contact activated macrophages 
were isolated using the FACS ARIA and put into trizol as well as unactivated M-
CSF derived macrophages from the same donor. Once all the samples had been 
collected  the  RNA  was  extracted  from  all  samples  at  GSK  Stevenage  and 
analysed for quality. The samples which were analysed by the microarray are 
summarised in table 3.3 of chapter 3. Six age and sex matched healthy controls 
were recruited and macrophage cells before and after Tck cell contact activated 
were collected from all of these controls. 
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Patient  Gender  Age  Age and sex matched 
normal donor 
PsA 1 
PsA 2 
PsA 3 
PsA 4 
PsA 5 
PsA 6 
PsA 7 
PsA 8 
RA 1 
RA 2 
RA 3 
RA 4 
RA 5 
RA 6 
RA 7 
RA 8 
Female 
Female 
Male 
Male 
Male 
Female 
Male 
Female 
Female 
Male 
Female 
Male 
Female 
Male 
Female 
Female 
53 
40 
34 
34 
80 
58 
54 
58 
71 
56 
62 
69 
78 
69 
69 
77 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
No 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
Table 6.1 Patient and normal donor samples collected 
 
6.6  Microarray analysis 
6.6.1 Signal histogram of normalised data 
The signal histogram of all the samples which were analysed by the microarray is 
shown  in  figure  3.3  of  chapter  3.  Upon  inspection  of  the  histogram  it  was 
discovered that one of the cell contact activated samples was an outlier as it 
clearly had a distinct signal intensity compared to the other samples which were 
analysed. The reasons for this sample being an outlier are unknown but since the 
other  samples  have  similar  signal  intensities  it  is  most  likely  to  be  due  to  a 
problem with the individual sample or the labelling of that particular sample. 
Due  to  this  sample  being  an  outlier  it  may  potentially  skew  the  data 
interpretation and therefore was removed from further data analysis. 
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6.6.2 Principle component analysis 
The PCA plot shown in Figure 6.6 has previously been shown in chapter 3 but it is 
represented in this chapter to demonstrate the outlier cell contact activated 
macrophage sample indicated by the blue circle on the left hand side of the 
graph in (A). Once this sample had been removed the PCA analysis graph was 
analysed to look for trends in the data since samples represented in the same 
area of the graph are considered to be genetically similar. Each circle on the 
graph represents a sample and each colour represents a condition.  
Figure 6.6 (B) demonstrates the PCA plot of the samples once the cell contact 
outlier sample had been removed. This plot demonstrates that the cell contact 
activated  macrophages  (blue  circles)  are  genetically  distinct  from  the  M-CSF 
activated macrophages (red circles) indicating that transcriptional changes take 
place once the macrophages are put into cell contact with Tcks for 2 hours. 
However, it can also been seen that the cell contact activated samples (blue 
circles)  appear  to  be  genetically  distinct  from  the  synovial  fluid  activated 
macrophage samples (yellow circles) which could argue against the cell contact 
macrophages not having a similar genetic profile to the synovial fluid. This will 
be explored further in the following sections. 306 
 
 
Figure 6.6 Principle component analysis of all microarray samples 
PCA was performed on the microarray samples to try and identify trends in the data. Graph (A) 
indicates the normalised samples before the outlier was removed. The blue circle on the left hand 
side of the graph represents the outlying sample and it can been seen that it is distinct from all the 
other samples indicating that its genetic profile is dissimilar to that of the remaining microarray 
samples. Figure (B) shows PCA graph once the outlying cell contact sample had been removed. 
Each circle represents a sample and samples clustered in the same area of the graph are 
considered to be genetically similar. Each colour represents a sample condition; red is M-CSF 
treated macrophages, blue is cell contact activated macrophages, gold is synovial fluid derived 
CD14+ cells, green is patient blood CD14+ cells and purple is healthy blood CD14+ cells. This 
graph was previously shown in chapter 3. 307 
6.7   Cell contact activated macrophages compared to 
synovial fluid activated macrophages 
Cell  contact  dependent  activation  of  macrophages  by  synovial  T  cells  has 
previously been shown to play a role in arthritis and as a result an in vitro model 
of inflammatory arthritis has been developed by our group and others to mimic 
the cellular interactions taking place within the diseased joint. Investigations 
into  the  proinflammatory  cytokines  and  chemokines  released  by  the 
macrophages as a result of T cell interactions have taken place [269, 298, 308] 
as well as analysing the activated T cells [309]. One study by Gruaz et al [315] 
has also analysed the genetic profile of the macrophages after being stimulated 
by the isolated membranes of the human T cell line HUT-78. However there has 
been  no  comparative  analysis  of  the  in  vitro  cell  contact  stimulated 
macrophages and macrophages isolated from the arthritic joint.  
The  cell  contact  activated  macrophages  were  stimulated  with  fixed  cytokine 
activated T cells (Tcks) for 2 hours as we were interested in the early response 
genes that were differentially expressed in the macrophages. Previous analyses 
indicated that one of the cell contact activated macrophage samples was an 
outlier  due  to  its  abnormal  signal  intensity.  Therefore  this  sample  and  its 
matched unactivated macrophage sample was removed from further analysis.  
6.7.1.1   Statistical analysis of genes and elucidating similarly 
expressed genes between conditions using a Venn 
diagram 
All samples were pre-processed using the GC-RMA algorithm and quality control 
was performed on the three macrophage conditions i.e. cell contact, RA or PsA. 
In order to pass the quality control filter each gene had to have a signal value 
between 20 and 100% and be expressed in all of the samples of each condition. 
To  establish  the  presence  of  differentially  expressed  genes  in  the  three 
activated macrophage conditions paired T Tests were first performed with a p 
value cut off of 0.05 followed by the Benjamini and Hochberg multiple testing 
correction (MTC). However an MTC was unable to be used in the cell contact 
comparison  as  there  were  no  significantly  changed  genes  between  the 
unactivated  macrophages  and  cell  contact  activated  macrophages.  Since  a  p 
value cut off of 0.05 was used this means that 5% of the differentially expressed 308 
genes may be false positives and appearing by chance alone, a way to overcome 
this is to look at the p values of each gene as the higher the p value of the gene 
the less chance of it being a false positive.  This statistical analysis gave the 
following results:  
  Unactivated  M-CSF  macrophages  vs  cell  contact  activated  macrophages 
(n=5 matched samples) 3902 significantly expressed gene entities 
  RA PB vs RA SF (n=8 matched samples) 10879 significantly expressed gene 
entities 
  PsA PB vs PsA SF (n=8 matched samples) 7401 significantly expressed gene 
entities 
The up- and downregulated genes with a p value <0.05 from each of the three 
comparisons were then inputted into a Venn diagram to distinguish if there were 
similar genes being expressed by the activated macrophages conditions. 309 
 
Figure 6.7 Venn diagram of the significantly differentially expressed genes within the cell 
contact  activated  macrophages,  RA  synovial  fluid  macrophages  and  PsA  synovial  fluid 
macrophages 
Paired T Tests were performed between the unactivated and cell contact activated macrophages, 
RA blood and RA synovial fluid macrophages and between PsA blood and PsA synovial fluid 
macrophages. The up and downregulated genes in the activated macrophage samples were then 
put into a Venn diagram, blue represents the differentially expressed genes in the RA condition, 
green represents the PsA condition and red represents the cell contact activated macrophages. 
The genes that were expressed by cell contact macrophage samples and PsA or RA or by all three 
conditions were analysed further. 
Figure  6.7  shows  differentially  expressed  genes  in  all  three  conditions,  blue 
represents the significantly expressed genes between RA PB and RA SF CD14
+ 
samples, green represents the significantly changed genes between PsA PB and 
PsA  SF  while  red  represents  the  significantly  expressed  genes  between 
unactivated  M-CSF  macrophages  and  cell  contact  activated  macrophages. 
Analysing the Venn diagram it can be seen that there are three groups of genes 
being expressed in cell contact activated and synovial fluid macrophages: 
  Genes  expressed  in  all  conditions  (cell  contact,  RA  SF  and  PsA  SF 
macrophages). 590 genes 
  Genes expressed in cell contact macrophages and PsA SF macrophages. 
221 genes 
  Genes expressed in cell contact macrophages and RA SF macrophages. 664 
genes 310 
The  Venn  diagram  also  indicates  that  only  a  small  proportion  of  the  genes 
expressed  by  the  RA  or  the  PsA  synovial  fluid  are  expressed  within  the  cell 
contact activated macrophages. 10% (811 of 7401 genes) of PsA genes and 11% 
(1254  of  10879)  of  RA  genes  are  expressed  in  the  cell  contact  activated 
macrophages. 
The three gene groups listed above were then subjected to fold change analysis 
where the cut off threshold was set at a fold change ≥ 2. This analysis gave the 
following results: 
  149 genes expressed in all three conditions (c.c, RA SF, PsA SF) 
  40 genes expressed in both cell contact macrophages and PsA SF 
  146 genes expressed in both cell contact macrophages and RA SF  
Since  the  basis  of  this  investigation  was  to  determine  how  similar  the  cell 
contact activated macrophages were to the synovial fluid macrophages, the gene 
lists generated from the fold change analysis were scrutinised further to only 
include genes that were up or downregulated in both the cell contact samples 
and the synovial fluid samples. This is due to the discovery that many genes 
were  being  expressed  in  different  directions,  for  example  a  gene  that  was 
upregulated  in  the  cell  contact  activated  samples  was  downregulated  in  the 
synovial fluid samples. As a result the number of similar genes from cell contact 
and synovial fluid macrophages decreased further: 
  110 genes expressed in all three conditions (72 downregulated genes and 
38 upregulated genes) 
  18  genes  expressed  in  cell  contact  macrophages  and  PsA  SF  (6 
downregulated genes and 12 upregulated genes) 
  128  genes  expressed  in  cell  contact  macrophages  and  RA  SF  (88 
downregulated genes and 40 upregulated genes) 311 
6.7.1.2   DAVID analysis of the differentially expressed genes in 
cell contact activated macrophages and synovial fluid 
macrophages 
DAVID software was used to analyse the up- and downregulated genes that were 
changed in the cell contact macrophages and the synovial fluid macrophages to 
determine the overall biological functions of these genes. DAVID analysis did not 
find any significantly overrepresented processes within the gene list expressed in 
both the cell contact and PsA SF macrophage samples, which was likely to be 
due to the small number of genes within the list. Figure 6.8 demonstrates the 
top  ten  overrepresented  biological  processes  associated  with  the  upregulated 
genes found in all 3 macrophage conditions (A) and the downregulated genes 
found in all 3 macrophage conditions (B). The results of this analysis indicate 
that the macrophage samples are upregulating genes associated with immune 
response and response to stimulus and stress. The same macrophage samples are 
also downregulating genes associated with intracellular signalling cascade and 
regulation  of  myeloid  cell  differentiation.  Figure  6.9  shows  the  biological 
processes associated with the upregulated genes found in both the cell contact 
and RA SF macrophages conditions (A) and the biological processes associated 
with the downregulated genes in both the cell contact and RA SF macrophage 
conditions  (B).  The  upregulated  genes  are  involved  in  processes  such  as 
intracellular signal transduction and phosphorylation. The downregulated genes 
are involved in processes such as cellular metabolism and T cell differentiation. 312 
 
Figure 6.8 Up- and downregulated biological processes in cell contact, RA SF and PsA SF 
macrophages 
DAVID software was used to analyse the genes which were differentially expressed in all three 
macrophage conditions to determine overrepresented biological processes associated with the 
genes. The top ten significantly overrepresented processes are shown here with a p value <0.05 
which is equivalent to a –log p value > 1.30 313 
 
Figure  6.9  Up-  and  downregulated  biological  processes  in  cell  contact  and  RA  SF 
macrophages 
DAVID software was used to analyse the genes which were differentially expressed in cell contact 
and RA SF macrophage conditions to determine overrepresented biological processes associated 
with the genes. The top significantly overrepresented processes are shown here with a p value 
<0.05 which is equivalent to a –log p value > 1.30 314 
6.8  Discussion 
The  in  vitro  model  of  inflammatory  arthritis  consists  of  direct  cell  contact 
activating  M-CSF  differentiated  macrophages  with  cytokine  activated  T  cells. 
Microarray  analysis  of  one  cell  type  requires  a  pure  cell  population  as 
contaminating  cells  would  have  an  effect  on  the  genetic  profiles  obtained. 
Therefore we devised a method of isolating the activated macrophages from the 
T cells by CFSE staining the T cells and using the FACS ARIA to separate the cells 
based  on  their  fluorescence.  This  method  ensured  that  no  antibody  or  CFSE 
staining of the macrophages took place as any manipulation of these cells may 
have altered their genetic profile. However, the FACS ARIA plots indicated that a 
large  amount  of  cellular  debris  had  been  collected  in  the  macrophage  cell 
fraction  which  may  have  ultimately  affected  the  macrophage  purity  and 
subsequently  the  transcriptomic  profile  of  the  cell  contact  activated 
macrophages. 
A  2  hour  timepoint was  demonstrated  to  be the  appropriate duration  of  cell 
contact activation for the macrophages due to variability in the quality and yield 
of RNA after this time.  It is difficult to fully explain these variable findings. 
However,  the  low  quality  RNA  in  the  cell  contact activated  macrophages,  as 
visualised by the empty electropherogram plots seen after t = 8hours in Figure 
6.4,  may  be  due  to  very  low  amounts  of  RNA  being  run  through  the  Agilent 
Bioanalyser The sequential decrease in the yield of macrophage RNA over the 
duration of the cell contact activation was also an unusual finding but may be 
due to increased apoptosis  and cell  loss  which  would  therefore  decrease the 
yield of RNA from the cells. As a result of these findings, we decided to analyse 
the macrophages after they had been cell contact activated for 2 hours, it was 
also decided that this timepoint was more appropriate for analysing the early 
response genes that would be differentially expressed within the macrophages. 
Crucially  however  this  may  not  represent  the  gene  profile  present  in  a 
chronically activated macrophage derived from within the synovial compartment 
and in this sense the outcome was perhaps predictable. 
After completion of the microarray experiment and removal of the outlier cell 
contact macrophage sample from further analysis a PCA plot of the samples was 
setup to identify trends in the data since samples clustered within the same area 315 
of the PCA graph are considered to be genetically similar  [354]. This analysis 
identified that the M-CSF differentiated macrophages were genetically distinct 
from the Tck activated macrophages which suggests that being in cell contact 
with the Tcks for 2 hours induced a transcriptional change in the macrophages. 
However, the PCA analysis also demonstrated that the cell contact macrophages 
were genetically distinct from the synovial fluid macrophages. 
Previous work has demonstrated that the cytokine activated T cells (Tcks) used 
in this in vitro system are similar to RA synovial T cells, as they up-regulate the 
same cell surface activation markers and adhesion molecules and also induce the 
production  of  various  cytokines  and  chemokines  from  macrophages  in  a  cell 
contact dependent manner [298, 308, 309]. Recently, a microarray analysis of 
monocytes activated for 24 hours by PMA and PHA stimulated T cell membrane 
fragments was performed by Gruaz et al who analysed the anti-inflammatory 
effects of high-density lipoproteins (HDL) on the transcriptome of the activated 
monocytes. They discovered that 666 probe sets were altered in the activated 
monocytes compared to unactivated monocytes indicating that T cell contact 
activation of monocytes does have an effect on the transcriptome of the cells 
[315]. Hence, for our study it was hypothesised that cell contact activation of 
macrophages by fixed Tcks for 2 hours should indicate the early response genes 
upregulated by the macrophages. Given that the Tcks have been demonstrated 
to be similar to synovial T cells, the genes upregulated in these macrophages 
should be similar to those expressed in the synovial fluid CD14
+ cells. 
The  three  macrophage  conditions  of  cell  contact,  PsA  synovial  fluid  and  RA 
synovial fluid were compared to their matched unactivated or baseline samples, 
which in  this  comparison  were unactivated  M-CSF  macrophages,  RA  PB  CD14
+ 
cells and PsA CD14
+ cells. After determining the differentially up- and down-
regulated  genes  in  these  activated  conditions  a  Venn  diagram  was  used  to 
discover if any genes overlapped with those of the other conditions. The initial 
results of the Venn diagram were disappointing as it demonstrated that only 10% 
of the total significantly expressed genes in the PsA SF condition and 11% of the 
total expressed genes in the RA SF condition were expressed in the cell contact 
macrophages indicating that these conditions were not significantly similar. A 2-
fold change analysis was subsequently performed on the gene lists which were 
then examined further to ensure that they were all differentially expressed in 316 
the same direction. For example, if a gene was differentially expressed in both 
the cell contact activated and PsA synovial fluid conditions it had to be either 
up-regulated or down-regulated in both conditions but could not be up-regulated 
in one condition and down-regulated in the other since we were investigating 
the similarities between the conditions. This resulted in further decreasing the 
size of the gene lists and of the 54,675 probe sets on the Affymetrix GeneChips 
less than 130 were expressed in each of the three gene lists of i) expressed in 
cell contact, RA SF and PsA SF conditions, ii) expressed in cell contact and RA 
SF, iii) expressed in cell contact and PsA SF. 
DAVID analysis was performed on the up- and down-regulated genes in each of 
the  three  comparisons  to  determine  the  biological  function  of  the  similarly 
expressed genes. DAVID analysis of the genes present in all conditions indicated 
that all three macrophage types were up-regulating genes involved in response 
to  stimuli.  In  the cell  contact  macrophages  this  would  be  as  a  result  of  Tck 
contact and in the synovial fluid macrophages this would be as a result of direct 
cell  contact  as  well  as  the  pro-inflammatory  environment.  All  three  cell 
conditions  are  also  up-regulating  genes  associated  with  the  immune  response 
and its  regulation,  this  would  be expected  in  the  synovial  fluid  macrophages 
since  it  has  been  well  documented  that  the  cellular  influx  into  the  joint  is 
exposed to many pro-inflammatory mediators [537, 682-685] which would result 
in the up-regulation of these genes. However, it is reassuring to observe that the 
cell contact activated macrophages also up-regulate genes involved in immune 
system regulation since these cells are used as an in vitro model of arthritis. 
This also reflects the observations seen in the Gruaz et al microarray analysis of 
monocytes activated with PMA and PHA stimulated T cells which demonstrated 
an  up-regulation  of  cytokines  and  mediators  involved  in  the  immune  system 
[315].  The  biological  processes  of  the  down-regulated  genes  in  all  three 
conditions  include  intracellular  signalling  cascade,  RNA  polymerase  II 
transcription, and regulation of myeloid cell differentiation suggesting that the 
macrophages  could  be  trying  to  regulate  the  increased  transcription  and 
signalling  observed  in  cell  contact activated  and  synovial  cells  as  a  result  of 
extracellular stimuli. 
DAVID  analysis  of  the  genes  up-  and  down-regulated  in  the  cell  contact 
macrophages and the RA synovial fluid macrophages demonstrated that the up-317 
regulated  genes  were  involved  in  processes  such  as  signal  transduction  and 
intracellular  signalling  cascade.  Signal  transduction  pathways  provide  an 
intracellular  mechanism  by  which  cells  can  respond  and  adapt  to  their 
environment.  Proinflammatory  stimuli  found  within  the  synovial  environment 
can  activate  signalling  cascades  within  a  cell  to  alter  gene  transcription  and 
protein expression. Several signal transduction pathways have been implicated in 
RA such as mitogen-activated protein kinase (MAPK) and NF-κB as well as the 
transcription factors janus kinase (JAK) and signal transducer and activator of 
transcription (STAT) [688, 689]. Signal transduction pathways, specifically NF-κB 
but  not  PI-3  kinase,  have  also  previously  been  shown  to  play  a  role  in  the 
production and secretion of pro-inflammatory cytokines within the cell contact 
activated macrophages [298]. The results from this DAVID analysis highlight the 
importance  of  signal  transduction  and  intracellular  signalling  in  allowing  the 
synovial macrophage to contribute to the pro-inflammatory milieu found in the 
synovium and also emphasises the ability of the cell contact model of arthritis to 
replicate this biological process found in the synovial macrophage.  
The biological processes of the down-regulated genes in RA synovial fluid and 
cell  contact  activated  macrophages  were  metabolic  process,  T  cell 
differentiation and regulation of IFN-α production. IFN-α is a proinflammatory 
cytokine  that  is  present  within  the  synovial  fluid  of  RA  patients  and  the 
macrophage cells may be down-regulating genes associated with its production 
as an anti-inflammatory regulatory mechanism [690]. The T cell differentiation 
process  is  a  misleading  title  as  two  of  the  three  genes  associated  with  this 
function (the transcription factor Ikaros and the phosphatase PTPN22/Lyp) have 
been demonstrated to be expressed in macrophages as well as T cells [691, 692] 
and the third gene, ZNF278, a zinc finger repressor of gene expression has not 
been previously demonstrated to be present in T cells. This result highlights the 
point that the genes associated with each biological process may need to be 
analysed further to understand why the process is associated with the gene list 
since genes can appear in several biological process pathways and each gene can 
be expressed by more than one cell type.  
DAVID analysis could not be performed on the shared PsA synovial fluid and cell 
contact activated macrophages due to the small number of genes within this 
gene  list.  However,  analysis  of  the  gene  list  demonstrates  that  both  PsA 318 
macrophages  and  cell  contact  activated  macrophages  are  upregulating 
inflammatory genes such as the cytokine TNFα which has a pronounced role in 
the pathogenesis of arthritis. These two macrophage types are also upregulating 
genes  such  as  NRP2  (neuropilin  2)  which  is  a  surface  receptor  originally 
identified as a factor involved in nerve fibre repulsion during neuronal growth 
[693]. Neuropilin 2 positive nerve fibres have been detected in the synovium of 
rheumatoid arthritis patients and soluble neuropilin 2 has also been detected in 
the synovial fluid of these patients where it was hypothesised to aggrevate the 
loss of sympathetic nerve fibres which is observed in RA  [694]. Consequently 
despite the low numbers of genes that are the same in the PsA and cell contact 
macrophages,  the  genes  that  are  shared  between  the  subgroups  are  of  an 
inflammatory  phenotype  and  have  been  demonstrated  to  be  involved  in  the 
destructive phenotype of arthritis. 
The  common  genes  between  all  three  conditions  and  between  cell  contact 
activated  macrophages  and  RA  synovial  fluid  macrophages  were  revealed  to 
share  biological  processes  such  as  immune  system  regulation,  which 
demonstrates that after just 2 hours the Tck contact activation is eliciting an 
immune response in the M-CSF macrophages similar to that seen in synovial fluid 
derived macrophages. Nevertheless, this study has also demonstrated that of all 
the genes differentially expressed between RA PB and RA SF CD14
+ and between 
PsA PB and PsA SF CD14
+ only 11% and 10%, respectively, of those genes are also 
differentially  expressed  between  the  M-CSF  and  cell  contact  activated 
macrophages.  This  result  would  indicate  that  the  cell  contact  model  of 
inflammatory arthritis may not be a suitable in vitro model for arthritis since the 
cell contact activation does not appear to effectively replicate the same level of 
transcriptional expression within the M-CSF macrophage compared to a synovial 
fluid macrophage isolated from a patient. 
Nonetheless, there are several possible reasons for this discrepancy. Firstly, the 
FACS ARIA separation suggested that a large proportion of collected events for 
the macrophage cell fraction was celluar debris which may have been created 
during the removal of the macrophages from the culture wells after cell contact 
activation. The presence of this debris would affect the overall purity of the 
macrophage  cells  and  may  have  contained  cellular  components  and  nuclear 
material  which  could  have  affected  the  transcriptomic  measurement  and 319 
analysis. In addition,  due to time restrictions only 6 normal donors were able to 
be  recruited  for  the  cell  contact  activation  samples  and  since  one  of  these 
samples  was  the  outlier  identified  at  the start  of  the  microarray  analysis  its 
removal meant that only 5 matched cell contact samples were compared to 8 
matched RA and 8 matched PsA samples. Therefore the full spectrum of the cell 
contact  transcriptome  may  not  have  been  analysed.  The  cell  contact  donors 
were also only age and sex matched to the PsA patients who had a smaller mean 
age  compared  to  the  RA  patients.  Many  papers  have  described  the  effect  of 
aging on epigenetics such as altered DNA methylation and histone modification 
which  in  turn  impact  on  chromatin  folding  [695],  women  are  also  more 
predisposed  to  rheumatic  diseases  due  to  hormonal  as  well  as  genetic 
differences between males and females [696]. Hence not including age and sex 
matched  donors  to  the  RA  patients  may  have  automatically  discarded  genes 
associated with these two factors.  
As noted at the outset of my discussion, the final and most important variable 
which  may  have  affected  the  gene  expression  of  the  cell  contact  activated 
macrophages was the duration of activation. During the cell contact model the 
macrophages are usually stimulated for 24 hours with the Tcks before analysis, 
however  due  to  our  interest  in  the  early  response  genes  expressed  in  the 
macrophages  and  the  variability  in  the  macrophage  quality  and  yield  it  was 
decided  to analyse  the  cells  after  a  shorter  duration.  Consequently  trying  to 
compare macrophages which have been activated for 2 hours to macrophages 
from  the  synovial  fluid  which  have  been  activated  for  an  unknown  duration 
presents problems. A recent paper which analysed the stability and temporal 
changes in inflammatory gene expression in TNFα stimulated murine fibroblasts 
found  three  groups  of  mRNA  expression:  group  1  genes  had  a  peak  mRNA 
expression at 0.5 hours after stimulation but their expression was unstable and it 
fell to baseline after 1 hour; group 2 genes had a peak expression at 2 hours 
however upon the removal of the TNFα stimulus their expression fell to baseline; 
group 3 genes had peak expression 12 hours after the stimulus, these genes were 
transcribed  at  a  slow  rate  but  the  resulting  mRNA  was  very  stable  [697].  
Subsequently if the same pattern of mRNA expression was occurring within the 
cell  contact  activated  macrophages  then  analysing  these  cells  after  2  hours 
would only detect the group 2 genes as mRNA from the group 1 genes would 320 
probably already be in the process of degradation and the group 3 genes would 
not be expressed at a detectable level. 
In summary, despite the cell contact activated macrophages only sharing 10-11% 
of  the  genes  expressed  in  RA  or  PsA  synovial  fluid  macrophages  those  genes 
involve a high proportion of immune system regulation genes indicating that this 
system is upregulating the types of genes thought to be involved in the perpetual 
immune activation seen in macrophages of the arthritic joint. However, to fully 
elucidate  the  appropriateness  of  this  cell  contact  system  as  a  model  of 
inflammatory arthritis an extended microarray experiment would have to be set 
up in which each RA and PsA patient had an age- and sex-matched donor for the 
cell  contact  activation  and  particular  care  was  taken  when  isolating  the 
macrophage cells from the cell contact to ensure a high cell purity. The cell 
contact  activated  cells  would  ideally  be  activated  over  a  timecourse  of  1-24 
hours to determine the different groups of genes being expressed within these 
cells over time.  
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Chapter 7 Validation of an in vitro live cell imaging 
system 322 
7.1  Introduction 
The macrophage  – T cell co-culture experiment is a well established  in vitro 
model of inflammatory arthritis. The method of cytokine activation of the T cells 
for this in vitro model confers a pro-inflammatory synovial phenotype which can 
induce the release of several cytokines and chemokine from the macrophages via 
direct cellular contact as has previously demonstrated by the vast amount of 
research performed by our group and several others [298, 308, 309, 408]. Whilst 
we have obtained a wealth of information regarding several aspects of the in 
vitro  model  such  as  the  signalling  pathways  involved  in  the  cytokine  and 
chemokine  release  from  the  macrophages  as  well  as  the  adhesion  molecules 
upregulated by the cytokine activation of the T cells, there are still important 
facets  of  this  model  which  have  not  been  explored.  One  important  question 
which we addressed in the previous chapter is how similar is the transcriptome 
of  the  Tck  cell  contact  activated  macrophage  compared  to  the  synovial 
macrophage. However, another important aspect of the cell contact model is 
determining how the macrophages and Tcks in this model interact and how long 
these interactions last for; this information can be determined using in vitro live 
cell imaging.  
Live cell imaging is a widely used technique which has become more sensitive 
and efficient in recent years with the introduction of new imaging techniques 
and machines such as two-photon laser scanning microscopy. A large amount of 
the current work using live cell imaging has focused on the in vivo interactions 
between DCs and T cells within the lymph node [698]. These studies have been 
very informative in determining the behaviour of the T cell  – DC interactions 
during antigen presentation. Such studies have revealed that when T cells are 
moving around the lymph node they follow a chaotic trajectory with random 
movements and are not directed by chemotatic gradients over large distances as 
was previously thought [699]. Live cell imaging has also demonstrated that T cell 
may make several contacts of a short duration with antigen loaded DCs before 
forming a stable cell-cell immunological synapse contact with one DC. The use of 
live cell imaging has made it possible to visualise the movement of the T cells 
towards the DCs during antigen presentation and several papers have proposed 
models for the type of movements and behaviours observed by the T cells before 
they form stable, long-lived interactions such as ―drive by‖ which is a situation 323 
where the T cell will have a short interaction with the DC but will then move 
away from the DC and carry on migrating [700]. 
Despite  the  wealth  of  knowledge  about  the  interactions  of  T  cells  and  DCs 
gained from live cell imaging there has been far fewer  investigation into the 
interactions between T cells and macrophages either  in vivo or in vitro. One 
study performed by Underhill et al imaged such interactions using OVA specific 
murine T cells containing a reporter construct which caused the cell to express 
green  fluorescent  protein  (GFP)  upon  productive  engagement  with  OVA 
presenting macrophages. Using in vitro live cell imaging this group demonstrated 
that  90%  of  the  T  cells  appeared  to  move  around  the  surface  of  individual 
macrophages  and  50%  of  T  cells  migrated  from  one  macrophage  to  another 
during 3 hours of time lapse imaging. Underhill et al also determined that the T 
cell — macrophage interactions had to be sustained for 2 hours for the T cell to 
become fully activated and express GFP however due to the behaviour of the T 
cells this activation may be the summing up of multiple activatory signals during 
the numerous interactions with the macrophages [701]. This study was analysing 
the T cell — macrophage interactions in the presence of antigen and at present 
there  are  no  studies  analysing  such  in  vitro  interactions  in  an  antigen 
independent environment. 
Histological analysis of the inflamed synovium has shown that macrophages are 
found in close contact with T cells [286] indicating that direct cell contact may 
be  a  mechanism  causing  the  production  of  pro-inflammatory  cytokines. 
Subsequent studies using the in vitro cell contact model have demonstrated this 
observation  to  be  correct  since  the  incubation  of  synovial-like  Tcks  with 
macrophages  induces  the  production  of  pro-inflammatory  cytokines  and 
chemokines  as  well  as  anti-inflammatory  cytokines  such  as  IL-10  [269,  308]. 
Despite the large amount of experimental work on the cell contact model of 
arthritis there are still gaps in our knowledge regarding the mechanisms of the 
cell—cell  interactions  and  the  behaviour  of  the  cells  during  the  co-culture. 
Therefore  we  set  out  to  use  an  inverted  microscope  to  image  these  antigen 
independent interactions in real time. We aimed to determine the number and 
duration  of  Tck—macrophage  interactions  and  the  overall  area  of  these 
interactions. Different variables such as using inactivated T cells or fixed Tcks 
were analysed to visualise their effects on the interaction measurements. Once 324 
the behaviour and movement of the cells during the cell contact model have 
been fully understood, the live cell in vitro imaging system could then be used 
to analyse the impact that blocking molecules or proteins may have on the Tck—
macrophage  interaction.  It  was  our  intention  to  bring  this  imaging  system 
together with the preceding microarray data to visualise the effect of altering 
key genes, which had identified as being differentially expressed in the synovial 
macrophages,  on  the  cellular  interactions  taking  place  and  also  whether  this 
may be affecting the cytokine/chemokine profile of the cell contact. 325 
7.2  Real-time imaging 
Figure 7.1 demonstrates the experimental set up to allow real time imaging of 
the cell contact events. The conditions being compared may differ from those in 
the figure however the general experimental set up was the same. Macrophages 
were isolated from a healthy donor and stimulated for 5 days with M-CSF before 
being  stained  with  the  red  fluorescent  dye  CMTPX  and  plated  out  onto  a 
specialised imaging culture chamber for 24 hours to allow the cells to adhere. T 
cells isolated from the same donor which were treated under differing conditions 
were  stained  with  the  green  fluorescent  dye  CFSE  and  cultured  with  the 
macrophages. The cultures were incubated for 2 or 24 hours (as indicated in the 
text) and then imaged on an inverted microscope. Each condition was imaged for 
varying lengths of time therefore each co-culture set up was often staggered for 
each condition to maintain a constant incubation time before being imaged.  326 
 
Figure 7.1 Outline of in vitro real time imaging experimental setup 
An example of the experimental set up for real time imaging demonstrating how a comparative 
analysis between a macrophage (Mø) and Tck culture compared to a macrophage and 
unstimulated T cell culture would be set up. For this experiment macrophages and T cells are 
isolated from the donor, T cells are stimulated for 6 day with cytokines to generate cytokine 
activated T cells (Tcks) and the monocytes are stimulated for 5 days with M-CSF before being 
stained red with a CMTPX dye and plated out onto two imaging chamber for 24 hours to allow them 
to adhere to the chamber. On day 6 T cells are isolated from the same donor and stained green 
with CFSE and the Tcks are also stained green. Each of the two T cell conditions are then 
incubated with macrophages and the two cell contacts are incubated for a specified duration before 
being imaged on the microscope. 327 
7.2.1 Imaging on the microscope 
Once the cell contact experiments had been cultured for the specified duration 
the  co-cultures  were  imaged  on  an  inverted  microscope  which  had  a  heated 
stage to maintain the cultures at 37ºC. For each imaging condition three movies 
were taken of three separate areas of the co-culture chamber. Once the area to 
be visualised had been chosen the microscope was set up to take three images 
every 12 seconds. The three images consisted of a green fluorescent image, a 
brightfield  image  and  a  red  fluorescent  image  as  shown  in  Figure  7.2.  The 
brightfield image was taken to ensure that the camera remained aligned while 
the green and red fluorescent images were merged to obtain a single timepoint 
image. When all of the merged imaged were played in sequence they produced a 
real time movie of the in vitro cell contact model of inflammatory arthritis. 
  
Figure 7.2 Example of the images taken by the inverted microscope for the real time imaging 
During the real time imaging the inverted microscope takes three consecutive images. An image of 
the green fluorescence, a brightfield image and an image in red fluorescence (top three images of 
panel). The red and the green fluorescent images are then merged to make the single timepoint 
image (bottom image of panel). The brightfield image is not used in the final timepoint image but is 
taken to ensure that the microscope remains aligned.  328 
7.2.2  Quantitative measurements of imaging 
Once generated, the real-time images and movies were analysed to determine if 
there  is  a  difference  in  the  interactions  between  experimental  conditions. 
Volocity is specific imaging software which allows factors such as the number 
and duration of T cell-macrophage interactions to be examined as well as the 
colocalization coefficient between the two cell types.  
7.2.2.1   Number and duration of interactions 
The  number  and  duration  of  each  macrophage-T  cell  interaction  during  the 
course of the real time movies were calculated using the Volocity software. This 
software has specific functions that can detect red fluorescence (representing 
the  macrophage  cells)  and  green  fluorescence  (representing  the  T  cells)  and 
then determine where these two fluorescence signals intersect i.e. where the 
two cell types are interacting. The software measures the interactions taking 
place  in  the  field  of  view  for  the  first  time  frame  of  the  movie  and  then 
calculates how long these interactions last for the duration of the imaging. It 
also measures any new interactions and their duration taking place during the 
co-culture  therefore  enabling  the  user  to  determine  exactly  how  many 
interactions  took  place  between  the  two  cell  types  and  how  long  these 
interactions last for. The basis for how the software identifies these cell-cell 
interactions is shown in Figure 7.3. 
7.2.2.2   Colocalization coefficient 
The Volocity software can also be used to measure the colocalization coefficient 
of  the  macrophage-T  cell  interactions.  In  the  context  of  digital  fluorescence 
imaging, colocalization can be described as the detection of signal at the same 
pixel localisation in each of two channels. The two channels are made up of 
images of two different fluorochromes taken from the same sample area. The 
Volocity software therefore detects how many yellow pixels are in each time 
frame image as the yellow pixels are representing the position where the two 
fluorescent colours (green and red) are overlapping and hence where the two 
different  cell  types  are  interacting.  The  colocalization  coefficient  therefore 
analyses the area of interaction between the two cell types, it has an advantage 
over the number and duration analysis as statistical analyses can be made on the 329 
colocalization coefficient values between two different experimental conditions 
to  determine  if  there  is  a  significant  difference  between  the  areas  of 
colocalization. In summary there are two different methods of analysis for the 
real time movies generated of the in vitro model of inflammatory arthritis. They 
are both constructive methods of analysis and enable the amount and duration 
of interactions as well as the overall areas of interactions to be measured. 330 
 
Figure 7.3  Volocity software method for determining the macrophage-T cell interactions 
Each macrophage-T cell culture movie is made up of individual frames taken by the microscope 
which, when played in sequence, produces the real time movie. To determine the number and 
duration of interactions taking place during each movie Volocity begins by analyses the first time 
frame of the movie. In this image Volocity identifies objects which are fluorescing green (T cells) 
and identifies objects which are fluorescing red (macrophages). It highlights each new object it 
identifies in a different colour. The software then identifies the areas of intersection between the red 
and green objects and each area is classed as an interaction between the two cell types. The 
software will then track these interactions and any new interactions which form during the movie 
and determine how long each interaction lasted for. The cartoons on the right hand side of the 
figure depict how the software views the cells and locates the areas of interaction. 331 
7.3  Comparison of cytokine activated T cells to 
unstimulated T cells 
In the cell contact model of inflammatory arthritis the T cells are stimulated 
with a specific cytokine cocktail for 6 days, this stimulation induces an activated 
T  cell  (Tck)  phenotype  which  resembles  T  cells  isolated  from an  RA  synovial 
joint. Not only do these Tcks express a similar cell surface ligand and activatory 
marker  phenotype  as  the  synovial  T  cells  they  also  induce  a  similar  pro-
inflammatory  cytokine  and  chemokine  profile  in  macrophages  by  direct  cell 
contact [269, 298, 308, 309]. To establish whether the cytokine activation of the 
T  cells  induced  more  interactions  with  the  macrophages  or  a  larger  area  of 
interactions a comparative analysis of Tcks and inactivated T cells took place.  
Figure  7.4  is  a  representative  of  three  independent  experiments  performed. 
Since each co-culture condition was imaged three times in separate areas of the 
culture  chamber  panel,  Figure  7.4  (A)  shows  individual  time  frames  of  a 
representative movie for each culture condition taken at t=0, t=60 seconds and 
t=120  seconds  for  the  macrophage—T  cell  co-culture  (top  panel)  and  the 
macrophage—Tck  co-culture  (bottom  panel).  The  white  arrows  on  the 
macrophage—Tck  co-culture  images  indicate  Tck  cell  movement  during  the 
course of the movie. Upon comparison of the two sets of images it can be seen 
that many Tcks are clustered around the macrophages which is not visualised in 
the non activated T cells images. Consequently, the cytokine stimulation of the 
T cells would appear to induce a higher rate of clustering and interaction with 
the macrophages compared to T cells from the same donor which have not been 
stimulated.  
This  pattern  of  interaction  can  also  been  seen  in  the  two  real  time  movies 
represented by the panel of images in part (A) of Figure 7.4. The supplementary 
file  designated  movie  1  demonstrates  the  inactive  T  cell  —  macrophage 
interactions. It can be seen that there is little T cell movement within the field 
of view. There are also only a small number of interactions taking place between 
the T cells and the macrophages which appear to be stable. The movie for the 
Tck—macrophage co-culture is supplementary file movie 2 and from this short 
movie  it  can  be  seen  that  the  majority  of  interactions  are  stable  long-lived 
interactions where many Tcks have clustered around one macrophage indicating 332 
their increased activation status compared to the inactivate T cells. There are 
only a small number of Tcks which have not formed stable interactions moving 
though the field of view therefore it is difficult to comment on the migration 
pattern of the Tcks. It is likely that in the 24 hours prior to the imaging of the 
co-culture the majority of the Tcks have already formed and established stable 
interactions with the macrophages therefore a shorter imaging timepoint may be 
necessary in order to visualise the how the Tcks migrate and behave. I note also 
that the experiment is not performed under formal flow conditions which might 
alter the adhesive activities of cells. 
Volocity  analysis  was  used  to  analyse  the  movies  in  order  to  determine  the 
number and duration of interactions which are shown in Figure 7.4 (B). These 
graphs  show  the  number  of  interactions  on  the  y  axis  and  the  duration  of 
interactions in time frames on the x axis. One time frame is equivalent to a 
duration of 12 seconds since this is the unit of time between each image being 
taken on the microscope. The graphs represent the average number and duration 
of interactions throughout the three movies taken of each co-culture condition. 
The graph on the left hand side demonstrates that the Tcks (red line) have more 
sustained interactions with the macrophages. These interaction last for a longer 
duration which is identified by the peak of interactions just before time frame 
200 and at time frame 250 which is not seen in the T cell co-culture (black line). 
Due to the difficulty in visualising the difference in the number of short duration 
interactions between the two co-culture conditions all interactions which lasted 
up to 10 minutes, equivalent to 50 time frames, were plotted on a separate 
graph  (demonstrated  by  the  right  hand  side  graph).  Analysing  this  graph 
illustrates  that  as  well  as  having  more  sustained  interactions  with  the 
macrophages  the  Tcks  also  have  a  higher  number  of  shorter  duration 
macrophage interactions compared to the T cells. This can be most easily seen 
at time frames 5 to 10 where the Tcks consistently exhibit a higher number of 
interactions  compared  to  the  T  cells.  Volocity  analysis  of  the  colocalization 
coefficient in Figure 7.4 (C) reveals that the average area of interaction was 
significantly higher in the three movies of the Tck co-culture compared to the 
three movies of the T cell co-culture (p<0.0001). 
Hence these results demonstrate that cytokine activation of the T cells does 
induce  more  interactions  with  the  macrophages,  these  interactions  are  more 333 
sustained and have a significantly larger area. However, analysis of the movies 
demonstrates  that  there  is  little  Tck  movement  towards  the  macrophages  as 
most of the Tcks have migrated towards and maintained their interactions with 
the macrophages in the 24 hour period prior to microscope imaging. Since we 
are also interested in visualising how the Tcks migrate towards and interact with 
the macrophages it was decided to analyse the co-culture experiments after a 
shorter 2 hour duration of incubation.  334 
 
Figure 7.4 Imaging Tcks or non-activated T cells incubated with macrophages for 24 hours 
The two co-culture experiments were analysed after 24 hours of incubation, three fields of view 
were imaged from each condition. Figure (A) shows single images from the real time movie taken 
at t=0, t=60 seconds and t=120 seconds from the cell contact containing macrophages and non 
activated T cells (top panel) and the cell contact containing macrophages and Tcks (bottom panel). 
The white arrows on the bottom panel of images indicate Tck cell movement during the course of 
the imaging. These images are a representative of the three movies which were taken of each 
condition. Figure (B) indicates the number and duration of macrophage-T cell interactions 
throughout the course of the movies. The duration of interactions is represented in time frames 335 
where one time frame is equivalent to 12 seconds. The data points represent the average value 
taken from the three movies of the macrophage-T cell co-culture (black line) and the macrophage-
Tck co-culture (red line). The graph on the left indicates all the interactions which occur for the 
duration of the movies. Since the number of short interactions is difficult to visualise on this graph 
the short duration interactions lasting no longer than 10 minutes (50 time frames) have been 
plotted on the right hand side graph. Figure (C) demonstrates the average colocalization coefficient 
of the two co-cultures (mean plus standard deviation). Colocalization coefficient is a measure of the 
area of interaction between the macrophages and T cells and this result demonstrates that there is 
a significantly higher amount of interaction taking place in the Tck co-culture compared to the T cell 
co-culture (p<0.0001). 
 
7.3.1  Comparison of Tcks and T cells after 2 hours of co-culture 
with macrophages 
I next examined cellular contacts between macrophages and T cells/Tcks after a 
2 hour duration of incubation. Since we also planned to use this model system to 
analyse  the  effect  of  different  proteins/molecules  identified  from  the 
microarray  on  this  inflammatory  model  of  arthritis,  analysing  the  co-culture 
system after 2 hours would also allow us to identify early effects of targeting or 
manipulating these proteins.  
Figure 7.5 is a representative of three independent experiments that measured 
the interactions between macrophages and non-activated T cells or Tcks after 2 
hours of co-culture. Figure (A) is displaying screen shots taken from the movie of 
the  macrophages  incubated  with  non-activated  T  cells  (upper  panel)  or 
incubated  with  Tcks  (lower  panel).  Examination  of  the  two  image  panels 
revealed that even after 2 hours of incubation the macrophages and T cells are 
already in contact with one another. This demonstrates that the T cells require 
only a short duration of time in which to establish their interactions with the 
macrophages.  Upon  comparison  of  the  two  panels  of  screenshots,  the 
macrophage-Tck co-culture appear to have substantial clustering of the T cells 
around the macrophages compared to the non-activated T cell –macrophage co-
culture. This clustering of the Tcks around the macrophages is not distributed 
evenly  throughout  the  field  of  view  and  is  localised  to  a  subgroup  of 
macrophages. The reason for this is unclear at present but it may be due to an 
increased activation of the macrophage subset causing increased expression of 
cell surface activatory markers or increased chemokine or cytokine expression 
from these cells which could be causing the Tcks to cluster around them. 336 
The  representative  movie  for  the  macrophage—T  cell  2  hour  co-culture  is 
designated movie 3 in the supplementary files. Upon observing this real time 
movie it is clear, especially at the start of the movie, that all of the T cells are 
moving in the same direction and they all change their direction of movement at 
the same time.  This would indicate that rather than undergoing independent 
random movement the T cells are all moving throughout the field of view as a 
result  of  an  external  variable  which  could  possibly  be  the  external  airflow. 
Despite this variable, several of the inactive T cells have formed stable contacts 
with the  macrophages  indicating  that  the two  cell  types  can  establish  stable 
interactions after just 2 hours of co-culture. Analysing the migrating T cells in 
the movie demonstrates that these T cells appear to only briefly interact with 
the macrophages before moving away. These short interactions may be due to 
the T cells being inactivate and therefore are not expressing the high level of 
adhesion molecules needed to form strong interactions upon the first encounter 
of the macrophages. In addition the external air flow could be playing a role in 
moving the T cells away from the macrophages before the establishment of the 
stable interactions. This is in contrast to the small number of stable interactions 
which have formed between the two cell types which may have formed during 
the 2 hour co-culture in a 37ºC incubator without the influence of external air 
flow. 
The  representative  movie  for  the  macrophage—Tck  2  hour  co-culture  is 
designated movie 4 in the supplementary files. Analysis of this movie indicates 
that the Tcks have formed stable interactions emphasising the observation that 
the  Tcks  only  need  a  few  hours  to  form  stable  cell  contacts  with  the 
macrophages.  In  the  middle  of  the  field  of  view  in  the  movie  there  is  a 
macrophage  dense  region  around  which  many  Tcks  have  clustered.  This 
clustering of T cells was not seen in the inactive T cell movie indicating that the 
Tcks have a greater capacity for macrophage cell contact. As was visualised in 
the  previous  movie,  the  external  air  flow  appears  to  be  influencing  the 
movement of the Tcks as all of the Tcks are moving in the same direction though 
the field of view, making it difficult to distinguish the migration pattern of the 
Tcks. However, although their movement appears to be influenced by the air 
flow  the  Tcks  are  demonstrating  more  short  duration  interactions  with  the 
macrophages compared to the inactive T cells. This observation is not due to the 337 
selection of the field of view as three areas were selected at random for this 
analysis and the same pattern of airflow was visualised in all  three fields of 
view. In addition, the Tcks appear to interact for longer with the macrophages 
before moving away in comparison to the inactive T cells which appear to only 
interact briefly. 
Panel  (B)  of  Figure  7.5  is  showing  the  number  and  duration  of  interactions 
occurring between the macrophages and the non-activated T cell or the Tcks. 
The  left  hand  graph  indicates  the  average  number  and  duration  of  the 
macrophage-T cell interaction which took place during the two conditions. The 
interactions between the macrophages and Tcks are indicated by the red line 
and the interactions between the macrophages and the non-activated T cells are 
indicated by the black line. On the left hand graph it is difficult to visualise the 
number of interactions lasting for a short duration however both the Tcks and 
the non-activated T cells appear to have a similar number of interactions lasting 
for the maximal duration of 265 time frames (53 minutes). Due to the difficulty 
in viewing the number of interactions lasting for a short duration, this data was 
re-graphed specifically analysing interactions which lasted for up to 10 minutes 
in  duration.  This  graph  can be  seen on the  right hand  side  of  panel  (B)  and 
demonstrates  that  the  Tcks  (red  line)  had  an  increased  number  of  short 
interactions with the macrophages compared to the non-activated T cells (black 
line).  Volocity  analysis  of  the  area  of  interaction  (colocalization  coefficient) 
within each of the movies was also calculated and the results are shown in panel 
(C). The colocalization coefficient is significantly higher (p<0.0001)  when the 
Tcks are co-cultured with the macrophages compared to the non-activated T 
cells indicating a higher area of interaction. These results correspond with those 
that  were  observed  during  comparison  of  the  images  in  panel  (A)  and 
supplementary movies 3 and 4 where it was observed that more Tcks appeared 
to be in contact and clustered around the macrophages compared to the non-
activated T cells.  
In  summary,  this  2  hour  imaging  condition  has  verified  the  results  of  the 
Tck/non-activated T cell imaging performed after 24 hours of co-culture as it 
has demonstrated at this timepoint that cytokine activated T cells have a higher 
number  of  interactions  with  the  macrophages  and  these  interactions  have  a 
larger area. The results of the 2 hour co-culture imaging also inform us that the 338 
T  cells  interact  with  the  macrophages  after  a  relatively  short  duration  of 
incubation and it is not necessary to incubate the co-culture for 24 hours before 
imaging. Performing imaging after such a short incubation has its advantages as 
the initial movement and interactions of the T cells with the macrophages can 
be  visualised  along  with  the  early  effects  of  adding  inhibitory  molecules  or 
targeting specific genes within the co-culture system. 339 
 
Figure 7.5 Imaging Tcks or non-activated T cells incubated with macrophages for 2 hours  
The two co-culture experiments were analysed after 2 hours of incubation. Figure (A) shows single 
images from the real time movie taken at t=0, t=60 seconds and t=120 seconds from the cell 
contact containing macrophages and non activated T cells (top panel) and the cell contact 
containing macrophages and Tcks (bottom panel). Figure (B) indicates the number and duration of 
macrophage-T cell interactions throughout the course of the movies. The data points represent the 
values taken from the macrophage-T cell co-culture (black line) and the macrophage-Tck co-
culture (red line). The graph on the left indicates all the interactions which occur during the movies. 
Since the number of short interactions is difficult to visualise on this graph the short duration 
interactions lasting for up to 10 minutes (50 time frames) have been plotted on the right hand side 
graph. Figure (C) demonstrates the average colocalization coefficient of the two co-cultures. 
Colocalization coefficient is a measure of the area of interaction between the macrophages and T 
cells and this result demonstrates that there is a significantly higher amount of interaction taking 
place in the Tck co-culture compared to the T cell co-culture (p<0.0001). 340 
7.4  Comparison of fixed and live Tcks after 2 hours co-
culture with macrophages 
Once it had been established that the Tcks, which have a phenotype similar to 
RA synovial T cells, have more interactions compared to non-activated T cells we 
decided  to  develop  and  validate  the  in  vitro  imaging  system  further  by 
comparing fixed Tcks to live Tcks. We hypothesised that the live Tcks would be 
able to actively migrate towards the macrophages and therefore would have a 
larger number of interactions with the macrophages compared to fixed Tcks. 
Figure 7.6 is a representative of five experiments which took place to image the 
fixed and live Tck co-culture conditions with live macrophages. For the fixation 
process 2% paraformaldehyde was used which fixes the cells through cross linking 
the  proteins.  Consequently,  the  fixed  Tcks  will  still  have  the  cell  surface 
markers and adhesion molecules needed to interact with the macrophages but 
they will not be able to actively migrate or chemotax towards the macrophages 
or  produce  cytokines  or  chemokines  which  could  activate  the  macrophages. 
Panel (A) of Figure 7.6 is showing the screen shots from one of the three fields 
of view taken for each imaging condition for this experiment. The screen shots 
are  taken  at  0,  60  and  120  seconds  after  the  commencement  of  imaging. 
Comparison of the two sets of screenshots demonstrates that there are very few 
interactions taking place between the macrophages and fixed Tcks however the 
live Tcks have clustered around the macrophages and are interacting with them. 
This can also be visualised in the real time movies taken of these conditions. 
Supplementary file movie 5 is the representative field of view taken of the fixed 
Tcks—macrophages after 2 hours of co-culture. Upon analysis of this movie it is 
clear that there are very few interactions taking place between the fixed Tcks 
and the macrophages. Furthermore, there appears to be a very small number of 
stable interactions between the fixed Tcks and the macrophages, the Tcks which 
are moving around the field of view are seen to very briefly interact with the 
macrophages before moving away. The supplementary file movie 6 represents 
the live Tcks from the same donor imaged after 2 hours of co-culture. This movie 
demonstrates that the live Tcks are highly activated and have clustered around 
and acquired stable interactions with the macrophages. Some of the Tcks are 
interacting  with  two  macrophages  at  the  same  time  and  can  be  visualised 341 
spreading over the surface of the macrophage in order to increase the area of 
interaction. The external air flow does not appear to be playing a large role in 
the movement of the live Tcks as was seen in previous movies. In addition, it can 
also  be  visualised  that  once  a  Tck  becomes  within  close  proximity  of  a 
macrophage  it  is  more  likely  to  interact  with  the  macrophage  rather  than 
migrate past it which is what is observed in the fixed Tck movie. 
Part (B) of Figure 7.6 reveals the average number and duration of interactions 
that took place throughout the imaging conditions. Each condition was imaged 
three times therefore the points on this graph represent the mean number and 
duration of interactions which took place. These results demonstrate that the 
live Tcks (red line) had substantially more interactions than the fixed Tcks; the 
difference was so striking there was no need to display the interactions lasting 
for up to 10 minutes in duration as was done in the previous figures. The graph 
also demonstrates that the live cells not only had numerous short interactions 
with the macrophages but also had interactions lasting for a long duration which 
is demonstrated by the peak of interactions at approximately 130 time frames. 
Panel (C) of Figure 7.6 demonstrates that the mean area of interaction between 
the macrophages and the Tcks was significantly higher (p<0.0001) in the live cell 
co-culture compared to the fixed cell co-culture. These results along with the 
preceding  ones  verify  our  hypothesis  that  the  live  Tcks  would  have  more 
interactions with the macrophages compared to the fixed Tcks. Whilst this result 
was not surprising since fixed Tcks are unable to migrate, this condition was an 
important one to set up as it ensured that our in vitro system was functional and 
that our methods of analysis were accurate and reliable. 
Unfortunately  time  restrictions  meant  that  no  further  experiments  using  our 
validated in vitro real time imaging system could be performed and therefore 
the imaging method could not be used for its intended purpose of imaging the 
effect  of  blocking  proteins  discovered  during  the  microarray  analysis  to  be 
upregulated in the synovial fluid macrophages. If time had permitted we would 
have  imaged  the  cell  contact  after  siRNA  treating  the  macrophages  to 
knockdown  plexin  A1  production.  Plexin  A1  is  a  gene  which  was  highly 
upregulated in our RA and PsA synovial fluid microarray samples compared to 
their matched blood samples, it is a surface receptor for semaphorin ligands and 342 
has been demonstrated to have a role in immune regulation and axonal guidance 
[444, 618].  Hence imaging the effect of siRNA knockdown of plexin A1 could 
have  demonstrated  if  it  played  a  role  in  Tck—macrophage  interaction  and 
whether silencing plexin A1 in the macrophage had an impact on the number, 
duration or area of cellular interactions. 
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Figure 7.6 Imaging fixed or live Tcks incubated with macrophages for 2 hours 
The two co-culture experiments were analysed after 2 hours of incubation. Figure (A) shows single 
images from the real time movie taken at t=0, t=60 seconds and t=120 seconds from the cell 
contact containing macrophages and fixed Tcks (top panel) and the cell contact containing 
macrophages and live Tcks (bottom panel). These images are a representative of the three movies 
which were taken of each condition. Figure (B) indicates the number and duration of macrophage-T 
cell interactions throughout the course of the movies. The data points represent the average value 
taken from the three movies of the macrophage- fixed Tck co-culture (black line) and the 
macrophage-live Tck co-culture (red line). Figure (C) demonstrates the average colocalization 
coefficient of the two co-cultures (mean plus standard deviation). Colocalization coefficient is a 
measure of the area of interaction between the macrophages and T cells and this result 
demonstrates that there is a significantly higher amount of interaction taking place in the live Tck 
co-culture compared to the fixed Tck co-culture (p<0.0001). 344 
7.5  Discussion 
This project has demonstrated the validation work required to verify an in vitro 
imaging model of inflammatory arthritis, and we have illustrated the effects of 
changes to the model through fixing the Tcks or by adding unstimulated T cells 
to  the  culture.  In  addition,  this  work  has  allowed  the  visualisation  of  the 
dynamic  nature  of  the  interactions  between  the  cytokine  activated  Tcks  and 
macrophages.  The  inflammatory  cell  contact  model  has  previously  been 
demonstrated to be a robust model of arthritis since the cytokine activation of 
the T cells induces a phenotype similar to T cells found in the RA synovium [269, 
298,  308,  309].  However,  previous  work  has  only  analysed  the 
cytokine/chemokine profiles of the macrophage—Tck co-culture, the activatory 
markers present on the Tcks or the inflammatory signalling pathways which are 
activated in the macrophage as a result of co-culture. Hence, we set out to 
visualise  and  measure  the  interactions  that  take  place  within  this  co-culture 
model with the eventual aim of imaging the effect of blocking specific proteins 
shown to be upregulated in the synovial macrophage by combining this work with 
the microarray results of the preceding chapters.  
The first set of experiments which were performed compared the interactions 
between a macrophage—Tck to a macrophage —T cell co-culture that had been 
incubated  for  the  standard  duration  of  24  hours.  The  results  of  these 
experiments revealed that on average the Tcks engaged in a higher number of 
interactions with macrophages compared to the unstimulated donor matched T 
cells.  These  Tck  interactions  also  lasted  for  a  longer  duration  and  had  a 
significantly higher surface area compared to the T cell interactions. Recently, 
Brennan  et  al  showed  that  the  cytokine  activation  of  T  cells  results  in  the 
upregulation of T cell activation markers such as CD25, CD69 and HLA-DR as well 
as adhesion molecules such as L-selectin, integrin β-1 (CD29), integrin β-2 (CD18) 
and CD49d an integrin alpha subunit that in combination with CD29 make up the 
integrin very late antigen-4 (VLA-4) [309]. These adhesion molecules are known 
to interact with receptors which are present on the surface of macrophages, 
such as VCAM-1 which interacts with Tck VLA-4 and ICAM-1 which interacts with 
Tcks  CD18.  Consequently,  the observations  of  increased  interactions  between 
Tcks and macrophages with a higher surface area compared to those between 
inactivated  T  cells  and  macrophages  is  unsurprising  since  the  Tcks  have 345 
previously  been  shown  to  express  adhesion  molecules  which  will  aid  in  their 
establishment and maintenance of interactions with the macrophages. Analysis 
of the numerous movies taken of the two co-culture conditions demonstrated 
that while many stable interactions had formed between the Tcks/T cells and 
the  macrophages  there  were  very  few  Tcks  or  T  cells  which  were  actively 
migrating or moving throughout the field of view. This result indicated that most 
of  the  Tcks/T  cells  had  already  established  and  maintained  their  stable 
interactions with the macrophages in the 24 hours prior to the commencement 
of the real time imaging. 
Since part of this investigation was to visualise the movement of the T cells 
within  the  cell  contact  system  and  visualise  the  establishment  of  these 
interactions  it  was  decided  to  analyse  the  co-culture  system  after  a  shorter 
duration of incubation. An incubation period of 2 hours was decided upon before 
the commencement of the real time imaging. This short incubation period should 
allow the T cell movement to be observed and the establishment of short and 
stable  interactions  as  a  previous  study  analysing  murine  T  cell  macrophage 
interactions  demonstrated  that  the  T  cells  move  from  one  macrophage  to 
another after 2 hours of real time imaging  [701]. In addition, using a 2 hour 
incubation  period  before  imaging  the  co-culture  would  coordinate  well  with 
using this in vitro imaging system alongside the microarray results to visualise 
the  function  of  particular  genes.  The  microarray  analysis  took  place  after  2 
hours of co-culture to analyse the early response genes that are changed in the 
macrophages therefore imaging this co-culture system after 2 hours will allow 
the  visualisation  of  the  effect  these  early  response  genes  have  on  the 
interactions between the Tcks and macrophages. 
Imaging  the  Tck—macrophage  co-culture  in  comparison  to  the  T  cell—
macrophage  co-culture  after  2  hours  of  incubation  correlated  well  with  the 
previous analyses of the co-culture after 24 hours. The number of short duration 
interactions and the colocalization coefficient was higher in the Tck co-culture 
compared to the T cell co-culture however both co-culture systems had a similar 
average  number  of  long-duration  stable  interactions.  Hence  not  only  are  the 
Tcks having more short duration interactions with the macrophages but the area 
of these interactions is also significantly larger, this observation may be caused 
by the increased expression of adhesion molecules on the surface of the Tcks 346 
after cytokine activation as previously described [309]. Analysis of the movies 
from these co-culture experiments unfortunately did not reveal a large amount 
of information regarding the independent movement of the T cells/Tcks due to 
external factors influencing their movement. In each movie the Tcks/T cells can 
be observed to all move in a single direction before changing their direction of 
movement simultaneously which leads to the conclusion that external air flow 
may be causing the movement of the T cells. 
Despite  the  external  air  flow,  which  was  not  consistent  throughout  the 
experiements,  patterns  of  interaction  can  still  be  noted  from  these  movies. 
During the numerous Tck—macrophage co-cultures which were set up the Tcks 
were  seen  to  cluster  around  specific  macrophages  and  were  not  evenly 
distributed  throughout  the  field  of  view.  Studies  analysing  murine  T  cell—DC 
interactions  in  the  absence  of  antigen  have  demonstrated  that  the  rate  of 
contacts is not solely the result of random collision events. Chemokines, such as 
CCL3  and  CCL4,  produced  at  the  site  of  T  cell-DC  conjugates  increases  the 
chance of migrating CCR5-expressing CD8
+ T cells to contact DCs by a factor of 2 
to 4 [702]. In addition in vitro observations have revealed that T cell movement 
and behaviour can be influenced by the presence of surface bound chemokines 
on the DC. Friedman et al demonstrated that when T cells encounter APCs which 
have  been  pulsed  with  CCR7  ligands  in  the  absence  of  antigen  they  remain 
attached  to  the  APCs  for  several  minutes  by  a  uropodal  tether.  It  was  also 
demonstrated that this attachment was reduced by 62% in the presence of a 
blocking antibody to ICAM-1 [703]. In the human in vitro model of inflammatory 
arthritis Tcks have been demonstrated to express the chemokine receptor CCR5 
and  to  a  lesser  extent  CCR7  [309]  therefore  the  movement  and  cellular 
interaction of these Tcks could be influenced by the expression of chemokines 
from the macrophages. Since the CCR5 ligands CCL3 and CCL4, otherwise known 
as  MIP-1α  and  MIP-1β,  are  expressed  by  activated  macrophages  [578]  the 
clustering of Tcks around certain macrophages may the result of these subsets of 
macrophages expressing a higher level of chemokine ligands which causes the 
specific migration and interaction of Tcks to these cells. Once these Tcks are in 
close contact with the macrophages their cellular contacts and maintenance of 
stable interactions will be mediated by adhesion molecules previously associated 
with Tcks and macrophages such as L-selectin and ICAM-1. There is no clustering 347 
pattern of inactive T cells around the macrophages seen in the T cell movies 
which is most likely due to the lack of chemokine receptors expressed on the T 
cells  that  ensures  these  T  cells  are  not  moving  by  a  chemotactic  gradient 
towards the macrophages and  only interact with the macrophages by random 
chance. 
In conclusion imaging the co-culture after 2 hours of incubation rather than 24 
hours showed a similar pattern of colocalization coefficient but the advantage of 
imaging  after  such  a  short  incubation  allows  the  movement  and  brief 
interactions of the Tcks/T cells with the macrophages to be observed whereas 
the was very little T cell movement when the co-culture was analysed after 24 
hours. However, it must be noted that the Tck/T cell movement may not be 
entirely random during the real time imaging as the behaviour and motion of 
these cells may be influenced by the external air flow outside of the imaging 
chamber. 
Once it had been established that the Tcks, which have a phenotype similar to 
RA synovial T cells, partake in more cellular interactions with the macrophages 
compared to non-activated T cells it was decided to validate the in vitro imaging 
system further by comparing fixed Tcks to live Tcks after 2 hours of co-culture. 
Fixation of the Tcks before incubating them with the macrophages results in T 
cells  which  express  all  the  surface  bound  chemokine  receptors  or  adhesion 
molecules which are known to be upregulated on Tcks [309] but are unable to 
actively migrate towards the macrophages. Analysis of the graphs in Figure 7.6 
which represent one of five experiments clearly indicates that live Tcks have 
more  interactions  with  the  macrophages  compared  to  fixed  Tcks  and  these 
interactions last for a longer duration and have a significantly higher surface 
area. These results validated our hypothesis that the live Tcks are able to move 
towards  the  macrophages  and  respond  to  the  chemokines  and  adhesion 
molecules  present  on  the  surface  of  the  macrophages.  Analysis  of  the 
representative movies demonstrated that fixed Tcks do form stable interactions 
with  the  macrophages,  since these  cells  cannot  actively  migrate  towards  the 
macrophages this would indicate that these interactions are the result of random 
movement of the fixed Tcks possibly influenced by the external air flow aiding 
the cells in their movement. Combining these results would indicate that the 
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random movement as well as chemotaxis through the production of chemokines 
from the macrophages. Analysis of the fixed and live Tck co-cultures enabled the 
validation of the  in vitro imaging system and ensured that this inflammatory 
arthritis model produced reliable and reproducible results. 
This  imaging  system  had  provided  us  with  interesting  results  regarding  the 
movement and interaction of cells within the cell contact model of arthritis but 
there are several areas of improvement for future experiments. One such area 
would be to reduce the influence of the external airflow on the T cell movement 
through the use of a heated chamber which surrounds the in vitro system. This 
modification would subsequently allow the observation of the independent T cell 
movement and migration rather than the cell movement being influenced by the 
air flow. The use of z stacks to take images at different focal depths of the field 
of view should also be considered as this would enable a 3D image of the cells 
within the field of view to be acquired. The z stack information would reveal the 
3D area of interaction between the Tcks and macrophages, which would be more 
informative than the current 2D area measured in the preceding experiments. 
Such  z  stack  information  would  also  enable  a  more  accurate  colocalization 
coefficient to be measured between the Tcks and the macrophages. Also the use 
of  a  3D  collagen  matrix  would  make  the  movement  of  the  cells  more 
physiological  and  would  be  representative  of  the  environment  within  the 
synovial joint. Several experiments were set up using a collage matrix (data not 
shown) but the inability to focus on the cells made it impossible to image their 
interaction.  However,  such  imaging  capacity  is  available  using  a  confocal 
microscope which is more advanced than the inverted microscope used for the 
current study. In summary, the use of a collagen matrix in addition to measuring 
z  stacks  on  more  advanced  confocal  microscope  would  greatly  enhance  the 
amount of information gained from this in vitro imaging system.  
In addition, time restrictions meant that this imaging model could not be used 
for its intended purpose of imaging the effect of blocking genes identified from 
the microarray analysis performed in this project (see chapter 4) to ascertain 
whether the interactions between the macrophages and synovial-like Tcks were 
affected. For example imaging the effect of silencing the plexin A1 gene would 
be of interest as these experiments may determine whether this cell surface 349 
associated  protein,  which  was  found  to  be  highly  upregulated  in  RA  and  PsA 
synovial macrophages, has a role in the synovial T cell—macrophage interaction. 
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Chapter 8: General Discussion 
At the outset of my studies many microarray investigations had been performed 
to analyse the trancriptomic signature of RA and PsA either by whole blood or 
whole tissue profiling [318-320, 325-327, 329, 330, 340, 341] but very few had 
analysed the individual cell subsets which drive the pathogenesis of disease.  I 
therefore sought to determine the expressed genetic profiles of matched blood 
and synovial fluid CD14
+ monocytes and macrophages from RA and PsA patients 
to  determine  how  the  macrophages  change  their  transcriptome  once  they 
migrate from the blood into the inflamed synovial joint. I also sought to compare 
these profiles to  those of healthy blood CD14
+ monocytes and to cell-contact 
activated macrophages, representing an in vitro model of inflammatory arthritis. 
Analysis of the microarray data comparing i) healthy blood, ii) RA blood and iii) 
PsA blood CD14
+ cells revealed the unexpected result that the overall genetic 
profiles of these three monocyte types were remarkably similar and there were 
very few genes that could distinguish one monocyte subset from another. This 
result  was  in  contrast  to  previous  microarray  analyses  which  have  found  a 
distinct disease signature in RA and PsA blood compared to healthy control blood 
[326, 329, 330, 340, 341]. The discrepancy between microarray results may be 
due to differences in sample numbers as my study only included 5 healthy donors 
and were age- and sex-matched to the PsA patients only. Despite this, my results 
suggested that the monocytes within RA and PsA are not responsible for the gene 
expression differences seen in other PBMC microarray studies between healthy 
and arthritic patients indicating that other cells within the peripheral blood may 
be  causing  the diseased genetic signature. Numerous microarray studies have 
proposed  the  use  of  genetic  data  from  patient  PBMCs  to  discover  molecular 
discriminators  indicating  a  response  to  treatment  or  disease  progression. 
However, since my data suggest that the RA and PsA blood monocytes do not 
have a differentiating disease signature compared to healthy controls it may not 
be  appropriate  to  use  this  cell  subset  as  a  marker  of  disease  or  treatment 
response. 
Comparison of matched blood and synovial fluid CD14
+ cells from the RA and PsA 
patients  also  revealed  some  novel  findings.  Unsurprisingly,  the  synovial  fluid 
genetic  signature  was  vastly  different  to  that  of  the  matched  blood  samples 351 
therefore  demonstrating  that  the  monocytes  only  develop  a  disease  specific 
signature once they exit the blood and enter the diseased joint. In addition, 
upon comparison of the differentially expressed genes it was discovered that 
over 50% of the expressed genes in the synovial fluid CD14
+ cells compared to 
the blood cells were the same in both RA and PsA. This result was unexpected 
given previous analyses by Baeten et al who suggested that the macrophages in 
SpA and RA were different since they found SpA (including PsA) macrophages 
expressed  higher  levels  of  markers  of  alternative  activation  compared  to  RA 
macrophages [255] and SpA synovial fluid but not RA was able to polarise blood 
monocytes to express the alternative activation marker CD163 [253]. However, 
analysis of the genetic transcriptome generated by my study demonstrated a 
similar  level  of  alternative  activation  markers,  such  as  CD204  or  mannose 
receptor, expressed in the PsA CD14
+ and RA CD14
+ SF cells. Indeed, I also found 
similar levels of classical activation markers such as CD86 expressed in both RA 
and  PsA  SF  cells  demonstrating  that  within  this  study  the  RA  and  PsA 
macrophages do not have a preferential activation phenotype which contradicts 
the previous findings. The reasons for this may be due to the Baeten et al study 
analysing the effects of SF on healthy blood monocytes rather than analysing the 
diseased  macrophages  isolated  from  the  source  of  inflammation  as  was 
performed in our study as the effect of the cell-cell contact that takes place 
within the synovium in addition to the SF environment may play a role in the 
expression of activation markers and macrophage polarization. However, further 
studies  on  the  phenotype  of  the  macrophages  and  protein  expression  of 
activation markers are required to test this hypothesis.  
Due  to  the  same  genes  being  differentially  expressed  in  the  RA  and  PsA  SF 
macrophages compared to their matched blood monocytes many of the same 
canonical  pathways  were  significantly  associated  with  these  genes  lists. 
Interestingly,  the  top  pathway  was  LXR  activation  which  has  previously  been 
associated  with  RA  but  is  a  novel  finding  for  PsA.  Work  performed  by  our 
research  group  prior  to  this  observation  had  demonstrated  that  LXR  agonism 
exacerbated articular damage in CIA a murine model of arthritis. In addition, ex 
vivo culture of RA PB derived monocytes which were LPS stimulated and treated 
with  two  LXR  agonists  showed  an  increase  in  IL-6  and  TNFα  production, 
suggesting LXRs have a pro-inflammatory role in arthritis [527]. However in the 352 
present investigation several of the RA and PsA SF macrophage genes associated 
with  this  LXR  canonical  pathway  are  constituents  of  the  anti-inflammatory 
lipoptotein HDL. HDL has been previously shown to mediate anti-inflammatory 
effects within RA since HDL can block the pro-inflammatory cytokine production 
from monocytes induced by T cell contact through binding to the T cell surface 
activating  factors  [558].  Consequently,  the  net  inflammatory  effect  of  the 
upregulated LXR pathway in the RA and PsA SF macrophages is yet to be defined 
and should be the focus of further investigations. 
Analysis  of  the  highly  upregulated  genes  in  both  of  the  RA  and  PsA  SF 
macrophage subsets compared to the PB monocytes resulted in the identification 
of two novels genes that had not been previously associated with arthritis. One 
of  these  genes  was  legumain  which  is  a  lysosomal  cysteine  protease  that 
specifically cleaves protein substrates such as MMP2, cathepsins and fibronectin 
[429, 431] which are all found within the synovium of arthritis patients. My work 
revealed that legumain was found at the mRNA and protein level in RA and PsA 
SF  CD14
+  cells  and  was  physiologically  active;  in  addition  M-CSF  matured 
macrophages could be induced to express legumain when cultured in RA or PsA 
SF under hypoxic conditions.  Therefore,  I hypothesise that legumain is highly 
upregulated  by  macrophages  once  they  enter  the  hypoxic  pro-inflammatory 
environment  of  the  synovium  and  is  required  by  the  cell  to  activate 
glycoproteins or enzymes being produced or taken up by the cell which therefore 
contribute to the destructive inflammation seen in the synovium. Legumain was 
also seen to be expressed on the cell surface of the synovial macrophages and 
has also been shown to be excreted from cells  [665] and therefore could be 
activating destructive enzymes such as MMPs within the synovial fluid milieu. 
Plexin A1 was the second novel gene discovered by the microarray analysis to be 
highly upregulated in the RA and PsA SF macrophages compared to the blood 
monocytes.  Plexin  A1  is  a  cell  surface  receptor  which  binds  to  semaphorin 
ligands and has previously been shown to be important for T cell-DC interactions 
and subsequent T cell activation [444, 623]. Due to the large body of literature 
describing  macrophage  interactions  with  other  cell  types  in  the  arthritic 
synovium causing subsequent activation and pro-inflammatory mediator release I 
hypothesised  that  plexin  A1  expression  on  the  synovial  macrophages  may  be 
playing  a  role  in  the  cellular contacts  taking  place  between  these  and other 353 
synovial cells. In our study, plexin A1 was shown to be expressed at the protein 
and RNA level and knocking down the gene using siRNA demonstrated that it may 
be  playing  a  potential  pro-inflammatory  role.  Nevertheless  our  studies  were 
hampered by the inability to discover the presence of  the most widely know 
plexin  A1  ligand,  semaphorin  6D,  on  activated  or  synovial  T  cells  despite  it 
previously being detected on activated murine T cells [645]. However, plexin A1 
is  known  to  have  several  semaphorin  ligands  and  whilst  our  initial  studies 
suggested these may be expressed at the RNA level in synovial membrane and 
synovial fibroblasts more investigation is required to elucidate what role plexin 
A1 and its ligands could be playing in arthritic disease. 
Analysis of the expressed genetic signature of the Tck activated macrophages, 
(postulated to represent an in vitro model of inflammatory arthritis [298, 309, 
314]), in comparison to synovial fluid derived macrophages demonstrated that 
only 10% of the expressed genes in the cell contact activated macrophages were 
expressed in RA or PsA synovial fluid macrophages. This would imply that this in 
vitro system may not be a suitable model of arthritis; however my analysis was 
confounded  by  several  variables  particularly  the  duration  of  macrophage 
activation  by  the  Tcks  which  was  restricted  to  2  hours.  Therefore  further 
investigation especially involving a more extensive timecourse of macrophage 
activation is required to fully elucidate the relevance of this in vitro model to an 
in vivo disease process. 
The real time imaging performed on the in vitro cell contact model of arthritis 
provided  some  interesting  observations  on  the  variables  influencing  the 
interactions between the T cells and macrophages. It was discovered that the 
number of individual interactions between the macrophages and T cells was high 
at 2 hours of co-culture due to the Tcks moving around the field of view and 
interacting with several macrophages. This observation may help to explain why 
there were so few genes in the 2 hour cell contact activated macrophages that 
were shared with the SF macrophages as stable interactions with the Tcks, which 
would  activate  the  macrophages,  were  not  fully  formed  after  2  hours  of  co-
culture. Unfortunately time restrictions meant that this imaging system could 
not be used for its intended purpose which was imaging the effect of blocking 
genes identified in the microarray analysis. These experiments may have allowed 
us  to  visualise  whether  these  genes,  i.e.  plexin  A1,  played  a  role  in  the 354 
interaction of macrophages with other cell types such as the synovial T cell like 
Tck. 
While this new evidence of the genetic signatures of RA and PsA synovial fluid 
macrophages has been informative, several avenues of investigation remain to 
be  explored.  Future  studies  must  identify  the  role  of  plexin  A1  within  the 
synovial  fluid  macrophages  and  the  semaphorin  ligand  it  is  potentially 
interacting with. In addition, understanding the consequences of high levels of 
active legumain within the RA and PsA synovium through the use of legumain 
knockout mice and further functional analyses is of paramount importance as it 
represents an entirely novel enzyme with arthritic disease relevant functions. 
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